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Abstract 
A hydroxyl-directed syn-hydroboration of propargyl alcohols was developed (Scheme 1). 
This protocol allows for the one-pot transformations of propargyl alcohols into trisubstituted 
allyl alcohols. A transient linker was employed to extend the ‘reach’ of the propargyl alcohol to 
direct the hydroborating agent. Subsequent in situ oxidation of the borane and transition-metal 
catalyzed cross-couplings with alkynyl-, alkenyl-, aryl- and alkylhalides were demonstrated. 
 
Scheme 1. Hydroxyl-directed hydroboration/Suzuki cross-coupling sequence. 
With reliable access to highly functionalized and stereodefined alkenylstannanes from 
previous works in our group, we sought to utilize this motif in complex molecule synthesis. 
Tubelactomicin A (246) was selected as an ideal target, containing an intriguing 
(hydroxymethyl)acrylic acid motif in the southern domain (Scheme 2). To realize our goal, a 
palladium catalyzed oxidative methoxy carbonylation of alkenylstannanes was developed, which 
provides direct access to ,-unsaturated ester motifs in a single step. This in turn enabled a 
significant improvement in the route to fragment 272. 
 
Scheme 2. Palladium-catalyzed oxidative methoxy carbonylation and formal synthesis of tubelactomicin A. 
Next, we developed a methodology to convert alkenylstannanes to ketones, as this type of 
transformation had been previously limited to alkenylsilanes and alkenylboranes. Inspired by 
the well-known Chan-Lam coupling, we discovered that hydroxyl flanked alkenylstannanes 
could be transformed into -acetoxy ketones in a copper-mediated process (Scheme 3). The 
reaction is proposed to proceed via copper species 419. Furthermore, we found that stannanes 
XX 
 
lacking an assisting hydroxyl group could be converted into the corresponding ketones utilizing 
copper(II) trifluoroacetate. 
 
Scheme 3. Copper-mediated synthesis of -acetoxy ketones from alkenyl stannanes. 
Additionally, a reliable and broadly applicable method for the fluorination of 
alkenylstannanes was developed (Scheme 4). A mild protocol employing silver 
diphenylphosphinate and F-TEDA-PF6 allowed access to various alkenyl fluorides. This method 
was then applied to the synthesis of biologically interesting peptide isosters such as 530. 
 
Scheme 4. Silver-mediated fluorination of alkenylstannanes. 
Lastly, we achieved a highly convergent and efficient synthesis of 5,6-dihydrocineromycin B 
(615) utilizing multiple catalytic methods developed in our laboratory, namely ring-closing 
alkyne metathesis (RCAM), trans-selective hydrostannation, and methyl-Stille cross-coupling 
(Scheme 5). Furthermore, the late-stage functionalization of alkenylstannane 647 enabled 
divergent preparation of five additional non-natural analogs for biological evaluation. 
 
Scheme 5. Synthesis of 5,6-dihydrocineromycin B and congeners. 
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Überblick 
Eine neue hydroxyl-dirigierte syn-Hydroborierung von Propargylalkoholen wurde in der 
frühen Phase dieser Arbeit entwickelt (Abbildung 1). 
 
Abbildung 1. Hydroxyl-dirigierte Hydroborierung/Suzuki Kreuzkupplung Sequenz. 
Diese bis dahin unbekannte Methode erlaubt die Eintopftransformation von 
Propargylalkoholen in dreifach substituierte Olefine. Dazu wurde die intermediäre Bildung eines 
Halbacetals genutzt um die ‚Reichweite‘ des Propargylalkohols zu erhöhen und das 
Hydroborierungsreagenz zu dirigieren. Anschließende in situ Oxidation und Kreuzkuppung mit 
Alkinyl-, Alkenyl-, Aryl- und Alkylhalogeniden sowie die Anwendung in der Totalsynthese wurde 
demonstriert. 
Um das volle Potential der aus der ruthenium-katalysierten trans-Hydrostannierung von 
Alkinen hervorgehenden hochfunktionalisierten Alkenylstannane auszuschöpfen, wurde eine 
Formalsynthese vom Tubelactomicin A (246) initiiert (Abbildung 2).  
 
Abbildung 2. Palladium-katalysierte oxidative Methoxycarbonylierung und formale Synthese von Tubelactomicin A. 
Dieser komplexe Naturstoff weist neben einer Reihe anderer Funktionalitäten ein 
interessantes Hydroxymethylacrylsäuremotiv auf. In der Literatur wurde Fragment 272 in einer 
25-stufigen, linearen Sequenz synthetisiert. Ein hoch effizienter Zugang zu 
Hydroxymethylacrylsäuremotiven wurde daraufhin entwickelt, der auf einer neuen 
palladiumkatalysierten, oxidativen Methoxycarbonylierung basiert. Eine Vielzahl von ,-
XXII 
 
ungesättigten Estern konnte erhalten sowie die Anwendung der neuen Methodik in einer 
effizienten Formalsynthese von Tubelactomicin A demonstriert werden. 
Die Umsetzung von Alkenylmetalloiden in die entsprechenden Carbonylverbindungen ist in 
der Literatur auf den Einsatz von Alkenylsilanen und Alkenylboranen beschränkt. Um diese 
Lücke zu schließen, entwickelten wir eine kupfermediierte Oxidation von Alkenylstannanen 
(Abbildung 3). Es konnte gezeigt werden, das hydroxysubstituierte Alkenylstannane in der 
Gegenwart von Kupfer(II)acetat in die entsprechenden -Acetoxyketone umgesetzt werden 
können. Die Umwandlung läuft wahrscheinlich über eine Transmetallierung unter Bildung einer 
Alkenylkupferspezies 419 ab. Weiterhin ist die Synthese von Ketonen ohne benachbarte 
Hydroxygruppe mit Hilfe von Kupfer(II) trifluoracetat möglich. 
 
Abbildung 3. Kupfer(II)acetat vermittelte formale Oxidation von Alkenylstannanen. 
Ein hochaktuelles Thema ist seit langem die Fluorierung organischer Verbindungen. 
Obwohl frühe Arbeiten zur Umsetzung von Alkenylstannanen in die entsprechenden Fluoride 
existieren, wurden die Limitierungen dieser Arbeiten bis heute nicht behoben. Wir konnten mit 
Hilfe eines zwar bekannten aber kaum untersuchten Silbersalzes in Gegenwart von einem 
Selectfluorderivat einen effizienten Zugang zu Alkenylfluoriden entwickeln (Abbildung 4). Die 
milden Reaktionsbedingungen erlaubten uns weiterhin, biologisch interessante Peptidisostere 
wie zum Beispiel Verbindung 530 zu synthetisieren.  
 
Abbildung 4. Silber-vermittelte Fluorierung von Alkenylstannanen. 
Abschließend konnte ein hochkonvergenter Zugang zu 5,6-Dihydrocineromycin B erarbeitet 
werden, der zum großen Teil auf in dieser Arbeitsgruppe entwickelten, katalytischen 
Transformationen beruht. Schlüsselschritte der Synthese stellen eine ring-schließend 
Alkinmetathese (RCAM), die erwähnte Hydrostannierung und eine Methyl-Stille-Kreuzkupplung 
dar. Außerdem konnte das intermediär erhaltene Alkenylstannan im Kontext einer 
divergierenden Totalsynthese zur Darstellung von fünf nicht-natürlichen Analoga genutzt 
werden. 
Chapter 1 - Introduction 
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1. Introduction 
1.1. Developing Ideal Chemistry 
The complexity of organic molecules has inspired the imagination of synthetic chemists for 
more than a century. Tools for the construction of nearly every conceivable structural motif have 
been developed and the field matured considerably over more challenging molecules being 
synthesized. Nowadays, as chemists continue to innovate and develop elegant methodologies, 
they must not only consider the feasibility of a process but also its economic impact. Concepts 
like atom economy[1] or step economy[2] have evolved to allow the practitioner to quantify the 
efficiency of their designed approach.[3] When faced with a synthetic problem, e.g. the synthesis 
of a natural product, chemists have to foresee potential pitfalls and develop their strategy 
accordingly. An ideal synthesis plan should rapidly build up complexity in the minimum number 
of steps possible (Figure 1). A practical synthesis design balances the demands of practicality 
and ideality.  
 
Figure 1. Developing ideal syntheses by Wender and Miller.[2b] 
In pursuit of such ‘ideal’ synthesis, new tools are constantly being developed and refined. 
Carbon-carbon multiple bonds are extremely versatile scaffolds for functionalization and rapid 
generation of molecular complexity. For example, alkynes can be transformed into regio- and 
stereodefined olefins which may then be converted into a highly decorated alkane motif. 
This thesis is concerned with the development of novel, step-economical protocols for the 
derivatization of alkynes with particular focus on transformations of resulting alkenylmetalloids 
in the context of complex molecule synthesis. 
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1.2. Hydrometalations of Internal Alkynes 
The stereospecific hydrometalation of an internal alkyne presents an important 
transformation in organic chemistry (Figure 2). The resulting alkenylmetalloids are valuable 
substrates for a range of powerful cross-coupling methodologies, allowing access to 
stereodefined, trisubstituted olefins. Consequently, hydroborations, hydrostannylations and 
hydrosilylations constitute the most notable members in this field and have found numerous 
applications.[4] Classically, hydroelementation reactions occur in a syn-fashion. The ability of 
chemists to control the regio- and stereoselectivity of these reactions is vital for synthetic utility. 
Major advances in the last two decades yielded a number of valuable protocols for the highly 
selective synthesis of alkenylmetalloids. 
 
Figure 2. Stereodivergent hydrometalation of internal alkynes. 
1.2.1. Mechanism of Metal-catalyzed syn-Selective Hydrometalations of Internal 
Alkynes 
Most metal catalyzed hydrometalations of alkynes operate by one of the two mechanistic 
pathways which in analogy to hydrogenations, are termed ‘dihydride’ or ‘monohydride’  
(Figure 3). 
 
Figure 3. Typical hydrometalation pathways. 
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In the dihydride mechanisms, activation of the metalloid hydride ([Y]H) by oxidative 
addition to the metal catalyst precedes hydrometalation (A) or bismetalation (B), providing 
regioisomeric products I and II after reductive elimination, depending on whether insertion of 
the alkyne occurs at the [M]H (A) or [M]Y (B) bond. These ‘dihydride’ mechanisms are 
generally referred to as Chalk-Harrod (A) and modified-Chalk-Harrod mechanisms (B), 
respectively.[5] 
In the ‘monohydride’ mechanisms, a series of -bond metathesis steps leads to III/IV with 
only hydride (C) or metalloid (D) ever being bonded to the metal center. As pathways (A) and 
(C) and pathways (B) and (D) give rise to the same regioisomeric products, identification of the 
operating mechanism can be difficult. 
1.2.2. Mechanism of Metal-catalyzed trans-Selective Hydrometalations of Internal 
Alkynes 
In 2001, Trost and Ball demonstrated that the trans-selective hydrosilylation of terminal 
and internal alkynes is possible under ruthenium catalysis.[6] Recently, our group presented a 
ruthenium catalyzed system which effects regioselective trans-selective addition of silanes, 
boranes, stannanes and even dihydrogen to alkynes.[7] The versatility and mild conditions of the 
trans-selective hydrosilylation and hydrostannation have been documented in numerous total 
syntheses.[4d] 
Subsequent mechanistic investigations provided evidence for a pathway which differs 
significantly from the mechanisms illustrated in Figure 3. In the initiating step, activation of the 
metalloid hydride occurs to give ruthenacyclopropene V with concomitant hydrometalation of 
the alkyne (Figure 4) (for the sake of clarity, Cp is drawn interchangeably for Cp*). Complex V 
may equilibrate via transient cation VI with isomeric metallacyclopropene VII before addition of 
[Y]. trans-Selectivity is thus explained by the reduced steric clash of H and Cp*-ligand compared 
to R’ and Cp*-ligand. Reductive elimination closes the catalytic cycle (VIII) and reforms cationic 
ruthenium species IX after complexation.  
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Figure 4. Mechanistic proposal for the ruthenium catalyzed trans-selective hydrometalation. 
Although being still a matter of debate, this model accounts well for the observed trans-
selectivity.[8] During their studies on the trans-selective hydrosilylation, Trost and Ball focused 
on the utilization of cationic [CpRu(MeCN)3]PF6 and [Cp*Ru(MeCN)3]PF6 as precatalysts. High 
E/Z-selectivities were generally obtained, however, strong electronic or steric biases were 
necessary to achieve appreciable regiocontrol. In 2014, it was found that flanking protic groups, 
e.g. alcohols or amides, dictate the regioselectivity of this transformation when the neutral 
complex [Cp*RuCl]4 or its precursor [Cp*RuCl2]n are used as precatalysts in the trans-selective 
hydrostannation, hydrosilylation, and hydrogermylation.[7b, 7e] A model, supported by single-
crystal X-ray analysis and computational studies, was elaborated that accounts for the observed 
regioselectivity (Scheme 1). Hydrosilylation in the presence of [Cp*Ru(MeCN)3]PF6 
preferentially delivers the silicon distal (003) to the alcohol, whereas neutral [Cp*RuCl]4 shows 
a propensity for proximal silylation (002). A similar trend was observed in the trans-selective 
hydrogermylation of propargyl alcohols. 
 
Scheme 1. Typical example for the regiodivergent hydrosilylation of propargyl alcohols; ⦁ = CMe. 
This result can be rationalized, by considering the top view model IX. Hydrogen bonding of 
the chloride ligand to both the -coordinated propargyl alcohol and to the incoming metalloid 
hydride results in the formation of a rigid network. Consequently, hydride delivery occurs 
preferentially at the position which is distal to the alcohol. 
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The utilization of neutral ruthenium catalysts also led to the exclusive formation of the 
proximal product in the trans-selective hydrostannation (Scheme 2). The cationic ruthenium 
complex also showed an inherent preference for proximal selectivity but gave a less favorable 
isomer ratio. 
 
Scheme 2. Hydroxyl-assisted trans-selective hydrostannation. 
Subsequent studies broadened the scope of this reaction even further, allowing for its 
application in natural product synthesis (Scheme 3). Terminal (007) and internal olefins, as well 
as silyl protecting groups (008) or protected alkynes (009) are well tolerated. It was also shown 
that shifting the directing group by one (010) or two carbon atoms engenders no detrimental 
effect on regio- or stereoselectivity. 
 
Scheme 3. Representative examples for the directed trans-selective hydrostannation. 
1.2.3. Applications of trans-Selective Hydrosilylations in Total Synthesis 
The majority of trans-selective hydro-metalations reported in the literature relate to the 
hydrosilylation of alkynes due to its long and successful history. The mild reaction conditions 
and excellent functional group tolerance render this methodology highly attractive for total 
synthesis. In most instances, the resulting alkenylsilanes are protodesilylated to provide net 
trans-reduction of the alkyne as illustrated in Scheme 4.  
In the total syntheses of lactimidomycin[9] and tulearin C[10], Fürstner and coworkers 
employed the ruthenium catalyzed hydrosilylation for the overall trans-reduction of an internal 
alkyne (011 and 013) which was obtained via ring-closing alkyne metathesis (RCAM) (Scheme 
4). This powerful combination enabled the late-stage introduction of an E-olefin with high 
stereoselectivity under mild conditions in the presence of sensitive functional groups (012 and 
014). 
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Scheme 4. trans-selective hydrosilylation for net reduction of alknyes. 
Clark and Romiti[11] prepared alkenyl silanes 016 which were subsequently utilized in a 
Fleming-Tamao oxidation to access amphidinolides T1, T3 and T4 from common precursor 015 
(Scheme 5). In the synthesis of lasanolide A, Trost and coworkers engaged alkenyl silane 018 in 
an ensuing Hiyama-Denmark cross coupling.[12] 
 
Scheme 5. Ruthenium catalyzed trans-hydrosilylation as prelude for follow-up chemistry. 
Synthetic applications have demonstrated the versatility of alkenylsilanes in complex 
molecule synthesis although examples are limited. 
1.2.4. Application of trans-Selective Hydrogenation in Total Synthesis 
In 2013, Fürstner and coworkers reported the first ruthenium catalyzed trans-selective 
hydrogenation of internal alkynes.[13] A mechanistic proposal that accounts for the observed 
selectivity, as well as the formation of over-reduction and isomerization products was supported 
by NMR studies and single-crystal X-ray analysis.[14] In the same year, the first application of this 
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novel transformation for the late-stage installation of an E-olefin was impressively 
demonstrated in the large scale synthesis of brefeldin A (023) (Scheme 6).[7c] 
Fragments 019 and 020 were joined by an enantioselective alkynylation to yield triyne 
021. Routine functional group manipulations set the stage for the RCAM providing access to 
enyne 022. Ruthenium catalyzed trans-selective hydrogenation and global deprotection 
delivered brefeldin A (023) in good overall yield. Notably, this single approach generated more 
material than all previous attempts combined. The cooperation of RCAM and trans-selective 
hydrogenation allows expeditious access to stereodefined double bonds in a highly atom 
economical way. 
 
Scheme 6. Endgame in total synthesis of brefeldin A (023). 
1.2.5. Applications of trans-Selective Hydrostannations in Total Synthesis 
At the outset of this project, no application of the ruthenium catalyzed trans-selective 
hydrostannation, in the context of natural product synthesis, had been reported. However, trans-
alkenylstannanes had previously been obtained via radical hydrostannations of alkynes with 
appreciable regio- and stereoselectivities. Notable examples are presented in Scheme 7. In a 
study towards the synthesis of maytansine, Khuong-Huu and coworkers employed a radical 
hydrostannation of propargyl alcohol 024 to access fragment 025.[15] Hale and coworkers 
exploited a doubly O-directed, regio- and stereoselective radical hydrostannation with 
triphenylstannane in the presence of triethylborane as an initiator to obtain fragment 027.[16] 
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Scheme 7. Radical trans-selective hydrostannation of alkynes. 
Given the diversity of Stille cross-coupling protocols, the synthesis of stereodefined 
alkenylstannanes is of much greater interest to the synthetic community than their 
corresponding silyl counterparts.[17] At the same time, due to the potential toxicity of 
alkenylstannanes, methods to introduce and convert other alkenylmetalloids remain highly 
desirable. 
1.3. Concluding Remarks 
trans-Hydrometalation methodologies represent a powerful complement to their 
established syn-selective counterparts. The synthetic utility of the resulting alkenylmetalloids 
and the possibility to conduct these transformations at the late stages of complex molecule 
syntheses, render this an exciting area of research. This thesis will expand the scope of directed 
hydrometalations (chapter 2), as well as develop novel transformations of the resulting 
alkenylmetalloids (chapters 3-5). Finally, the applicability of the methodologies disclosed herein 
is demonstrated in the context of a diverted total synthesis (chapter 6). 
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2. Directed Hydroboration of Propargyl Alcohols and Suzuki Cross-
coupling for the Selective Synthesis of Trisubstituted Olefins 
2.1. Introduction 
2.1.1. Historic Background on Hydroboration 
The first hydroboration of a carbon-carbon multiple bond was described in 1948 by Hurd.[1] 
He observed the hydroboration of ethylene at 100°C in the gas phase with diborane to yield 
triethylborane. This result was later mechanistically investigated by Wheatly and Pease[2] and 
refined by Brown and coworkers.[3] In a landmark discovery, Brown and coworkers found that 
the addition of ethereal solvents promotes the hydroboration of alkenes with diborane, allowing 
the conversion of terminal olefins to alkyl boranes to proceed at room temperature.[4] The first 
hydroboration of an alkyne was reported in 1966. In a seminal publication, Woods and 
coworkers utilized borane 044 at high temperatures to access alkenylboronates 041 (Scheme 
1)[5]. By using the less hindered and therefore more reactive catecholborane 045 in ethereal 
solvents, Brown and coworkers were able to access a variety of catecholboronates 042.[6] In 
1992, Knochel reported the synthesis of pinacolborane 046, one of the most widely used 
boranes to date.[7] It was found that 046 readily reacts with terminal alkynes at temperatures as 
low as 0°C in non-ethereal solvents.[8] 
 
Scheme 1. Evolution of alkyne hydroborations. 
2.1.2. Mechanistic Considerations 
The mechanism of alkene hydroboration has been studied in detail by Brown and Pasto. 
Two possible pathways have been proposed. A dissociative pathway was mainly advocated by 
Brown on the basis of numerous kinetic studies.[9] An associative pathway is favored according 
to Pasto[10] and Schleyer[11]. Furthermore, some mechanistic insight has been gained by 
computational methods.[12]  
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From kinetic studies, Brown deduced that prior to association of the alkene, the Lewis base 
dissociates from the boron center (049). He found that excess Lewis-base present in the 
reaction medium effectively suppresses hydroboration. Upon coordination of the alkene, the 
crucial hydroboration takes place and the product alkane 050 is again complexed by the Lewis 
base (051).  
An alternative pathway has been put forward by Pasto and Schleyer who proposed an 
associative pathway in which the Lewis base is replaced in a SN2-like mode by the alkene (052). 
They argue that according to the Hammond postulate, the hydroboration proceeds through a 
very early transition state as the activation barrier is extremely low, involving very little 
rehybridization of the olefin carbons. In BH3·THF, the boron atom is sp3 hybridized which results 
in SN2-like displacement of THF over the course of the reaction by an overlap between the -
electron system of the olefin and the *-orbital on boron. As the reaction proceeds through a 
very early transition state, the displacement of THF would not have significant effect on the 
entropy of activation of the reaction. 
In contrast, very little is known about the mechanism of hydroboration of alkynes although 
analogous reactivity to alkenes has been proposed. 
 
Figure 1. Brown's dissociative pathway (blue) and Pasto's associative pasthway (red). 
2.1.3. State of the Art in Directed Hydroborations 
As the hydroboration of an unsymmetrical alkyne can give rise to two regioisomers, a 
plethora of studies has been conducted attempting to access both regioisomers in a highly 
selective fashion. The regiochemical outcome is predominantly influenced by the steric 
properties of the alkyne and the hydroborating agent, though electronic factors have also shown 
to influence regiochemistry. Such substrate control can be overridden by intramolecular 
delivery of the borane or by organometallic catalysis. The most commonly employed 
hydroborating agents are depicted in Figure 2. 
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Figure 2. Commonly employed borane sources. 
A selection of the most relevant examples of regioselective hydroboration is presented 
below to summarize the current state of the art. 
2.1.3.1. Uncatalyzed Regioselective Hydroboration of Alkynes and Alkenes 
Systematic studies have been conducted by Zweifel[13] and Brown[14] who treated a variety 
of methyl-capped alkynes with thexylborane (056) or 9-BBN (054), respectively, followed by an 
oxidative work-up (Table 1). A correlation between increased steric demand of the R-
substituent and enhanced selectivity towards the methyl ketone B was observed. For example, 
treating 2-hexyne (R=Pr) with ThxBH2 or 9-BBN results in low regioselectivity in both cases. 
Employing the same reagents for the hydroboration of bulkier neo-heptyne (R=tBu), the product 
is obtained with much enhanced regioselectivity. 
Table 1. Regioselective hydroboration of methyl-capped alkynes. 
 
 
 
 
 
 
 
Not only the steric bias of the alkyne has a tremendous impact on the regiochemical 
outcome, also the steric bulk of the hydroborating agent is of critical importance. Cha and 
coworkers reported that an alkoxyl alkylborane, formed on treatment of thexylborane (056) 
with one equivalent of an alcohol, delivers the methyl ketone in a far more selective fashion.[15] It 
R 
ThxBH2 
A : B 
9-BBN
A : B 
ThxBHOiPr
A : B 
ThxBHCl·SMe2 
A : B
Pr 39 : 61 22 : 78 39 : 61 2 : 98 
iPr 19 : 81 4 : 96 n.d. n.d. 
Cy 22 : 78 4 : 96 n.d. n.d. 
tBu 3 : 97 1 : 99 n.d. n.d. 
Ph 43 : 57 65 : 35 17 : 83 3 : 97 
Chapter 2 – Directed Hydroboration of Propargyl Alcohols 
 
14 
was found that by increasing the size of the alkoxide on the borane, the regioselectivity could be 
improved. Interestingly, despite its lower steric bulk, chloro thexylborane delivered the same 
product in an even more selective fashion which might be due to an increased electrophilicity of 
the boron center.[16] 
Intramolecular delivery of the hydroborating agent was first proposed by Zweifel and 
coworkers.[17] They found that by treating methoxy enynes 060 and 063 with 
dicyclohexylborane, the observed regioselectivity strongly depended on the olefin geometry 
(Scheme 2). Based on these results, coordination of the borane to the vinyl ether prior to 
hydroboration was proposed (064). It should be noted at this point that the double bond 
geometry of vinyl ethers 061 and 062 equilibrates under the basic oxidative work-up 
conditions. 
 
Scheme 2. Regioselective hydroboration of enynes by Zweifel and coworkers. 
This explanation has been questioned as similar models for alkene hydroboration failed to 
predict the observed regio- or stereochemical outcome. For example, Heathcock reported a 
diastereoselective hydroboration/oxidation sequence as part of a total synthesis (Scheme 3).[18] 
Although it seems tempting to deem an intramolecular borane delivery responsible for the 
observed outcome, the result can also be explained by considering Kishi’s model.[19] 
Furthermore, it was found that a minimum of two equivalents of borane was necessary to reach 
full conversion. An intermolecular hydroboration invoking a transition state in accordance to 
Kishi’s model correctly predicts the observed regio- and stereochemical outcome. 
 
Scheme 3. Intramolecular vs. intermolecular hydroboration. 
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Additional examples have been reported in the literature but no general model has been put 
forward. Furthermore, no reports on the intramolecular hydroboration of internal alkynes have 
been disclosed to date. 
Some examples of intramolecular hydroboration of alkenes can be found in recent work 
from the Vedejs group (Scheme 4).[20] After activation of BH3·SMe2 (070) with TfOH, a highly 
reactive hydroborating agent (071) is formed. Upon treatment of a variety of homoallyl alcohols 
with 071, the corresponding 1,3-diols 075 were obtained after oxidative work-up with near 
perfect regioselectivity, albeit in modest yields.  
 
Scheme 4. Intramolecular hydroboration of homoallyl alcohols. 
The intramolecular delivery was confirmed by conducting the reaction in the presence of 
five equivalents of cyclohexene. After oxidative work-up, no cyclohexanol was detected and the 
isolated yields were comparable to those obtained in the absence of cyclohexene. Besides 
homoallyl alcohols, homoallyl amines and phosphines can also serve as substrates in this 
transformation. Surprisingly though, no attempts were made to extend the scope towards the 
alkynyl counterparts.[21]  
2.1.3.2. Catalytic Regioselective Hydroboration of Alkynes and Alkenes 
The field of metal-catalyzed hydroboration of alkynes has received considerably more 
attention than its uncatalyzed ancestors. The results of these endeavors have been recently 
reviewed and a selection of the most illustrative examples will be given below.[8b, 8c, 22] One of the 
most prominent examples stems from the recent work of Tsuji and coworkers (Scheme 5).[23] 
They found that by treating protected propargyl and homopropargyl alcohols under copper 
catalysis in the presence of modified XantPhos ligands 082 and 083, a regiodiverse formal 
hydroboration can be accomplished. 
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Scheme 5. Regiodivergent formal hydroboration of alkynes by Tsuji and coworkers. 
The differences in regioselectivity of the two protocols can be attributed to the different 
copper species obtained during the catalytic cycle (Figure 3). When pinacol borane is employed, 
a copper hydride forms which undergoes a regioselective hydrocupration of the alkyne followed 
by a -bond metathesis to furnish -hydroborated products. If bis(pinacolato)diboron is 
utilized, a boryl copper species forms that undergoes borylcupration. In the presence of 
methanol, the resulting alkenyl copper species is protonated and the copper alkoxide re-enters 
the catalytic cycle.  
 
Figure 3. Proposed catalytic cycle of the copper-mediated regiodivergent hydroboration by Tsuji and coworkers. 
This has been confirmed by adding MeOD instead of MeOH to quench the alkenyl copper 
species. The observation that the copper resides after hydro- or borylcupration next to the 
alcohol functionality was not rationalized. It can only be speculated at this point if electronic or 
steric factors are accountable for the high regioselectivity.  
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Another very similar protocol has been disclosed by McQuade and coworkers who applied a 
copper-NHC complex to achieve good selectivity with protected propargyl alcohols.[24] The major 
drawback of that procedure lies in the necessity of using a p-nitrobenzene protecting group that 
can only be cleaved in two steps.  
An alternative approach has been reported by Shi and coworkers (Scheme 6).[25] By reacting 
sodium cyanoborohydride with propargyl amines, ammonium borohydrides were obtained. In 
the presence of a gold catalyst, these reagents underwent a highly endo-selective hydroboration 
to give aminoboranes 084 - 087 in good to excellent yield. Additionally, the group demonstrated 
the cleavage of the cyano group by treatment with lithium aluminumhydride or replacement 
with phenylmagnesium bromide. 
 
Scheme 6. Gold catalyzed endo-selective hydroboration by Shi and coworkers. 
Over the past decades, Suginome and coworkers disclosed significant contributions to the 
field of carboboration.[26] The underlying concept of tethering a reactive borane source to a 
(homo)propargyl alcohol is directly relevant to the development of our own methodology. An 
illustrative example is shown in Scheme 7.[27] Depending on the ligand employed, the group was 
able to obtain either the (E)- or (Z)-carboborated products, 090 or 091, respectively. The use of 
sterically demanding tricyclohexyl- or tris(t-butyl)phosphine favors the (E)-configured product 
while the less bulky trimethylphosphine favors the (Z)-carboborated product after cross-
coupling of the in situ formed alkenyl palladium 092 with vinyl zirconium species 089. 
 
Scheme 7. Stereodivergent carboboration of alkynes by Suginome and coworkers. 
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This outcome can be rationalized by steric repulsion between the bulky phosphine ligand 
on the palladium and the di-iso-propylamine substituent on the borane. The structure of the 
intermediate palladium species was confirmed by X-ray crystallography. 
2.1.4. (Alkyl)-Suzuki Miyaura Cross-coupling 
The Suzuki cross-coupling is unquestionably one of the most powerful transformations in 
organic chemistry and has been reviewed numerous times in both articles[28] and 
monographs[29]. Despite having been studied for more than a decade[30], the alkyl Suzuki cross-
coupling remains highly challenging. Only a limited number of protocols have been disclosed 
that employ alkyl halides as coupling partners. These include palladium[31], nickel[32], copper[33] 
and iron[34] catalyzed processes. As part of this project we were interested in developing a 
robust cross-coupling protocol that would allow us to combine any alkyl halide with an in situ 
formed alkenyl boronic acid. From the above mentioned protocols, only three seem to be 
applicable to our system as these employ alkenyl boronic acid derivatives (Scheme 8).  
 
Scheme 8. Palladium catalyzed alkyl Suzuki cross-coupling protocols. 
Especially challenging in this specific transformation is the suppression of -hydride 
elimination from the intermediate alkyl-palladium species. In their landmark publication, Fu and 
coworkers found that the sterically demanding di(t-butyl)methyl phosphine ligand performed 
exceptionally well.[31d] The barrier for -hydride elimination was even high enough to obtain a 
single-crystal X-ray structure of the intermediate alkyl-palladium species. It is believed, that the 
unparalleled mild reaction conditions i.e. anhydrous base and low temperatures in combination 
with an extremely fast oxidative addition, effectively suppress -hydride elimination. Only upon 
warming to >50°C does -hydride elimination become a major issue. Ensuing studies could not 
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improve upon the seminal conditions; however, it was found that aqueous bases and aprotic 
solvents can also be employed as demonstrated Itami[31a] and Nishihara.[31c] 
2.1.5. Motivation 
With the disclosure of the trans-selective ruthenium catalyzed hydroboration of alkynes, 
our group has reported a highly valuable tool for the stereoselective synthesis of trisubstituted 
olefins.[35] This transformation shows a broad functional group tolerance and delivers valuable 
building blocks for potential late-stage diversification in natural product synthesis. The major 
drawback though lies in the lack of regioselectivity. So far no protocol could be developed that 
overrides substrate control. To overcome this obstacle we sought to develop a method that 
exploits the possible directing effects of propargyl alcohols. The resulting alkenylboronates 
would then be amenable to the aforementioned alkyl Suzuki cross-coupling to give rise to 
trisubstituted allyl alcohols. As the resulting (Z)-but-2-en-1-ols constitute important motifs in 
natural products, this would enable us to access a plethora of biologically relevant products. A 
selection of possible targets is shown in Scheme 9 wherein the critical (Z)-but-2-en-1-ol motif is 
highlighted in red.[36] 
 
Scheme 9. Possible applications for directed hydroboration/Suzuki cross-coupling. 
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Besides their application in total synthesis, the alkenylboronates may also be useful 
synthons for the introduction of various functional groups as illustrated in Scheme 10. 
 
Scheme 10. Possible transformations of the resulting alkenylboronates. 
2.1.6. General Considerations and Rationale 
As emphasized in the previous discussion, the most promising way to affect regioselective 
hydroboration appears to tether a suitable borane source to the propargyl alcohol. For 
geometric reasons, the borane cannot be directly attached to the alcohol functionality as a four-
membered intermediate would have to form for intramolecular borane delivery. To increase the 
‘reach’ of the propargyl alcohol, an extending linker has to be attached first. This idea can either 
be realized by a transient hemilabile or covalently attached linker. The general concept is 
presented in Scheme 11. 
 
Scheme 11. General concept of hemilabile linker assisted hydroboration. 
Some inspiration has been taken from a report by Denmark and coworkers (Scheme 12).[37] 
By tethering disiloxane 110 to propargyl alcohol 109, followed by hydrosilylation and cross-
coupling, a ‘library’ of (E)- or (Z)-but-2-en-1-ols was accessed depending on the catalyst 
employed in the hydrosilylation.  
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Scheme 12. Three step sequence for the functionalization of propargyl alcohols by Denmark et al.. 
As the siloxane in 112 is cleaved under the cross-coupling conditions, no additional 
deprotection step is required. The major drawback though lies in the utilization of the rather 
limited Hiyama-Denmark coupling that predominantly employs activated electrophiles.[38] In our 
investigation, we also sought to employ a hemilabile linker which can be installed and cleaved 
during the hydroboration/cross-coupling event. With that requirement in mind, we were mainly 
interested in reactive carbonyl derivatives that can form hemiacetals, imides or carbonates in 
situ. It was expected that under the strongly basic conditions of the ensuing Suzuki cross-
coupling, this hemilabile linker can effectively be cleaved such that no additional steps are added 
to the hydroboration/Suzuki cross-coupling sequence. 
2.2. Results and Discussion 
2.2.1. Reaction Development 
At the outset of this endeavor, a suitable linker and borane source had to be identified. As 
one of the hydrides on the borane has to react with the linker and the other one with the alkyne, 
we had to focus on monoalkyl boranes. Furthermore, it was expected from the works of Cha and 
coworkers[15] that thexyl alkoxyboranes are suitable hydroborating agents for alkynes. 
Therefore, we initiated the study with thexylborane as the hydroborating agent. Thexylborane 
(056) can conveniently be prepared as a stock solution in THF by mixing BH3·THF and 2,3-
dimethylbutene (Scheme 13).[39] The resulting solution can be stored for prolonged periods in 
the fridge under an argon atmosphere without noticeable loss of activity.  
 
Scheme 13. Preparation of thexylborane. 
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In solution, 056 exists as a mixture of its dimer 114 and THF-stabilized monomer. Because 
of the steric bulk, only the monoalkyborane is formed. The concentration of the obtained stock 
solution was determined by titration of an aliquot with EtOH/H2O with a gas burette under ice 
cooling. Other boranes were also tested during the development of this protocol and prepared in 
a similar way. The choice of the linker proved to be more difficult. A screening was initiated in 
which the resulting alkenyl borane was first oxidized with trimethylamine-N-oxide (TMAO)[40] 
and the resulting borinate trapped as the neopentyl boronate as exemplified in Scheme 14. 
 
Scheme 14. Development of a directed hydroboration protocol. 
Prior to addition of 056, the free propargyl alcohol was allowed to react with 
trichloroacetonitrile[41], p-toluenesulfonyl isocyanate[42], p-nitrobenzaldehyde or methyl 
trifluoropyruvate[43] to yield the corresponding linkages in situ. Thexylborane (056) was then 
added at 78 °C. After warming to room temperature, oxidative work-up, and trapping, 
alkenylboronate 118 was obtained. The results are presented in Table 2 and the linkers 
employed are given in Figure 4. 
 
Figure 4. Linkers employed in the directed hydroboration with ThxBH2. 
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Table 2. Optimization of directed hydroboration of propargyl alcohols with ThxBH2. 
 
ain THF; bdetermined by crude NMR 
 
 
 
Entry Linker Temp. Additive Conc.a  : b comment 
1 - 78 °C to r.t. - 0.5 M 1.5 : 1 
full 
conversion 
2 A 78 °C to r.t. - 0.5 M - 
no vinyl 
species 
3 B 78 °C to r.t. - 0.5 M - 
no vinyl 
species 
4 C r.t. - 0.5 M - 
no 
hemiacetal 
formation 
5 D 78 °C to r.t - 0.5 M/0.1 M 4.0 : 1 
full 
conversion 
6 D 25 °C to r.t - 0.5 M/0.1 M 3.5 : 1 
full 
conversion 
7 D r.t. - 0.1 M 2.5 : 1 
full 
conversion 
8 D 25 °C to r.t Pentane 0.1 M 3.5 : 1 
full 
conversion 
9 D 25 °C to r.t CH2Cl2 0.1 M 3.5 : 1 
full 
conversion 
10 D 25 °C to r.t PhMe 0.1 M 3.5 : 1 
full 
conversion 
11 D 78 °C to r.t 1 eq. Me2S 0.1 M 2.0 : 1 
full 
conversion 
12 D 78 °C to r.t 1 eq. Ph3P 0.1 M 1.5 : 1 
full 
conversion 
13 D 78 °C to r.t 1 eq. Et3N 0.1 M 1.0 : 2 
low 
conversion 
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The results in Table 2 demonstrate the low inherent selectivity for the site of hydroboration 
of the propargyl alcohol (entry 1). Interestingly, linkers A, B and C failed to deliver any product 
at all (entries 2-4). Only hemiacetal D (entry 5) provided the product and, as anticipated, gave an 
improved /-ratio compared to the parent propargyl alcohol. Unfortunately though, attempts 
to improve regioselectivity by changing temperature, solvent or concentration were all met with 
failure (entries 6-10). Adding common Lewis bases like Me2S, PPh3 or Et3N only led to a 
deterioration or even reversal of regioselectivity (entries 11-13). 
To test our hypothesis that a cyclic boroxinane is formed as an intermediate, the different 
stages of this transformation were followed by NMR (Scheme 15). As expected, the electronic 
nature of the alkyne changes significantly upon hemiacetal formation: the -carbon experiences 
a downfield shift of 2.0 ppm while the -carbon is shifted upfield by 4.4 ppm (120). This can be 
attributed to the strong negative inductive effect of the hemiacetal. After ThxBH2 addition, a new 
boron species is observed as is evident from the boron downfield shift from 23.3 ppm 
(thexylborane) to 42.2 ppm. This signal corresponds to a RR’BOR’’ species which is in good 
accordance with our proposed dioxaborinane intermediate 122.[44] Furthermore, a splitting of 
the two protons at C1 of the allylic alcohol is observed which advocates the formation of cyclic 
intermediate. Additionally, one of these protons experiences a downfield shift of 0.3 ppm. After 
oxidative work-up and trapping with pinacol, a new alkenylboron species (124) is formed that is 
well precedented in the literature.[45] Based on this study we felt confident that a boroxinane is 
formed during the course of the reaction, and that the intermediate hemiacetal should play a 
major role in dictating the regiochemical outcome. 
 
Scheme 15. NMR study of pyruvate directed hydroboration. 
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2.2.2. Initial Substrate Scope 
With the optimized conditions in hand, we sought to determine the scope of the reaction. In 
some cases the corresponding pinacol boronates were isolated as shown in Scheme 16. The 
isolated yields correspond to pure products. In general it was possible to separate both 
regioisomers on silica. 
 
 
Scheme 16. Directed hydroboration and pinacol boronate formation. 
The in situ formed alkenyl boronic acids were also coupled under standard Suzuki 
conditions with either aryl or vinyl halides. After a brief screening, (dppf)PdCl2 in the presence 
of aqueous 3 M KOH proved optimal and provided the desired product in reliably moderate to 
good yield. Generally, the Suzuki cross-coupling showed full conversion in less than 1 h at 60 °C. 
The results are presented in Scheme 17. The crude regiochemical outcome was determined by 
NMR analysis but the yields shown correspond to pure isolated -products.  
As is evident from Scheme 17, primary alcohols furnish the corresponding products in much 
higher yield compared to their secondary counterparts (compare 130 to 134). A variety of 
functional groups is tolerated including acetals (139), halides (138), silyl ethers (135), esters 
(143) and internal olefins (145). Aryl iodides and vinyl bromides couple equally well, e.g. 130 
and 149.  
Besides demonstrating an impressive substrate scope, these results raise an important 
question: why do primary alcohols provide higher yields and regioselectivities than secondary 
ones? This seems counter-intuitive to our initial hypothesis since one would expect that an 
increasing Thorpe-Ingold effect in secondary alcohols should lead to an increase in 
regioselectivity.  
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Scheme 17. Substrate scope of the directed hydroboration/Suzuki cross-coupling sequence (*yields refer to pure ). 
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2.2.3. Mechanistic investigation 
Although it seems reasonable to propose a reaction of the borane with the hemiacetal prior 
to hydroboration, the experiments conducted to this point do not provide sufficient evidence to 
support or refute this hypothesis. Our mechanistic investigation thus sought to answer three 
major questions: 1) what is the order of events? 2) what determines the regiochemical outcome? 
3) how is the other regioisomer formed? 
At first, a study was conducted aiming at answering the question how the hemiacetal linker 
influences the regioselectivity of the hydroboration (Table 3). Therefore, derivatives of both the 
linker and the borane were prepared and exposed to the reaction conditions to gain insight into 
the actual mechanism.  
Table 3. Determination of reaction pathway: intramolecular vs. intermolecular. 
 
 
The first two entries are added for clarity and reflect the standard conditions with and 
without the pyruvate linker. Entries 3 and 4 show that the regioselectivity is independent of the 
Entry R Borane conditions 
NMR ratio 
 :  
HPLC ratio 
 :  
comment 
1  
 
78 °C to r.t. 2.3 : 1 2.0 : 1 - 
2 
  
78 °C to r.t. 4.5 : 1 4.0 : 1 - 
3 
  
60 °C, 18 h 4.3 : 1 3.7 : 1 - 
4 
  
40 °C, 18 h 4.4 : 1 4.5 : 1 70% yield 
5 
  
78 °C to r.t. 
no 
hydroboration 
no 
hydroboration 
- 
6 
  
78 °C to r.t. - 2.2 : 1 
34% 
conversion 
after 18 h 
7 
  
78 °C to r.t. - - 
very low 
conversion 
8 
  
78 °C to r.t. - - 
very low 
conversion 
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reaction temperature and indicate that the regioselectivity is possibly dictated by the inherent 
reactivity of the propargyl alcohol. When 9-BBN is used instead of thexylborane, no 
hydroboration takes places (entry 5). As the reactivity of 9-BBN is similar to that of 
thexylborane, this result indicates that the reaction of the borane source with the hemiacetal is 
faster than with the alkyne. If the hydroxy group on the hemiacetal is replaced by a chloride to 
prevent tethering (entry 6) very low conversion is observed with low regioselectivity. This 
indicates that it is almost certainly not thexylborane itself that reacts intermolecularly with the 
alkyne moiety, as the observed selectivity is identical to the outcome of the control experiment 
(entry 1). Interestingly, when chloro thexylborane or methoxy thexylborane are employed, no 
conversion is observed. As these two boranes resemble the electronic nature of the presumably 
in situ formed tethered alkoxy thexylborane, it seems likely that the actual hydroborating agent 
is a tethered alkoxyborane. To probe the influence of the electronic nature of the alkyne, 1-
hexynol was compared to trifluorobutynol both with and without the pyruvate linker by NMR 
spectroscopy (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 : 1 
4 : 1 
1 : 3 
1 : 2 
C3 C2 
C3 

C2 

C2 

C3 

C3C2 

 
Figure 5. NMR spectra of 1-hexynol and trifluorobutynol with and without pyruvate linker (13C{1H} in CDCl3@298K). 
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By comparing the first two spectra it is evident that attaching the linker to the propargyl 
alcohol results in an increased electron density on C2 and a decrease on C3 due to their up- and 
downfield shifts, respectively. This is reflected by an increased (C2-C3) from 8.1 ppm to 
14.5 ppm. In the case of trifluorobutynol this trend is reversed, as C3 is more deshielded than C2. 
By attaching the pyruvate linker, (C3-C2) decreases from 12.5 ppm to 7.8 ppm reflecting a 
shift of electron density towards the alcohol carbon. A schematic representation is given in 
Figure 6. The charges qualitatively represent the relative electron density at each carbon atom. 
 
Figure 6. Effect of pyruvate linker to electronic structure of alkyne. 
Based on the results of this study, it seems reasonable to propose that the borane adds 
across the alkyne such that the boron preferentially ends up at the carbon atom of highest electron 
density. In the first case the electron density is increased at C2 by linking an electron 
withdrawing substituent to the alcohol. Therefore, the regioselectivity increases from 2:1 to 4:1. 
In trifluorobutynol, the inherent polarity of the alkyne is reversed compared to hexynol. Here C3 
is the most electron-rich carbon. By attaching the pyruvate linker to the alcohol, the polarity is 
reduced and as a result the observed regioselectivity decreases from 1:3 to 1:2.  
These results are counterintuitive as one would expect that the hydroboration would 
simply follow Markovnikov rules. During this process a formal positive charge next to the borane 
is generated which is best stabilized at the position of highest electron density. This would result 
in the opposite regiochemical outcome. Based on these observations, a possible mechanism is 
proposed. 
In the first step, hemiacetal 150 attacks the Lewis base adduct of thexylborane and 
displaces the Lewis base, in most cases THF. The newly formed adduct 151 then directs the 
borane across the alkyne to form transient intermediate 152. This can be understood as a 3c-2e 
system. According to the observations made by the NMR experiments, the triangular complex is 
distorted towards the -carbon as this carries the higher electron density. From this adduct, two 
possible pathways are conceivable. If the borane transfers one of its hydrides to the -position 
then the unwanted regioisomer 155 is formed. If the hydride is transferred to the -position, 
then the resulting borane can react with the hemiacetal to extrude hydrogen via -bond 
Chapter 2 – Directed Hydroboration of Propargyl Alcohols 
 
30 
metathesis to give adduct 153. This would finally yield boroxinane 154 as the predominant 
product. 
 
Scheme 18. Proposed mechanistic rational for the directed intramolecular hydroboration of alkynes. 
This proposal is in good agreement with the observations made in the NMR and 
regioselectivity studies: 
1) Extraneous Lewis bases slow down and decrease the selectivity of the reaction (Table 2) as 
they compete with the hemiacetal for binding the borane in the pre-equilibrium. 
2) If this reaction would yield a thermodynamic and a kinetic product, then a temperature 
dependence of the regioselectivity would be expected. As the regioselectivity is independent of 
the temperature (Table 3 entries 2-4), the outcome is solely dictated by the inherent selectivity 
of the substrate. This control can be conclusively explained considering an intramolecular 
pathway. 
3) The complexation of the borane precedes the actual hydroboration event as for geometric 
reasons (Baldwin rules and ring-strain) the unwanted -isomer can only be formed before 
boron-oxygen bond formation (Table 3, entries 5-8). 
 
Figure 7. 6-exo-hydroboration vs. 7-endo-hydroboration. 
4) The regioselectivity is determined by the electronic and steric environment of the propargyl 
hemiacetal (Scheme 17, Figure 5). This explains why secondary propargyl alcohols provide 
products with lower regioselectivity, as the electronic bias is overridden by steric repulsion of 
the bulky borane and the alcohol substituent. 
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Our mechanistic proposal closely resembles the hypothesis of Vedejs and coworkers for the 
intramolecular hydroboration of alkenes. Their general concept is again shown in Scheme 19. It 
is proposed that the activated borane species 071 first forms a Lewis pair adduct 072 with the 
homoallyl alcohol on displacement of Me2S. In the next step the alkene extrudes a leaving group 
on the borane to give adduct 073. This complex can then undergo the crucial hydroboration 
furnishing borane 074. Upon reaction with the previously displaced leaving group, the resulting 
oxaborolane expels hydrogen and forms borinane 075. 
 
Scheme 19. Directed intramolecular hydroboration of alkenes according to Vedejs[20c]. 
Having established a protocol for the directed hydroboration/Suzuki cross-coupling and 
conducted a mechanistic investigation, we pursued to extend the substrate scope further. 
2.2.4. Extended Substrate Scope and Development of an Alkyl Suzuki Coupling Protocol 
As proposed in Section 2.2.3, the hemiacetal linker only serves as an anchor for 
thexylborane to direct the borane towards the alkyne. In principle, other alkynols could also 
serve as good substrates for the directed intramolecular hydroboration. Indeed, since 
homopropargyl alcohols may be able to form 5-membered boroxinane intermediates, the 
hemiacetal linker may even be unnecessary for these substrates. As can be seen from Scheme 20, 
the results are disappointing, giving low regioselectivities and moderate isolated yields. 
Interestingly though, a trend can be deduced whereby an increase in the Thorpe-Ingold effect 
results in an increase in regioselectivity (156 to 158).  
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Scheme 20. Substrate scope of the directed hydroboration/Suzuki cross-coupling sequence (*yields refer to pure ). 
Employing terminal alkynols and trapping the resulting hydroboration products as their 
respective trifluoroborate salt to assist their purification, a variety of alkenyl borates was 
obtained (Scheme 21). 
 
 
Scheme 21. Trifluoroborate salts obtained after hydroboration/oxidation. 
The hydroboration showed perfect selectivity for the terminal alkenyl borate irrespective of 
the length of the tether. Furthermore, the reaction can be conducted with equimolar amounts of 
alkynol and thexylborane and provides in one-pot the trifluoroborate from the alkynol. Other 
protocols found in the literature employ more than two equivalents of a borane and require  a 
chromatographic work-up before trifluoroborate formation.[46] The present protocol is therefore 
a major advance for the synthesis of these versatile building blocks.  
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As mentioned in the introduction, for complex molecule synthesis an alkyl Suzuki cross-
coupling protocol is of great interest as the resulting (Z)-but-2-en-1-ol motif is prominently 
featured in natural products. To this end an efficient cross-coupling protocol was developed 
(Scheme 22). 
 
Scheme 22. Optimization of alkyl Suzuki cross-coupling. 
 
After considerable optimization, we were able to identify conditions that allowed us to 
accomplish the synthesis of trialkylsubstituted olefin 167 in 61% yield in a single 
transformation. No intermediate purification was necessary and the (precious) alkynol could be 
utilized as the limiting reaction partner. As reported by Fu and coworkers, (tBu)2MeP proved to 
be the ligand of choice. Palladium acetate was identified as the optimal pre-catalyst in 
conjunction with aqueous potassium hydroxide as base. Furthermore, high concentrations are 
essential to obtain appreciable conversion. 
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Finally, the hydroboration/Suzuki cross-coupling protocol was extended to alkynyl Suzuki 
coupling with iodopropyne (Scheme 23).  
 
Scheme 23. Enyne formation via directed hydroboration/alkynyl Suzuki cross-coupling (J. Preindl). 
In the model system with 1-hexyne, enyne (168) was obtained in 67% yield, whereas more 
elaborate fragments could be synthesized in 57% (syn-169) and 53% (anti-170), respectively. 
To demonstrate the feasibility of this new directed hydroboration/Suzuki cross-coupling 
protocol, this transformation was implemented into a total synthesis project directed towards 
the synthesis of putative orevactaene (Scheme 24).[47] The crucial (Z)-but-2-en-1-ol motif is 
again highlighted in red. This application constitutes also one of the rare examples of an alkynyl 
Suzuki cross-coupling employing alkenylboronates as the coupling partners.[48] 
 
Scheme 24. Retrosynthetic analysis of orevactaene (J. Preindl). 
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2.3. Conclusion and Outlook 
In summary, we have developed a useful protocol for the transformation of 
(homo)propargyl alcohols to trisubstituted olefins via a directed hydroboration/Suzuki cross-
coupling sequence. The directing effect of the pyruvate linker was studied in detail and 
determined to be primarily electronic in nature. Additionally, a practical alkyl Suzuki cross-
coupling protocol was established which is highly relevant for natural product synthesis. 
Furthermore, we were able to access a variety of terminal vinyl trifluoroborates in a one-pot 
sequence which tolerates the presence of protic functional groups. Finally, an alkynyl Suzuki 
cross-coupling served as one of the cornerstones in the total synthesis of putative orevactaene. 
The results presented in this chapter are summarized in Scheme 25. 
 
Scheme 25. Summary of products obtained via directed hydroboration. 
2.4. Literature 
[1] D. T. Hurd, J. Am. Chem. Soc. 1948, 70, 2053-2055. 
[2] A. T. Whatley, R. N. Pease, J. Am. Chem. Soc. 1954, 76, 835-838. 
[3] H. C. Brown, J. Chandrasekharan, K. K. Wang, Pure Appl. Chem. 1983, 55, 1387-1414. 
[4] a) H. C. Brown, B. C. S. Rao, J. Am. Chem. Soc. 1959, 81, 6423-6428; b) H. C. Brown, B. C. S. 
Rao, J. Am. Chem. Soc. 1956, 78, 2582-2588. 
[5] W. G. Woods, P. L. Strong, J. Am. Chem. Soc. 1966, 88, 4667-4671. 
[6] a) H. C. Brown, S. K. Gupta, J. Am. Chem. Soc. 1972, 94, 4370-4371; b) H. C. Brown, S. K. 
Gupta, J. Am. Chem. Soc. 1971, 93, 1816-1818. 
Chapter 2 – Directed Hydroboration of Propargyl Alcohols 
 
36 
[7] C. E. Tucker, J. Davidson, P. Knochel, J. Org. Chem. 1992, 57, 3482-3485. 
[8] a) B. M. Trost, Z. T. Ball, Synthesis 2005, 2005, 853-887; b) I. Beletskaya, A. Pelter, 
Tetrahedron 1997, 53, 4957-5026; c) R. Barbeyron, E. Benedetti, J. Cossy, J.-J. Vasseur, S. 
Arseniyadis, M. Smietana, Tetrahedron 2014, 70, 8431-8452. 
[9] a) K. K. Wang, C. G. Scouten, H. C. Brown, J. Am. Chem. Soc. 1982, 104, 531-536; b) K. K. 
Wang, H. C. Brown, J. Am. Chem. Soc. 1982, 104, 7148-7155; c) K. K. Wang, H. C. Brown, J. 
Org. Chem. 1980, 45, 5303-5306; d) J. Chandrasekharan, H. C. Brown, J. Org. Chem. 1985, 
50, 518-520; e) H. C. Brown, C. G. Scouten, K. K. Wang, J. Org. Chem. 1979, 44, 2589-2591; 
f) H. C. Brown, J. Chandrasekharan, J. Am. Chem. Soc. 1984, 106, 1863-1865. 
[10] a) D. J. Pasto, B. Lepeska, T. C. Cheng, J. Am. Chem. Soc. 1972, 94, 6083-6090; b) D. J. Pasto, 
B. Lepeska, V. Balasubramaniyan, J. Am. Chem. Soc. 1972, 94, 6090-6096. 
[11] a) N. J. R. Van Eikema Hommes, P. v. R. Schleyer, J. Org. Chem. 1991, 56, 4074-4076; b) T. 
Clark, D. Wilhelm, P. von Rague Schleyer, J. Chem. Soc., Chem. Comm. 1983, 606-608. 
[12] a) X. Wang, Y. Li, Y. D. Wu, M. N. Paddon-Row, N. G. Rondan, K. N. Houk, J. Org. Chem. 
1990, 55, 2601-2609; b) M. DiMare, J. Org. Chem. 1996, 61, 8378-8385. 
[13] G. Zweifel, G. M. Clark, N. L. Polston, J. Am. Chem. Soc. 1971, 93, 3395-3399. 
[14] H. C. Brown, C. G. Scouten, R. Liotta, J. Am. Chem. Soc. 1979, 101, 96-99. 
[15] J. S. Cha, W. W. Seo, J. M. Kim, O. O. Kwon, Bull. Kor. Chem. Soc. 1996, 17, 892-899. 
[16] H. C. Brown, N. Ravindran, J. Am. Chem. Soc. 1976, 98, 1785-1798. 
[17] G. Zweifel, M. R. Najafi, S. Rajagopalan, Tetrahedron Lett. 1988, 29, 1895-1897. 
[18] C. H. Heathcock, E. T. Jarvi, T. Rosen, Tetrahedron Lett. 1984, 25, 243-246. 
[19] G. Schmid, T. Fukuyama, K. Akasaka, Y. Kishi, J. Am. Chem. Soc. 1979, 101, 259-260. 
[20] a) G. Wang, E. Vedejs, Org. Lett. 2009, 11, 1059-1061; b) M. Scheideman, G. Wang, E. 
Vedejs, J. Am. Chem. Soc. 2008, 130, 8669-8676; c) R.-A. F. Rarig, M. Scheideman, E. 
Vedejs, J. Am. Chem. Soc. 2008, 130, 9182-9183. 
[21] R.-A. F. Rarig, PhD thesis, The University of Michigan 2010. 
[22] a) M. Zaidlewicz, A. Wolan, M. Budny, in Comprehensive Organic Synthesis II Elsevier, 
Amsterdam, 2014; b) D. G. Hall, Boronic Acids: Preparation and Applications in Organic 
Synthesis, Medicine and Materials (Volume 1 and 2), Second Edition, 2011. 
[23] K. Semba, T. Fujihara, J. Terao, Y. Tsuji, Chem. Eur. J. 2012, 18, 4179-4184. 
[24] J. K. Park, B. A. Ondrusek, D. T. McQuade, Org. Lett. 2012, 14, 4790-4793. 
[25] Q. Wang, S. E. Motika, N. G. Akhmedov, J. L. Petersen, X. Shi, Angew. Chem. 2014, 126, 
5522-5526. 
[26] M. Suginome, Chem. Rec. 2010, 10, 348-358. 
[27] M. Daini, A. Yamamoto, M. Suginome, J. Am. Chem. Soc. 2008, 130, 2918-2919. 
[28] a) N. Miyaura, A. Suzuki, Chem. Rev. 1995, 95, 2457-2483; b) R. Martin, S. L. Buchwald, 
Acc. Chem. Res. 2008, 41, 1461-1473; c) C. C. C. Johansson Seechurn, M. O. Kitching, T. J. 
Chapter 2 – Directed Hydroboration of Propargyl Alcohols 
37 
Colacot, V. Snieckus, Angew. Chem. Int. Ed. 2012, 51, 5062-5085; d) F.-S. Han, Chem. Soc. 
Rev. 2013, 42, 5270-5298; e) A. Suzuki, Angew. Chem. Int. Ed. 2011, 50, 6722-6737. 
[29] a) A. Molnar, Palladium-Catalyzed Coupling Reactions, 2013; b) T. J. Colacot, New Trends 
in Cross-Coupling, Theory and Applications, 2016; c) E.-i. Negishi, Handbook of 
Organopalladium Chemistry for Organic Synthesis, 2002. 
[30] N. Miyaura, K. Yamada, A. Suzuki, Tetrahedron Lett. 1979, 20, 3437-3440. 
[31] a) K. Tonogaki, K. Soga, K. Itami, J.-i. Yoshida, Synlett 2005, 2005, 1802-1804; b) G.-R. 
Peh, E. A. B. Kantchev, J.-C. Er, J. Y. Ying, Chem. Eur. J. 2010, 16, 4010-4017; c) Y. 
Nishihara, Y. Okada, J. Jiao, M. Suetsugu, M.-T. Lan, M. Kinoshita, M. Iwasaki, K. Takagi, 
Angew. Chem. Int. Ed. 2011, 50, 8660-8664; d) J. H. Kirchhoff, M. R. Netherton, I. D. Hills, 
G. C. Fu, J. Am. Chem. Soc. 2002, 124, 13662-13663; e) T. Brenstrum, D. A. Gerristma, G. M. 
Adjabeng, C. S. Frampton, J. Britten, A. J. Robertson, J. McNulty, A. Capretta, J. Org. Chem. 
2004, 69, 7635-7639. 
[32] a) G. A. Molander, O. A. Argintaru, I. Aron, S. D. Dreher, Org. Lett. 2010, 12, 5783-5785; b) 
G. A. Molander, O. A. Argintaru, Org. Lett. 2014, 16, 1904-1907; c) F. González-Bobes, G. C. 
Fu, J. Am. Chem. Soc. 2006, 128, 5360-5361; d) T. Di Franco, N. Boutin, X. Hu, Synthesis 
2013, 45, 2949-2958. 
[33] a) C.-T. Yang, Z.-Q. Zhang, Y.-C. Liu, L. Liu, Angew. Chem. Int. Ed. 2011, 50, 3904-3907; b) 
Y.-Y. Sun, J. Yi, X. Lu, Z.-Q. Zhang, B. Xiao, Y. Fu, Chem. Comm. 2014, 50, 11060-11062. 
[34] a) T. Hatakeyama, T. Hashimoto, Y. Kondo, Y. Fujiwara, H. Seike, H. Takaya, Y. Tamada, T. 
Ono, M. Nakamura, J. Am. Chem. Soc. 2010, 132, 10674-10676; b) R. B. Bedford, P. B. 
Brenner, E. Carter, T. W. Carvell, P. M. Cogswell, T. Gallagher, J. N. Harvey, D. M. Murphy, 
E. C. Neeve, J. Nunn, D. R. Pye, Chem. Eur. J. 2014, 20, 7935-7938. 
[35] B. Sundararaju, A. Fürstner, Angew. Chem. Int. Ed. 2013, 52, 14050-14054. 
[36] a) C. Zhang, J. Li, J. Su, Y. Liang, X. Yang, K. Zheng, L. Zeng, J. Nat. Prod. 2006, 69, 1476-
1480; b) M. Tsuda, H. Shigemori, M. Ishibashi, T. Sasaki, J. Kobayashi, J. Org. Chem. 1992, 
57, 3503-3507; c) S.-Y. Cheng, Z.-H. Wen, S.-F. Chiou, C.-H. Hsu, S.-K. Wang, C.-F. Dai, M. Y. 
Chiang, C.-Y. Duh, Tetrahedron 2008, 64, 9698-9704; d) E. Cartagena, A. Bardón, C. A. N. 
Catalán, Z. N. J. de Hernández, L. R. Hernández, P. Joseph-Nathan, J. Nat. Prod. 2000, 63, 
1323-1328. 
[37] S. E. Denmark, W. Pan, Org. Lett. 2003, 5, 1119-1122. 
[38] Y. Nakao, T. Hiyama, Chem. Soc. Rev. 2011, 40, 4893-4901. 
[39] E.-i. Negishi, H. C. Brown, Synthesis 1974, 1974, 77-89. 
[40] a) R. Köster, Y. Morita, Justus Liebigs Annalen der Chemie 1967, 704, 70-90; b) G. W. 
Kabalka, J. Organomet. Chem. 1977, 125, 273-280. 
[41] V. H. L. Wong, T. S. A. Hor, K. K. Hii, Chem. Comm. 2013, 49, 9272-9274. 
Chapter 2 – Directed Hydroboration of Propargyl Alcohols 
 
38 
[42] S. K. Alamsetti, A. K. Å. Persson, T. Jiang, J.-E. Bäckvall, Angew. Chem. Int. Ed. 2013, 52, 
13745-13750. 
[43] G.-q. Shi, W.-l. Cai, J. Org. Chem. 1995, 60, 6289-6295. 
[44] a) J. A. Soderquist, J. Ramos, K. Matos, Tetrahedron Lett. 1997, 38, 6639-6642; b) H. C. 
Brown, M. Srebnik, T. E. Cole, Organometallics 1986, 5, 2300-2303. 
[45] H. Li, P. J. Carroll, P. J. Walsh, J. Am. Chem. Soc. 2008, 130, 3521-3531. 
[46] G. A. Molander, D. E. Petrillo, J. Am. Chem. Soc. 2006, 128, 9634-9635. 
[47] J. Preindl, PhD thesis, TU Dortmund 2016. 
[48] a) H. Masayuki, M. Yuzuru, N. Yutaka, A. Akira, Chem. Lett. 1984, 13, 1029-1032; b) M. 
Hoshi, Y. Masuda, A. Arase, Bull. Chem. Soc. Jpn. 1985, 58, 1683-1689; c) I. Rivera, J. A. 
Soderquist, Tetrahedron Lett. 1991, 32, 2311-2314; d) T. Ishiyama, M. Yamamoto, N. 
Miyaura, Chem. Lett. 1996, 25, 1117-1118; e) J. Gerard, L. Hevesi, Tetrahedron 2004, 60, 
367-381; f) R. P. Murelli, A. K. Cheung, M. L. Snapper, J. Org. Chem. 2007, 72, 1545-1552; 
g) Y. Sasaki, Y. Horita, C. Zhong, M. Sawamura, H. Ito, Angew. Chem. Int. Ed. 2011, 50, 
2778-2782; h) H.-Y. Bin, X. Wei, J. Zi, Y.-J. Zuo, T.-C. Wang, C.-M. Zhong, ACS Catal. 2015, 5, 
6670-6679. 
 
Chapter 3 - Carbonylation of Alkenylstannanes 
39 
3. Hydroxyl-Assisted Carbonylation of Alkenyltin Derivatives: 
Development and Application to a Formal Synthesis of 
Tubelactomicin A 
3.1. Introduction 
3.1.1. Palladium Catalyzed Carbonylation Reactions of Aryl and Vinyl Halides 
The conversion of aryl or vinyl (pseudo)halides to carbonyl derivatives in the presence of 
carbon monoxide represents an important transformation in organic synthesis.[1] In 1974, Heck 
and coworkers described the palladium catalyzed conversion of aryl and vinyl halides to the 
corresponding esters under atmospheric pressure of carbon monoxide.[2] Since this landmark 
discovery, reaction optimization has led to the development of protocols utilizing essentially 
stoichiometric amounts of carbon monoxide at moderate temperatures.[3] Furthermore, the 
intermediate acyl palladium species can be trapped with a variety of different reaction partners 
including alcohols, amines, silanes or carbon nucleophiles (Scheme 1).[4]  
 
Scheme 1. General carbonylative coupling of organic halides. 
In their initial disclosure, Heck and coworkers proposed a mechanistic rationale that has 
not been significantly altered over the past decades (Figure 1). The first step comprises the 
oxidative insertion of palladium(0) into the carbon (pseudo)halide bond of 190 (step I). In the 
presence of carbon monoxide a migratory insertion takes place forming acyl palladium species 
192 (step II). Transmetalation (step III) with the nucleophile occurs with extrusion of M-X, 
wherein M can be hydrogen or a metalloid. Adduct 193 undergoes reductive elimination (step 
IV) furnishing product 194 while reforming the catalyst to close the catalytic cycle.  
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Figure 1. Catalytic cycle of the palladium catalyzed carbonylation of organic halides. 
Key to success of this chemistry is the orchestration of the order of events, as migratory 
insertion of carbon monoxide has to precede transmetalation. Fascinating extensions of this 
chemistry have been reported over the past years. Carbonylative Heck cyclizations undoubtedly 
constitute a highlight. This chemistry has been reviewed by Negishi and coworkers and 
systematically ordered by the type of events taking place.[5] One of the most striking examples is 
the cyclization of pentayne 195 with formation of a lactone (196) in the terminating event 
(Scheme 2).[6] 
 
Scheme 2. Heck cyclization/carbonylation cascade by Negishi and coworkers. 
The synthesis of the required alkenyl halides can be cumbersome, although being for most 
purposes an attractive solution.[7] As most alkenyl halides are formed by metal-halide exchange, 
an oxidative coupling of the corresponding metal species offers a striking shortcut.  
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3.1.2. Palladium Catalyzed Oxidative Cross-Coupling 
The field of oxidative cross-coupling has received substantial attention over the past years. 
Despite this fact, it can still be considered of being in its infancy as most of the protocols suffer 
from severe selectivity issues.[8] In this transformation, two nucleophilic reaction partners 
undergo cross-coupling in the presence of an extraneous oxidant (XY) (Figure 2). 
 
Figure 2. Catalytic cycle in the palladium catalyzed oxidative cross-coupling. 
At the outset of the reaction, and similar to the traditional cross-couplings, an oxidative 
addition takes place to yield 197 (step I). In contrast though, XY does not represent a coupling 
partner and therefore both of the residues are not transferred over the course of the reaction. 
The obtained palladium(II) species 197 undergoes transmetalation with the first nucleophile 
198 to give 199 (step II). A second transmetalation event (step III) with 200 follows to furnish 
201. The palladium(0) precatalyst is restored after product formation (202) via reductive 
elimination (step IV). 
As mentioned earlier, homocoupling constitutes the central issue and some strategies have 
been developed to overcome this obstacle. The easiest solution lies in the utilization of an excess 
of the less reactive coupling partner thereby facilitating the quench of intermediate 199. 
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This approach has been exploited for example in the cross-coupling between two Grignard 
reagents (Scheme 3).[9] Alternatively, by fine-tuning the coupling partners and the catalytic 
system, selective cross-couplings are also possible as demonstrated by Lei and coworkers.[10] By 
employing alkynyl stannanes and alkyl zinc reagents in the presence of desyl chloride as the 
oxidant, a highly chemoselective coupling was achieved. 
 
Scheme 3. Representative examples of oxidative cross-couplings. 
Recent solutions also include the in situ formation of one of the reaction partners by C-H 
activation. Ensuing cross-coupling with boronic acids provides access to a variety of interesting 
motifs.[11] Boronic acid derivatives appear to be predestined reaction partners as they are less 
susceptible towards homocoupling and fairly stable under the usually harsh reaction conditions 
of C-H activation. 
3.1.3. Palladium Catalyzed Oxidative Carbonylation of Boronic Acid Derivatives 
In a recent report, Yamamoto described the oxidative alkoxy carbonylation of aryl and 
alkenyl boronic acids under palladium catalysis (Scheme 4).[12] Although the concept had already 
previously been disclosed by Uemura[13] and Suzuki[14], no general method had evolved.  
 
Scheme 4. Substrate scope of the oxidative methoxy carbonylation of pinacol boronates by Yamamoto. 
It was found, that the method tolerates a variety of functional groups and substitution 
patterns on the pinacol boronate. Most strikingly, alkenyl boronates proved to be suitable 
reaction partners, although minor amounts of homocoupling by-products were observed.  
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A catalytic cycle (Figure 3) was proposed based on a combination of the carbonylation 
process (Figure 1) and the oxidative cross-coupling (Figure 2).  
 
Figure 3. Catalytic cycle for the oxidative alkoxy carbonylation of pinacol boronates. 
Specifically, and in contrast to traditional carbonylative cross-coupling, a transmetalation 
(step I) precedes the migratory insertion of carbon monoxide (step II). After ligand exchange 
and reductive elimination (step III), the resulting palladium(0) is oxidized and reenters the 
catalytic cycle (step IV). Interestingly, it was found that the reaction did not proceed with 
potassium trifluoroborates as coupling partners, although other boronic acid derivatives 
delivered the products in moderate to good yields. Furthermore, the addition of bases inhibited 
the reaction. A transition state model was developed based on these observations as well as on 
computational studies (Scheme 5). 
 
Scheme 5. Mechanistic rational for the oxidative alkoxy carbonylation of boronates. 
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It was found that MeOH plays a key role in activating the Pd-1,4-benzoquinone (BQ) 
complex by protonation. As a result, a hydrogen-bond network was proposed (215). In this 
model, MeOH is coordinated by the boronate, which has two major consequences. Initially, it 
increases the acidity of the MeOH proton and thereby the electrophilicity of 1,4-BQ. Secondly, it 
activates the boronate towards transmetalation. This process can be understood as a proton-
coupled electron transfer reaction from palladium to 1,4-BQ. The resulting palladium(II) species 
216 is in equilibrium with the corresponding CO-complex 217. Replacement of 1,4-
hydroquinone by MeOH (218) and ligand-induced migratory insertion of carbon monoxide 
provides the acyl palladium complex 219 which undergoes reductive elimination to give 
benzoate 220. Intermediate Pd(0) is captured by 1,4-BQ and PPh3 to reform 215. 
To the best of our knowledge there is only one report in the literature in which stannanes 
are employed under oxidative carbonylation reactions (Scheme 6).[15] 
 
Scheme 6. Oxidative palladium catalyzed carbonylation of aryl chlorostannanes by Uemura and coworkers. 
Under the reported conditions variable amounts of the corresponding benzoic acids and 
ketones were obtained depending on the Ph-to-Cl-ratio on the stannane. As the usage of CuCl2 as 
a (stoichiometric) oxidant in the presence of alkenylstannanes leads to the formation of alkenyl 
chlorides, this methodology cannot be applied to the synthesis ,-unsaturated esters.[16] 
3.1.4. State of the Art the Synthesis of Acrylates from Alkenyltin Derivatives 
The ready accessibility of stereodefined alkenylstannanes by ruthenium-catalyzed trans-
selective hydrostannation of alkynes prompted us to develop an efficient method to access ,-
unsaturated ester motifs. Prior to our own contribution, four concepts have been disclosed to 
convert stannanes to acid derivatives (Scheme 7). Tin-lithium exchange and subsequent 
trapping with electrophiles (examples 1-2), tin-halide exchange preceding alkoxy carbonylation 
(example 3) or cross-coupling with chloroformates (example 4). 
 
Scheme 7. Commonly employed methods for the R-Sn to R-CO2R' conversion. 
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3.1.4.1. Activation and Subsequent Carboxylation with CO2 or Equivalent Reagent 
A very robust way to access ,-unsaturated esters from alkenyltin derivatives is the 
activation of the carbon-tin bond by addition of an alkyllithium reagent. The intermdiate 
alkenyllithium formed via tin lithium exchange is trapped with either CO2[17] or equivalent 
reagents like carbonates[18] (Scheme 8). 
 
Scheme 8. Representative examples of alkenyltin to carboxylic acid derivative by tin-lithium exchange. 
Although an operationally simple protocol, the use of strongly nucleophilic organolithium 
reagents to activate the stannane renders this method incompatible with a variety of 
electrophilic functional groups. Additionally, the overall moderate yield of the process has 
prevented its use as a convenient method for the synthesis of ,-unsaturated esters. 
3.1.4.2. Tin-Halide Exchange and Subsequent Palladium Catalyzed Carbonylation 
One of the most prominent ways to transform alkenyltin derivatives into the corresponding 
,-unsaturated esters is based on tin halide exchange followed by traditional palladium 
catalyzed carbonylation (Scheme 9). In the first step, highly functionalized alkenylstannanes are 
transformed by treatment with I2 or Br2 or the respective succinimides (NIS, NBS) into the 
corresponding halides. In the second step, a traditional palladium catalyzed alkoxy 
carbonylation provides the targeted material 226 and 228. 
Kazmeier and coworkers[19] utilized this methodology to access a variety of modified 
peptides 226 while Kibayashi and coworkers[20] trapped the acyl palladium species to form a 
lactone in their approach to pumiliotoxin alkaloids (228). 
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Scheme 9. Representative examples for tin halide exchange followed by carbonylation. 
Although offering an attractive solution to this long-standing problem, the indirect 
transformation of the alkenylstananne via the corresponding halide entails some difficulties. The 
use of electrophilic halogenating agents like iodine or NIS can lead to undesired side-reactions 
like isomerizations or halogenations of olefins or electron-rich arenes. Furthermore, this 
protocol requires the isolation of the intermediate alkenylhalide. Lastly, this method does not 
tolerate other (pseudo)halides as these are potential reaction partners in their own right. 
3.1.4.3. Palladium Catalyzed Cross-coupling with Chloroformates 
The cross-coupling between chloroformates and alkenylstannanes was described by 
Jousseaume and coworkers in 1991 to access a variety of ,-unsaturated esters and amides. 
The use of catalytic [(Ph3P)2PdBnCl] and HMPA as cosolvent proved to be optimal (Scheme 
10).[21] A similar result was reported in the same year by Kang and coworkers.[22] The moderate 
yields were attributed to pronounced decomposition of the chloroformate at high temperatures. 
Interestingly, similar conditions were reported by Soderquist and coworkers who extended the 
scope of the reaction to more demanding substrates.[23] Very recently, Yamada and coworkers 
used this methodology to access a set of unsymmetric vinyl malonate structures.[24] 
 
Scheme 10. Palladium catalyzed cross-coupling of alkenylstannanes with chloroformates. 
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An important improvement was reported by Crowley and Stansfield by adding catalytic 
copper iodide[25] to the reaction mixture(Scheme 11).[26] Ishihara and coworkers found that 
catalytic CuCN exhibited a similar effect.[27] 
 
Scheme 11. Palladium and copper cocatalyzed chloroformate cross-coupling. 
The most elaborate example has been described by Whitby and coworkers in their total 
synthesis of 9-hydroxyfarnesoic acid (241) (Scheme 12).[28]  
 
Scheme 12. Endgame in the total synthesis of 9-hydroxyfarnesoic acid (241) by Whitby and coworkers. 
Crucial to success was the addition of methyl chloroformate over 1 h by syringe pump to the 
reaction mixture to prevent decomposition of 239. Furthermore, by decreasing the catalyst 
loading the yield could be increased to >60%. It has been reported that chloroformates 
disproportionate under palladium catalysis to give the corresponding symmetric carbonates and 
phosgene, leading to the formation of symmetric ketones and catalyst deactivation.[29] 
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3.1.5. Motivation 
At the outset of this project, we wanted to establish a new protocol that would allow us to 
directly transform alkenylstannanes into ,-unsaturated esters without the need for protecting 
groups. As we were aiming for applying this new method in the context of total synthesis, we 
also had to ensure that the new transformation is sufficiently mild to tolerate a variety of 
functionalities. We did not want to abandon chloroformates outright as they offer a well 
precedented approach. With a solution to this problem in hand, a plethora of potential target 
molecules come into reach (Figure 4). The crucial (E)-hydroxymethyl acrylic acid motif is 
highlighted in red. 
 
Figure 4. Possible target molecules for the carbonylative Stille coupling: 242[30], 243[31], 244[32], 245[33], 246[34], 
247[35]. 
3.2. Results and Discussion 
3.2.1. Development of an Oxidative Palladium Catalyzed Carbonylation 
Our initial goal was to evaluate the feasibility of the direct cross-coupling of chloroformates 
or their derivatives with a suitable alkenylstannane. As the required starting materials stem 
from the directed trans-hydrostannation of (homo)propargyl alcohol derivatives, the 
development was purposely initiated without protecting groups. The reaction shown in Table 1 
was chosen as our model system. Incompatibility of the free alcohol in 248 with the reaction 
conditions was expected and an evaluation of existing protocols quickly affirmed our 
anticipations. Besides targeted product 249, mainly proto-destannation (250) and allene 
formation (251) was observed. 
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Table 1. Optimization of conditions for cross-coupling with isobutyl chloroformate. 
 
adetermined by crude NMR analysis; 
b
slow add'n of substrates over 2 h; cslow add'n of catalyst over 2 h. 
 
 
Entry 
XCO2iBu 
(eq) 
[Pd] 
(mol%) 
Ligand 
(mol%) 
Additive 
(eq) 
Solvent 
(conc.) 
T [°C] 
t [h] 
Ratio 
(A : B : C)a 
1 
ClCO2iBu 
(1.5) 
(PPh3)2PdBnCl 
(5) 
- - 
PhMe 
(0.125 M) 
60, 12 1 : 0 : 0 
2 
ClCO2iBu 
(1.5) 
Pd2dba3·CHCl3 
(2.5) 
PPh3 
(12.5) 
- 
DME 
(0.125 M) 
60, 12 1 : 0 : 2 
3 
ClCO2iBu 
(1.5) 
(PPh3)2PdBnCl 
(5) 
- 
CuI 
(0.05) 
THF 
(0.125 M) 
50, 0.5 0 : 0 : 1 
4 
ClCO2iBu 
(1.5) 
(PPh3)4Pd 
(5) 
- 
TBADPP 
(1.1) 
CuTC 
(1.05) 
DMF 
(0.2 M) 
r.t., 5 
min 
0 : 0 : 1 
5 
ClCO2iBu 
(1.5) 
- - 
CuTC 
(1.05) 
DMF 
(0.2 M) 
r.t., 5 
min 
0 : 0 : 1 
6 
tolSCO2iBu 
(1.1) 
(PPh3)4Pd 
(5) 
- 
CuTC 
(1.2) 
THF/Hex 
(0.063 M) 
50, 12 0 : 1 : 1.3 
7 
tolSCO2iBu 
(1.1) 
Pd2dba3·CHCl3 
(2.5) 
AsPh3 
(12.5) 
CuDPP 
(1.2) 
THF/Hex 
(0.125 M) 
r.t., 12 0 : 1 : 2 
8 
tolSCO2iBu 
(1.1) 
Pd2dba3·CHCl3 
(2.5) 
(furyl)3P 
(20) 
CuDPP 
(1.2) 
THF/Hex 
(0.125 M) 
r.t., 12 0 : 1 : 1 
9 
ClCO2iBu 
(1.1) 
Pd2dba3·CHCl3 
(2.5) 
AsPh3 
(10) 
- 
THF 
(0.25 M) 
60, 12 1 : 2.1 : 0 
10 
ClCO2iBu 
(2.0) 
Pd2dba3·CHCl3 
(2.5) 
AsPh3 
(10) 
- 
THF 
(0.25 M) 
60, 12 1 : 1.7 : 0 
11 
ClCO2iBu 
(2.0) 
Pd2dba3·CHCl3 
(2.5) 
AsPh3 
(10) 
- 
THF 
(0.5 M) 
60, 12 1 : 0.6 : 0 
12 
ClCO2iBu 
(1.5) 
Pd2dba3·CHCl3 
(2.5) 
AsPh3 
(12.5) 
- 
THF 
(0.125 M) 
60, 12 1 : 1.4 : 0b 
13 
ClCO2iBu 
(1.2) 
Pd2dba3·CHCl3 
(2.5) 
AsPh3 
(12.5) 
- 
THF 
(0.125 M) 
60, 12 1 : 3.1 : 0c 
14 
ClCO2iBu 
(1.2) 
Pd2dba3·CHCl3 
(5.0) 
AsPh3 
(25.0) 
- 
THF 
(0.125 M) 
60, 12 1 : 5.6 : 0c 
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The standard conditions reported in the literature failed to provide appreciable conversions 
or product-to-protodestannation ratios (entries 1-3).[17, 21, 23] Palladium-black formation in all 
cases indicated the lability of the in situ formed catalyst. Addition of CuTC or CuI did only result 
in rapid protodestannation (entries 4-5).[36] Employing the corresponding thiocarbonate under 
Liebeskind-Srogl conditions led for the first time to the formation of significant amounts of 
product along with protodestannation (entries 6-8).[37] Although being ultimately unsuccessful 
in this case, thiocarbonates have not been used in a Liebeskind-Srogl cross-coupling before. 
Unfortunately proto-destannation could not be suppressed. Finally, changing the ligand from 
Ph3P to Ph3As in the absence of copper salts led to the formation of product with suppression of 
proto-destannation (entry 9-11). The outstanding performance of Ph3As in Stille cross-couplings 
has been reported by Farina and coworkers, showing a significant rate acceleration compared to 
Ph3P.[38] Palladium-black formation was still observed, though at a lower rate compared to 
phosphine ligands. It was surmised, that the conversion could be boosted by reducing the 
contact time between the reagents and the catalyst to a minimum. After considerable screening, 
it was found that slow addition of a preformed catalyst solution over 2 h to a refluxing mixture of 
the reaction partners reliably provided >85% conversion without substantial amounts of 
protodestannation (entries 12-14). With these optimized conditions we felt confident to employ 
other chloroformates as well. Unfortunately, after switching from iso-butyl chloroformate to 
methyl chloroformate, the conversion significantly dropped to 62% under otherwise identical 
conditions (Scheme 13). 
 
Scheme 13. Optimized conditions for the coupling with chloroformates 
Therefore, we decided to investigate the viability of an oxidative palladium catalyzed 
carbonylation as an alternative. We began our studies with a screening of suitable palladium and 
ligand combinations (Table 2).  
The originally reported conditions (entry 1) failed to provide any product;[12] rapid 
palladium-black formation was observed instead. Changing to other phosphine ligands did not 
result in much improvement and starting material was mainly recovered (entries 2-7). From the 
previous attempts with chloroformates we learned that Ph3As performed remarkably well. 
Changing the ligand to Ph3As resulted in substantial improvement (entry 8). With the optimal 
ligand in hand, we continued to examine the influence of the palladium source (entries 9-12). It 
was found that cationic palladium salts proved significantly more effective than Pd(OAc)2. The 
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increased rate was attributed to the in situ formation of the corresponding acids in the presence 
of MeOH. 
Table 2. Palladium source and ligand optimization in the oxidative carbonylation. 
 
adetermined by crude NMR analysis. 
 
 
 
 
Entry 
[Pd] 
(mol%) 
Ligand 
(mol%) 
Additive 
(eq) 
Solvent 
(conc.) 
T [°C] 
t [h] 
ratio 
(A : B : C)a 
1 
Pd(OAc)
2
 
(5.0) 
PPh
3
 
(12.5) 
1,4-BQ 
(1.0) 
MeOH 
(0.1 M) 
70 , 12 n.r. 
2 
Pd(OAc)
2
 
(10) 
JohnPhos 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
r.t. , 12 n.r. 
3 
Pd(OAc)
2
 
(10) 
BiphenylCy
2
P 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
r.t., 12 1 : 0.10 : 0 
4 
Pd(OAc)
2
 
(10) 
PCy
3
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 0.50 : 0 
5 
Pd(OAc)
2
 
(10) 
PhPCy
2
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 0.23 : 0 
6 
Pd(OAc)
2
 
(10) 
Cy
2
tBuP 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 0.68 : 0 
7 
Pd(OAc)
2
 
(10) 
tBu
2
MeP 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 0.70 : 0 
8 
Pd(OAc)
2
 
(10) 
AsPh
3
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 2.70 : 0 
9 
PdCl
2
 
(10) 
AsPh
3
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 0.83 : 0 
10 
(PhCN)
2
PdCl
2 
(10) 
AsPh
3
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 4.22 : 0 
11 
Pd(TFA)
2
 
(10) 
AsPh
3
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
r.t., 12 1 : 2.00 : 0 
12 
(MeCN)
4
Pd(BF
4
)
2
 
(10) 
AsPh
3
 
(20) 
1,4-BQ 
(1.5) 
MeOH 
(0.5 M) 
r.t., 12 1 : 7.48 : 0 
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A related observation had been made by Bäckvall and coworkers when they studied the 
oxidation of 1,3-dienes with Pd(OAc)2 and 1,4-BQ as the stoichiometric oxidant (Scheme 14).[39] 
By increasing the acidity of the reaction medium, a significant rate acceleration was observed. 
The electron transfer from the ligated palladium to the 1,4-BQ ligand was found to be the rate 
determining step. Obviously, protonation of the 1,4-BQ results in an increased electrophilicity 
and thereby an increased oxidation potential. To gain insight into this transformation, Bäckvall 
and coworkers treated isolated (COD)Pd(BQ) with AcOH, TFA and MsOH and the respective 
NMR spectra were recorded. It was found that only TFA and MsOH promoted a two-electron 
oxidation of palladium. As TFA can be handled more conveniently and is milder than MsOH, it 
was chosen for further refinement of the methodology (Table 3). 
 
Scheme 14. Proton coupled electron transfer in Pd/1,4-BQ mediated oxidation of dienes. 
The addition of 50 mol% of TFA to the reaction had a significant impact (Table 3, entries 1 
and 2). Essentially full conversion was achieved at ambient temperature. Over the course of the 
optimization it was noted that the lipophilic stannane was insufficiently soluble in MeOH. 
Decreasing the concentration from 0.5 M to 0.25 M led to exclusive product formation without 
competing protodestannation (entry 3). Efficacy was substantially reduced when the catalyst or 
TFA loadings were decreased (entries 4-6). With the optimized conditions in hand the substrate 
scope of this novel transformation was investigated (Figure 5). 
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Table 3. Optimization of reaction conditions for oxidative methoxy carbonylation. 
 
adetermined by crude NMR analysis; bisolated yield. 
 
Figure 5. Substrate scope of the oxidative palladium-catalyzed methoxy carbonylation. 
Entry 
[Pd] 
(mol%) 
Ligand 
(mol%) 
Additive 
(eq) 
Solvent 
(conc.) 
T [°C] 
t [h] 
ratio 
(A : B : C)a 
1 
Pd(OAc)
2
 
(10) 
AsPh
3
 
(20) 
1,4-BQ (1.5) 
MeOH 
(0.5 M) 
70 , 12 1 : 2.70 : 0 
2 
Pd(OAc)
2 
(10) 
AsPh
3
 
(20) 
1,4-BQ (1.5) 
TFA (0.50) 
MeOH 
(0.5 M) 
r.t., 12 1 : 4.18 : 0 
3 
Pd(OAc)
2
 
(5) 
AsPh
3 
(10) 
1,4-BQ (1.5) 
TFA (0.40) 
MeOH 
(0.25 M) 
r.t., 12 
0 : 1.00 : 0 
(78%)b 
4 
Pd(OAc)
2
 
(5) 
AsPh
3 
(10) 
1,4-BQ (1.5) 
TFA (0.20) 
MeOH 
(0.25 M) 
r.t., 12 1 : 1.00 : 0 
5 
Pd(OAc)
2
 
(2.5) 
AsPh
3
 
(5) 
1,4-BQ (1.5) 
TFA (0.40) 
MeOH 
(0.25 M) 
r.t., 12 1 : 6.38 : 0 
6 
Pd(OAc)
2
 
(2.5) 
AsPh
3
 
(5) 
1,4-BQ (1.5) 
TFA (0.20) 
MeOH 
(0.25 M) 
r.t., 12 1 : 1.51 : 0 
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It was found that the palladium-catalyzed oxidative methoxy carbonylation is compatible 
with a variety of functional groups and also amenable to large-scale synthesis (249b). Primary, 
secondary and tertiary alcohols are well tolerated, as are nitriles (252), silyl ethers (259), acid 
sensitive allyl alcohols (260), esters (256) and alkenyl bromides (255). The latter is of 
particular interest as alkenyl bromides serve as common substrates in traditional palladium 
catalyzed carbonylation reactions. This example underlines the mechanistic proposal that no 
palladium(0) exits the catalytic cycle as it is rapidly oxidized by 1,4-BQ. Interestingly though, 
TBS or MOM protected propargyl alcohols (262 and 263) do not participate in this 
transformation which highlights the importance of the flanking hydroxyl group. Additionally, 
terminal olefin 261 decomposed under the reaction conditions. A mechanistic proposal based on 
the work of Yamamoto is formulated in Figure 6. 
For every transition state, two possible structures have to be considered as the exact role of 
TFA is unknown. In the first step, transmetalation from tin to palladium leads to intermediate 
264. TFA acts as a promoter by pre-organizing the reaction partners in a hydrogen bonding 
network. A direct hydrogen-bonding between the ligated 1,4-BQ and the allyl alcohol could be a 
viable alternative (265). 
 
Figure 6. Catalytic cycle of the oxidative palladium catalyzed methoxy carbonylation. 
After ligand exchange and migratory insertion of carbon monoxide, acyl palladium species 
266 or 267 are obtained. The following reductive elimination/proton coupled electron transfer 
step is accelerated by TFA via protonation of 1,4-BQ, leading to an increased oxidation potential. 
Next, the resulting palladium enolate 270 is protonated to extrude 1,4-hydroquinone. The 
unconfined palladium(II), which is stabilized by the Ph3As ligand, is immediately ligated by 
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another equivalent of 1,4-BQ to reenter the catalytic cycle. The predominant reason for the 
failure of phosphine ligands is their increased reduction potential for palladium(II) compared to 
Ph3As.  
An alternative pathway similar to the one proposed by Yamamoto[12] in which palladium(0) 
plays a major role was deemed unlikely for two reasons: 1) It was found that in a stoichiometric 
experiment with Pd(TFA)2 but without 1,4-BQ oxidant, full conversion was observed yielding a 
1:2 mixture of product to protodestannation. 2) As an alkenyl bromide endures the reaction, no 
intermediate palladium(0) can be formed as this would lead to rapid decomposition.  
With these results in hand, we set out to apply this new methodology to the synthesis of a 
natural product. 
3.2.2. Formal Synthesis of Tubelactomicin A 
3.2.2.1. Motivation 
As presented in Figure 4, the (hydroxylmethyl)acrylic acid motif is a recurring feature in 
many natural products. The most attractive of the possible targets shown is tubelactomicin A 
(246). Two total syntheses have been disclosed to date by Tadano[40] and Tatsuta[41], and one 
study towards the total synthesis was reported by Ryu[42]. Key fragment 272 in the synthesis of 
Tadano and coworkers has previously been accessed in 25 steps in a highly linear manner and 
was selected as our target molecule. The retrosynthetic analysis is shown in Figure 7. The group 
utilized a Stille cross-coupling between iodide 273 and stannane 272 followed by desilylation 
and macrolactonization to access the carbon skeleton of tubelactomicin A (246). Furthermore, 
as other members of the same family can potentially be addressed via the same key 
intermediate, our contribution would allow us to prepare a variety of natural and unnatural 
analogs.[43]  
 
Figure 7. Retrosynthetic analysis of to Tadanao and coworkers. 
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3.2.2.2. The Tubelactomicin Family of Natural Products 
Tubelactomicin A (246) was isolated by Igarashi et al. from the strain MK703-102F1 found 
in a soil sample in Suwashi, Japan in 2000.[34, 44] In 2001, the same group disclosed the isolation 
of tubelactomicins B (274), D (275) and E (276).[45] No structure of tubelactomicin C was 
reported. 
 
Figure 8. Structures of tubelactomicins A, B, D, E. 
Tubelactomicin A (246) shows strong and specific antimicrobial activities against 
Mycobacterium including some drug-resistant strains. Furthermore, 246 exhibits no acute 
toxicity in mice at a dose of 100 mg/kg (intravascular).[34] The structure of 246 was elucidated 
by NMR, HRMS, IR and UV analyses, and the absolute stereochemistry was established by 
crystallization of a carboxamide derivative.[44] With the completed total synthesis of Tadano and 
coworkers the proposed structure was confirmed.  
246 comprises a 16-membered lactone ring (blue) and a trans-decalin backbone (red) as 
illustrated in Figure 9. It comprises 9 stereogenic centers (colored circles) of which 6 are located 
in the southern domain and one of them being quaternary (green circle). Furthermore, a (E,E)-
diene is part of the lactone ring (orange). The crucial (hydroxylmethyl)acrylic acid motif is 
highlighted in blue in the right hand structure.  
 
Figure 9. Key features of tubelactomicin A (246). 
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3.2.2.3. Previous Syntheses of Tubelactomicin A 
As the major goal of this project was to establish a new route to key fragment 272 which 
represents a formal synthesis of tubelactomicin A, only synthetic approaches towards the 
northern fragment are discussed. The key steps in the synthesis of Tadano and coworkers are 
illustrated in Scheme 15.[40c]  
 
Scheme 15. Synthesis of the northern fragment by Tadano and coworkers. 
The carbon chain was evolved stepwise, starting from methyl (R)-lactate to give the 
required northern fragment in an impressive overall yield of 12% after 25 steps. Key steps 
include a Baylis-Hillman reaction, a syn-selective Evans-aldol reaction, a Corey-Fuchs 
alkynylation and finally a Pattenden hydrostannylation. 
In the synthesis of Tatsuta and coworkers, a slightly different intermediate was targeted as 
the crucial cross-coupling event was projected to be a Suzuki cross-coupling (Scheme 16).[41] 
This choice prohibited the prior installation of the ester moiety as its hydrolysis was assumed. 
Downstream introduction of the carboxylic acid was realized via a NiO2 catalyzed oxidation.[46] 
Two of the three required stereocenters stem again from a ‘chiral pool’ building block, in this 
case 2-deoxy-L-ribonolactone. The cornerstones of this approach are a highly selective Peterson 
olefination, a Wacker oxidation, a Corey-Fuchs alkynylation and a Corey-Bakshi-Shibata 
reduction. The final fragment was accessed in 14 steps with an overall yield of 6%. 
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Scheme 16. Synthesis of the northern fragment by Tatsuda and coworkers. 
3.2.2.4. Retrosynthetic Analysis and Forward Formal Synthesis  of Tubelactomicin A – Part I 
As the crucial alkenylstannane necessary for the Stille cross-coupling has to be introduced 
at the end of the synthesis, we decided to access this motif utilizing the Hodgson olefination 
(Scheme 17).[47]  
 
Scheme 17. First retrosynthetic analysis for the formal synthesis of tubelactomicin A. 
This traced us back to propargyl alcohol 292 which in turn could result from asymmetric 
Carreira addition of aldehyde 293 and alkyne 294.[48] Aldehyde 293 was thought to derive from 
an asymmetric hydroformylation of acrolein acetal 295 following a recently disclosed procedure 
from Morken and coworkers.[49] Alkyne 294 could originate from opening of (R)-propylene 
oxide with butynyllithium and a subsequent alkyne zipper reaction.[50] 
We began our journey with the hydroformylation of 295 according to Morken and 
coworkers.[49] In their contribution, a variety of allyl alcohol derivatives were exposed to 
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asymmetric hydroformylation conditions to yield different Roche-type aldehydes. We were 
particularly interested in the hydroformylation of the acrolein acetal 295 as this would enable 
us to pursue the synthesis with minimal redox manipulations. Attempts to reproduce the 
literature example were initially met with failure (Table 4). Neither the isomeric ratio nor the 
enantiomeric excess could be replicated. After considerable optimization it was found that 
optimal results were ensured when a stock solution of the rhodium salt was added to a freshly 
prepared ligand/substrate mixture. Upon completion, the crude aldehyde obtained had to be 
used immediately as prolonged exposure to air or silica led to significant deterioration of the 
enantiomeric excess. 
Table 4. Optimization of enantioselective hydroformylation by Morken and coworkers. 
 
adetermined by GCMS of crude mixture; bdetermined by chiral GCMS; *indicates stock solution in PhMe;  
‡ ee determined of crude reaction mixture without prior purification. 
With the required aldehyde 293 in hand, we were able to quickly assemble the main 
fragments employing routine chemistry (Scheme 18). Opening of (R)-propylene oxide with 
butynyllithium[51] proved to be straightforward in the presence of DMPU as cosolvent.[52] An 
alkyne zipper reaction with KOtBu/lithio diaminopropane[50] and subsequent TIPS protection 
furnished alkyne 294. Carreira addition worked uneventfully to provide propargyl alcohol 292 
in good yield and excellent diastereoselectivity.[48a] Subsequent trans-selective hydrostannation 
Entry 
Rh(CO)
2
(acac) 
(mol%) 
Ligand 
(mol%) 
conc. 
[mol/L] 
H
2
/CO 
[bar] 
T 
[°C] 
T 
[h] 
ratioa 
(A : B) 
eeb 
(%) 
1 0.20* 0.22* 1.43 15 80 12 n.d. 80 [R] 
2 0.20* 0.22* 1.43 15 60 12 4.3 : 1 84 [R] 
3 0.20* 0.22* 2.5 15 40-60 12+12 1.2 : 1 7.3 [R] 
4 0.29 0.35 2.5 12 80 12 1.7 : 1 71 [S] 
5 0.36 0.59 1.25 12 80 12 1.6 : 1 70 [S] 
6 0.23 0.52 2.5 12 60 12 1.7 : 1 74 [S] 
7 0.20* 0.22* 1.7 32 60 4 2.3 : 1 72 [S] 
8 0.20* 0.22* 1.7 32 40 12 1.8 : 1 72 [S] 
9 0.16 0.32 2.5 32 60 12 3.0 : 1 84 [R] 
10 0.18 0.36 10 32 60 12 3.5 : 1 33 [R] 
11 0.05* 0.20 2.5 32 60 12 14 : 1 78 [R] 
12 0.10* 0.20 2.5 32 60 4 3.6 : 1 88 [R]‡ 
13 0.05* 0.32 2.5 32 60 4 13 : 1 94 [R]‡ 
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followed by a palladium catalyzed oxidative methoxy carbonylation according to the new 
procedure disclosed herein gave rise to ,-unsaturated ester 300.  
 
Scheme 18. First attempt for the formal synthesis of tubelactomicin A. 
As it was anticipated that deprotection of the cyclic acetal in the presence of a MOM 
protecting group would be problematic, it was decided to install the MOM ether at a later stage 
of the synthesis. The formation of an intermediate oxonium ion during the deprotection step had 
to be suppressed as these are known to cause epimerization of -chiral aldehydes. Literature 
precedents are scarce but in a recent disclosure, Leighton and coworkers were able to deprotect 
an -chiral dioxolane[53] by employing the method of Fujioka and Kita.[54] By treating acetals with 
TESOTf or TMSOTf in the presence of pyridine bases, the group was able to show that 
epimerizable aldehydes can be deprotected without intermediate formation of an oxonium ion. 
Key to success is the formation of stable pyridinium adducts (305) that are hydrolyzed upon 
work-up (Table 5). Furthermore, free alcohols are silyl protected in situ which rendered this 
methodology especially attractive for our synthesis (304).  
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Table 5. Optimization of deprotection conditions for cyclic acetal. 
 
Entry Conditions Resulta 
1 
aq. TFA 
CH
2
Cl
2
 (0.01 M), r.t. multiple aldehydes formed 
2 
cat. TsOH 
acetone (0.1 M), r.t. 
no reaction (after 18h) 
3 
aq. HCl (10 equiv.) 
THF (0.07 M), r.t. 
no reaction (after 18h) 
4 
TMSOTf (5 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.04 M), 78 °C to 0 °C 
20% conversion, 4% product,  
15% byproduct 
5 
BBr
3
(5 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.04 M), 78 °C to 0 °C 
Decomposition 
6 
BCl
3
(5 equiv.), 2,6-lutidine (10 equiv.) 
 CH
2
Cl
2
 (0.04 M), 78 °C to 0 °C 
Decomposition 
7 
TMSOTf (5 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.04 M), 78 °C to r.t. ~ 50% conversion 
8 
TMSOTf (5 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.2 M), 78 °C to r.t. 70% conversion, 3 species 
9 
TMSOTf (5 equiv.), 2,4,6-collidine  
(20 equiv.), CH
2
Cl
2
 (0.2M), 0 °C 40% conversion, 3 species 
10 
TMSOTf (10 equiv.), 2,4,6-collidine  
(20 equiv.), CH
2
Cl
2
 (0.2 M), 0 °C 20% conversion, 3 species 
11 
TMSOTf (10 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.4 M), 0 °C 60% conversion, 3 species 
12 
TMSOTf (10 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.4 M), 10 °C 10% conversion, n.d. 
13 
TMSOTf (10 equiv.), 2,6-lutidine (10 equiv.) 
CH
2
Cl
2
 (0.4 M), 10 °C to r.t. 50% conversion, mainly desired 
14 
1,3-propanedithiol (1.5 equiv.), BF
3
Et
2
O  
(10 mol%), CH
2
Cl
2
 (0.2 M), r.t. 
decomp. 
adetermined by crude NMR analysis 
A variety of conventional methods for acetal cleavage failed or led to decomposition (entries 
1-3). TMSOTf provided some conversion (entry 4) whereas BCl3 or BBr3 (entries 5-6) only 
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decomposed the starting material. This result can be ascribed to interference of the free alcohol 
and formation of HX in situ. After some optimization, it was found that multiple aldehydes were 
formed in cases where some conversion was observed (entry 7-13); this was attributed to 
significant epimerization. Finally, transacetalization to a dithiane was probed. The 
corresponding thioacetals are known to be deprotected under much milder conditions.[55] 
Unfortunately this attempt was also met with failure. 
At this stage we had to abandon our original strategy and turn our attention towards the 
synthesis of more conveniently handled building blocks. As the cyclic acetal proved to be the 
major pitfall, we decided to replace it by a different protecting group or by a protected alcohol. 
This traced us back to a range of different Roche aldehydes. These were accessed by the same 
hydroformylation reaction employed earlier with comparable results and tested in the 
previously successful Carreira alkynylation (Scheme 19). We quickly found, that no conversion 
was observed no matter which protecting group was tested. Neither TBS or PMB protected allyl 
alcohols 306a and 306b nor acetals 306c or 306d provided any product (307). 
 
Scheme 19. Attempted Carreira alkynylation of different Roche aldehydes. 
The Carreira alkynylation has been proven in the past to be problematic in mismatched 
cases especially with bulky neighboring groups on the aldehyde. Striking examples can be found 
in the literature.[56] A possible explanation why acrolein acetal 293 behaved so differently than 
all other Roche aldehydes, might be its reduced steric demand. The strong Thorpe-Ingold effect 
of the gem-dimethyl group in the backbone results in compression of the dioxane ring and 
thereby in a reduction of steric bulk. At this point we devised a new route which is detailed in 
the next section. 
3.2.2.5. Retrosynthetic Analysis and Forward Formal Synthesis  of Tubelactomicin A – Part II 
We learned from the previous attempt that we had to access an intermediate bearing a 
protected alcohol that could later be transformed into the required aldehyde for the Hodgson 
olefination. As the synthesis of the alkyne part was already established, we planned to introduce 
the syn-aldol motif by an asymmetric Noyori reduction.[57] This would allow us to quickly 
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assemble the carbon backbone and set the stereocenters with high enantiomeric excess and 
diastereoselectivity. 
 
Scheme 20. Second retrosynthetic analysis for the formal synthesis of tubelactomicin A. 
To this end, the synthesis illustrated in Scheme 21 was executed. Alkyne 294 from the 
previous attempt was first acylated with methyl chloroformate. The resulting propionic ester 
then undergoes Claisen condensation with tert-butyl propiolate to give -keto ester 309.[58] 
Noyori reduction under transfer hydrogenation conditions furnished syn-propargyl alcohol in 
excellent enantiomeric excess and diastereoselectivity employing a modified catalyst.[57] LiBH4 
reduction in the presence of MeOH in refluxing THF cleanly provided diol 310.[59] trans-Selective 
hydrostannation[60] worked uneventfully giving the product as a single regioisomer, and was 
followed by selective TBS protection of the primary alcohol. The critical oxidative palladium-
catalyzed methoxy carbonylation delivered ,-unsaturated ester 311 in good yield. MOM 
protection and TBS deprotection set the stage for the crucial Hodgson olefination. Dess-Martin 
periodinane oxidation delivered the critical aldehyde which was used without further 
purification in the olefination reaction.[61] TIPS removal with TBAF completed the formal 
synthesis of tubelactomicin A (272). 
 
Scheme 21. Formal synthesis of tubelactomicin A. 
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The synthesis comprised 14 steps and gave an overall yield of 4%, cutting the step count of 
the previous synthesis almost in half. Key transformations include a highly enantio- and 
diastereoselective Noyori transfer reduction, a directed trans-hydrostannation, a novel oxidative 
palladium-catalyzed methoxy carbonylation and a Hodgson olefination. With significant 
amounts of key fragment 272 in hand, future studies will aim to complete the total synthesis of 
tubelactomicin A (246). 
3.3. Conclusion and Outlook 
With the new condition presented herein, we have developed a powerful tool for the direct 
conversion of alkenylstannanes into ,-unsaturated esters. Under these mild reaction 
conditions, a variety of highly functionalized esters could be accessed (Scheme 22). By 
combining the knowledge gained from studies on Stille cross-coupling[38], allylic oxidation[39] and 
aryl boronic acid oxidative carbonylation[12], a new protocol has been implemented. 
Furthermore, the viability of this methodology was successfully proven in the context of a formal 
synthesis of tubelactomicin A. Future studies will focus on the total synthesis of tubelactomicin A 
and congeners.  
 
Scheme 22. Palladium catalyzed oxidative methoxy carbonylation. 
Oxidative cross-coupling reactions of alkenylstannanes, e.g. Heck-reactions or cross-
couplings with other organometalloids, could yield additional highly valuable protocols and hold 
some promise for future development. 
3.4. Literature 
[1] a) R. Skoda-Foldes, L. Kollar, Curr. Org. Chem. 2002, 6, 1097-1119; b) A. Brennführer, H. 
Neumann, M. Beller, Angew. Chem. Int. Ed. 2009, 48, 4114-4133. 
[2] A. Schoenberg, I. Bartoletti, R. F. Heck, J. Org. Chem. 1974, 39, 3318-3326. 
[3] Z. Xin, T. M. Gøgsig, A. T. Lindhardt, T. Skrydstrup, Org. Lett. 2012, 14, 284-287. 
[4] C. F. J. Barnard, Organometallics 2008, 27, 5402-5422. 
[5] E.-i. Negishi, G. Wang, G. Zhu, in Metal Catalyzed Cascade Reactions (Ed.: T. J. J. Müller), 
Springer Berlin Heidelberg, Berlin, Heidelberg, 2006, pp. 1-48. 
[6] T. Sugihara, C. Coperet, Z. Owczarczyk, L. S. Harring, E.-i. Negishi, J. Am. Chem. Soc. 1994, 
116, 7923-7924. 
Chapter 3 - Carbonylation of Alkenylstannanes 
65 
[7] S. V. Ley, Synthesis: Carbon with one heteroatom attached by a single bond, Vol. 2, 
Pergamon, 1995. 
[8] W. Shi, C. Liu, A. Lei, Chem. Soc. Rev. 2011, 40, 2761-2776. 
[9] G. Cahiez, C. Duplais, J. Buendia, Angew. Chem. Int. Ed. 2009, 48, 6731-6734. 
[10] Y. Zhao, H. Wang, X. Hou, Y. Hu, A. Lei, H. Zhang, L. Zhu, J. Am. Chem. Soc. 2006, 128, 
15048-15049. 
[11] X. Chen, C. E. Goodhue, J.-Q. Yu, J. Am. Chem. Soc. 2006, 128, 12634-12635. 
[12] Y. Yamamoto, Adv. Synth. Catal. 2010, 352, 478-492. 
[13] a) C. Sik Cho, T. Ohe, S. Uemura, J. Organomet. Chem. 1995, 496, 221-226; b) T. Ohe, K. 
Ohe, S. Uemura, N. Sugita, J. Organomet. Chem. 1988, 344, C5-C7. 
[14] a) N. Yamashina, S. Hyuga, S. Hara, A. Suzuki, Tetrahedron Lett. 1989, 30, 6555-6558; b) 
N. Miyaura, A. Suzuki, Chem. Lett. 1981, 10, 879-882. 
[15] T. Ohe, S.-i. Motofusa, K. Ohe, S. Uemura, Bull. Chem. Soc. Jpn. 2001, 74, 1343-1348. 
[16] S. M. E. Simpkins, M. D. Weller, L. R. Cox, Chem. Comm. 2007, 4035-4037. 
[17] C. Nativi, M. Taddei, A. Mann, Tetrahedron 1989, 45, 1131-1144. 
[18] M. Alami, F. Liron, M. Gervais, J.-F. Peyrat, J.-D. Brion, Angew. Chem. Int. Ed. 2002, 41, 
1578-1580. 
[19] J. Deska, U. Kazmaier, Angew. Chem. Int. Ed. 2007, 46, 4570-4573. 
[20] S. Aoyagi, S. Hirashima, K. Saito, C. Kibayashi, J. Org. Chem. 2002, 67, 5517-5526. 
[21] a) B. Jousseaume, H. A. Kwon, J.-B. Verlhac, F. Denat, J. Dubac, Synlett 1993, 1993, 117-
118; b) L. Balas, B. Jousseaume, H. Shin, J. B. Verlhac, F. Wallian, Organometallics 1991, 
10, 366-368. 
[22] K.-T. Kang, S. Sin Kim, J. Chul Lee, Tetrahedron Lett. 1991, 32, 4341-4344. 
[23] J. A. Soderquist, I. Rosado, Y. Marrero, C. Burgos, ARKIVOC 2001, iv, 12-19. 
[24] S. Fujiwara, R. Cadou, Y. Yamaoka, K. Takasu, K.-i. Yamada, Eur. J. Org. Chem. 2015, 2015, 
1264-1272. 
[25] V. Farina, S. Kapadia, B. Krishnan, C. Wang, L. S. Liebeskind, J. Org. Chem. 1994, 59, 5905-
5911. 
[26] a) J. M. Percy, K. Stansfield, P. J. Crowley, K. Stansfield, Chem. Comm. 1997, 2033-2034; b) 
P. J. Crowley, A. C. Moralee, J. M. Percy, N. S. Spencer, Synlett 2000, 2000, 1737-1740. 
[27] S. Yamada, M. Noma, K. Hondo, T. Konno, T. Ishihara, J. Org. Chem. 2008, 73, 522-528. 
[28] S. Dixon, G. J. Gordon, R. J. Whitby, Chem. Comm. 2005, 4303-4305. 
[29] N. Baggett, K. W. Buck, A. B. Foster, R. Jefferis, J. M. Webber, Carbohydr. Res. 1967, 4, 343-
351. 
[30] D. B. Stierle, Phytochem. 1986, 25, 743-745. 
[31] Y.-J. Tseng, A. F. Ahmed, C.-F. Dai, M. Y. Chiang, J.-H. Sheu, Org. Lett. 2005, 7, 3813-3816. 
Chapter 3 - Carbonylation of Alkenylstannanes 
 
66 
[32] Y. Lu, Y.-C. Lin, Z.-H. Wen, J.-H. Su, P.-J. Sung, C.-H. Hsu, Y.-H. Kuo, M. Y. Chiang, C.-F. Dai, J.-
H. Sheu, Tetrahedron 2010, 66, 7129-7135. 
[33] W.-W. Tao, J.-A. Duan, Y.-P. Tang, N.-Y. Yang, J.-P. Li, Y.-F. Qian, Phytochem. 2013, 94, 249-
253. 
[34] M. Igarashi, C. Hayashi, Y. Homma, S. Hattori, N. Kinoshita, M. Hamada, T. Takeuchi, J. 
Antibiot. 2000, 53, 1096-1101. 
[35] C. J. Hernández-Guerrero, E. Zubía, M. J. Ortega, J. L. Carballo, Tetrahedron 2006, 62, 
5392-5400. 
[36] A. Furstner, J.-A. Funel, M. Tremblay, L. C. Bouchez, C. Nevado, M. Waser, J. Ackerstaff, C. 
C. Stimson, Chem. Comm. 2008, 2873-2875. 
[37] R. Wittenberg, J. Srogl, M. Egi, L. S. Liebeskind, Org. Lett. 2003, 5, 3033-3035. 
[38] V. Farina, B. Krishnan, J. Am. Chem. Soc. 1991, 113, 9585-9595. 
[39] H. Grennberg, A. Gogoll, J. E. Baeckvall, Organometallics 1993, 12, 1790-1793. 
[40] a) K.-i. Tadano, Eur. J. Org. Chem. 2009, 2009, 4381-4394; b) T. Motozaki, K. Sawamura, A. 
Suzuki, K. Yoshida, T. Ueki, A. Ohara, R. Munakata, K.-i. Takao, K.-i. Tadano, Org. Lett. 
2005, 7, 2261-2264; c) T. Motozaki, K. Sawamura, A. Suzuki, K. Yoshida, T. Ueki, A. Ohara, 
R. Munakata, K.-i. Takao, K.-i. Tadano, Org. Lett. 2005, 7, 2265-2267. 
[41] S. Hosokawa, M. Seki, H. Fukuda, K. Tatsuta, Tetrahedron Lett. 2006, 47, 2439-2442. 
[42] J.-Y. Kim, G.-S. Hwang, S.-M. Lee, J.-H. Han, E.-Y. Kim, D.-H. Ryu, Bull. Kor. Chem. Soc. 2009, 
30. 
[43] K. Sawamura, K. Yoshida, A. Suzuki, T. Motozaki, I. Kozawa, T. Hayamizu, R. Munakata, K.-
i. Takao, K.-i. Tadano, J. Org. Chem. 2007, 72, 6143-6148. 
[44] M. Igarashi, H. Nakamura, H. Naganawa, T. Takeuchi, J. Antibiot. 2000, 53, 1102-1107. 
[45] T. Takeuchi, M. Igarashi, H. Naganawa, M. Hamada,  (Ed.: J. P. Office), Japan, 2001. 
[46] K. Nakagawa, R. Konaka, T. Nakata, J. Org. Chem. 1962, 27, 1597-1601. 
[47] a) D. M. Hodgson, L. T. Boulton, G. N. Maw, Tetrahedron 1995, 51, 3713-3724; b) D. M. 
Hodgson, Tetrahedron Lett. 1992, 33, 5603-5604. 
[48] a) D. E. Frantz, R. Fässler, E. M. Carreira, J. Am. Chem. Soc. 2000, 122, 1806-1807; b) D. 
Boyall, F. López, H. Sasaki, D. Frantz, E. M. Carreira, Org. Lett. 2000, 2, 4233-4236; c) D. 
Boyall, D. E. Frantz, E. M. Carreira, Org. Lett. 2002, 4, 2605-2606; d) N. K. Anand, E. M. 
Carreira, J. Am. Chem. Soc. 2001, 123, 9687-9688. 
[49] Z. Yu, M. S. Eno, A. H. Annis, J. P. Morken, Org. Lett. 2015, 17, 3264-3267. 
[50] Y. Wu, J. Gao, Org. Lett. 2008, 10, 1533-1536. 
[51] Y. Sridhar, P. Srihari, Eur. J. Org. Chem. 2013, 2013, 578-587. 
[52] T. Mukhopadhyay, D. Seebach, Helv. Chim. Acta 1982, 65, 385-391. 
[53] S. Ho, C. Bucher, J. L. Leighton, Angew. Chem. Int. Ed. 2013, 52, 6757-6761. 
Chapter 3 - Carbonylation of Alkenylstannanes 
67 
[54] H. Fujioka, T. Okitsu, Y. Sawama, N. Murata, R. Li, Y. Kita, J. Am. Chem. Soc. 2006, 128, 
5930-5938. 
[55] a) Y. Honda, M. Sakai, G.-i. Tsuchihashi, Chem. Lett. 1985, 14, 1153-1156; b) Y. Honda, E. 
Morita, K. Ohshiro, G.-i. Tsuchihashi, Chem. Lett. 1988, 17, 21-24. 
[56] a) O. Sharon, C. Monti, C. Gennari, Tetrahedron 2007, 63, 5873-5878; b) C. Monti, O. 
Sharon, C. Gennari, Chem. Comm. 2007, 4271-4273. 
[57] Z. Fang, M. Wills, J. Org. Chem. 2013, 78, 8594-8605. 
[58] J. S. Lee, J. Shin, H. J. Shin, H.-S. Lee, Y.-J. Lee, H.-S. Lee, H. Won, Eur. J. Org. Chem. 2014, 
2014, 4472-4476. 
[59] K. Soai, A. Ookawa, J. Org. Chem. 1986, 51, 4000-4005. 
[60] a) S. M. Rummelt, J. Preindl, H. Sommer, A. Furstner, Angew. Chem. Int. Ed. 2015, 54, 
6241-6245; b) S. M. Rummelt, A. Furstner, Angew. Chem. Int. Ed. 2014, 53, 3626-3630; c) 
S. M. Rummelt, K. Radkowski, D. A. Rosca, A. Furstner, J. Am. Chem. Soc. 2015, 137, 5506-
5519. 
[61] a) A. B. Smith, T. M. Razler, G. R. Pettit, J.-C. Chapuis, Org. Lett. 2005, 7, 4403-4406; b) A. 
B. Smith, T. M. Razler, R. M. Meis, G. R. Pettit, J. Org. Chem. 2008, 73, 1201-1208. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - Carbonylation of Alkenylstannanes 
 
68 
 
 
 
 
 
 
 
 
 
Chapter 4 – Oxidation of Alkenylstannanes 
69 
4. Oxidation of Alkenylstannanes to (Hydroxy)ketones 
4.1. Introduction 
4.1.1. Conversion of C-M to C-O bonds – State of the Art 
4.1.1.1. Fleming-Tamao Oxidation of Silanes 
The late stage introduction of carbon-oxygen bonds is an important task in natural product 
synthesis. An important solution to this problem is the Fleming-Tamao oxidation of organic 
silanes wherein a C-Si bond is converted into a C-O bond and occurs with retention of 
configuration as exemplified in Scheme 1.[1]  
 
Scheme 1. Fleming oxidation under retention of configuration. 
Under Fleming conditions, the phenyl group of silane 334, upon activation with a strong 
electrophile, undergoes ipso-displacement by a counterion X to give 336 (Scheme 2). After 
addition of an oxidant such as a peracid, ligand exchange takes place (337). Ensuing 1,2-
migration from silicon to oxygen via 337 affords alcohol 339 after hydrolysis.  
 
Scheme 2: Mechanism of the Fleming oxidation. 
 
 
 
 
 
Chapter 4 – Oxidation of Alkenylstannanes 
70 
Under oxidative, basic conditions, Tamao and Kumada used monoalkoxysilanes for a similar 
transformation in the presence of a fluoride source (Scheme 3). 
 
Scheme 3. Tamao-Kumada oxidation. 
As illustrated in Scheme 3, the silane bears at least one heteroatom, and therefore 
preactivation as in the Fleming oxidation is unnecessary. Although exact mechanisms are still 
unknown, Tamao has developed a mechanistic proposal based on observations with H2O2 as the 
oxidant (Scheme 4).[2] Silane 342 is activated by an extraneous fluoride source to yield a 
pentacoordinated silane 343. As this opens up a second coordination site on silicon and thereby 
rendering the silane more electrophilic, the silicon center can in turn be attacked by peroxide to 
give hexacoordinated 344. Subsequent 1,2-migration and hydrolysis generates the target 
alcohol 339. 
 
Scheme 4. Mechanism of the Tamao-Kumada oxidation. 
In the past decades, this useful transformation has experienced a number of advancements, 
especially concerning the nature of the silane employed. For example, strained siletanes undergo 
Fleming-Tamao oxidation without prior activation (Scheme 5).[1c]  
 
Scheme 5. Fleming-Tamao oxidation of strained silanes by Dudley and coworkers. 
With the rise of transition-metal catalyzed hydrosilylations[3], the importance of the 
Fleming-Tamao oxidation as a tool for organic synthesis has increased dramatically.[4] Silanes 
can easily be introduced in an asymmetric fashion and serve as masked hydroxy groups. This 
strategy has found many applications in the past years.[5] 
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Barett and coworkers utilized a late-stage Fleming-Tamao oxidation in their endeavor 
towards an enantioselective synthesis of ()-pranamicin (Scheme 6).[6] It should be noted that an 
alkyl TBS group did not participate in this transformation. Trost and Rudd reported a modified 
Fleming oxidation under strongly nucleophilic conditions towards the total synthesis of ()--
kainic acid.[7] 
 
Scheme 6. Recent examples of Fleming-Tamao oxidation in total synthesis. 
Besides alkyl silanes, alkenyl silanes can also be subjected to Fleming-Tamao conditions to 
yield the corresponding carbonyls. This process has become of special interest with the 
disclosure of the trans-selective hydrosilylation by Trost and coworkers.[5b, 8] The late-stage 
introduction of carbonyls has also found numerous applications in total synthesis and two 
recent examples from the groups of Marshall[9] and Leighton[10] are presented in Scheme 7.  
 
Scheme 7. Fleming-Tamao oxidation of alkenyl silanes as key steps. 
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The intramolecular hydrosilylation/oxidation sequence of internal alkynes has been 
developed as a tool to install a carbonyl group at discrete positions. Employing a platinum 
catalyst the 5-exo-dig cyclization product 357 is obtained[11], whereas the application of a 
cationic ruthenium catalyst on similar alcohol substrate 359, selectively furnishes the 6-endo-
dig cyclization product 360.[8h] Oxidation under Tamao-conditions delivers the corresponding 
(homo)aldol products 358 and 361, respectively. 
 
Scheme 8. Regiodivergent hydrosilylation of alkynes. 
This strategy still suffers from the requirement of an additional transformation to install the 
silane which might lead to interferences with other protic groups in the same molecule. 
Furthermore, it was found that unreacted silane leads to rapid catalyst deactivation which 
necessitates a tedious purification step after alkoxysilane formation.[12] Generally, the 
orthogonality with silyl protecting groups can be a major concern in total synthesis. 
4.1.1.2. Oxidation of Boranes 
Another well-established approach for the transformation of C-M to C-O bonds is the 
oxidation of the carbon-boron bond with basic peroxide to access alcohols or carbonyls.[13] With 
a plethora of methodologies available for the selective hydroboration of alkenes[14], the late-
stage introduction of alcohols via the corresponding boranes proved to be the method of 
choice.[15] This strategy has only rarely been used for the introduction of carbonyls which might 
be attributed to the lack of methodology available to selectively obtain the corresponding 
alkenyl boranes by hydroboration. Two elegant protocols employing the prior installation of 
alkenyl boranes have been developed by Walsh and coworkers (Scheme 9).[15b, 16] Although being 
a useful approach, the borane can only be installed in discrete positions at the outset of the 
synthesis. Furthermore, the use of strong oxidizing agents like TBHP prohibits the presence of 
other sensitive functional groups in the molecule. 
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Scheme 9. Multicomponent approach for the synthesis of hydroxyketones by Walsh and coworkers. 
An alternative way to transform the C-B bond to a C-O bond has independently been 
reported by the groups of Chan, Evans and Lam.[17] They showed that aryl boronic acids undergo 
copper mediated cross coupling reactions with alcohols or amines to give the corresponding 
arylated products (Scheme 10). Generally, excess copper(II) acetate and boronic acid in the 
presence of amine base was employed and the reaction run under aerobic conditions to ensure 
full conversion. 
 
Scheme 10. Chan-Evans-Lam coupling of boronic acids. 
In 2009, Stahl and coworkers disclosed the mechanism of the reaction based on evidence 
for the existence of CuI, CuII and CuIII species in the catalytic cycle (Scheme 11).[18] First, a 
copper(II)-boronic acid adduct is formed (step I). This adduct then undergoes transmetalation 
from boron to copper (step II). The resulting copper species is oxidized by another equivalent of 
copper(II) to give an aryl-copper(III) adduct (step III) that rapidly undergoes reductive 
elimination. In the presence of MeOH, the corresponding anisol derivate and a copper(I) species 
(steps IV) are obtained. Under an oxygen atmosphere, the resulting copper(I) species are 
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reoxidized and reenter the catalytic cycle. This mechanism (left hand picture) can be understood 
as the synthetic equivalents of nature’s oxygenases.  
 
Scheme 11. Catalytic mechanism of the Chan-Evans-Lam coupling. 
More recently, the cross-coupling between alkenyl boronic acids and alcohols has received 
much attention as the resulting vinyl ethers are useful intermediates in organic synthesis.[19] 
Merlic and coworkers showed that the coupling of terminal alkenyl boronic acids in neat alcohol 
provides ready access to a variety of vinyl ethers (Scheme 12).  
 
Scheme 12. Synthesis of vinyl ether by Merlic and coworkers.[19c, 19k] 
Other research groups have shown that trifluoroborates[19i] or carboxylates[19j] can be 
valuable coupling partners in this reaction. Although being a very successful transformation for 
boronic acid derivatives, the potential of other aryl- or alkenylmetal species still demands 
further investigation. 
4.1.1.3. Chan-Evans-Lam Coupling of Stannanes 
In 2000, Lam and coworkers reported the use of aryl stannanes as coupling partners in the 
Chan-Evans-Lam coupling, although with limited success.[20] Under the optimized conditions 
only half of the yield compared to the corresponding boronic acid was obtained. Furthermore, 
long reaction times and the use of the trimethyltin derivative were required to obtain 
appreciable results. Two years later, an optimized protocol was disclosed employing TBAF as 
the base (Scheme 13).[21]  
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Scheme 13. Chan-Evans-Lam coupling with aryl stannanes by Lam and coworkers. 
Since the seminal work by Lam and coworkers was disclosed, only two examples utilize aryl 
stannanes under Chan-Evans-Lam conditions for the synthesis of aryl ethers (Scheme 14).  
 
Scheme 14. Chan-Evans-Lam coupling with aryl stannanes. 
Iranpoor and coworkers employed triphenylchloro stannane as the coupling partner and 
triethylamine as the solvent.[22] However, exclusively phenylether and aniline formation was 
reported. Additionally, Vakalopoulos and coworkers disclosed a coupling reaction that required 
3.5 equivalents of the stannane to obtain the biaryl ether in moderate yield.[23] Both procedures 
suffer from severe limitations e.g. the utilization of chloro triphenylstannane or low yields. 
Nevertheless, it was shown that the transformation of the C-Sn bond to a C-O bond is a priori 
feasible under copper catalysis.  
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4.1.1.4. Miscellaneous Protocols for the C-Sn to C-O Transformation 
The first example of the oxidation of a C-Sn bond was disclosed by Shibasaki and coworkers 
yielding a mixture of oxygenated products in low yields.[24] In 1988, Yamamoto and coworkers 
found that alkenyl stannanes can be transformed into the corresponding vinyl ethers by 
treatment with Pb(OAc)4 (Scheme 15).[25] In 1999, Falck and coworkers disclosed an oxidation of 
aryl stannanes under conditions similar to those used in the Fleming-Tamao oxidation of 
silanes.[26] It is imperative to introduce a perfluoroethyl group on the stannane, to render the 
metal center sufficiently electrophilic for oxidation by basic peroxide.  
 
Scheme 15. Oxidation of alkenylstannanes. 
Recently, Ritter and coworkers developed a protocol to access trifluoromethyl ethers 
(Scheme 16). Under strongly oxidative conditions, aryl stannane 390 was treated with 
superstoichiometric amounts of AgPF6 to afford trifluoromethyl aryl ether 391 in high yield. 
 
Scheme 16. Ether formation by Ritter and coworkers. 
Despite the fact that some methods have been established in the literature, the utility of 
alkenyl stannanes as masked hydroxyl- or carbonyl groups is still massively underdeveloped. 
Furthermore, all procedures presented herein pose strong limitations. 
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4.1.2. Motivation 
As the directed trans-hydrostannation of (homo)propargyl alcohols reliably delivers 
stannylated (homo)allyl alcohols, we sought of a way to exploit this motif to access 
hydroxyketones. An alternative protocol to the commonly employed Fleming-Tamao oxidation is 
of great interest considering orthogonality with other protecting groups. Furthermore, as we are 
interested in applying the new methodology in the context of natural product synthesis, mild 
procedures that tolerate a variety of functional groups are preferred. Some potential targets that 
might come into reach of total synthesis are given in Figure 1. The crucial hydroxyketone motif 
is highlighted in red.  
 
Figure 1. Possible natural products accessible by oxidation of alkenylstannanes; 392[27], 393[28], 394[29], 395[30]. 
4.2. Results and Discussion 
4.2.1. Reaction Development and Substrate Scope 
We decided to investigate the possibility to achieve an oxidation of alkenylstannanes by 
employing the marginally effective Chan-Evans-Lam-type conditions to form the corresponding 
vinyl ether (Table 1).  
The original conditions according to the Chan-Evans-Lam coupling protocol failed to deliver 
any coupling products. Instead, the -acetoxy ketone 397 was isolated in 17% yield (entry 1). 
We quickly found that increasing the equivalents of copper acetate led to an increased 
conversion of starting material (entry 3), but addition of pyridine (entry 2) or fewer equivalents 
of base (entry 4) resulted in diminished efficacy. Interestingly, running the reaction under an 
oxygen atmosphere inhibited the conversion completely (entry 5). Screening of different 
solvents revealed that polar, aprotic solvents like DMF or DMSO effectively promote the reaction 
(entries 11-12). Apolar or less polar solvents like toluene, pentane, acetonitrile, THF or acetone 
all failed to furnish appreciable amounts of the product (entries 6-10). As DMSO is less toxic than 
DMF and more conveniently handled, it was selected as the solvent of choice for further 
optimization (Table 2). 
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Table 1. Initial reaction development of copper mediated formal oxidation. 
 
adetermined by crude NMR analysis. 
 
 
 
 
Entry 
Reagent 
(mol%) 
Modification 
Base 
(eq) 
Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
1 
Cu(OAc)2 
(100) 
p-tBuC6H4OH 
(2) 
Et3N 
(5) 
CH2Cl2 
(0.125 M) 
r.t., 12 1 : 2.1 : 1.5 
2 
Cu(OAc)2 
(100) 
p-tBuC6H4OH 
(2) 
C5H5N 
(5) 
CH2Cl2 
(0.125 M) 
r.t., 12 1 : 0.33 : 0.16 
3 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
CH2Cl2 
(0.125 M) 
r.t., 12 1 : 9.5 : 11 
4 
Cu(OAc)2 
(200) 
- 
Et3N 
(1.5) 
CH2Cl2 
(0.125 M) 
r.t., 12 1 : 0.28 : 0.69 
5 
Cu(OAc)2 
(200) 
O2 balloon 
Et3N 
(5) 
CH2Cl2 
(0.125 M) 
r.t., 12 1 : 0 : 0 
6 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
PhMe 
(0.125 M) 
r.t., 12 1 : 0.02 : 0.01 
7 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
MeCN 
(0.125 M) 
r.t., 12 0 : 1.0 : 2.1 
8 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
pentane 
(0.125 M) 
r.t., 12 1 : 0.04 : 0.01 
9 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
Me2CO 
(0.125 M) 
r.t., 12 1 : 0.15 : 0.21 
10 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
THF 
(0.125 M) 
r.t., 12 1 : 0.43 : 0.07 
11 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
DMSO 
(0.125 M) 
r.t., 12 0.13 : 1 : 2.72 
12 
Cu(OAc)2 
(200) 
- 
Et3N 
(5) 
DMF 
(0.125 M) 
r.t., 12 0 : 1 : 3.3 
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To suppress protodestannation, the reaction was run under strictly anhydrous conditions 
which resulted in a significant drop of selectivity (entry 1). With copper acetate hydrate (entry 
2) or reagent grade solvent (entry 3), virtually no conversion was observed. Gratifyingly, by 
heating the mixture to 45°C, full conversion of starting material and excellent selectivity was 
obtained (entry 4). In order to decrease the amount of protodestannation, other organic and 
inorganic bases were tested, albeit no improvement was achieved (entries 5-11). It should be 
noted that in the presence of potassium carbonate rapid conversion but slightly diminished 
selectivity was observed (entry 8). Changing the equivalents of base and copper salt led only to a 
minor improvement in the product ratio; therefore we decided to preserve the initial 
stoichiometries (entries 12-14). To evaluate the influence of an extraneous oxidant, the reaction 
was run in degassed solvent (entry 15) or under air (entry 16), which had no significant impact. 
When the reaction was finally run under an atmosphere of oxygen, only protodestannation was 
observed (entry 17). 
Table 2. Optimization of copper mediated formal oxidation of alkenylstannanes. 
 
Entry 
Reagent 
(mol%) 
Modification 
Base 
(eq) 
Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
1 
Cu(OAc)2 
(200) 
3Å mole 
sieves 
Et3N 
(5) 
DMSO 
(0.125 M) 
r.t., 12 0 : 1 : 1.00 
2 
Cu(OAc)2* 
(200) 
- 
Et3N 
(5) 
DMSO 
(0.125 M) 
r.t., 12 1 : 0 : 0.03 
3 
Cu(OAc)2* 
(200) 
- 
Et3N* 
(5) 
DMSO‡ 
(0.125 M) 
r.t., 12 1 : 0 : 0.00 
4 
Cu(OAc)2* 
(200) 
- 
Et
3
N* 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 7.64 
5 
Cu(OAc)2* 
(200) 
- 
Cy
2
NMe 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 4.58 
6 
Cu(OAc)2* 
(200) 
- 
iPr
2
Net 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 7.50 
7 
Cu(OAc)2* 
(200) 
- 
DBU 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 0.12 
8 
Cu(OAc)2* 
(200) 
- 
K
2
CO
3
 
(5) 
DMSO‡ 
(0.125 M) 
45, 2 0 : 1 : 6.10 
9 
Cu(OAc)2* 
(200) 
- 
K
3
PO
4
 
(3) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 2.06 
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adetermined by crude NMR analysis; *reagent grade quality; ‡reagent grade, 212 ppm H2O. 
With this new protocol in hand, we set out to evaluate the synthetic potential of this novel 
transformation. An array of different stannanes was subjected to the optimized reaction 
conditions and the results are shown in Scheme 17. Primary (399), secondary (403), and 
tertiary alcohols (401) participate equally well. An experiment with 2.5 mmol of substrate 
proved the scalability of the reaction without loss of efficiency (396). Furthermore, silyl ether 
398 is tolerated which would be inconceivable under standard Fleming-Tamao conditions. 
Halides (402), other free alcohols (404), nitriles (405), and phthalimides (406) do not affect the 
reaction. Importantly, enantiopure alcohol (407) can be transformed into the corresponding 
acetoxy ketones without loss of stereochemical information. When protected alcohol 400 was 
employed as a substrate, the respective alkenyl acetate was isolated. Homoallylstannanes serve 
as productive substrates as well, furnishing aldol products 408 and 409, respectively. 
Interestingly, if a second alcohol is present in the homoallylic position, a rarely described 
oxetane ring is formed (410).[31] Attempts to expand the scope to simple homoallylstannanes 
failed, as purification of the oxetanes proved difficult as well as their hydrolysis with aqueous 
acids. Nevertheless, considering their unexplored nature this transformation might hold some 
promise for future developments.  
Substrates bearing additional degrees of unsaturation in conjugation with the 
alkenylstannanes, a free acid or the corresponding amides result in exclusive protodestannation. 
Entry 
Reagent 
(mol%) 
Modification 
Base 
(eq) 
Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
10 
Cu(OAc)2* 
(200) 
- 
NaHCO
3
 
(5) 
DMSO‡ 
(0.125 M) 
45, 6 0 : 1 : 1.65 
11 
Cu(OAc)2* 
(200) 
- 
NaOAc 
(5) 
DMSO‡ 
(0.125 M) 
45, 2 0 : 1 : 1.17 
12 
Cu(OAc)2* 
(200) 
- 
Et
3
N* 
(10) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 6.87 
13 
Cu(OAc)2* 
(200) 
- 
Et
3
N* 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 9.79 
14 
Cu(OAc)2* 
(300) 
- 
Et
3
N* 
(10) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 11.73 
15 
Cu(OAc)2* 
(200) 
open to air 
Et
3
N 
(5)* 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 5.46 
16 
Cu(OAc)2* 
(200) 
degassed 
DMSO 
Et
3
N 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 6.00 
17 
Cu(OAc)2* 
(200) 
O
2
 balloon 
Et
3
N* 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 1 : 0.30 : 0 
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Scheme 17. Substrate scope of the copper acetate mediated oxidation. 
With these encouraging results in hand, we sought to extend the scope of this 
transformation to the synthesis of ketones with no flanking free alcohol. To this end, we quickly 
encountered that the conversion of alkenylstannes into the corresponding ketones was 
straightforward in the presence of Cu(O2CCF3)2 (Scheme 18). In contrast to the formation of 400 
in the presence of copper(II) acetate, formation of the respective vinyl trifluoroacetate was not 
observed. 
 
Scheme 18. Substrate scope of the copper trifluoroacetate mediated oxidation. 
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Finally, it was found that other copper carboxylates lead to the formation of different 
carboxy ketones (Scheme 19). When copper isobutyrate was used in the place of copper(II) 
acetate, the corresponding isobutyric ester was isolated. Copper trifluoroacetate in the presence 
of sodium benzoates yields the respective benzoate, presumably via in situ formation of 
copper(II) benzoate. 
 
Scheme 19. Copper mediated keto carboxylate formation. 
4.2.2. Preliminary Results for the Oxidation of Alkenylsilanes 
With the optimal conditions in hand, we examined the possibility to extend this 
transformation to the conversion of alkenylsilanes into the corresponding ketones (Table 3). 
This could be a useful alternative to the ubiquitously applied Fleming-Tamao oxidation. 
Triethoxysilane derivative 417 was chosen as a model substrate and exposed to the established 
reaction conditions. 
Under the standard conditions, only protodesilylation was obtained (entry 1). Using dry 
solvents and reagents (entries 2) or potassium carbonate as a base (entry 3) had no impact on 
the reaction outcome. In the presence of water, product formation was observed as well as 
protodesilylation (entry 4). As fluoride additives are common activators for silanes, different 
fluoride sources were subsequently screened. At room temperature potassium fluoride provided 
superior results (entry 7) compared to cesium fluoride (entries 5-6) or sodium fluoride (entry 
8). Gratifyingly, upon heating rapid conversion of the starting material was observed (entry 9). 
Interestingly, the analogous dimethylbenzyl silane derivative was inert under these conditions 
(entry 10). All efforts to improve the selectivity by changing fluoride sources and 
stoichiometries of copper(II) acetate were unsuccessful (entries 11-14). Nevertheless, it seems 
reasonable to assume that this methodology offers the possibility to develop an alternative 
protocol to the Fleming-Tamao oxidation of silanes. 
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Table 3. Optimization of copper mediated oxidation of alkenylsilanes. 
 
adetermined by crude NMR analysis; *reagent grade quality; ‡reagent grade, 212 ppm H2O 
 
 
 
Entry 
Reagent 
(mol%) 
[Si] 
Base 
(eq) 
Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
1 
Cu(OAc)2* 
(200) 
Si(OEt)3 
Et3N 
(5)* 
DMSO‡ 
(0.125 M) 
45, 12 0 : 1 : 0 
2 
Cu(OAc)2* 
(200) 
Si(OEt)3 
Et3N 
(5) 
DMSO 
(0.125 M) 
45, 12 0 : 1 : 0.06 
3 
Cu(OAc)2* 
(200) 
Si(OEt)3 
K2CO3 
(5) 
DMSO‡ 
(0.125 M) 
45, 12 
1 : 0.92 : 
0.05 
4 
Cu(OAc)2* 
(200) 
Si(OEt)3 
Et3N 
(5)* 
DMSO/H2O, 
9:1 
(0.125 M) 
45, 12 0 : 1 : 1.25 
5 
Cu(OAc)2* 
(200) 
Si(OEt)3 
CsF 
(1) 
DMSO‡ 
(0.125 M) 
r.t., 12 0 : 1 : 0.73 
6 
Cu(OAc)2* 
(200) 
Si(OEt)3 
CsF 
(2) 
DMSO‡ 
(0.125 M) 
r.t., 12 0 : 1 : 1.28 
7 
Cu(OAc)2* 
(200) 
Si(OEt)3 
KF · 2 H2O 
(2) 
DMSO‡ 
(0.125 M) 
r.t., 12 0 : 1 : 1.39 
8 
Cu(OAc)2* 
(200) 
Si(OEt)3 
NaF 
(2) 
DMSO‡ 
(0.125 M) 
r.t., 12 0 : 1 : 0.25 
9 
Cu(OAc)2* 
(200) 
Si(OEt)3 
KF · 2 H2O 
(3) 
DMSO‡ 
(0.125 M) 
50, 2 0 : 1 : 2.96 
10 
Cu(OAc)2* 
(200) 
SiBnMe2 
KF · 2 H2O 
(2) 
DMSO‡ 
(0.125 M) 
50, 12 1 : 0 : 0 
11 
Cu(OAc)2* 
(300) 
Si(OEt)3 
KF · 2 H2O 
(3) 
DMSO‡ 
(0.125 M) 
50, 2 0 : 1 : 2.77 
12 
Cu(OAc)2* 
(200) 
Si(OEt)3 
TBAF · 3 H2O 
(3) 
DMSO‡ 
(0.125 M) 
50, 2 0 : 1 : 0.38 
13 
Cu(OAc)2* 
(200) 
Si(OEt)3 
TMAF 
(3) 
DMSO‡ 
(0.125 M) 
50, 2 0 : 1 : 1.85 
14 
Cu(OAc)2* 
(200) 
Si(OEt)3 
KF · 2 H2O 
(3), Et3N (5) 
DMSO‡ 
(0.125 M) 
50, 1 0 : 1 : 1.23 
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4.2.3. Mechanistic Proposal 
Based on the observations made during the investigation of the substrate scope, a 
mechanistic rationale can be proposed (Scheme 20). 
 
Scheme 20. Mechanistic proposal for the formation of acetoxy ketones. 
In accordance to the work of Stahl and coworkers,[18] in the first step a transmetalation from 
tin to copper occurs with extrusion of tributyltin acetate to give 419. This transformation could 
be a radical process as under an oxygen atmosphere no conversion was observed and oxygen 
has been reported to be a good radical inhibitor.[32] The resulting alkenylcopper species then 
undergoes reductive elimination to afford vinyl acetate 420, giving off copper(0). This proposal 
was confirmed as vinyl acetate 400 was isolated when a methylated allyl alcohol was employed. 
It was noticed in all examples that large amounts of a brown precipitate, presumably copper(0), 
formed after full conversion. Furthermore, when the reaction was run under air no such 
precipitate was observed, although full conversion was obtained. This advocates that the 
copper(0) formed is reoxidized under air. Finally, the neighboring alcohol captures intermediate 
acetate 420 and tautomerization gives acetoxy ketone 421. In the presence of copper 
trifluoroacetate, the corresponding vinyl acetates are supposedly hydrolyzed under the reaction 
conditions as these are highly reactive acyl transfer reagents (Scheme 21).  
 
Scheme 21. Mechanism of the copper trifluoroacetate mediated ketone formation. 
The formation of oxetane 429 provides further evidence for the intermediacy of an alkenyl 
copper species and can be rationalized as follows (Scheme 22). Stannane 426 undergoes 
transmetalation to yield alkenyl copper 427. Subsequently, the neighboring homoallylic alcohol 
forms a 5-membered ring by replacing the remaining acetate on the copper species, giving 
intermediate 428. Reductive elimination then furnishes oxetane 429 with the extrusion of 
copper(0). 
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Scheme 22. Copper mediated oxetane formation. 
4.3. Conclusion and Outlook 
By drawing inspiration from the important contributions of Chan, Evans and Lam, a new 
protocol for the formal oxidation of alkenylstannanes was developed. Under optimized 
conditions, it is now possible to transform alkenylstannanes into functionalized ketones. The 
respective acetoxyketones could be isolated in moderate to good yields without epimerization of 
neighboring stereocenters. Furthermore, the synthesis of plain ketones is possible by changing 
copper(II) acetate to copper(II) trifluoroacetate. When other copper carboxylates are employed, 
the corresponding -carboxy ketones are obtained. Finally, a reasonable reaction mechanism of 
the reaction was proposed. 
The syntheses of vinyl ethers, amides or enamines would constitute important objectives 
for future developments. Especially the synthesis of stereodefined enamines is of great interest 
as these are important intermediates in C-C bond forming processes.[33] With this exceptionally 
mild protocol the natural products shown in Figure 1 might be accessible by means of 
RCAM/hydrostannation/late-stage oxygenation. 
 
Scheme 23. Copper mediated formal oxidation of alkenylstannanes. 
4.4. Literature 
[1] a) K. Tamao, M. Kumada, K. Maeda, Tetrahedron Lett. 1984, 25, 321-324; b) K. Tamao, M. 
Akita, M. Kumada, J. Organomet. Chem. 1983, 254, 13-22; c) J. D. Sunderhaus, H. Lam, G. B. 
Dudley, Org. Lett. 2003, 5, 4571-4573; d) I. Fleming, R. Henning, D. C. Parker, H. E. Plaut, 
P. E. J. Sanderson, J. Chem. Soc., Perkin Trans. 1 1995, 317-337; e) I. Fleming, J. Dunoguès, 
R. Smithers, in Organic Reactions, John Wiley & Sons, Inc., 2004; f) I. Fleming, P. E. J. 
Sanderson, Tetrahedron Lett. 1987, 28, 4229-4232; g) I. Fleming, R. Henning, H. Plaut, J. 
Chem. Soc., Chem. Comm. 1984, 29-31. 
[2] H. Fujimoto, T. Yabuki, K. Tamao, K. Fukui, J. Mol. Struct. THEOCHEM 1992, 260, 47-61. 
[3] a) Y. Nakajima, S. Shimada, RSC Advances 2015, 5, 20603-20616; b) B. Marciniec, 
Hydrosilylation - A Comprehensive Review on Recent Advances, Springer Netherlands, 
2009. 
Chapter 4 – Oxidation of Alkenylstannanes 
86 
[4] G. R. Jones, Y. Landais, Tetrahedron 1996, 52, 7599-7662. 
[5] a) H. Usuda, M. Kanai, M. Shibasaki, Tetrahedron Lett. 2002, 43, 3621-3624; b) B. M. 
Trost, J. D. Sieber, W. Qian, R. Dhawan, Z. T. Ball, Angew. Chem. Int. Ed. 2009, 48, 5478-
5481; c) L. F. Tietze, N. Tölle, D. Kratzert, D. Stalke, Org. Lett. 2009, 11, 5230-5233; d) L. 
Chabaud, Y. Landais, P. Renaud, Org. Lett. 2005, 7, 2587-2590; e) E. P. Balskus, E. N. 
Jacobsen, J. Am. Chem. Soc. 2006, 128, 6810-6812. 
[6] A. G. M. Barrett, J. Head, M. L. Smith, N. S. Stock, A. J. P. White, D. J. Williams, J. Org. Chem. 
1999, 64, 6005-6018. 
[7] B. M. Trost, M. T. Rudd, Org. Lett. 2003, 5, 1467-1470. 
[8] a) B. M. Trost, M. R. Machacek, Z. T. Ball, Org. Lett. 2003, 5, 1895-1898; b) B. M. Trost, M. 
J. Bartlett, Org. Lett. 2012, 14, 1322-1325; c) B. M. Trost, Z. T. Ball, K. M. Laemmerhold, J. 
Am. Chem. Soc. 2005, 127, 10028-10038; d) B. M. Trost, Z. T. Ball, T. Jöge, Angew. Chem. 
Int. Ed. 2003, 42, 3415-3418; e) B. M. Trost, Z. T. Ball, T. Jöge, J. Am. Chem. Soc. 2002, 124, 
7922-7923; f) B. M. Trost, Z. T. Ball, Synthesis 2005, 2005, 853-887; g) B. M. Trost, Z. T. 
Ball, J. Am. Chem. Soc. 2005, 127, 17644-17655; h) B. M. Trost, Z. T. Ball, J. Am. Chem. Soc. 
2003, 125, 30-31; i) B. M. Trost, Z. T. Ball, J. Am. Chem. Soc. 2001, 123, 12726-12727. 
[9] J. A. Marshall, K. C. Ellis, Org. Lett. 2003, 5, 1729-1732. 
[10] C. N. Foley, J. L. Leighton, Org. Lett. 2015, 17, 5858-5861. 
[11] K. Tamao, K. Maeda, T. Tanaka, Y. Ito, Tetrahedron Lett. 1988, 29, 6955-6956. 
[12] S. E. Denmark, W. Pan, Org. Lett. 2001, 3, 61-64. 
[13] a) H. C. Brown, G. Zweifel, J. Am. Chem. Soc. 1961, 83, 3834-3840; b) C. F. Lane, J. Org. 
Chem. 1974, 39, 1437-1438; c) G. W. Kabalka, H. C. Hedgecock, J. Org. Chem. 1975, 40, 
1776-1779. 
[14] K. Burgess, M. J. Ohlmeyer, Chem. Rev. 1991, 91, 1179-1191. 
[15] a) J. R. Waas, A. Sidduri, P. Knochel, Tetrahedron Lett. 1992, 33, 3717-3720; b) H. Li, P. J. 
Carroll, P. J. Walsh, J. Am. Chem. Soc. 2008, 130, 3521-3531. 
[16] M. M. Hussain, J. Hernández Toribio, P. J. Carroll, P. J. Walsh, Angew. Chem. Int. Ed. 2011, 
50, 6337-6340. 
[17] a) P. Y. S. Lam, C. G. Clark, S. Saubern, J. Adams, M. P. Winters, D. M. T. Chan, A. Combs, 
Tetrahedron Lett. 1998, 39, 2941-2944; b) D. A. Evans, J. L. Katz, T. R. West, Tetrahedron 
Lett. 1998, 39, 2937-2940; c) D. M. T. Chan, K. L. Monaco, R.-P. Wang, M. P. Winters, 
Tetrahedron Lett. 1998, 39, 2933-2936. 
[18] A. E. King, T. C. Brunold, S. S. Stahl, J. Am. Chem. Soc. 2009, 131, 5044-5045. 
[19] a) D. J. Winternheimer, C. A. Merlic, Org. Lett. 2010, 12, 2508-2510; b) B. M. Trost, D. C. 
Koester, A. N. Herron, Angew. Chem. Int. Ed. 2015, 54, 15863-15866; c) R. E. Shade, A. M. 
Hyde, J.-C. Olsen, C. A. Merlic, J. Am. Chem. Soc. 2010, 132, 1202-1203; d) A. Redden, R. J. 
Perkins, K. D. Moeller, Angew. Chem. Int. Ed. 2013, 52, 12865-12868; e) T. D. Quach, R. A. 
Chapter 4 – Oxidation of Alkenylstannanes 
87 
Batey, Org. Lett. 2003, 5, 1381-1384; f) M. Murata, K. Satoh, S. Watanabe, Y. Masuda, J. 
Chem. Soc., Perkin Trans. 1 1998, 1465-1466; g) P. Y. S. Lam, G. Vincent, C. G. Clark, S. 
Deudon, P. K. Jadhav, Tetrahedron Lett. 2001, 42, 3415-3418; h) P. Y. S. Lam, G. Vincent, 
D. Bonne, C. G. Clark, Tetrahedron Lett. 2003, 44, 4927-4931; i) F. Huang, T. D. Quach, R. 
A. Batey, Org. Lett. 2013, 15, 3150-3153; j) Q. Feng, K. Yang, Q. Song, Chem. Comm. 2015, 
51, 15394-15397; k) D. G. Chan, D. J. Winternheimer, C. A. Merlic, Org. Lett. 2011, 13, 
2778-2781. 
[20] P. Y. S. Lam, C. G. Clark, S. Saubern, J. Adams, K. M. Averill, D. M. T. Chan, A. Combs, Synlett 
2000, 674-676. 
[21] P. Y. S. Lam, G. Vincent, D. Bonne, C. G. Clark, Tetrahedron Lett. 2002, 43, 3091-3094. 
[22] N. Iranpoor, H. Firouzabadi, E. Etemadi Davan, A. Rostami, A. Nematollahi, J. Organomet. 
Chem. 2013, 740, 123-130. 
[23] A. Vakalopoulos, X. Kavazoudi, J. Schoof, Tetrahedron Lett. 2006, 47, 8607-8610. 
[24] A. Nishida, M. Shibasaki, S. Ikegami, Chem. Pharm. Bull. 1986, 34, 1423-1433. 
[25] a) M. Yamamoto, H. Izukawa, M. Saiki, K. Yamada, J. Chem. Soc., Chem. Comm. 1988, 560-
561; b) M. Yamamoto, S. Irie, M. Miyashita, S. Kohmoto, K. Yamada, Chem. Lett. 1989, 18, 
221-222. 
[26] J. R. Falck, J.-Y. Lai, D. V. Ramana, S.-G. Lee, Tetrahedron Lett. 1999, 40, 2715-2718. 
[27] J. Arunpanichlert, V. Rukachaisirikul, Y. Sukpondma, S. Phongpaichit, O. Supaphon, J. 
Sakayaroj, Arch. Pharm. Res. 2011, 34, 1633-1637. 
[28] Y. Lu, C.-Y. Huang, Y.-F. Lin, Z.-H. Wen, J.-H. Su, Y.-H. Kuo, M. Y. Chiang, J.-H. Sheu, J. Nat. 
Prod. 2008, 71, 1754-1759. 
[29] A. Bardon, C. A. N. Catalan, A. B. Gutiérrez, W. Herz, Phytochem. 1988, 27, 2989-2990. 
[30] M. Tsuda, T. Endo, J. i. Kobayashi, J. Org. Chem. 2000, 65, 1349-1352. 
[31] a) E. Wenkert, T. S. Arrhenius, B. Bookser, M. Guo, P. Mancini, J. Org. Chem. 1990, 55, 
1185-1193; b) L. M. Dollinger, A. R. Howell, J. Org. Chem. 1996, 61, 7248-7249; c) A. R. 
Howell, R. Fan, A. Truong, Tetrahedron Lett. 1996, 37, 8651-8654; d) K. Tanino, K. 
Aoyagi, Y. Kirihara, Y. Ito, M. Miyashita, Tetrahedron Lett. 2005, 46, 1169-1172; e) Y. 
Fang, C. Li, J. Am. Chem. Soc. 2007, 129, 8092-8093; f) P. J. Hickford, J. R. Baker, I. Bruce, K. 
I. Booker-Milburn, Org. Lett. 2007, 9, 4681-4684; g) P. S. Sabila, A. R. Howell, Tetrahedron 
Lett. 2007, 48, 8353-8355. 
[32] V. A. Bhanu, K. Kishore, Chem. Rev. 1991, 91, 99-117. 
[33] J. P. Adams, J. Chem. Soc., Perkin Trans. 1 2000, 125-139. 
 
 
Chapter 4 – Oxidation of Alkenylstannanes 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 - Fluorination of Alkenylstannanes 
89 
5. Fluorination of Alkenylstannanes and Synthesis of Peptide 
Bioisosters 
5.1. Introduction 
5.1.1. Fluorination in Organic Chemistry 
5.1.1.1. Late-stage Introduction of Fluorine 
The role of fluorine in synthetic and medicinal chemistry receives an ever increasing 
attention and over the past decades numerous review articles[1] and monographs[2] covered this 
topic. Fluorine plays a unique role in influencing the conformation, solubility, potency, 
permeability or degradability of small molecules. The late-stage introduction of fluorine is of 
great interest as it allows the modification of complex molecules without changing the synthetic 
route. Furthermore, small molecules from natural sources can be employed. An impressive 
example stems from the work of Groves and coworkers, who employed a manganese porphyrine 
catalyst in combination with iodosobenzene and silver fluoride to activate C-H bonds in a highly 
selective manner (Scheme 1).[3]  
 
Scheme 1. Selective fluorination of sclareolide by Groves and coworkers. 
Instead of relying on catalyst selectivity, a common strategy to introduce fluorine is the 
conversion of existing functionalities. In a recent disclosure, Li and coworkers showed that 
aliphatic carboxylic acids undergo silver catalyzed decarboxylative fluorination (Scheme 2).[4] 
 
Scheme 2. Silver catalyzed decarboxylative fluorination by Li and coworkers. 
Another strategy involves the selective activation of the substrate prior to the fluorination 
event by triflation. The resulting aryl triflates have recently been demonstrated to undergo 
fluorination with nucleophilic fluorinating agents. Important contributions have been made by 
the Buchwald group and a representative example with estrone triflate is shown in Scheme 3.[5]  
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Scheme 3. Palladium catalyzed fluorination of aryl triflates by Buchwald and coworkers. 
A related catalytic system was used to convert aryl bromides into the corresponding 
fluorides, exemplified by the fluorination of the vascular disorder drug Nicergoline (456) 
(Scheme 4).[6] 
 
Scheme 4. Palladium catalyzed fluorination of aryl bromides by Buchwald and coworkers. 
In 2011, Ritter and coworkers showed that phenols are converted into the corresponding 
fluorides utilizing Phenofluor[7] (Scheme 5).[8] In this elegant approach, no prior activation of the 
phenol is necessary as exemplified by the conversion of zearalenone into the corresponding 
fluorinated analog. Furthermore, the PhenoFluor reagent is a benchstable, easy-to-handle solid. 
 
Scheme 5. Deoxyfluorination of phenols by Ritter and coworkers. 
Other groups have used similar strategies employing aminodifluorosulfinium salts as 
deoxyfluorinating agents (Scheme 6). [9] XtalFluor-E was utilized for the direct transformation of 
androstenolone into the corresponding fluoride without the need of preceding activation of the 
hydroxyl group.  
 
Scheme 6. Deoxyfluorination of alcohols with XtalFluor-E by L’Heureux et al.. 
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5.1.1.2. Synthesis of Fluoroalkenes – State of the Art 
The synthesis of fluoroalkenes has received less attention and only few general protocols 
have been developed. A common way to install a fluorine atom is the application of existing 
olefination protocols utilizing a fluorine bearing reagent. In this vein, Wittig-[10] or Julia-
Kocienski-olefinations[11] have been developed, though with limited success (Scheme 7). 
 
Scheme 7. Olefination with methylenefluoride building blocks. 
A related approach was devised by Olah and coworkers exploiting an alkylation/elimination 
sequence to access different alkenyl fluorides (Scheme 8).[12] 
 
Scheme 8. Synthesis of fluorovinyl sulfones by Olah and coworkers. 
The major drawback of these approaches lies in the low E/Z selectivity along with a limited 
substrate scope. To circumvent these issues, different strategies have evolved. One elegant 
approach is the directed, gold catalyzed hydrofluorination of alkynes disclosed by Miller and 
coworkers (Scheme 9).[13] To control regioselectivity, propargyl alcohol and amine derivatives 
were employed that were able to coordinate to the cationic gold complex. 
 
Scheme 9. Gold catalyzed hydrofluorination by Miller and coworkers. 
Finally, Nevado and de Haro reported a gold mediated [1,3]-sigmatropic rearrangement of 
propargyl acetates to install the alkenyl fluoride (Scheme 10).[14] 
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Scheme 10. Gold catalyzed fluorination by Nevado and de Haro. 
Another very attractive way to install fluorine at a distinct position in an organic compound 
is the fluorination of an organometallic intermediate. Predominantly, boronic acid derivatives[15], 
silanes[15j, 16], and stannanes are employed. As we are mainly interested in the conversion of 
alkenylstannanes into the corresponding fluorides, the following chapter will cover that 
particular transformation. 
5.1.1.3. Synthesis of Csp2-F by Tin-Fluoride Exchange – State of the Art 
The first report of a tin-fluoride exchange on sp2-carbons was disclosed in 1981 by Adam 
and coworkers (Scheme 11).[17] By exposing phenyl tributylstannane (473) to fluorine gas at 
cryogenic temperature, the formation of fluorobenzene was observed. This initial discovery led 
to further developments by the same group employing acetyl hypofluorite.[18] Later, Chambers 
and coworkers demonstrated the utility of cesium fluoroxysulfate.[19] 
 
Scheme 11. Fluorination of aryl stannanes. 
Since these early reports, numerous advancements have been reported in the literature as 
fluorine gas or acetyl fluoride are difficult to handle, hazardous reagents. The most significant 
contributions were made by Tius and Kawakami in the early 90’s.[20] They found that 
alkenylstannanes (478) can be effectively fluorinated with xenon difluoride in the presence of a 
silver salt (Scheme 12). At the same time, Widdowsen and coworkers showed that cesium 
fluoroxysulfate is also capable of delivering the corresponding fluorides from alkenylstannanes 
(478).[21] McCarthy and coworkers utilized F-TEDA-BF4 (Selectfluor®)[22] for the synthesis of 
gem-vinyl fluorides 481.[23]  
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Scheme 12. Advancements in the synthesis of alkenyl fluorides from stannanes. 
This methodology has found applications in the synthesis of building blocks and 
pharmaceutically interestingly compounds (Scheme 13).[24]  
 
Scheme 13. Recent examples of alkenylfluoride synthesis via tin-fluoride exchange. 
In 2009, Ritter and coworkers found that an amalgamation of the conditions reported by 
Tius and McCarthy yields a highly effective protocol for the fluorination of aryl stannanes 
(Scheme 14).[25] One year later the same group reported a catalytic-in-silver protocol with an 
extended substrate scope and elucidated the role of the silver salt.[26] 
 
Scheme 14. Fluorination of aryl stannanes by Ritter and coworkers. 
 
 
Chapter 5 - Fluorination of Alkenylstannanes 
94 
5.1.2. Mechanistic Proposal for the Silver-mediated Fluorination of Stannanes 
In the first step, stannane 487 reacts with the silver salt to give the dinuclear silver-cluster 
488 (Scheme 15). Upon fluorination of the alkenylsilver, a formal two-electron oxidation with 
formation of a silver-silver bond gives complex 489. Reductive elimination furnishes 490 and 
recovers silver(I). During this process, the counterion of the silver salt captures the tributyltin 
cation. The resulting tin species can undergo hydrolysis or alcoholysis with the free alcohol to 
deliver HX. This potentially acidic species, e.g. TfOH or TsOH, can lead to rapid 
protodestannation of the starting material. Therefore, if the counterion X on silver has a weak 
corresponding acid, then protodestannation can be avoided. 
 
Scheme 15. Mechanistic proposal of the silver mediated tin-fluoride exchange. 
5.1.3. Motivation 
As is apparent from the examples outlined above, a general procedure for the 
transformation of alkenylstannanes into the corresponding fluorides is still lacking. Although 
major advancements have been disclosed for the conversion of aryl stannanes, these have not 
been extended to alkenyl derivatives. For example, Ritter and coworkers applied the catalytic 
protocol to the conversion of a terminal alkenylstannane which gave an isolated yield of 35%.[26] 
They attributed the low yield to the volatility of the product but no attempts were made to 
develop an optimized procedure. With the possibility to selectively access stereodefined 
alkenylstannanes, we sought of a way to explore the possibilities to synthesize the 
corresponding fluorides. Furthermore, as vinyl chlorides and bromides are abundant in nature, 
the corresponding fluoride analogs constitute interesting synthetic and biological targets. Lastly, 
fluoride isosters of amides can ultimately be addressed in an efficient manner.  
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5.2. Results and Discussion 
5.2.1. Initial Screening Results for the Tin-Fluoride Exchange 
We began our studies with standard substrate 248 (Table 1). At the outset, the most 
relevant conditions reported in the literature were tested to evaluate their potential in the 
synthesis of alkenylfluorides. Furthermore, as copper(II) salts are capable of forming the 
corresponding alkenylcopper species, copper(II) fluoride was also examined as a potential 
fluorinating agent. 
Table 1. Initial screening for the tin-fluoride exchange. 
 
adetermined by crude NMR analysis. 
Entry 
Ag-salt 
(mol%) 
F+-source 
(eq) 
Additive 
(eq) 
Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
1 - 
CuF2 
(2) 
Et3N (5) 
O2 
DMSO 
(0.125 M) 
r.t., 18 1 : 0 : 0 
2 - 
CuF2 
(2) 
Et3N (5) 
3Å MS 
DMSO 
(0.125 M) 
r.t., 18 1 : 6.4 : 0 
3 - 
CuF2 
(2) 
Et3N 
(5) 
DMSO 
(0.125 M) 
r.t., 18 1 : 0.9 : 0 
4 - 
CuF2 
(2) 
Et3N 
(5) 
DMSO 
(0.125 M) 
50°C,  18 1 : 2.2 : 0 
5 
AgOTf 
(10) 
F-TEDA-PF6 
(1.5) 
NaHCO3 
(2) 
Acetone 
(0.05 M) 
r.t., 18 0 : 1 : 0.9 
6 
Ag2O 
(5) 
F-TEDA-PF6 
(1.5) 
NaOTf (1) 
NaHCO3 (2) 
Acetone 
(0.05 M) 
r.t., 18 7.6 : 1 : 6.0 
7 
AgOTf 
(20) 
F-TEDA-BF4 
(1.2) 
Bu4NOP(O)Ph2 (2.0) 
Acetone 
(0.05 M) 
r.t., n.a. 0 : 1 : 0.8 
8 
AgOTf 
(20) 
F-TEDA-PF6 
(1.2) 
Bu4NOP(O)Ph2 (2.0) 
Acetone 
(0.05 M) 
r.t., n.a. 0 : 1 : 0.7 
9 
AgOTf 
(20) 
F-TEDA-PF6 
(1.2) 
Bu4NOP(O)Ph2 (2.0) 
DTBMP (0.2) 
Acetone 
(0.05 M) 
r.t., n.a. 0 : 1 : 0.5 
10 
AgOTf 
(40) 
F-TEDA-BF4 
(1.2) 
Bu4NOP(O)Ph2 (3.0) 
H2O/PhF 
(0.05 M) 
r.t., n.a. 0 : 1 : 0.0 
11 
AgOTf 
(200) 
F-TEDA-BF4 
(1.2) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 1.1 
12 
AgOTf 
(200) 
F-TEDA-PF6 
(1.2) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 1.9 
Chapter 5 - Fluorination of Alkenylstannanes 
96 
We found that copper(II) fluoride exclusively led to protodestannation of the starting 
material (entries 1-4). Under the reported catalytic-in-silver conditions of Ritter and 
coworkers[26], unsatisfying conversion was observed (entries 5-6). The low selectivity (entry 5) 
and low conversion (entry 6) led us to examine the role of a suitable tin scavenger. According to 
the mechanistic proposal from Ritter and coworkers, in situ formation of HX promotes 
protodestannation. 
Fürstner and others have previously reported that the addition of tetrabutylammonium 
diphenylphosphinate (TBDPP) to Stille cross-coupling reactions exhibited a promoting effect by 
quenching tributyltin halides.[27] Unfortunately, the addition of TBDPP alone or in conjunction 
with di-tert-butylmethyl pyridine (DTBMP)[20a] did not lead to any improvement (entries 7-10). 
With these results in hand, we found that the previously reported stoichiometric protocol might 
offer a possible solution (entries 11-12)[25]. In accordance to Ritter and coworkers, employing F-
TEDA-PF6 instead of Selectfluor® (F-TEDA-BF4) a significant improvement in selectivity was 
observed. 
5.2.2. Optimization of Reaction Conditions for the Tin-Fluoride Exchange 
With the optimal fluorinating agent identified, we examined the role of other parameters on 
the reaction outcome (Table 2). As the employed silver salt exhibits a major impact on the 
reaction outcome, different silver salts were tested. Although we found no beneficial effect of 
TBDPP in the catalytic version of the fluorination, we decided to exam silver 
diphenylphosphinate (AgDPP) in a stoichiometric protocol.  
The synthesis of AgDPP is straightforward and was disclosed by Wiberg and coworkers in 
1981.[28] Reaction of silver nitrate with in situ formed sodium diphenylphosphinate in water 
provides AgDPP as a non-hygroscopic, bench-stable solid in quantitative yield. We were pleased 
to discover that this reagent performed much better than all other silver sources (e.g. AgOTf or 
AgOTs) (entries 1-3), emphasizing the importance of the silver counterion. Again, a marked 
difference in selectivity between F-TEDA-BF4 and F-TEDA-PF6 was observed (entry 4). Different 
solvents or solvent combinations did not result in any improvement of selectivity (entries 5-12).  
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Table 2. Further screening of reaction parameters for tin-fluoride exchange. 
 
adetermined by crude NMR analysis. 
The first improvement was made by increasing the amount of F-TEDA-PF6 from 150 mol% 
(entry 1) to 200 mol% (entry 2) (Table 3). Performing the reaction under ice cooling had only a 
minor impact on the selectivity (entry 3). This approach was not pursued further as the reaction 
time increased dramatically. In their disclosure[20a], Tius and Kawakami noted that increased 
reaction times led to an increase in protodestannation. This was attributed to insufficient 
quenching of the intermediate silver species. This proposal was quickly confirmed, as slow 
addition of the fluorinating agent resulted in a decrease in selectivity (entry 4) whereas slow 
addition of the stannane afforded increased selectivity (entry 5). Extending the addition time 
Entry 
Ag-salt 
(mol%) 
F+-source 
(eq) 
Additive Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
1 
AgOTf 
(200) 
F-TEDA-PF6 
(1.2) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 1.9 
2 
AgOTs 
(200) 
F-TEDA-PF6 
(1.2) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 0.4 
3 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 2.4 
4 
AgOP(O)Ph2 
(200) 
F-TEDA-BF4 
(1.2) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 0.5 
5 
AgOP(O)Ph2 
(200) 
F-TEDA-BF4 
(1.2) 
3 Å MS 
Acetone 
(0.05 M) 
50°C,  48 0.8 : 1 : 2.7 
6 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
3 Å MS 
Acetone 
(0.05 M) 
50°C,  48 0.7 : 1 : 1.1 
7 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
DMF 
(0.05 M) 
r.t., 0.25 0 : 1 : 2.1 
8 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
DMSO 
(0.05 M) 
r.t., 0.25 0 : 1 : 0.0 
9 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
THF 
(0.05 M) 
r.t., 0.25 0 : 1 : 0.0 
10 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
MeCN 
(0.05 M) 
r.t., 0.25 0 : 1 : 2.1 
11 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
Acetone/DMF 
(0.05 M) 
r.t., 0.25 0 : 1 : 2.4 
12 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.2) 
- 
Acetone* 
(0.05 M) 
r.t., 0.25 0 : 1 : 1.7 
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from 30 minutes to 1 h and finally reducing the amount of silver salt, provided the product in 
excellent selectivity with only minor amounts of protodestannation (entries 6-11). AgDPP in the 
absence of F-TEDA-PF6 furnished exclusively protodestannation product 492 (entry 12). F-
TEDA-PF6 in absence of AgDPP in turn yields an undefined mixture of products (entry 13).  
Table 3. Final adjustments of reaction conditions. 
 
adetermined by crude NMR analysis. 
Entry 
Ag-salt 
(mol%) 
F+-source 
(eq) 
Additive 
(eq)/comment 
Solvent 
T [°C] 
t [h] 
Ratioa 
(A : B : C) 
1 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(1.5) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 2.6 
2 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
- 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 3.1 
3 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
- 
Acetone 
(0.05 M) 
0°C, 18 0 : 1 : 4.1 
4 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
dropwise 
addition of  
F-TEDA-PF6 
Acetone 
(0.05 M) 
r.t., 0.25 0 : 1 : 2.6 
5 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
syringe pump 
addition of 
stannane 
Acetone 
(0.05 M) 
r.t., 0.5 0 : 1 : 4.4 
6 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
syringe pump 
addition of 
stannane 
Acetone 
(0.05 M) 
r.t., 1.0 0 : 1 : 5.8 
7 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
syringe pump 
addition of 
stannane 
Acetone 
(0.04 M) 
r.t., 1.0 0 : 1 : 2.7 
8 
AgOP(O)Ph2 
(120) 
F-TEDA-PF6 
(2.0) 
syringe pump 
addition of 
stannane 
Acetone 
(0.05 M) 
r.t., 1.0 0 : 1 : 11 
9 
AgOP(O)Ph2 
(120) 
F-TEDA-PF6 
(1.2) 
syringe pump 
addition of 
stannane 
Acetone 
(0.05 M) 
r.t., 1.0 0 : 1 : 3.4 
10 
AgOP(O)Ph2 
(200) 
F-TEDA-PF6 
(2.0) 
syringe pump 
addition of 
stannane 
Acetone 
(0.05 M) 
r.t., 0.5 0 : 1 : 4.4 
11 
AgOP(O)Ph2 
(120) 
F-TEDA-PF6 
(2.0) 
syringe pump 
1.0 mmol 
Acetone 
(0.05 M) 
r.t., 1.0 0 : 1 : 13 
12 
AgOP(O)Ph2 
(120) 
- - 
Acetone 
(0.05 M) 
r.t., 1.0 0 : 1 : 0 
13 - 
F-TEDA-PF6 
(2.0) 
- 
Acetone 
(0.05 M) 
r.t., 18 
mixture of 
prod. 
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Having established a protocol for the tin-fluoride exchange of alkenylstannes, the scope of 
this reaction was probed on a variety of different substrates (Scheme 16). 
 
 
Scheme 16. Substrate scope of the silver-mediated tin-fluoride exchange. 
A range of different functional groups was evaluated. Neighboring primary (494), 
secondary (496) and tertiary alcohols (495) do not affect the reactivity. Free alcohols (497), 
nitriles (498), aldehydes (502), silyl protecting groups (507), esters (506) or pthalimides (499) 
are well tolerated. Furthermore, the neighboring alcohol is not essential for reactivity (505). 
Tosylamides 500 and 503, and homoallylic alcohols (504) also serve as fruitful substrates. To 
confirm the retentive nature of this transformation, single-crystal X-ray analysis of amide 503 
provided conclusive evidence. Additionally, X-ray analysis of the corresponding stannane 508 
was obtained. Both structures are shown in Figure 1. Evidently, the trans-arrangement of the 
double-bond is conserved during the process. Another noticeable feature in fluorinated 
tosylamide 503 is the orientation of the amide hydrogen towards the alkenyl fluoride. It has 
been proposed in the literature that this hydrogen bonding is essential to stabilize a preferred 
conformation.  
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5.2.3. Aminofluoroolefins as Peptide Bioisosters 
5.2.3.1. Background and Application of Aminofluoroolefins 
Peptides play an important role in biology and medicine as they function as hormones, 
enzyme substrates or neurotransmitters in the human body. Although being potentially very 
potent compounds for drug-use, their lack of bioavailability and stability is a major concern. 
These drawbacks stem from the lability of the amide bond to hydrolysis during metabolism. To 
circumvent this pitfall, strategies have evolved to replace sensitive positions in peptides by 
mimetic motifs to improve the biological profile.[29] One of these approaches involves the 
replacement of the amide carbonyl by an alkenylfluoride (Figure 2). These aminofluoroolefins 
have been shown to mimic the steric and electronic nature of an amide but lack their hydrolytic 
lability.  
 
Figure 2. Amide vs. aminofluoroolefin. 
Peptidomimetics with this structural motif were evaluated as peptidase IV(CD26)[30] and 
IV(DPP IV)[31] inhibitors, GPR54-agonists[32], hepatitis C virus NS5A inhibitors[33], small alpha-
helical anti-HIV analogs[34], transporter probes (PEPT1)[35] or CXCR4 antagonists[36]. 
Peptidomimetic analogs of established drugs, e.g. KRN7000[37] or Enalapril[38] demonstrate 
improved metabolic stability. Consequently, a variety of methods have been developed to access 
this important motif. 
 
Figure 1. X-ray crystal structures of alkenylstannane 508 and corresponding fluoride 503. 
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5.2.3.2. State of the Art in the Preparation of Aminofluoroolefins 
The first reports on the synthesis and biological properties of aminofluoroolefins were 
unveiled by Allmendinger and coworkers in 1990 (Scheme 17).[39] In these landmark 
communications, syntheses of (E)- and (Z)-isomeric aminofluoroolefins were disclosed.  
A Reimer-Tiemann-type reaction of 2,3-dihydrofuran under phase-transfer conditions 
delivered key fluorinated building block 509. Hydrolysis and protection provided access to 
aldehyde 510. With this intermediate in hand, either the primary amine 511 or the secondary 
amine 512 was accessed in 8 or 5 steps, respectively. 
 
Scheme 17. Synthesis of aminofluoroolefins by Allmendinger and coworkers. 
An enantioselective variant employing a different strategy was also reported starting from 
vinyl ether 513 (Scheme 18). Cyclopropanation and ring opening delivered aldehyde 514 which 
underwent a Duthaler-Hafner-type aldol reaction[40]. The corresponding allyl amine was 
accessed via an Overman rearrangement to give amide 516. Functional group manipulations 
finally furnished aminofluoroolefin 517 in good yield and high enantiomeric excess.  
 
Scheme 18. Enantioselective synthesis of aminofluoroolefins. 
Other methods involving metal catalyzed or organocatalytic defluorinations of gem-
difluoroolefins have been developed. The group of Otaka disclosed a number of different 
strategies in the past years (Scheme 19). Aldehyde 518 is treated under Stetter-type conditions 
to yield aminofluoroolefin ester 519 via redox defluorination of the gem-difluoroolefin.[41]  
Chapter 5 - Fluorination of Alkenylstannanes 
102 
 
Scheme 19. Redox defluorination by Otaka and coworkers. 
Similar strategies involve the reduction of gem-difluoroolefins with stoichiometric 
samarium diiodide[42] or chromium dichloride[43], catalytic palladium(0)[44] or under classic 
Stetter conditions with potassium cyanide.[45] An interesting modification of these procedures is 
the reduction of 520 with a cuprate and subsequent treatment with an electrophile, e.g. allyl 
bromide as reported by Fujii and coworkers (Scheme 20).[35, 46] 
 
Scheme 20. Copper mediated defluorination/alkylation by Fujii and coworkers. 
A different approach to convert gem-difluoroolefins into the corresponding fluoroolefins, 
exploits a SN2’-displacement of one of the fluorides by an organometallic reagent. The group of 
Taguchi found that this displacement could be realized by the addition of copper reagents in the 
presence of trimethylaluminum (Scheme 21)[47]. The high syn-selectivity was attributed to an 
activation of one of fluorides by the Lewis acid. 
 
Scheme 21. Aluminum and copper mediated allylic displacement by Taguchi and coworkers. 
Similar protocols have been disclosed by the same group to extend the scope of this 
reaction.[48] Another approach was followed by Pannecoucke and coworkers by asymmetric 
addition of organometallic reagents to Ellman’s sulfoximines (Scheme 22).[49] These substrates 
have been proven to undergo highly diastereoselective 1,2-additions with a variety of carbon 
nucleophiles to furnish the corresponding amines.[50] 
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Scheme 22. Diastereoselective adddition of Grignard reagents to sulfoximines by Pannecoucke and coworkers. 
Recently the diastereoselective reduction of the respective ketimines has also been 
reported.[51] Alternative methods include the organocatalytic monofluorovinylation of imines[52] 
or the stereoselective opening of gem-difluorocyclopropanes.[53] 
5.2.3.3. Synthesis of Aminofluoroolefins by Tin-Fluoride Exchange 
We developed a route to access aminofluoroolefins by late-stage fluorination of the 
corresponding alkenylstannane. In contrast to the presented approaches, our strategy allows us 
to assemble the carbon backbone independent of available fluorinated building blocks (Scheme 
23). 
 
Scheme 23. Synthesis alkenylstannane precursor for aminofluoroolefin synthesis. 
First, a pyrrolidine catalyzed condensation of iso-valeraldehyde with chiral amine 526 
furnished sulfoximine 527. Diastereoselective addition of hexynylmagnesium chloride delivered 
protected propargyl amine 528 with good yield and excellent diastereoselectivity. Acid-
mediated hydrolysis and protection with diphenylphosphonyl chloride provided access to 529 
which smoothly underwent ruthenium-catalyzed hydrostannation, yielding alkenylstannane 
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530 in a concise way. Notably, all residues of the propargyl amine can be altered, simply by 
employing different aldehydes, alkynes and protecting groups, respectively.  
The fluorination under optimized reaction conditions worked uneventfully and in generally 
good yield (Scheme 24). 
 
 
Scheme 24. Fluoropeptidomimetics obtained by tin-fluoride exchange. 
As evident from this library, different protecting groups on the nitrogen are tolerated, 
exemplified by the Bus- [54], Nosyl- or Cbz-groups. Furthermore, a diphenylphosphinamide is 
compatible as well. This approach potentially allows access to variety of new peptidomimetics 
that could not be easily prepared by any previous method. 
5.3. Conclusion and Outlook 
A protocol for the conversion of alkenyltin derivatives into the corresponding fluorides was 
developed. By employing AgDPP as a mediator and F-TEDA-PF6 as the fluorinating agent, a 
library of new alkenylfluorides was successfully synthesized (Scheme 25). This new procedure 
tolerates a variety of functional groups and the required reagents are bench-stable and easy-to-
handle solids. Furthermore, the same protocol provided access to interesting peptidomimetics 
comprising an aminofluoroolefin substructure.  
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The utility of this method will be tested in the context of late-stage diversification to permit 
the synthesis of non-natural analogs. 
 
Scheme 25. Silver mediated fluorination of alkenylstannanes. 
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6. Diverted Total Synthesis of 5,6-Dihydrocineromycin B 
6.1. Introduction 
6.1.1. Diverted Total Synthesis 
In 2006, Danishefsky introduced the term ‘diverted total synthesis’ (DTS).[1] The idea behind 
this concept is the proposition that natural products are not optimized for the biological activity 
that mankind desires. Structural modifications are therefore often necessary to improve their 
biological profile. This strategy has found numerous applications in total synthesis and 
medicinal chemistry and a selection will be presented in the following section.[2] 
6.1.1.1. Diverted Total Synthesis of Latrunculin B 
In 2003, Fürstner and coworkers disclosed a concise total synthesis of latrunculin B (557) 
(Scheme 1).[3] The three main fragments 550, 551 and 554 were joined together by an aldol 
reaction, an acylation followed by a ring-closing-alkyne metathesis (RCAM). Subsequent Lindlar 
reduction and deprotection of 556 furnished latrunculin B (557). 
 
Scheme 1. Total synthesis of latrunculin B by Fürstner and coworkers. 
This highly modular synthetic strategy was then used to create a library of unnatural 
analogs that were tested for their microfilament disrupting activity (Scheme 2).[2l] Variations in 
ring sizes or degrees of unsaturation could easily be introduced by modification of carboxylate 
fragment 554 or aldehyde 550. Additionally, the thiazolidinone moiety in fragment 551 could 
be replaced by an analogous oxazolidinone. Interestingly, it was found that bis-desmethyl-oxo-
analog 566 exhibited higher activity than latrunculin B and proved to be as potent as latrunculin 
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A (562), the most active member in this natural product family. Furthermore, the scalable route 
to 566 was significantly shorter than that to latrunculin B (557). 
 
Scheme 2. Natural latrunculin B analogs and latrunculin A by Fürstner and coworkers. 
6.1.1.2. Diverted Total Synthesis of Amphidinolide V 
In 2007, the same group reported a total synthesis of amphidinolide V 571 (Scheme 3).[4] At 
the outset of this synthetic endeavor the absolute configuration of the target was unknown. 
Therefore, a small library of compounds was prepared to ultimately unravel the absolute 
configuration.[5] The highly modular approach allowed the group to rapidly access various 
stereoisomers. Additional modification of the side-chain was achieved to determine its role in 
biological activity. 
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Scheme 3. Synthesis and structure of amphidinolide V and its analogs by Fürstner and coworkers. 
Cytotoxicity assays of the analogs against P388 murine lymphoma cells revealed that 
inversion of any stereoconfiguration or the alkene geometry led to complete loss of biological 
activity. In addition, only small changes on the side-chain were tolerated. In summary, 
biologically active synthetic analogs can be obtained, provided that the core structure of 
amphidinolide V is retained. 
6.1.1.3. Diverted Total Synthesis of Migrastatin 
In 2003, Danishefsky and coworkers accomplished a total synthesis of migrastatin (578) 
(Scheme 4).[6] Subsequent biological evaluation of its analogs revealed that the glutaramide side-
chain was nonessential for bioactivity.[2f, 7] With ether analog 589 the most potent member was 
finally encountered.[2g, 8] Analog 589 is an effective inhibitor of transwell cancer cell migration of 
human breast cancer cell lines. The highly convergent synthesis plan enabled efficient and 
selective modifications of the desired positions in the molecule, ultimately leading 589 that was 
more potent than the natural product itself.  
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Scheme 4. Diverted total synthesis of migrastatin (578) and its analogs by Danishefsky and coworkers. 
6.1.1.4. Diverted Total Synthesis of Promysalin 
Determination of the biological mode of action of a natural product can be aided by diverted 
total synthesis. A total synthesis of promysalin (590) was recently disclosed by Wuest and 
coworkers and its biological profile was evaluated (Scheme 5).[9] During these studies, it was 
found that promysalin (590) effectively inhibits the growth of Pseudomonas aeruginosa at 
nanomolar concentrations. It was hypothesized that promysalin acts as a chelating agent for 
intracellular Fe3+ through a hydrogen-bonding network. This proposal could be validated by 
synthesizing a small library of compounds.[2e] Biological evaluation of the analogs quickly 
revealed that only minor perturbations of the parent structure were tolerated and that the 
methylated analogs 598 and 600 were essentially inactive. Only the fluoro-derivative 596, 
desoxy-derivate 599 and olefin-derivative 601 exhibited biological activity comparable to the 
parent compound.  
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Scheme 5. Diverted total synthesis of promysalin and its analogs by Wuest and coworkers. 
6.1.1.5. Diverted Total Synthesis of Actinophyllic Acid 
Total synthesis of actinophyllic acid (606) was recently achieved by Martin and coworkers 
(Scheme 6).[2j, 10] The key step involving a Lewis acid mediated carbocation/-nucleophile 
cascade allows rapid access to intermediate 604. After routine manipulations, 606 was obtained 
in good overall yield. In addition, the analogs highlighted and the natural product itself were 
screened for their ability to induce cell death in Hs578t human breast cancer cell lines. Although 
actinophyllic acid (606) was completely inactive, analog 612 exhibited appreciable potency and 
was additionally tested against other cell lines (human lymphoma U937, human lung cancer 
A549 and human glioblastoma U87) having IC50 values of ∼5-8 μM, respectively. 
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Scheme 6. Total synthesis of actinophyllic acid and analogs by Martin and coworkers. 
In summary, diverted total synthesis proved to be an important tool for the development of 
new pharmaceutical lead structures and provides insight into the mode of action of these 
compounds. Furthermore, new pharmacophores made available by the assembly line can be 
tested for their biological activity and might in turn serve as new lead structures, c.f. migrastatin 
analog 589.  
6.1.2. Isolation and Biological Activity of 5,6-Dihydrocineromycin B 
Cineromycin B (613) was isolated in 1966 by Miyairi et al.[11] (Figure 1). Thirty years later, 
Zeeck and coworkers reported the isolation of additional members of the cineromycin family 
from Streptomyces Sp. Gö 40/10 and Streptomyces griseoviridis (FH-S 1832) in 1996[12] and 
1999[13], respectively. The characteristic feature of this class of natural products is the 14-
membered macrolactone with an (S)-configured tertiary alcohol at positions 4. Position 7 bears 
an additional oxygen functionality, generally in the alcohol oxidation state. Different degrees of 
unsaturation, inverted stereochemistry (619), methylation (617), or oxidation state (618) 
distinguish the group members. In a preliminary biological evaluation, 5,6-dihydrocineromycin 
B (615) and other cineromycin metabolites showed weak activity against Staphylococcus aureus. 
This result is in stark contrast to the reported significant antibacterial activity of albocycline 
(617) against methicillin-resistant Staphylococcus aureus (MRSA).[14]  
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Figure 1. Structures of isolated members of the cineromycin family. 
6.1.3. Previous Syntheses of 5,6-Dihydrocineromycin B 
Due to its relatively ‘simple’ structure but promising biological profile, 5,6-
dihydrocineromycin B (615) has received much attention from the synthetic community. Two 
total syntheses and one formal synthesis have been disclosed to date and will be discussed in 
this scetion. 
6.1.3.1. Total Synthesis of 5,6-Dihydrocineromycin B by Tietze and Völkel 
In 2001, Tietze and Völkel reported the first total synthesis of 5,6-dihydrocineromycin B 
(615).[15] Their retrosynthetic route is illustrated in Figure 2. It consists of an unselective 
addition of alkyllithium 624, derived from the corresponding iodide, into aldehyde 621. 
Macrolactonization and functional group manipulations finalize the synthesis of 615. The 
required acid was obtained via hydroboration/oxidation of terminal olefin 624. Aldehyde 621 
was obtained by hydroboration/Suzuki cross-coupling of 622 with iodide 623. The chiral 
homoallyl alcohol 624 was synthesized from asymmetric allylation of ketone 625. 
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Figure 2. Retrosynthetic analysis of 5,6-dihydrocineromycin B by Tietze and Völkel. 
In the forward sense, alcohol 622 was protected and subjected to hydroboration/Suzuki 
cross-coupling with 623, followed by selective deprotection and oxidation to give aldehyde 621 
(Scheme 7). Iodide 624 was prepared in 7 steps starting from ketone 625.[16] The two fragments 
were joined via alkyllithium addition to give after silylation and hydroboration/oxidation 
alcohol 627. seco-Acid 628 was obtained in 3 additional steps. Macrolactonization, Saegusa 
oxidation, and deprotection of TBDPS and PMB protecting groups furnished 615 as a single 
diastereomer in 19 steps from ketone 625 with an overall yield of 1%. 
 
Scheme 7. Total synthesis of 5,6-dihydrocineromycin B by Tietze and Völkel. 
The major drawback in this synthesis is the non-stereoselective 1,2-addition of the 
alkyllithium species derived from iodide 624 to aldehyde 621, even though the undesired 
diastereomer could be recycled by oxidation and Noyori reduction with only modest 
diastereoselectivity.  
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6.1.3.2. Total synthesis of 5,6-dihydrocineromycin B by Zhai and coworkers 
Another total synthesis of 5,6-dihydrocineromycin B (615) was reported by Zhai and 
coworkers in 2009 following an alternative strategy.[17] The key retrosynthetic analysis is 
illustrated in Figure 3 and consists of ring-closing Horner-Wadsworth-Emmons (HWE) 
olefination and Steglich esterification. The crucial fragments 630 and 632 were derived from the 
‘chiral pool’ building blocks geraniol (631) and (‒)-linalool (633), respectively.  
 
Figure 3. Retrosynthetic analysis of 5,6-dihydrocineromycin B by Zhai and coworkers. 
The forward synthesis commenced with conversion of geraniol (631) into tosylate 634 in 3 
steps by Sharpless epoxidation, reductive epoxide opening and tosylation (Scheme 8). Reductive 
detosylation and Mitsunobu inversion furnished alcohol 630. The second fragment was made 
from (‒)-linalool via TES protection, selective oxidative cleavage followed by alkylation and 
oxidation to give aldehyde 632. Wittig olefination and saponification yielded acid 635. Steglich 
esterification and subsequent oxidative cleavage of alkene 629, and crucial HWE olefination 
delivered macrocycle 636. As reported previously by Tietze and Völkel, the ensuing Noyori 
reduction furnished the alcohol in 615 with modest diastereoselectivity of 2.5:1. Desilylation 
completed the total synthesis of 5,6-dihydrocineromycin B in 12 steps in the longest linear 
sequence with an overall yield of 7%. The major drawback of this synthesis is again the poor 
enantioselectivity in the formation of the alcohol at position 7. 
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Scheme 8. Total synthesis of of 5,6-dihydrocineromycin B by Zhai and coworkers. 
6.1.3.3. Formal synthesis of 5,6-dihydrocineromycin B by Rao and coworkers 
A synthesis of TES-protected 5,6-dihydrocineromycin B was accomplished by Rao and 
coworkers in 2012.[18] Key disconnections are shown in Figure 4. A ring-closing alkene 
metathesis and Yamaguchi esterification were employed to join fragments 638 and 640. Alcohol 
638 was derived from 4-pentenol (639) whereas --unsaturated acid 640 originated from diol 
641. 
 
Figure 4. Retrosynthetic analysis of 5,6-dihydrocineromycin B by Rao and coworkers. 
The forward synthesis is presented in Scheme 9. 4-Pentenol (639) was elaborated in 4 steps 
to diol 642 including oxidation/Wittig reaction, DIBALH reduction, Sharpless epoxidation, and 
epoxide opening. Subsequent tosylation and reductive detosylation furnished alcohol 638. cid 
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640 was synthesized starting from propanediol (643). Selective protection, oxidation/Wittig 
reaction of 643 were followed by DIBALH reduction, Sharpless epoxidation, and reductive 
epoxide opening to give diol 641. Oxidation/HWE reaction and TES protection set the stage for 
PMB deprotection, another oxidation/alkylation/oxidation sequence, and final ester hydrolysis 
to furnish acid 640. Yamaguchi esterification, CBS reduction, and ring-closing alkene metathesis 
completed the formal synthesis of 5,6-dihydrocineromycin B (615) in 14 steps in the longest 
linear sequence with an overall yield of 11%. Although excellent stereocontrol was achieved at 
the previously problematic tertiary hydroxyl group at position 7, the crucial ring closing alkene 
metathesis gave only 40% yield. 
 
Scheme 9. Formal synthesis of 5,6-dihydrocineromycin B by Rao and coworkers. 
All approaches disclosed to date have major shortcomings. The syntheses of Tietze et al. and 
Zhai et al. were unable to provide a reliable access to only one diastereomer of the natural 
product, whereas the formal synthesis of Rao failed to deliver good yields in the key ring-closing 
event. Furthermore, all approaches hardly allow the concept of diverted total synthesis to be 
pursued as no intermediate amenable to late-stage diversification is passed through. 
6.1.4. Motivation 
Our goal was to design a route that exploits the possibility granted by the directed trans-
selective hydrostannation of propargyl alcohols.[19] In addition, late-stage installation of an 
alkenylstannane would enable us to introduce a variety of different functionalities and 
demonstrate the flexibility of this new tool (Figure 5). Having established new synthetic 
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transformations of alkenylstannanes in prior projects disclosed herein, stannane 645 served as 
the key intermediate. 
 
Figure 5. Concept for late-stage transformation of alkenylstannanes. 
6.2. Results and Discussion 
The following synthesis project was executed in close cooperation with Johannes Preindl[20] and 
Stephan M. Rummelt[21], their contributions are highlighted.  
6.2.1. Retrosynthetic Analysis 
As mentioned above, the key intermediate 647 obtained by directed trans-selective 
hydrostannation of a propargyl alcohol, would serve to access either 5,6-dihydrocineromycin B 
(615) or its analogs 646 (Figure 6). The crucial propargyl alcohol would in turn be derived from 
esterification and ring-closing alkyne metathesis (RCAM) of fragments 648 and 650 which can 
be traced back to ()-citronellene and ()-linalool, respectively.  
 
Figure 6. Retrosynthetic analysis of 5,6-dihydrocineromycin B (615). 
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6.2.2. Total Synthesis and DTS of 5,6-dihydrocineromycin B 
Our synthesis commenced with chemoselective ozonolysis of ()-citronellene (649) 
followed by oxidation of the resulting aldehyde to give acid 651 (Scheme 10). Subsequent 
iodolactonization and dehalogenation with tributyltin hydride furnished lactone 652.[22] Finally, 
dichloroolefination and copper-catalyzed lactone opening/methylation delivered alkynol 648 in 
good overall yield.[23] 
 
Scheme 10. Synthesis of alcohol 648 (J. Preindl). 
In order to prepare acid 650, ()-linalool (633) was subjected to TES protection and 
ozonolysis of the more electron-rich olefin[24] to give aldehyde 653, which then underwent 
Carreira alkynylation[25] and TBS protection to provide propargyl alcohol 654 (Scheme 11). 
Selective ozonolysis of the olefin in the presence of the alkyne followed by HWE olefination[26] 
furnished fragment 650 in high overall yield. 
 
Scheme 11. Synthesis of acrylic acid 650 (S. M. Rummelt). 
The two fragments were then joined by a Steglich esterification, and the resulting diyne was 
exposed to standard RCAM conditions to furnish alkyne 655 in good yield.[27] Double desilylation 
was accomplished with HF·pyridine, and the crucial trans-selective hydrostannation gave 
stannane 647 in high overall yield and >20:1 regioselectivity. 
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Scheme 12. Synthesis of key stannane 647 (H. Sommer, S. M. Rummelt). 
After some optimization, the crucial methyl Stille cross-coupling reaction[28] successfully 
completed the total synthesis of 5,6-dihydrocineromycin B (615). Notably >100 mg of the 
natural product were obtained in a single-batch in 10 longest linear steps (16 steps total) with 
an overall yield of 32% (Scheme 13). With stannane 647 in hand, we were able to prepare 
alkenyl chloride 656 and protodestannation product 657 in good yield. Furthermore, Lindlar 
reduction of the deprotected alkyne 655 gave the corresponding cis-olefin isomer 658. Finally, 
deprotection of alkyne 655 with TBAF unexpectedly yielded oxa-Michael adduct 659 in 
excellent yield. Its structure was confirmed by single-crystal X-ray crystallography. 
 
Scheme 13. Completion of DTS of 5,6-dihydrocineromycin B (J. Preindl, S. M. Rummelt, H. Sommer). 
With a substantial amount of stannane 647 in hand, the applicability of the protocols 
developed herein was probed. Stannane 647 smoothly underwent the oxidative palladium-
catalyzed methoxy carbonylation to give unsaturated ester 660 (Scheme 14). Copper-mediated 
oxidation furnished -acetoxy ketone 661. Finally, silver-mediated fluorination delivered 
alkenyl fluoride 662. 
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Scheme 14. Application of new methodologies in DTS of 5,6-dihydrocineromycin B. 
As shown in Scheme 13 and Scheme 14 the natural product and a total of seven analogs 
were obtained either from stannane 647 or its precursor alkyne 655.  
6.3. Conclusion and Outlook 
A highly convergent and efficient total synthesis of 5,6-dihydrocineromycin B has been 
described. Key transformations of this endeavor comprise a RCAM, a directed trans-selective 
hydrostannation, and an unprecedented methyl Stille cross-coupling. Furthermore, by exploiting 
the concept of diverted total synthesis, a variety of non-natural analogs was obtained. The key 
alkenylstannane 647 was utilized as a platform to showcase the newly developed reactions 
described in the previous chapters. Additional novel methodologies could be tested on stannane 
647 to demonstrate their feasibility in future natural product synthesis efforts. 
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7. Summary 
The work presented herein describes new methodologies for the selective synthesis of 
trisubstituted olefins and their applications. Five different topics which have been covered, are 
summarized in the following sections. 
7.1. Directed Hydroboration of Propargyl Alcohols and Suzuki Cross-Coupling 
for Selective Synthesis of Trisubstituted Olefins 
Hydroxyl-directed hydroboration/Suzuki cross-coupling of propargyl alcohols to yield 
stereodefined trisubstituted olefins was developed. It was found that an in situ generated 
hemiacetal enhanced the directing effect of the propargyl alcohol. Experimental data suggested 
that electronic and steric factors determine the regioselectivity of the reaction rather than 
covalent directing effects. The alkenylboronates formed in situ were directly transformed via 
Suzuki cross-coupling into various trisubstituted olefins. Numerous aryl-, alkenyl-, alkyl- and 
alkynyl-halides successfully underwent the cross-coupling (Scheme 1). This methodology has 
found a first application in the synthesis of putative orevactaene. 
 
Scheme 1. Hydroxyl-directed hydroboration/Suzuki cross coupling. 
7.2. Hydroxyl-Assisted Carbonylation of Alkenyltin Derivatives: Development 
and Application to a Formal Synthesis of Tubelactomicin A 
The recently disclosed ruthenium-catalyzed directed trans-selective hydrostannation of 
alkynes prompted us to develop robust and synthetically useful transformations of 
alkenylstannanes. To this end, hydroxyl-assisted palladium catalyzed oxidative methoxy 
carbonylation of alkenyltin derivatives was developed and then applied to the synthesis of 
(hydroxymethyl)acrylic acid motifs (Scheme 2). Previously reported conditions for the 
analogous transformation of boranes failed completely. After much experimentation, we 
discovered that the use of triphenylarsine as the ligand and an acidic reaction medium were 
crucial for the successful reaction outcome. Using this method, a series of highly functionalized 
,-unsaturated esters was synthesized including key intermediate 272 in the total synthesis of 
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tubelactomicin A. Our concise route allowed us to significantly reduce the step-count compared 
with a previously reported approach. 
 
Scheme 2. Palladium catalyzed oxidative methoxy carbonylation and formal synthesis of tubelactomicin A. 
7.3. Oxidation of Alkenylstannanes to (Hydroxy)ketones 
Numerous alkenylmetalloids have been shown to undergo oxidations to the corresponding 
ketones. However, stannane variants of this transformation have not been reported yet. Inspired 
by the seminal studies towards well-known Chan-Lam coupling, alkenylstannanes flanked by a 
hydroxyl group were exposed to stoichiometric copper(II)acetate in the presence of an amine 
base to give the corresponding functionalized -acetoxy ketones (Scheme 3). Furthermore, 
transformation of alkenylstannanes lacking an assisting hydroxyl group into the corresponding 
ketones were accomplished utilizing copper(II) trifluoroacetate. Initial mechanistic studies 
indicate the intermediacy of an alkenylcopper species. 
 
Scheme 3. Copper mediated oxidation of alkenylstannanes. 
7.4. Fluorination of Alkenylstannanes and Synthesis of Peptide Bioisosters 
Although alkenylfluorides constitute an important class of compounds in medicinal, 
agricultural and material chemistry, no general method has been reported to obtain this 
structural motif from the corresponding tin derivatives. A silver-mediated fluorination was 
developed utilizing a Selecfluor® derivative as fluorinating agent (Scheme 4). It was found that 
silver diphenylphosphinate effectively suppressed protodestannation while ensuring high 
isolated yields. Further refinement of the methodology enabled us to develop a general protocol 
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for the conversion of alkenylstannanes to the corresponding fluorides. In addition, this mild and 
functional group tolerant method allowed us to synthesize a library of peptide bioisosters 
exemplified by 530. 
 
Scheme 4. Fluorination of alkenylstannanes and synthesis of bioisosters. 
7.5. Diverted Total Synthesis of 5,6-Dihydrocineromycin B 
Finally, the utility of the directed trans-selective hydrostannation and subsequent catalytic 
reactions was demonstrated in the total synthesis of 5,6-dihydrocineromycin B. In a highly 
catalysis-based approach, the natural product itself along with five non-natural analogs was 
synthesized via late-stage diversification. To complete the synthesis of 615, a methyl-Stille 
cross-coupling was implemented to access the target in 10 longest linear steps (16 steps total) 
with high overall yield. The methodologies described herein were probed on stannane 647 
giving rise to fluoride 662, ester 660 and ketone 661, respectively. 
 
Scheme 5. Synthesis of 5,6-dihydrocineromycin B and congeners. 
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8. Experimental Procedures 
8.1. General Experimental Details 
If not indicated otherwise, all reactions were carried out under Ar in flame-dried glassware. 
Solvents 
The solvents were purified by distillation over the drying agents indicated and were transferred 
under Ar: THF, Et2O (Mg/anthracene), CH2Cl2, MeCN (CaH2), toluene, benzene (Na/K), MeOH 
(Mg). DMF and Et3N were dried by an absorption solvent purification system based on molecular 
sieves. Pyridine was purified by distillation over CaH2 and transferred under Ar. Technical grade 
solvents were used for flash chromatography and routine extractions. Mol sieves (3 Å, 4 Å and 
5 Å) were dried under high vacuum at >120 °C for 24 h. 
Chromatography 
For flash chromatography, Merck silica gel 60 (40–63 μm) was used. For thin layer 
chromatography (TLC), Macherey-Nagel (40x80 mm, Polygram® SIL >G/UV254 or Polygram® 
ALOX N/UV254) were used. Detection was accomplished under UV light (254 nm) or by staining 
with p-anisaldehyde, KMnO4, I2 or phosphomolybdic acid. 
NMR spectroscopy 
Spectra were recorded on a Bruker AV 400 spectrometer or a Bruker AV VIII 300 spectrometer 
in the solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling 
constants (J) in Hz. The solvent signals were used as references and the chemical shifts 
converted to the TMS scale (CDCl3: δC ≡ 77.16 ppm; residual CHCl3 in CDCl3: δH ≡ 7.26 ppm). 
119Sn NMR spectra were using Me4Sn as external standard. Multiplets are indicated by the 
following abbreviations: s: singlet, d: doublet, t: triplet, q: quartet, quint: quintet; hept: heptet, m: 
multiplet. The abbreviation "br" indicates a broad signal. 13C NMR spectra were recorded [1H]-
decoupled and the values of chemical shifts are rounded to one position after the decimal point. 
Infrared spectroscopy 
Spectra were recorded on an Alpha Platinum ATR spectrometer (Bruker) at room temperature, 
wavenumbers (?̃?) in cm-1.  
Mass spectrometry 
Finnigan MAT 8200 (70 eV), ESIMS: ESQ 3000 (Bruker). Accurate mass determinations: Bruker 
APEX III FT-MS (7 T magnet) or MAT 95 (Finnigan).  
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Optical rotation 
Optical rotations were measured on a 343 Plus (Perkin Elmer) or P8000-T (A. Krüss Optronic). 
Reagents 
Unless stated otherwise, all commercially available compounds (ABCR, Acros, Aldrich, Strem, 
Apollo Scientific, TCI, Fluorochem) were used as received. Thexylborane solution was prepared 
according to literature procedure and stored under argon at 4°C.[1] Thexylalkoxyboranes were 
prepared by reacting thexylborane in situ with the corresponding alcohols.[2] 
Thexylchloroborane was prepared by treatment of thexylborane in situ with 4 M HCl in 
dioxane.[3] [Cp*RuCl2]n[4] and [Cp*RuCl]4[5] were prepared according to literature procedures and 
stored under Argon. Commercial Bu3SnH is stabilized with 0.05% of 3,5-di-tert-butyl-4-
hydroxytoluene, which was not removed in the reactions described herein. The following 
compounds were prepared according to literature procedures: tert-butyl 3-hydroxydec-4-
ynoate[6], 4-methylpent-2-yn-1-ol[7], 3-phenylprop-2-yn-1-ol[8], 3-(cyclohex-1-en-1-yl)prop-2-yn-
1-ol[9], 4-(cyclohex-1-en-1-yl)but-3-yn-2-ol[10], 3-((tert-butyldimethylsilyl)oxy)propan-1-ol[11], 
tert-butyl(pent-4-yn-1-yloxy)diphenylsilane[12], 2-methylnon-4-yn-3-ol[13], undec-6-yn-5-ol[14], 1-
phenylnon-4-yn-3-ol[15], 1-(cyclohex-1-en-1-yl)-4-methylpent-1-yn-3-ol[16], 5-phenylpent-2-
ynal[17], dodec-3-yn-2-ol[18], tributyl(dibromomethyl)stannane[19].  
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8.2. Directed Hydroboration of Propargyl Alcohols and Suzuki Cross Coupling 
for the Selective Synthesis of Trisubstituted Olefins 
8.2.1. Representative procedure 1: Synthesis of Alkenylboronate Esters from Propargyl 
Alcohols 
2-Hexyn-1-ol (110 µL, 1.0 mmol, 1.0 equiv.) was dissolved in dry THF (1 mL) and the solution 
stirred at room temperature in a flame-dried Schlenk flask in the presence of 3 Å mol sieves 
(200 mg per mmol alkynol). Stirring was continued for 15 minutes before the mixture was 
cooled with an ice bath. Neat trifluoromethylpyruvic acid methylester (122 µL, 1.2 mmol, 
1.2 equiv.) was added and the mixture stirred until disappearance of starting material was 
judged by TLC (hexanes/ethyl acetate, 4:1, generally after 15 minutes of stirring for primary and 
about 30 minutes for secondary alcohols). Dry THF (10 mL) was added and the mixture cooled 
to 78 °C. ThxBH2 solution (1.14 mL, 1.05 M in THF, 1.2 mmol, 1.2 equiv.) was slowly added over 
1 minute. The mixture was stirred for 1 minute at the same temperature and was then allowed 
to warm to room temperature by removing the cooling bath. Upon warming vigorous bubbling is 
generally observed. The mixture was stirred for 15 minutes at room temperature before neat 
trimethylamine-N-oxide (90 mg, 1.2 mmol, 1.2 equiv.) was introduced followed by pinacol 
(354 mg, 3.0 mmol, 3.0 equiv.). After 10 minutes, most of the insoluble TMAO disappears while 
the mixture warmed up. When disappearance of starting material was judged by TLC 
(hexanes/ethyl acetate, 4:1) the volatile materials were removed under reduced pressure and 
the crude residue was purified by flash chromatography (SiO2, hexanes/ethyl acetate) to yield 
the products as oils. 
 
(Z)-2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)hex-2-en-1-ol - (125) 
82% yield, (185 mg, 0.82 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
6.39 (tt, J = 7.3, 1.4 Hz, 1H), 4.27 (d, J = 1.4 Hz, 2H), 2.13 (q, J = 7.4 Hz, 
2H), 1.43 (h, J = 7.4 Hz, 2H), 1.27 (s, 12H), 0.91 (t, J = 7.4 Hz, 3H) ppm.  
13C NMR (101 MHz, CDCl3) δ 148.0, 83.7, 77.4, 60.6, 30.9, 24.9, 22.3, 
14.1 ppm. IR (film, CHCl3) 3457, 2977, 2873, 1757, 1631, 1372, 1300, 1139, 1005, 860 cm-1. 
HRMS (ESI): m/z calculated for C12H23O3BNa [M+Na+]: 249.16309, found 249.16324. 
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Ethyl (2E,5Z)-4-hydroxy-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)deca-
2,5-dienoate - (126) 
48% yield (336 mg, 0.95 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf 
= 0.41. 1H NMR (400 MHz, Chloroform-d) δ 6.43 (ddd, J = 7.8, 6.4, 1.2 
Hz, 1H), 5.98 – 5.91 (m, 1H), 4.87 (d, J = 4.7 Hz, 1H), 4.13 (q, J = 7.1 Hz, 
2H), 3.57 – 3.45 (m, 1H), 2.26 (dq, J = 15.3, 7.6 Hz, 1H), 2.17 – 2.08 (m, 
1H), 2.06 (d, J = 1.3 Hz, 3H), 1.46 – 1.27 (m, 5H), 1.24 (s, 8H), 1.21 (s, 6H), 0.88 (t, J = 7.1 Hz, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 167.2, 160.0, 149.3, 131.2, 114.5, 84.0, 74.6, 59.7, 31.1, 29.2, 
25.1, 24.3, 22.6, 15.5, 14.4, 14.0 ppm. IR (film, CHCl3) 2978, 2931, 1715, 1651, 1372, 1308, 
1207, 1136, 1042, 854, 697 cm-1. HRMS (ESI): m/z calculated for C19H33O5BNa [M+Na+]: 
375.23126, found 375.23132. 
 
(Z)-4-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-2-en-1-ol  - (127) 
69% yield (313 mg, 1.38 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.40. 
1H NMR (400 MHz, Chloroform-d) δ 6.17 (dt, J = 9.6, 1.3 Hz, 1H), 4.25 (d, J = 1.3 
Hz, 2H), 2.69 (dhept, J = 9.5, 6.6 Hz, 1H), 2.43 (s, 1H), 1.25 (s, 12H), 0.95 (d, J = 6.7 
Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 154.8, 128.5, 83.6, 60.5, 27.8, 24.9, 22.7 
ppm. 11B NMR (128 MHz, CDCl3) δ 27.9 ppm. IR (film, CHCl3) 3467, 2963, 1632, 1371, 1300, 
1141, 1008, 964, 862, 674 cm-1. HRMS (ESI): m/z calculated for C12H23O3BNa [M+Na+]: 
249.16324, found 249.16324. 
 
(Z)-3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)hex-3-en-2-ol - (128) 
55% yield (250 mg, 1.1 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.47. 
1H NMR (400 MHz, Chloroform-d) δ 6.21 (td, J = 7.2, 1.2 Hz, 1H), 4.68 – 4.55 
(m, 1H), 3.01 – 2.81 (m, 1H), 2.24 – 2.12 (m, 1H), 2.12 – 1.99 (m, 1H), 1.29 – 
1.22 (m, 23H), 0.98 (t, J = 7.6 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 147.0 
135.2, 83.6, 67.0, 25.0, 25.0, 24.6, 21.8, 13.7 ppm. 11B NMR (128 MHz, CDCl3) δ 27.82 ppm.  
IR (film, CHCl3) 3559, 2971, 1629, 1371, 1305, 1257, 1140, 1048, 975, 854, 696 cm-1. HRMS 
(ESI): m/z calculated for C12H23O3BNa [M+Na+]: 249.16321, found 249.16324. 
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(Z)-5-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-3-en-2-ol  - (129) 
52% yield (252 mg, 1.05 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.60.  
1H NMR (400 MHz, Chloroform-d) δ 6.04 (dd, J = 9.8, 1.1 Hz, 1H), 4.63 (qd, J = 6.5, 
1.1 Hz, 1H), 2.68 (ddq, J = 13.2, 9.8, 6.6 Hz, 2H), 1.30 – 1.24 (m, 15H), 0.99 (d, J = 6.6 
Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 152.2, 133.1, 
83.6, 67.1, 27.7, 25.5, 25.07, 24.7, 22.7 ppm. 11B NMR (128 MHz, CDCl3) δ 28.5 ppm. IR (film, 
CHCl3) 2865, 1630, 1371, 1304, 1257, 1142, 1051, 975, 859, 698 cm-1. HRMS (ESI): m/z 
calculated for C13H25O3BNa [M+Na+]: 263.17887, found 263.17889. 
 
8.2.2. Representative procedure 2: Suzuki Cross-Coupling of in situ Generated 
Alkenylboronic Acids from Propargyl Alcohols 
2-Hexyn-1-ol (220 µL, 2.0 mmol, 1.0 equiv.) was dissolved in dry THF (1.0 mL) equipped with 
3 Å mol sieves (200 mg per mmol alkynol) and the suspension stirred in an oven-dried Schlenk 
flask under an argon atmosphere. Methyl trifluoropyruvate (343 µL, 2.2 mmol, 1.1 equiv.) was 
added and stirring continued at room temperature until disappearance of starting material was 
judged by TLC (hexanes/ethyl acetate, 4:1). Then the mixture was diluted with THF (10 mL) and 
cooled to 78 °C before a solution of ThxBH2 in THF (2.2 mL, 1.0 M in THF, 2.2 mmol, 1.1 equiv.) 
was slowly added. The mixture was allowed to warm to room temperature and stirred for 1 h. 
Then, neat TMAO (233 mg, 2.1 mmol, 1.05 equiv.) was added followed after 15 minutes by 
degassed KOH (5.0 mL, 15 mmol, 3 M in water, 7.5 equiv.), 1-bromo-4-(tert-butyl)cyclohex-1-
ene (579 mg, 2.4 mmol, 1.2 equiv.) and [1,1'-bis-(diphenylphosphino)-ferrocene]-palladium(II)-
chloride-methylenechloride-complex (82 mg, 0.1 mmol, 5.0 mol%). The mixture was heated 
with a preheated oil-bath to 60 °C for 1 h before the reaction was quenched with brine at room 
temperature. The mixture was extracted two times with ethyl acetate, the combined organic 
layers were washed with brine, dried over magnesium sulfate and concentrated under reduced 
pressure. Flash chromatography (SiO2, hexanes/ethyl acetate) yielded pure products as a single 
regioisomer. 
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(Z)-2-(4-(tert-Butyl)cyclohex-1-en-1-yl)hex-2-en-1-ol - (130) 
85% yield (401 mg, 1.70 mmol, 2.0 mmol scale). 1H NMR (400 MHz, 
Chloroform-d) δ 5.95 (dt, J = 5.1, 2.1 Hz, 1H), 5.58 (t, J = 7.5 Hz, 1H), 4.34 (s, 2H), 
2.37 – 2.24 (m, 1H), 2.22 – 2.04 (m, 4H), 1.99 – 1.84 (m, 2H), 1.40 (dt, J = 14.7, 7.3 
Hz, 3H), 1.31 – 1.09 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H), 0.87 (s, 9H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 139.0, 135.4, 128.5, 124.0, 57.9, 44.1, 32.3, 30.2, 27.7, 27.5, 
27.3, 24.3, 23.3, 14.0 ppm. IR (film, CHCl3) 3330, 2956, 2870, 1468, 1364 1393, 1248, 1007, 914, 
805, 733, 663 cm-1. HRMS (ESI): m/z calculated for C16H28ONa [M+Na+]: 259.20323, found 
259.20322. 
 
(Z)-2-(4-Chlorophenyl)-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-ol - (131) 
55% yield (310 mg, 1.1 mmol). TLC (hexanes/ethyl acetate, 1:1), Rf = 0.64.  
1H NMR (400 MHz, Chloroform-d) δ 7.46 – 7.41 (m, 2H), 7.33 – 7.27 (m, 2H), 
6.02 (dd, J = 7.7, 6.4 Hz, 1H), 4.76 (t, J = 3.3 Hz, 1H), 4.53 (d, J = 12.4 Hz, 1H), 
4.47 – 4.39 (m, 2H), 4.31 (dd, J = 12.7, 7.8 Hz, 1H), 3.87 (ddd, J = 11.3, 9.0, 3.2 
Hz, 2H), 3.56 (dtd, J = 11.3, 4.2, 1.3 Hz, 1H), 2.76 (s, 1H), 1.88 – 1.68 (m, 2H), 1.66 – 1.48 (m, 4H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 142.9, 139.4, 133.5, 128.7, 127.7, 127.4, 97.3, 63.1, 62.1, 
60.07, 30.5, 25.4, 19.1 ppm. . IR (film, CHCl3) 3427, 2943, 2871, 1492, 1351, 1116, 1023, 814 
cm-1. HRMS (ESI): m/z calculated for C15H19ClO3Na [M+Na+]: 305.09150, found 305.09149. 
 
(Z)-2-(4-Fluorophenyl)-3-phenylprop-2-en-1-ol - (132) 
60% yield (138 mg, 0.605 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.71. 
1H NMR (400 MHz, Chloroform-d) δ 7.61 – 7.54 (m, 2H), 7.43 – 7.37 (m, 4H), 7.31 
(tdd, J = 5.2, 3.7, 2.8 Hz, 1H), 7.16 – 7.04 (m, 2H), 6.93 (s, 1H), 4.69 (s, 2H), 1.58 (s, 
2H) ppm. 13C NMR (101 MHz, CDCl3) δ 162.9, 160.5, 138.36, 136.0, 130.5, 128.2, 
127.7, 127.6, 127.5, 126.7, 114.9, 114.7, 59.7 ppm. IR (film, CHCl3) 3348, 3022, 
2929, 1598, 1506, 1225, 1159, 1008, 838, 701 cm-1. HRMS (ESI): m/z calculated for C15H13FONa 
[M+Na+]: 251.08435, found 251.08426. 
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(Z)-2-(4-Chlorophenyl)-3-(cyclohex-1-en-1-yl)prop-2-en-1-ol - (133) 
86% yield (426 mg, 1.72 mmol). TLC (hexanes/ethyl acetate, 10:1), Rf = 0.19.  
Mp: 63-66°C. 1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.39 (m, 2H), 7.34 – 
7.28 (m, 2H), 6.24 (d, J = 1.5 Hz, 1H), 5.80 (dq, J = 3.9, 1.8 Hz, 1H), 4.65 (s, 2H), 
2.17 (qq, J = 3.8, 2.1 Hz, 4H), 1.73 – 1.58 (m, 3H), 1.48 – 1.40 (m, 1H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 139.8, 136.6, 134.8, 133.1, 130.5, 129.0, 128.7, 127.9, 60.6, 29.1, 25.9, 22.9, 22.1 ppm. 
IR (film, CHCl3) 3228, 2925, 1618, 1490, 1321, 1092, 1008, 843, 820, 717, 536 cm-1. HRMS 
(ESI): m/z calculated for C15H17OClNa [M+Na+]: 271.08602, found 271.08601. 
 
(Z)-3-(4-(tert-Butyl)cyclohex-1-en-1-yl)hex-3-en-2-ol - (134) 
66% yield (311 mg, 1.3 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.47.  
1H NMR (400 MHz, Chloroform-d) δ 5.71 (dt, J = 3.4, 2.0 Hz, 1H), 5.30 (td, J = 7.3, 
4.3 Hz, 1H), 4.79 (q, J = 6.7 Hz, 1H), 2.28 – 2.04 (m, 4H), 1.84 (dddt, J = 14.8, 6.8, 4.6, 
2.0 Hz, 2H), 1.68 (s, 1H), 1.32 (dd, J = 6.7, 3.0 Hz, 3H), 1.29 – 1.09 (m, 2H), 0.98 (t, J = 
7.5 Hz, 3H), 0.86 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 144.6, 144.4, 137.3, 
137.3, 129.3, 129.2, 125.2, 125.0, 66.5, 66.3, 43.8, 32.3, 30.9, 30.8, 27.3, 24.5, 23.0, 22.9, 21.1, 
21.0, 14.7, 14.7 ppm. IR (film, CHCl3) 3381, 2961, 2871, 1468, 1364, 1248, 1107, 1061, 897 cm-1. 
HRMS (ESI): m/z calculated for C16H28O [M+]: 236.21383, found 236.21402. 
 
(Z)-4-((tert-Butyldimethylsilyl)oxy)-2-(4-chlorophenyl)but-2-en-1-ol - (135) 
67% yield (419 mg, 1.34 mmol). TLC (hexanes/ethyl acetate, 4:1),  
Rf = 0.71. 1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.35 (m, 2H), 7.35 
– 7.27 (m, 2H), 6.01 (t, J = 6.3 Hz, 1H), 4.50 (s, 2H), 4.42 (d, J = 6.3 Hz, 
2H), 2.32 (s, 1H), 0.93 (s, 9H), 0.12 (s, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 141.2, 139.4, 
133.5, 130.7, 128.7, 127.8, 60.7, 59.9, 26.1, 18.5, -5.0 ppm. IR (film, CHCl3) 3406, 2955, 2930, 
2857, 1492, 1471, 1365, 1254, 1082, 1011, 834, 775 cm-1. HRMS (ESI): m/z calculated for 
C16H25O2ClSiNa [M+Na+]: 335.12050, found 335.12046. 
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(Z)-3-(4-Chlorophenyl)-4-phenylbut-3-en-2-ol - (136) 
48% yield (249 mg, 0.96 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.56.  
1H NMR (400 MHz, Chloroform-d) δ 7.55 – 7.49 (m, 2H), 7.43 – 7.37 (m, 2H), 7.37 – 
7.28 (m, 5H), 6.66 (s, 1H), 5.15 (q, J = 6.5 Hz, 1H), 1.67 (s, 1H), 1.29 (d, J = 6.5 Hz, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 144.1, 138.9, 136.6, 133.4, 131.5, 130.2, 129.0, 
128.5, 128.29, 127.4, 66.0, 22.4 ppm. IR (film, CHCl3) 3365, 2974, 1489, 1444, 1371, 
1090, 1014, 837, 699, 509 cm-1. HRMS (ESI): m/z calculated for C16H15ClONa [M+Na+]: 
281.07056, found 281.07036. 
 
(Z)-3-(4-Chlorophenyl)-4-(cyclohex-1-en-1-yl)but-3-en-2-ol  - (137) 
45% yield (238 mg, 0.906 mmol, 2.0 mmol scale). 1H NMR (400 MHz, Chloroform-
d) δ 7.33 – 7.29 (m, 2H), 7.21 – 7.17 (m, 2H), 5.87 – 5.78 (m, 1H), 5.60 (td, J = 3.8, 1.8 
Hz, 1H), 5.10 (q, J = 6.6 Hz, 1H), 2.12 – 1.96 (m, 4H), 1.71 (s, 1H), 1.65 – 1.47 (m, 4H), 
1.16 (d, J = 6.6 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 141.8, 139.5, 134.6, 134.1, 
132.9, 130.1, 128.1, 127.7, 66.3, 29.3, 25.7, 22.8, 22.7, 22.1 ppm. IR (film, CHCl3) 
3377, 2927, 2833, 1488, 1446, 1369, 1269, 1089, 1014 1043, 895 928, 826 cm-1. HRMS (ESI): 
m/z calculated for C16H19OCl [M+]: 262.11244, found 262.11253. 
 
(Z)-2-(4-(tert-Butyl)cyclohex-1-en-1-yl)-6-chlorohex-2-en-1-ol - (138) 
75% yield (408 mg, 1.51 mmol). TLC (hexanes/ethyl acetate, 4:1),  
Rf = 0.62. 1H NMR (400 MHz, Chloroform-d) δ 5.98 (dt, J = 5.1, 2.2 Hz, 
1H), 5.52 (t, J = 7.6 Hz, 1H), 4.35 (s, 2H), 3.54 (t, J = 6.4 Hz, 2H), 2.37 (q, J 
= 7.3 Hz, 2H), 2.33 – 2.23 (m, 1H), 2.21 – 2.03 (m, 2H), 2.00 – 1.82 (m, 
4H), 1.57 (s, 1H), 1.31 – 1.10 (m, 2H), 0.87 (s, 9H).ppm. 13C NMR (101 MHz, CDCl3) δ 140.4, 
135.2, 126.0, 124.7, 57.7, 44.5, 44.0, 32.6, 32.2, 27.6, 27.5, 27.3, 25.2, 24.3 ppm. IR (film, CHCl3) 
3357, 2955, 2868, 1472, 1436, 1393, 1364, 1003, 914, 807, 738, 653 cm-1. HRMS (ESI): m/z 
calculated for C16H27OClNa [M+Na+]: 293.16438, found 293.16426. 
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(Z)-2-(4-Chlorophenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)hex-2-en-1-ol - (139) 
70% yield (434 mg, 1.40 mmol). TLC (hexanes/ethyl acetate, 4:1),  
Rf = 0.44. 1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.40 (m, 2H), 
7.32 – 7.27 (m, 2H), 5.82 (dd, J = 8.8, 7.1 Hz, 1H), 4.59 (d, J = 12.3 Hz, 
1H), 4.52 (dd, J = 5.6, 2.6 Hz, 1H), 4.46 – 4.38 (m, 1H), 3.91 – 3.84 (m, 1H), 3.80 (ddd, J = 9.9, 8.7, 
4.5 Hz, 1H), 3.53 – 3.44 (m, 2H), 2.76 (s, 1H), 2.51 (dtd, J = 14.6, 8.6, 6.0 Hz, 1H), 2.39 – 2.29 (m, 
1H), 1.93 – 1.65 (m, 4H), 1.61 – 1.46 (m, 4H) ppm. 13C NMR (101 MHz, CDCl3) δ 140.1, 139.3, 
132.8, 131.6, 128.5, 127.7, 99.6, 65.9, 63.7, 59.5, 31.0, 28.9, 25.4, 24.8, 20.4 ppm. IR (film, CHCl3) 
3436, 2941, 2869, 1491, 1353, 1137, 1121, 1029, 824 cm-1. HRMS (ESI): m/z calculated for 
C17H23O3ClNa [M+Na+]: 333.12274, found 333.12279. 
 
(Z)-2-(4-(tert-Butyl)cyclohex-1-en-1-yl)-6-((tert-butyldiphenylsilyl)-oxy)hex-2-en-1-ol  
- (140) 
74% yield (835 mg, 1.70 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.71 – 7.63 (m, 4H), 7.50 – 7.32 (m, 6H), 5.98 (dt, J = 5.2, 2.3 Hz, 1H), 5.55 
(t, J = 7.6 Hz, 1H), 4.36 (s, 2H), 3.69 (t, J = 6.1 Hz, 2H), 2.32 (q, J = 7.4 Hz, 
2H), 2.27 – 2.03 (m, 2H), 2.00 – 1.85 (m, 1H), 1.66 (s, 1H), 1.64 – 1.55 (m, 
2H), 1.33 – 1.10 (m, 2H), 1.06 (s, 10H), 0.89 (s, 9H) ppm. 13C NMR (101 
MHz, CDCl3) δ 139.8, 135.7, 135.4, 133.9, 129.74, 127.8, 127.7, 124.1, 63.1, 57.8, 44.1, 32.7, 32.3, 
27.7, 27.6, 27.3, 27.0, 24.4, 24.3, 19.3 ppm. IR (film, CHCl3) 2932, 2859, 1472, 1428, 1391, 1364, 
1108, 1007, 823, 739, 701, 613, 504 cm-1. HRMS (ESI): m/z calculated for C32H46O2SiNa [M+Na+]: 
513.31596, found 513.31593. 
 
(Z)-2-(4-Chlorophenyl)-5-phenylpent-2-en-1-ol - (141) 
52% yield (285 mg, 1.05 mmol). TLC (hexanes/ethyl acetate, 4:1),  
Rf = 0.44. 1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.27 (m, 6H), 7.22 
m, 3H), 5.90 (t, J = 7.7 Hz, 1H), 4.35 – 4.30 (m, 2H), 2.81 (t, J = 7.2 Hz, 2H), 
2.65 – 2.57 (m, 2H), 0.86 – 0.80 (m, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ 141.4, 139.6, 138.7, 
133.0, 131.5, 128.8, 128.6, 128.6, 127.7, 126.4, 59.6, 35.9, 30.6 ppm. IR (film, CHCl3) 3360, 2927, 
1491, 1453, 1092, 1012, 825, 750, 699 cm-1. HRMS (ESI): m/z calculated for C17H17OClNa 
[M+Na+]: 295.08605, found 295.08601. 
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(Z)-2-(4-(tert-Butyl)cyclohex-1-en-1-yl)-5-phenylpent-2-en-1-ol - (142) 
63% yield (375 mg, 1.26 mmol). TLC (hexanes/ethyl acetate, 10:1),  
Rf = 0.53. 1H NMR (400 MHz, Chloroform-d) δ 7.34 – 7.27 (m, 2H), 
7.24 – 7.16 (m, 3H), 5.95 (dt, J = 5.3, 2.2 Hz, 1H), 5.63 (t, J = 7.6 Hz, 1H), 
4.23 (d, J = 2.8 Hz, 2H), 2.73 (t, J = 7.4 Hz, 2H), 2.57 – 2.49 (m, 2H), 2.34 
– 2.24 (m, 1H), 2.23 – 2.05 (m, 2H), 2.00 – 1.87 (m, 2H), 1.33 – 1.13 (m, 2H), 1.01 (s, 1H), 0.89 (s, 
9H) ppm. 13C NMR (101 MHz, CDCl3) δ 141.7, 139.7, 135.3, 128.7, 128.5, 127.0, 126.1, 124.4, 
57.8, 44.0, 36.3, 32.3, 30.3, 27.7, 27.5, 27.3, 24.3 ppm. IR (film, CHCl3) 2957, 1453, 1364, 998, 
908, 730, 698 cm-1. HRMS (ESI): m/z calculated for C21H30ONa [M+Na+]: 321.21897, found 
321.21888. 
 
tert-Butyl (Z)-4-(4-chlorophenyl)-3-hydroxydec-4-enoate - (143) 
50% yield (350 mg, 0.99 mmol). TLC (hexanes/ethyl acetate, 10:1), 
Rf = 0.26. 1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.31 (m, 2H), 7.25 
(m, 2H), 5.60 (t, J = 7.4 Hz, 1H), 5.21 (dt, J = 10.1, 3.0 Hz, 1H), 3.17 (d, J = 2.9 
Hz, 1H), 2.51 (dd, J = 16.6, 10.1 Hz, 1H), 2.38 – 2.18 (m, 3H), 1.43 (s, 11H), 
1.37 – 1.28 (m, 4H), 0.98 – 0.83 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
172.3, 139.6, 139.4, 134.4, 132.9, 130.0, 128.1, 81.5, 66.9, 41.3, 31.6, 29.5, 28.2, 28.0, 22.7, 14.2 
ppm. IR (film, CHCl3) 3465, 2927, 1709, 1488, 1367, 1148, 1091, 1014, 831 cm-1. HRMS (ESI): 
m/z calculated for C20H29O3ClNa [M+Na+]: 375.16980, found 375.16974. 
 
(Z)-6-(4-Chlorophenyl)undec-6-en-5-ol - (144) 
56% yield (1.5 equiv. halide, 313 mg, 1.12 mmol). TLC (hexanes/ethyl 
acetate, 10:1), Rf = 0.53. 1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.31 
(m, 2H), 7.29 – 7.23 (m, 2H), 5.58 (t, J = 7.5 Hz, 1H), 4.79 (t, J = 7.1 Hz, 1H), 
2.34 – 2.17 (m, J = 7.2 Hz, 2H), 1.67 – 1.52 (m, 2H), 1.51 – 1.33 (m, 5H), 
1.33 – 1.09 (m, 3H), 0.93 (t, J = 7.1 Hz, 4H), 0.84 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 141.4, 139.8, 133.7, 132.7, 130.0, 128.1, 70.2, 35.5, 32.2, 28.2, 27.7, 22.6, 14.1 ppm.  
IR (film, CHCl3) 3364, 2956, 2928, 2859, 1488, 1465, 1092, 1014, 827 cm-1. HRMS (ESI): m/z 
calculated for C17H25OClNa [M+Na+]: 303.14869, found 303.14861. 
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(3E,6Z)-6-(4-Chlorophenyl)undeca-3,6-dien-5-ol - (145) 
40% yield (225 mg, 0.81 mmol). TLC (hexanes/ethyl acetate, 10:1),  
Rf = 0.33. 1H NMR (400 MHz, Chloroform-d) δ 7.26 – 7.22 (m, 2H), 7.19 – 
7.15 (m, 2H), 5.67 (dtd, J = 15.4, 6.3, 1.4 Hz, 1H), 5.57 – 5.53 (m, 1H), 5.49 
(ddt, J = 15.4, 5.8, 1.5 Hz, 1H), 5.21 (d, J = 6.1 Hz, 1H), 2.29 – 2.09 (m, J = 7.3 
Hz, 2H), 1.97 (qdt, J = 7.5, 6.3, 1.3 Hz, 2H), 1.60 (s, 1H), 1.43 – 1.25 (m, 4H), 0.93 – 0.82 (m, 6H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 140.3, 139.4, 134.1, 133.1, 132.8, 129.9, 129.7, 128.1, 71.1, 
32.0, 27.8, 25.4, 22.6, 14.1, 13.6 ppm. IR (film, CHCl3) 3356, 2959, 2928, 1489, 1460, 1091, 
1014, 965, 824 cm-1. HRMS (ESI): m/z calculated for C17H23OCl [M+]: 278.14389, found 
278.14374. 
 
(Z)-4-(4-Chlorophenyl)-2-methylnon-4-en-3-ol - (146) 
42% yield (226 mg, 0.85 mmol). TLC (hexanes/ethyl acetate, 20:1),  
Rf = 0.31.1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.36 (m, 2H), 7.29 – 
7.17 (m, 2H), 5.64 (t, J = 7.5 Hz, 1H), 4.33 (d, J = 9.8 Hz, 1H), 2.36 – 2.19 (m, 
J = 7.3 Hz, 2H), 1.69 (tdd, J = 11.5, 8.9, 5.8 Hz, 2H), 1.49 – 1.31 (m, 4H), 1.04 
(d, J = 6.5 Hz, 3H), 0.93 (t, J = 7.1 Hz, 3H), 0.69 (d, J = 6.7 Hz, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 140.7, 140.3, 134.9, 132.7, 129.9, 128.1, 76.2, 32.2, 31.9, 27.8, 22.6, 19.6, 19.0, 14.2 
ppm. IR (film, CHCl3) 3444, 2965, 2926, 2871, 1488, 1466, 1380, 1092, 1013, 827 cm-1. HRMS 
(ESI): m/z calculated for C16H23OClNa [M+Na+]: 289.13300, found 289.13296. 
 
(Z)-2-(4-Chlorophenyl)-1-(p-tolyl)hept-2-en-1-ol - (147) 
43% yield (273 mg, 0.87 mmol). TLC (hexanes/ethyl acetate, 10:1),  
Rf = 0.43.1H NMR (400 MHz, Chloroform-d) δ 7.28 – 7.23 (m, 2H), 7.18 – 
7.08 (m, 6H), 5.98 (s, 1H), 5.81 (dd, J = 7.7, 7.0 Hz, 1H), 2.43 – 2.25 (m, 5H), 
1.94 (s, 1H), 1.55 – 1.34 (m, 4H), 0.94 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 140.4, 139.4, 138.9, 136.9, 133.7, 132.9, 129.7, 129.2, 128.2, 
125.8, 71.2, 32.0, 28.21, 22.7, 21.2, 14.1 ppm. IR (film, CHCl3) 3395, 2956, 2925, 2871, 1489, 
1174, 1092, 1015, 825, 757 cm-1. HRMS (ESI): m/z calculated for C20H23ClONa [M+Na+]: 
337.13343, found 337.13296. 
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(Z)-1-((tert-Butyldimethylsilyl)oxy)-4-(4-chlorophenyl)non-4-en-3-ol - (148) 
55% yield (420 mg, 1.10 mmol). TLC (hexanes/ethyl acetate, 10:1),  
Rf = 0.66. 1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.32 (m, 2H), 
7.29 – 7.21 (m, 3H), 5.56 (t, J = 7.4 Hz, 1H), 5.05 (dd, J = 9.4, 3.4 Hz, 1H), 
3.78 (tddd, J = 10.3, 8.1, 6.1, 4.5 Hz, 2H), 2.90 (s, 1H), 2.38 – 2.20 (m, 2H), 
1.93 – 1.77 (m, 1H), 1.68 – 1.49 (m, 2H), 1.49 – 1.19 (m, 4H), 0.90 (s, 
9H), 0.06 (d, J = 2.2 Hz, 7H).ppm. 13C NMR (101 MHz, CDCl3) δ 141.3, 140.4, 133.3, 132.7, 130.0, 
128.0, 69.6, 62.1, 38.2, 32.2, 27.7, 26.0, 22.6, 18.3, 14.1, -5.3 ppm. IR (film, CHCl3) 3461, 2955, 
2929, 2858, 1710, 1489, 1470, 1255, 1091, 834, 777 cm-1. HRMS (ESI): m/z calculated for 
C21H35O2ClSiNa [M+Na+]: 405.19901, found 405.19871. 
 
(Z)-2-(4-Chlorophenyl)hex-2-en-1-ol - (149) 
71% yield (297 mg, 1.41 mmol). TLC (hexanes/ethyl acetate, 10:1),  
Rf = 0.29. 1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.36 (m, 2H), 7.33 – 
7.27 (m, 2H), 5.89 (t, J = 7.5 Hz, 1H), 4.55 (d, J = 5.4 Hz, 2H), 2.26 (q, J = 7.4 
Hz, 2H), 1.50 (h, J = 7.4 Hz, 2H), 1.32 (t, J = 5.5 Hz, 1H), 0.97 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 139.6, 137.9, 133.2, 132.9, 128.7, 127.7, 59.8, 30.5, 23.1, 14.0 ppm. IR (film, 
CHCl3) 3339, 2958, 2871, 1491, 1378, 1093, 1011, 822 cm-1. HRMS (ESI): m/z calculated for 
C12H15OClNa [M+Na+]: 233.07042, found 233.07036. 
 
8.2.3. Representative procedure 3: Suzuki cross-coupling of in situ generated 
alkenylboronic acids from homopropargyl alcohols 
3-Octyn-1-ol (287 µL, 2.0 mmol, 1.0 equiv.) was dissolved in dry THF (10 mL) containing 3 Å mol 
sieves (200 mg per mmol substrate). The suspension was stirred at 78 °C. A solution of ThxBH2 
in THF (2.2 mL, 1.0 M in THF, 2.2 mmol, 1.1 equiv.) was slowly added. The mixture was allowed 
to warm to room temperature and stirred for 1 h. Then, neat TMAO (245 mg, 2.2 mmol, 
1.1 equiv.) was added followed after 15 minutes by degassed KOH (5.0 mL, 3 M in water, 
15 mmol, 7.5 equiv.), 5-iodo-m-xylene (377 µL, 2.6 mmol, 1.3 equiv.) and [1,1'-bis-
(diphenylphosphino)-ferrocene]-palladium(II)-chloride-methylenechloride-complex (82 mg, 
0.1 mmol, 5.0 mol%). The mixture was heated with a preheated oil-bath to 60 °C for 1 h before 
the reaction was quenched with brine at room temperature. The mixture was extracted two 
times with ethyl acetate, the combined organic layers were washed with brine, dried over 
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magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate) yielded pure products as a single regioisomer. 
 
(E)-3-(3,5-Dimethylphenyl)oct-3-en-1-ol - (156) 
56% yield (259 mg, 1.12 mmol). TLC (hexanes/ethyl acetate, 10:1), Rf = 0.57. 
1H NMR (400 MHz, Chloroform-d) δ 6.98 (s, 2H), 6.90 (s, 1H), 5.81 (t, J = 7.3 
Hz, 1H), 3.63 (q, J = 6.7 Hz, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.33 (d, J = 0.8 Hz, 6H), 
2.25 (q, J = 7.3 Hz, 2H), 1.59 – 1.51 (m, 1H), 1.51 – 1.33 (m, 4H), 0.95 (t, J = 7.1 
Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 142.8, 137.8, 136.0, 131.8, 128.6, 124.3, 61.5, 33.3, 
32.2, 28.5, 22.6, 21.5, 14.2 ppm. IR (film, CHCl3) 3318, 2955, 2921, 2871, 1599, 1463, 1039, 840, 
705 cm-1. HRMS (ESI): m/z calculated for C16H24ONa [M+Na+]: 255.17184, found 255.17193. 
 
(E)-4-(3,5-Dimethylphenyl)hept-4-en-2-ol - (157) 
56% yield (243 mg, 1.11 mmol). TLC (hexanes/ethyl acetate, 10:1), Rf = 0.29. 
1H NMR (400 MHz, Chloroform-d) δ 6.95 (s, 2H), 6.89 (s, 1H), 5.77 (dd, J = 
7.7, 6.9 Hz, 1H), 3.77 (qd, J = 7.8, 6.7, 2.3 Hz, 1H), 2.71 (ddd, J = 13.8, 8.0, 0.6 Hz, 
1H), 2.62 (ddd, J = 13.8, 5.2, 0.7 Hz, 1H), 2.31 (t, J = 0.7 Hz, 6H), 2.29 – 2.20 (m, 
2H), 1.55 (d, J = 2.7 Hz, 1H), 1.18 (d, J = 6.2 Hz, 3H), 1.06 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 143.0, 137.9, 136.4, 133.8, 128.7, 124.5, 66.7, 39.7, 22.9, 22.2, 21.5, 14.5 ppm. IR 
(film, CHCl3) 3346, 2965, 2930, 1599, 1457, 1373, 1116, 1076, 939, 847, 706 cm-1. HRMS (ESI): 
m/z calculated for C15H22ONa [M+Na+]: 241.15642, found 241.15628. 
 
(E)-4-(4-Chlorophenyl)-2-methylnon-4-en-2-ol - (158) 
58% yield (310 mg, 1.16 mmol). TLC (hexanes/ethyl acetate, 10:1),  
Rf = 0.25. 1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 4H), 5.73 (t, J = 7.3 
Hz, 1H), 2.74 (s, 2H), 2.22 (q, J = 7.2 Hz, 2H), 1.47 – 1.34 (m, 4H), 1.33 (s, 1H), 
1.09 (s, 6H), 0.92 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 143.5, 
135.8, 134.8, 132.5, 128.6, 128.1, 72.2, 42.9, 31.9, 30.0, 29.3, 22.6, 14.2 ppm. IR (film, CHCl3) 
3407, 2960, 2927, 2858, 1490, 1465, 1376, 1141, 1091, 1011, 900, 826 cm-1. HRMS (ESI): m/z 
calculated for C16H23OClNa [M+Na+]: 289.13320, found 289.13296. 
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8.2.4. Representative procedure 4: Synthesis of Potassium Trifluoroborates from 
Terminal Alkynols 
2-Methylbenzyl alcohol (264 mg, 2.0 mmol, 1.0 equiv.) was dissolved in dry THF (10 mL) and the 
solution stirred at 78 °C in a flame-dried Schlenk-flask under an argon atmosphere. ThxBH2 
solution (2.29 mL, 1.05 M in THF, 2.40 mmol, 1.2 equiv.) was slowly added and after 5 minutes 
the mixture was allowed to warm to room temperature. During the warm-up vigorous gas 
evolution was generally observed, at about –25 °C. The mixture was then allowed to stir for 
about 5 minutes at room temperature before solid trimethylamine-N-oxide (180 mg, 2.4 mmol, 
1.2 equiv.) was added. After 10 minutes, most of the insoluble TMAO disappears while the 
mixture warmed up. Then water (4 mL) was added followed by solid KHF2 (709 mg, 6.0 mmol, 
3.0 equiv.) and stirring is continued at room temperature for 30 minutes before the volatile 
materials were removed under reduced pressure. The crude colorless solids were then extracted 
two times with boiling acetone/EtOH (25 mL, ~1:1) and once with acetone (25 mL), and the hot 
suspensions were filtered through a frit with suction. The combined extracts were dried again 
under reduced pressure and the solid material was recrystallized from acetone/MTBE. Organic 
by-products were successfully extracted with neat MTBE if necessary. By this means, analytically 
pure products were obtained generally as colorless, moisture and bench-stable solids. 
 
Potassium trifluoro(1-(2-(hydroxymethyl)phenyl)vinyl)borate - (161) 
85% yield (410 mg, 1.71 mmol). 1H NMR (400 MHz, DMSO-d6) δ 7.37 (m, Ar-
H, 2H), 7.13 (m, Ar-H, 2H), 6.69 (d, J = 18.0 Hz, CH2, 1H), 6.07 (dq, J = 18.2, 3.5 
Hz, CH2, 1H), 5.04 (s, OH, 1H), 4.54 (s, 2H) ppm. 13C NMR (101 MHz, DMSO-d6) 
δ 141.2, 138.0, 129.4, 126.7, 126.6, 125.5, 124.4, 60.8, 58.4 ppm. 11B NMR 
(96 MHz, DMSO-d6) δ 2.45 ppm. IR (neat): 3514, 3012, 2879, 1620, 1480, 1241, 1078, 941, 
735, 550 cm-1. HRMS (ESI): m/z calculated for C9H9OBF3 [M-K+]: 201.07036, found 201.07041. 
 
Potassium trifluoro(5-hydroxypent-1-en-2-yl)borate - (162) 
68% yield (260 mg, 1.35 mmol). 1H NMR (400 MHz, DMSO-d6) δ 5.53 – 5.36 
(m, 1H), 5.28 – 5.12 (m, 1H), 4.30 (s, 1H), 3.35 (t, J = 6.7 Hz, 2H), 1.99 – 1.78 
(m, 2H), 1.42 (dq, J = 8.7, 6.8 Hz, 2H) ppm. 13C NMR (101 MHz, DMSO-d6) δ 
133.3, 133.3, 60.7, 59.1, 32.8, 31.8 ppm. 11B NMR (96 MHz, DMSO-d6) δ 2.29 
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ppm. IR (neat): 3530, 2929, 1645, 1407, 1301, 1088, 998, 919, 750 cm-1. HRMS (ESI): m/z 
calculated for C5H9OBF3 [M-K+]: 153.07042, found 153.07041. 
 
Potassium trifluoro(4-hydroxybut-1-en-2-yl)borate - (163) 
79% yield (280 mg, 1.57 mmol). 1H NMR (400 MHz, DMSO-d6) δ 5.52 – 5.39 
(m, 1H), 5.32 – 5.18 (m, 1H), 4.28 (s, 1H), 3.34 (t, J = 7.4 Hz, 2H), 2.13 – 1.98 (m, 
2H) ppm. 13C NMR (101 MHz, DMSO-d6) δ 130.2, 130.1, 61.5, 58.7 ppm.  
11B NMR (96 MHz, DMSO-d6) δ 2.09 ppm. IR (neat): 3517, 2945, 1651, 1401, 
1243, 1089, 997, 940, 729, 592 cm-1. HRMS (ESI): m/z calculated for C4H7OBF3 [M-K+]: 
139.05475, found 139.05476. 
 
Potassium trifluoro(4-hydroxypent-1-en-2-yl)borate - (164) 
83% yield (320 mg, 1.67 mmol). 1H NMR (400 MHz, DMSO-d6) δ 5.52 – 5.41 
(m, 1H), 5.28 – 5.18 (m, 1H), 4.29 (s, 1H), 3.52 (q, J = 6.3 Hz, 1H), 2.12 – 2.00 (m, 
1H), 1.91 – 1.80 (m, 1H), 0.98 (d, J = 6.1 Hz, 3H) ppm. 13C NMR (101 MHz, 
DMSO-d6) δ 130.8, 130.7, 66.6, 46.4, 23.1 ppm. 11B NMR (96 MHz, DMSO-d6) δ 
2.07 ppm. IR (neat): 3317, 2966, 1644, 1295, 1091, 970, 848, 737, 590 cm-1. HRMS (ESI): m/z 
calculated for C5H9OBF3 [M-K+]: 153.07041, found 153.07041. 
 
Potassium trifluoro(4-hydroxy-5-methylhex-1-en-2-yl)borate - (165) 
93% yield (410 mg, 1.86 mmol). 1H NMR (400 MHz, DMSO-d6) δ 5.50 (dtd, J 
= 17.7, 6.5, 1.4 Hz, 1H), 5.30 – 5.15 (m, 1H), 4.01 (d, J = 5.2 Hz, 1H), 3.16 (tdd, J 
= 5.9, 5.1, 3.8 Hz, 1H), 1.96 (tdt, J = 6.9, 4.6, 1.4 Hz, 2H), 1.55 (pd, J = 6.8, 4.4 Hz, 
1H), 0.82 (d, J = 6.9 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (101 MHz, 
DMSO-d6) δ 131.0, 74.8, 41.3, 31.8, 19.5, 16.6 ppm. 11B NMR (96 MHz, DMSO-d6) δ 2.05 ppm.  
IR (neat): 3548, 2959, 1645, 1468, 1289, 1091, 927, 738 cm-1. HRMS (ESI): m/z calculated for 
C7H13OBF3 [M-K+]: 181.10168, found 181.10171. 
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8.2.5. Representative procedure 5: Alkyl Suzuki Cross-Coupling of in situ Generated 
Alkenylboronic Acids from Propargyl Alcohols 
2-Hexyn-1-ol (110 µL, 1.0 mmol, 1.0 equiv.) was dissolved in dry THF (1 mL) equipped with 3 Å 
mol sieves (200 mg per mmol substrate) and the suspension stirred in an oven-dried Schlenk 
flask under an argon atmosphere. Methyl trifluoropyruvate (167 µL, 1.25 mmol, 1.25 equiv.) was 
added and stirring continued at room temperature until disappearance of starting material was 
judged by TLC (hexanes/ethyl acetate, 4:1). Then the mixture was cooled to 78 °C before a 
solution of ThxBH2 in THF (1.34 mL, 0.93 M in THF, 1.25 mmol, 1.25 equiv.) was slowly added. 
The mixture was allowed to warm to room temperature and stirred for 1 h. Then neat TMAO 
hydrate (117 mg, 1.05 mmol, 1.05 equiv.) was added followed after 15 minutes by degassed KOH 
(2.5 mL, 7.5 mmol, 3M in water, 7.5 equiv.), Pd(OAc)2 (11 mg, 0.05 mmol, 5.0 mol%), di-tert-
butyl-(methyl)-phosphonium-tetrafluoroborate (25 mg, 0.1 mmol, 10 mol%) and 1-bromo-3-
phenylpropane (304 µL, 2.0 mmol, 2.0 equiv.). The mixture was stirred for 12 h at room 
temperature before the reaction was quenched with brine at room temperature. The mixture 
was extracted two times with ethyl acetate, the combined organic layers were washed with 
brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, hexanes/ethyl acetate) yielded pure product as a single regioisomer. 
 
(Z)-2-(3-Phenylpropyl)hex-2-en-1-ol - (167) 
61% yield (132mg, 0.61mmol). TLC (hexanes/ethyl acetate, 10:1), Rf = 0.21. 
1H NMR (400 MHz, Chloroform-d) δ 7.31 – 7.25 (m, 2H), 7.21 – 7.15 (m, 3H), 
5.33 (t, J = 7.5 Hz, 1H), 4.15 (d, J = 3.3 Hz, 2H), 2.66 – 2.57 (m, 2H), 2.21 – 2.14 
(m, 2H), 2.10 – 2.02 (m, 2H), 1.83 – 1.73 (m, 2H), 1.38 (h, J = 7.3 Hz, 2H), 1.08 (d, J = 4.8 Hz, 1H), 
0.90 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 142.7, 138.3, 129.2, 128.6, 128.4, 
125.8, 60.4, 35.8, 34.9, 30.3, 29.7, 23.3, 13.9 ppm. IR (film, CHCl3) 3324, 2929, 2957, 2860, 1496, 
1454, 1377, 1008, 898, 746, 697 cm-1. HRMS (ESI): m/z calculated for C15H22ONa [M+Na+]: 
241.15642, found 241.15628. 
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8.2.6. Studies on the Regioselectivity of Hydroxyl-directed Hydroboration 
Pure product after flash chromatography 
 
Hydroboration with thexylborane in the absence of trifluoromethylpyruvate 
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Hydroboration with thexylborane under standard conditions 
 
Hydroboration with thexylborane of chlorohemiacetal 
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All compounds were prepared according to representative procedure 2. 
(Z)-2-(4-Chlorophenyl)-4,4,4-trifluorobut-2-en-1-ol - (SI-1) 
21% yield (100 mg, 0.42 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.74.  
1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.30 (m, 2H), 7.29 – 7.22 (m, 2H), 6.19 
(t, J = 5.6 Hz, 1H), 4.58 (dq, J = 5.8, 2.9 Hz, 2H), 2.30 (s, 1H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 141.2 (q, J = 2.7 Hz), 134.8 (s), 133.7 (d, J = 1.7 Hz), 130.2 (q, J = 31.3 Hz), 
129.4 (s), 128.8 (s), 123.5 (q, J = 275.5 Hz), 59.6 (q, J = 3.7 Hz) ppm. IR (film, CHCl3) 
3368, 1651, 1493, 1340, 1257, 1110, 1012, 815, 711 cm-1. HRMS (ESI): m/z calculated for 
C10H8OClF3 [M]: 236.02138, found 236.02158. 
 
(Z)-3-(4-Chlorophenyl)-4,4,4-trifluorobut-2-en-1-ol - (SI-2) 
18% yield (85 mg, 0.36 mmol). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.48. 1H NMR 
(400 MHz, Chloroform-d) δ 7.37 – 7.30 (m, 2H), 7.29 – 7.22 (m, 2H), 6.19 (t, J = 5.6 
Hz, 1H), 4.58 (dq, J = 5.8, 2.9 Hz, 2H), 2.30 (s, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ 
141.2 (q, J = 2.7 Hz), 134.8 (s), 133.7 (d, J = 1.7 Hz), 130.2 (q, J = 31.3 Hz), 129.4 (s), 
128.8 (s), 123.5 (q, J = 275.5 Hz), 59.6 (q, J = 3.7 Hz) ppm. IR (film, CHCl3) 3344, 
2958, 2873, 1595, 1493, 1365, 1198, 1161, 1118, 1092, 1016, 908, 823, 624 cm-1. HRMS (ESI): 
m/z calculated for C10H8OClF3 [M]: 236.02138, found 236.02158. 
 
(Z)-2-(4-Chlorophenyl)hex-2-en-1-ol - (SI-3) 
1H NMR (400 MHz, Chloroform-d) δ 7.29 (s, 4H), 5.87 – 5.80 (m, 1H), 4.34 (dd, J 
= 7.0, 3.0 Hz, 2H), 2.51 – 2.43 (m, 2H), 1.41 – 1.29 (m, 3H), 0.87 (t, J = 7.4 Hz, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 142.2, 140.8, 133.1, 128.6, 127.9, 127.8, 59.8, 
32.0, 22.0, 13.9 ppm. IR (film, CHCl3) 3327, 2958, 2930, 2871, 1491, 1093, 1011, 
821 cm-1. HRMS (ESI): m/z calculated for C12H15OCl [M]: 210.08090, found 210.08114. 
 
 
 
Chapter 8 – Experimental Procedures 
150 
(E)-3-(4-Chlorophenyl)hex-2-en-1-ol - (SI-4) 
1H NMR (400 MHz, Chloroform-d) δ 7.41 – 7.36 (m, 2H), 7.32 – 7.27 (m, 2H), 
5.89 (t, J = 7.5 Hz, 1H), 4.55 (d, J = 4.8 Hz, 2H), 2.26 (q, J = 7.4 Hz, 2H), 1.50 (h, J = 
7.4 Hz, 2H), 1.39 – 1.30 (m, 1H), 0.97 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 139.7, 138.0, 133.2, 132.9, 128.7, 127.7, 59.8, 30.5, 23.1, 14.0 ppm.  
IR (film, CHCl3) 3327, 2959, 2931, 2871, 1491, 1091, 1012, 823 cm-1. HRMS 
(ESI): m/z calculated for C12H15OCl [M]: 210.08091, found 210.08114. 
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Synthesis of starting materials 
8.2.7. Representative procedure 6: Synthesis of Propargyl Alcohols from Aldehydes and 
Ketones 
A flame-dried 250 mL two-necked flask was equipped with a dropping funnel and charged with 
dry THF (100 ml) and 1-hexyne (6.61 mL, 57.5 mmol, 1.2 equiv.), and cooled with a dry-ice bath. 
n-Butyllithium (34.4 mL, 1.6 M in hexanes, 55 mmol, 1.1 equiv.) was slowly added via the 
dropping funnel and stirring was continued for 1 h before neat hydrocinnamaldehyde (6.58 mL, 
50 mmol, 1.0 equiv.) was added in one portion. After being stirred for 30 minutes, the dry-ice 
bath was removed and the mixture allowed to warm to room temperature. The reaction was 
quenched with saturated ammonium chloride solution, the mixture extracted two times with 
MTBE, the combined organic layers were washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Pure products were obtained after flash chromatography 
(SiO2, hexanes/ethyl acetate). 
 
1-Phenylnon-4-yn-3-ol - (SI-5) 
99% yield (10.7 g, 49.5 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.33 – 
7.27 (m, 2H), 7.25 – 7.17 (m, 3H), 4.37 (tt, J = 6.4, 2.0 Hz, 1H), 2.80 (t, J = 7.9 Hz, 
2H), 2.24 (td, J = 7.0, 2.0 Hz, 2H), 2.01 (tt, J = 7.8, 6.2 Hz, 2H), 1.62 – 1.48 (m, 2H), 
1.48 – 1.35 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 141.6, 128.6, 
128.5, 126.0, 86.1, 81.1, 62.2, 39.8, 31.6, 30.8, 22.1, 18.5, 13.7 ppm. IR (film, CHCl3) 3338, 3027, 
2955, 2931, 2861, 1603, 1496, 1454, 1379, 1328, 1134, 1030 1054, 914, 746, 699 cm-1. 
Analytical data in accordance with literature[15]. 
 
8.2.8. Representative procedure 7: Propargylation of Carbonyl Compounds with 
Propargyl Bromide[20] 
Magnesium turnings (1.6 g, 66 mmol, 1.58 equiv.) and HgCl2 (135 mg, 0.25 mmol, 1.0 mol%) 
were placed in an oven-dried two-necked flask equipped with a reflux condenser and stirred 
under an argon atmosphere. Diethyl ether (120 mL) was added followed by dropwise addition of 
propargyl bromide (6.68 mL, 80 wt% in toluene, 60 mmol, 1.2 equiv.). The mixture started to 
reflux and stirring was continued until almost all of the magnesium turnings were dissolved. 
Then iso-butyraldehyde (3.8 mL, 42 mmol, 1.0 equiv.) was added dropwise and stirring 
continued with the conversion monitored by TLC (hexanes/ethyl acetate, 4:1). After complete 
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consumption of the carbonyl compound the reaction was carefully quenched with saturated 
ammonium chloride solution and the pH brought to 1 with 2 M HCl. The mixture was extracted 
three times with MTBE, the combined extracts were dried over magnesium sulfate and 
concentrated under reduced pressure to give a crude oil. 
 
2-Methylhex-5-yn-3-ol - (SI-6) 
64% yield (3.0 g, 26.7 mmol). B.p. (0.1 mbar, 65-70 °C). 1H NMR (400 MHz, 
Chloroform-d) δ 3.45 (ddd, J = 7.4, 6.1, 4.5 Hz, 1H), 2.38 (ddd, J = 16.8, 4.5, 2.6 Hz, 
1H), 2.29 (ddd, J = 16.7, 7.4, 2.7 Hz, 1H), 2.01 (t, J = 2.7 Hz, 1H), 1.75 (dq, J = 13.5, 
6.8 Hz, 1H), 0.91 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
81.4, 74.7, 70.6, 32.7, 24.7, 18.8, 17.6 ppm. IR (film, CHCl3) 3411, 3306, 2962, 2875, 1674, 1469, 
1386, 1253, 1126, 1046, 999, 858, 627 cm-1. HRMS (ESI): m/z calculated for C7H12ONa [M+Na+]: 
135.078120, found 135.078034. 
 
Ethyl (E)-4-hydroxy-3-methyldec-2-en-5-ynoate - (SI-7) 
 
1-Hexyne (2.30 mL, 30 mmol, 1.0 equiv.) was dissolved in dry THF (40 mL) and the solution 
stirred in an oven-dried Schlenk flask under an argon atmosphere at 78 °C. n-Butyllithium 
(13.8 mL, 1.6 M in hexanes, 22 mmol, 1.1 equiv.) was slowly added and stirring continued for 
30 minutes at the same temperature before ethyl (E)-3-methyl-4-oxobut-2-enoate (3.0 mL, 
22 mmol, 1.1 equiv.) was added in one portion under vigorous stirring which was continued for 
10 minutes. The reaction was then quenched with saturated ammonium chloride solution. 
Aqueous HCl (2 M) was added until all solids were completely dissolved. The mixture was 
extracted two times with MTBE, the combined organic layers were washed with brine, dried 
over magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 9:1 to 6:1 to 4:1) yielded the product as a pale yellow oil (3.87 g, 
17.3 mmol, 86% yield). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.58. 1H NMR (400 MHz, 
Chloroform-d) δ 6.06 (p, J = 1.3 Hz, 1H), 4.77 (q, J = 1.8 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 2.26 – 
2.15 (m, 5H), 1.56 – 1.42 (m, 2H), 1.42 – 1.30 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 0.90 (t, J = 7.2 Hz, 
3H) ppm. 13C NMR (101 MHz, CDCl3) δ 166.9, 155.9, 116.0, 87.8, 78.1, 67.2, 60.1, 30.6, 22.1, 
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18.5, 15.2, 14.4, 13.7 ppm. IR (film, CHCl3) 3434, 2959, 2934, 2873, 1717, 1699, 1657, 1432, 
1368, 1295, 1210, 1146, 1040, 876 cm-1. HRMS (ESI): m/z calculated for C13H18O3Na [M+Na+]: 
245.11484, found 245.11481. 
 
1-(p-Tolyl)hept-2-yn-1-ol - (SI-8) 
 
1-Hexyne (2.52 mL, 22 mmol, 1.1 equiv.) was dissolved in dry THF (40 mL) and the solution 
stirred in an oven-dried Schlenk flask at 78 °C under an argon atmosphere. n-Butyllithium 
(13.1 mL, 1.6 M in hexanes, 21 mmol, 1.05 equiv.) was slowly added and stirring continued for 
30 minutes before 4-methylbenzaldehyde (2.37 mL, 20 mmol, 1.0 equiv.) was added. The 
conversion was monitored by TLC (hexanes/ethyl acetate, 4:1). After about 15 minutes, TLC 
showed complete consumption of starting material so the reaction was quenched with the 
addition of saturated ammonium chloride solution. Aqueous HCl (2 M) was slowly added until 
all solids had been dissolved. The mixture was extracted two times with MTBE, the combined 
organic layer were washed with brine, dried over magnesium sulfate and concentrated under 
reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 20:1 to 10:1) yielded the 
product as a colorless oil (1.13 g, 5.6 mmol, 28% yield). TLC (hexanes/ethyl acetate, 4:1), Rf = 
0.27. 1H NMR (400 MHz, Chloroform-d) δ 7.47 – 7.40 (m, 2H), 7.22 – 7.15 (m, 2H), 5.42 (dt, J = 
5.8, 2.0 Hz, 1H), 2.36 (s, 3H), 2.28 (td, J = 7.1, 2.0 Hz, 2H), 2.11 (d, J = 5.6 Hz, 1H), 1.59 – 1.48 (m, 
2H), 1.48 – 1.36 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 138.6, 138.1, 
129.33, 126.7, 87.6, 80.1, 64.8, 30.8, 22.1, 21.3, 18.7, 13.7 ppm. IR (film, CHCl3) 3366, 2957, 
2931, 2871, 1512, 1457, 1378, 1178, 1133, 992, 819, 757 cm-1. HRMS (ESI): m/z calculated for 
C14H18ONa [M+Na+]: 225.12498, found 225.12498. 
 
1-((tert-Butyldimethylsilyl)oxy)non-4-yn-3-ol - (SI-9) 
 
(COCl)2 (1.99 mL, 23.2 mmol, 1.16 equiv.) was dissolved in CH2Cl2 (50 mL) and the solution 
stirred at 60 °C in a flame-dried Schlenk flask. DMSO (3.41 mL, 48 mmol, 2.4 equiv.) in CH2Cl2 
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(10 mL) was added to the reaction mixture. After 5 minutes, 3-(tert-butyl-dimethyl-silanyloxy)-
propan-1-ol (3.81 g, 20 mmol, 1.0 equiv.) was added dropwise at 60 °C followed by dropwise 
addition of Et3N (14.1 mL, 101 mmol, 5.1 equiv.). The mixture was allowed to warm to room 
temperature and the reaction was quenched with water (100 mL). The phases were separated 
and the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed 
with brine, water and a second time with brine before being dried over magnesium sulfate. The 
solvents were removed under reduced pressure, the mixture was dissolved in diethyl ether, 
filtered over Celite® and the ether was removed under reduced pressure. The crude product 
was used without further purification for the next step. 
1-Hexyne (1.38 mL, 12 mmol, 1.2 equiv.) was dissolved in dry THF (25 mL) and the solution 
stirred in an oven-dried Schlenk flask on a dry-ice bath under an argon atmosphere. n-
Butyllithium (7.5 mL, 1.6 M in hexanes, 12 mmol, 1.2 equiv.) was added and stirring continued 
for 1 h at the same temperature before freshly prepared 3-((tert-butyldimethyl-
silyl)oxy)propanal (1.88 g, 10 mmol, 1.0 equiv.) was introduced. After 1 h, the mixture was 
allowed to warm to room temperature and the reaction was quenched with the addition of 
saturated ammonium chloride solution. The mixture was extracted two times with ethyl acetate, 
the combined organic layers were washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 10:1) 
yielded the product as a pale yellow oil (2.29 g, 8.5 mmol, 85% yield). TLC (hexanes/ethyl 
acetate, 10:1), Rf = 0.26. 1H NMR (400 MHz, Chloroform-d) δ 4.54 (tt, J = 4.3, 2.2 Hz, 1H), 3.97 
(ddd, J = 10.2, 7.6, 4.2 Hz, 1H), 3.77 (ddd, J = 10.4, 6.2, 4.5 Hz, 1H), 3.37 (s, 1H), 2.17 (td, J = 7.0, 
2.0 Hz, 2H), 1.91 (ddt, J = 14.1, 7.6, 4.5 Hz, 1H), 1.80 (dtd, J = 14.1, 6.3, 4.2 Hz, 1H), 1.53 – 1.29 (m, 
4H), 0.89 – 0.83 (m, 12H), 0.04 (s, 3H), 0.04 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 85.4, 
80.7, 61.9, 61.2, 39.2, 30.8, 25.9, 22.0, 18.5, 18.2, 13.7, -5.5 ppm. IR (film, CHCl3) 2955, 2929, 
2858, 1470, 1253, 1099, 1006, 939, 832, 775 cm-1. HRMS (ESI): m/z calculated for C15H30O2SiNa 
[M+Na+]: 293.19070, found 293.19073. 
 
6-Chlorohex-2-yn-1-ol - (SI-10) 
 
5-Chloro-1-pentyne (2.14 mL, 20 mmol, 1.0 equiv.) was dissolved in dry THF (20 mL) and the 
solution stirred in an oven-dried Schlenk flask under an argon atmosphere at 78 °C. n-
Butyllithium (12.5 mL, 1.6 M in hexanes, 20 mmol, 1.0 equiv.) was added dropwise and the 
Chapter 8 – Experimental Procedures 
158 
mixture placed on an ice bath for 15 minutes. Then, paraformaldehyde (1.62 g, 54 mmol, 
2.7 equiv.) was added in one portion and the mixture was warmed to 45 °C for 2 h with an oil 
bath. After being cooled again to room temperature, saturated ammonium chloride solution was 
added. The mixture was extracted two times with MTBE, the combined organic layers were 
washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
Flash chromatography (SiO2, hexanes/MTBE, 3:1) yielded the product as a colorless oil (2.15 g, 
15.4 mmol, 77% yield). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.28. 1H NMR (400 MHz, 
Chloroform-d) δ 4.25 (t, J = 2.2 Hz, 2H), 3.65 (t, J = 6.3 Hz, 2H), 2.42 (tt, J = 6.8, 2.2 Hz, 2H), 1.96 
(p, J = 6.6 Hz, 2H), 1.83 – 1.74 (m, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ 84.5, 79.5, 51.4, 43.8, 
31.3, 16.3 ppm. IR (film, CHCl3) 3340, 2918, 1433, 1290, 1131, 1010, 859, 726, 652 cm-1. HRMS 
(ESI): m/z calculated for C6H9OClNa [M+Na+]: 155.02346, found 155.02341. 
 
6-((tert-Butyldiphenylsilyl)oxy)hex-2-yn-1-ol - (SI-11) 
 
tert-Butyl(pent-4-yn-1-yloxy)diphenylsilane (3.23 g, 10 mmol, 1.0 equiv.) was dissolved in THF 
(10 mL) and the solution stirred in an oven-dried Schlenk flask under an argon atmosphere on a 
dry-ice bath. n-Butyllithium (6.56 mL, 1.6 M in hexanes, 10.5 mmol, 1.05 equiv.) was added 
dropwise and the mixture placed on an ice bath for 15 minutes. Then, paraformaldehyde 
(811 mg, 27 mmol, 2.7 equiv.) was added in one portion and the mixture was stirred for 18 h at 
room temperature. The reaction was then quenched with saturated ammonium chloride 
solution. The mixture was extracted two times with MTBE, the combined organic layers were 
washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
Flash chromatography (SiO2, pentane/ethyl acetate, 4:1) yielded the product as a colorless oil 
(1.72 g, 4.9 mmol, 49% yield). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.44. 1H NMR (400 MHz, 
Chloroform-d) δ 7.73 – 7.63 (m, 4H), 7.47 – 7.35 (m, 6H), 4.21 (t, J = 2.2 Hz, 2H), 3.74 (t, J = 6.0 
Hz, 2H), 2.38 (tt, J = 7.1, 2.2 Hz, 2H), 1.76 (tt, J = 7.1, 5.9 Hz, 2H), 1.49 (s, 1H), 1.06 (s, 9H) ppm. 
13C NMR (101 MHz, CDCl3) δ 135.7, 133.9, 129.7, 127.8, 86.2, 78.6, 62.4, 51.5, 31.6, 27.0, 19.4, 
15.4 ppm. IR (film, CHCl3) 3343, 2930, 2857, 1472, 1427, 1104, 1007, 972, 822, 700, 613, 504 
cm-1. HRMS (ESI): m/z calculated for C22H28O2SiNa [M+Na+]: 375.17508, found 375.17508. 
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4-((tert-Butyldimethylsilyl)oxy)but-2-yn-1-ol - (SI-12) 
 
But-2-yne-1,4-diol (8.61 g, 100 mmol, 4.0 equiv.), 1H-imidazole (2.04 g, 30 mmol, 1.2 equiv.) and 
catalytic amounts of DMAP were dissolved in THF (45 mL) and the solution stirred in an oven-
dried two-necked flask equipped with a dropping funnel at room temperature. tert-
Butylchlorodimethylsilane (3.77 g, 25 mmol, 1.0 equiv.) dissolved in THF (20 mL) was added 
dropwise over 15 minutes and stirring continued for 5 h at room temperature before the 
reaction was quenched with the addition of water. The mixture was extracted two times with 
ethyl acetate, the combined organic layers were washed with brine, dried over magnesium 
sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl 
acetate, 4:1) yielded the product as a yellowish oil (4.91 g, 24.5 mmol, 98% yield).  
TLC (hexanes/ethyl acetate, 10:1), Rf = 0.27. 1H NMR (400 MHz, Chloroform-d) δ 4.35 (t, J = 
1.8 Hz, 2H), 4.30 (dt, J = 6.2, 1.8 Hz, 2H), 1.62 – 1.56 (m, 1H), 0.90 (d, J = 2.9 Hz, 9H), 0.12 (d, J = 
2.9 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 84.6, 83.1, 51.9, 51.4, 26.0, 18.5, -5.0.ppm.  
IR (film, CHCl3) 3358, 2954, 2929, 2858, 1472, 1362, 1254, 1130, 1079, 1008, 831, 775 cm-1. 
HRMS (ESI): m/z calculated for C10H20O2SiNa [M+Na+]: 223.11251, found 223.11248. 
 
5-Phenylpent-2-yn-1-ol - (SI-13) 
 
But-3-yn-1-ylbenzene (1.41 mL, 10 mmol, 1.0 equiv.) was dissolved in THF (25 mL) and stirred 
in an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. n-Butyllithium 
(6.88 mL, 1.6 M in hexanes, 11 mmol, 1.1 equiv.) was added dropwise and the mixture placed on 
an ice bath for 60 minutes. Then, paraformaldehyde (811 mg, 27 mmol, 2.7 equiv.) was added in 
one portion and the mixture was stirred for 18 h at room temperature. The reaction was then 
quenched with saturated ammonium chloride solution. The mixture was extracted two times 
with MTBE, the combined organic layers were washed with brine, dried over magnesium sulfate 
and concentrated under reduced pressure. Flash chromatography (SiO2, pentane/ethyl acetate, 
4:1) yielded the product as a colorless oil (1.35 g, 8.4 mmol, 84% yield). TLC (hexanes/ethyl 
acetate, 10:1), Rf = 0.21. 1H NMR (400 MHz, Chloroform-d) δ 7.35 – 7.28 (m, 2H), 7.25 – 7.20 
(m, 3H), 4.23 (t, J = 2.2 Hz, 2H), 2.84 (t, J = 7.6 Hz, 2H), 2.52 (tt, J = 7.5, 2.1 Hz, 2H), 1.70 (s, 1H) 
ppm.  
Chapter 8 – Experimental Procedures 
160 
13C NMR (101 MHz, CDCl3) δ 140.6, 128.5, 128.5, 126.4, 85.8, 79.2, 51.4, 35.1, 21.0 ppm.  
IR (film, CHCl3) 3335, 3027, 2927, 2863, 1496, 1453, 1132, 1008, 744, 697, 504 cm-1. HRMS 
(ESI): m/z calculated for C11H12ONa [M+Na+]: 183.07807, found 183.07803. 
 
2-(Pent-4-yn-1-yloxy)tetrahydro-2H-pyran - (SI-14) 
 
Pent-4-yn-1-ol (1.86 mL, 20 mmol, 1.0 equiv.) and 3,4-dihydro-2H-pyran (2.01 mL, 22 mmol, 
1.1 equiv.) were dissolved in dry CH2Cl2 (30 mL) and the solution stirred in a single-necked flask 
at room temperature. A few crystals of PTSA were added and stirring was continued for 18 h. 
The reaction was quenched with the addition of water, the mixture was extracted twice with 
CH2Cl2, the combined organic layers were washed with aqueous NaOH (2 M), dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 20:1) yielded the product as a colorless oil (2.87 g, 17.0 mmol, 
85% yield). TLC (hexanes/ethyl acetate, 10:1), Rf = 0.64. 1H NMR (400 MHz, Chloroform-d) δ 
4.59 (dd, J = 4.3, 2.7 Hz, 1H), 3.93 – 3.76 (m, 2H), 3.58 – 3.40 (m, 2H), 2.31 (tdd, J = 6.9, 2.6, 1.0 
Hz, 2H), 1.94 (t, J = 2.7 Hz, 1H), 1.82 (tt, J = 7.1, 6.2 Hz, 3H), 1.75 – 1.64 (m, 1H), 1.64 – 1.45 (m, 
3H) ppm. 13C NMR (101 MHz, CDCl3) δ 98.9, 84.1, 68.6, 65.9, 62.4, 30.8, 28.8, 25.6, 19.7, 15.5 
ppm. IR (film, CHCl3) 3296, 2941, 2871, 1441, 1354, 1199, 1120, 1061, 1033, 992, 868, 627 cm-
1. HRMS (ESI): m/z calculated for C10H16O2Na [M+Na+]: 191.10430, found 191.10425. 
 
6-((Tetrahydro-2H-pyran-2-yl)oxy)hex-2-yn-1-ol - (SI-15) 
 
2-(Pent-4-yn-1-yloxy)tetrahydro-2H-pyran (2.87 g, 17.0 mmol, 1.0 equiv.) was dissolved in THF 
(50 mL) and the solution stirred in an oven-dried Schlenk flask under an argon atmosphere on a 
dry-ice bath. n-Butyllithium (11.7 mL, 1.6 M in hexanes, 18.7 mmol, 1.1 equiv.) was added 
dropwise and the mixture placed on an ice bath for 60 minutes. Then, paraformaldehyde (1.38 g, 
45.9 mmol, 2.7 equiv.) was added in one portion and the mixture was stirred for 18 h at room 
temperature. The reaction was then quenched with saturated ammonium chloride solution. The 
mixture was extracted two times with MTBE, the combined organic layers were washed with 
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brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, pentane/ethyl acetate, 3:1) yielded the product as a colorless oil (3.21 g, 
16.2 mmol, 95% yield). TLC (hexanes/ethyl acetate, 4:1), Rf = 0.24. 1H NMR (400 MHz, 
Chloroform-d) δ 4.58 (dd, J = 4.3, 2.8 Hz, 1H), 4.22 (t, J = 2.2 Hz, 2H), 3.91 – 3.77 (m, 2H), 3.57 – 
3.42 (m, 2H), 2.33 (tt, J = 7.1, 2.2 Hz, 2H), 2.03 (s, 1H), 1.86 – 1.75 (m, 3H), 1.75 – 1.64 (m, 1H), 
1.64 – 1.46 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 98.9, 85.8, 78.9, 66.0, 62.4, 51.4, 30.8, 
28.8, 25.5, 19.6, 15.8 ppm. IR (film, CHCl3) 3407, 2940, 2869, 1440, 1354, 1135, 1118, 1061, 
1018, 986, 900, 866, 809 cm-1. HRMS (ESI): m/z calculated for C11H18O3Na [M+Na+]: 221.11482, 
found 221.11481. Analytical data matched those reported.[21] 
 
Undec-6-yn-5-ol - (SI-16) 
 
1-Hexyne (2.76 mL, 24 mmol, 1.2 equiv.) was dissolved in dry THF (25 mL) and stirred in an 
oven-dried Schlenk flask at 78 °C under an argon atmosphere. n-Butyllithium (15 mL, 1.6M in 
hexanes, 24 mmol, 1.2 equiv.) was slowly added and stirring continued at the same temperature 
for 1 h before neat (E)-pent-2-enal (1.96 mL, 20 mmol, 1.0 equiv.) was added in one portion. 
After 1 h at 78 °C, the mixture was allowed to warm to room temperature and the reaction was 
quenched with the addition of saturated ammonium chloride solution. The mixture was 
extracted twice with ethyl acetate, the combined organic layers were washed with brine, dried 
over magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
pentane/diethyl ether, 10:1) yielded the product as a colorless liquid (2.23 g, 13 mmol, 
67% yield). TLC (hexanes/MTBE, 15:1), Rf = 0.31. 1H NMR (400 MHz, Chloroform-d) δ 5.90 
(dtd, J = 15.3, 6.3, 1.2 Hz, 1H), 5.58 (ddt, J = 15.3, 6.2, 1.6 Hz, 1H), 4.88 – 4.69 (m, 1H), 2.24 (td, J = 
7.1, 2.0 Hz, 2H), 2.13 – 2.04 (m, 2H), 1.80 – 1.75 (m, 1H), 1.54 – 1.46 (m, 2H), 1.46 – 1.36 (m, 2H), 
1.01 (t, J = 7.5 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H) ppm.13C NMR (101 MHz, CDCl3) δ 135.3, 128.7, 
87.0, 79.8, 63.4, 30.8, 25.1, 22.1, 18.6, 13.7, 13.3 ppm. IR (film, CHCl3) 3337, 2961, 2933, 2873, 
1460, 1379, 1147, 1083, 998, 966 cm-1. HRMS (ESI): m/z calculated for C11H18ONa [M+Na+]: 
189.12509, found 189.12498. 
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Methyl 2-chloro-3,3,3-trifluoro-2-(hex-2-yn-1-yloxy)propanoate[22] - (SI-17) 
 
1-Hexynol (1.10 mL, 10 mmol, 1.0 equiv.) was dissolved in dry toluene (10 mL) and stirred at 
room temperature in an oven-dried Schlenk flask under an argon atmosphere. Methyl-3,3,3-
trifluoropyruvate (1.12 mL, 11 mmol, 1.1 equiv.) was added dropwise and stirring continued for 
1 h at room temperature before the mixture was placed on an ice bath. Pyridine (2.43 mL, 
30 mmol, 3.0 equiv.) was added followed by dropwise addition of SOCl2 (1.09 mL, 15 mmol, 
1.5 equiv.) over 5 minutes. Stirring was continued for another 1 h under ice cooling and then at 
room temperature with the conversion monitored by TLC. The mixture was then poured onto 
ice-cold aqueous HCl (2 M) and extracted three times with MTBE. The combined organic layers 
were washed with brine, dried over magnesium sulfate and concentrated under reduced 
pressure. The crude yellow residue was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate, 20:1) to give the product as a colorless liquid (1.55 g, 5.69 mmol, 57% yield).  
TLC (hexanes/ethyl acetate, 10:1), Rf = 0.73. 1H NMR (400 MHz, Chloroform-d) δ 4.70 – 4.51 
(m, 2H), 3.92 (s, 3H), 2.21 (tt, J = 7.1, 2.2 Hz, 2H), 1.61 – 1.47 (m, 2H), 0.98 (td, J = 7.4, 1.7 Hz, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 162.7, 124.8, 122.0, 119.1, 116.3, 89.6, 73.2, 57.4, 54.6, 51.1, 
31.1, 21.9, 21.0, 13.6 ppm. IR (film, CHCl3) 2966, 2939, 2877, 2242, 1761, 1438, 1382, 1290, 
1255, 1193, 1025 1000, 944, 884 907, 794, 744, 680cm-1. HRMS (ESI): m/z calculated for 
C10H12O3ClF3Na [M+Na+]: 295.03215, found 295.03193. 
 
4,4,4-Trifluorobut-2-yn-1-ol[23] - (SI-18) 
 
Di-iso-propylamine (15.42 mL, 110 mmol, 2.2 equiv.) was stirred in diethyl ether (100 mL) in a 
two-necked flame-dried flask equipped with a dropping funnel on a dry-ice bath. n-Butyllithium 
(68.8 mL, 1.6 M in hexanes, 110 mmol, 2.2 equiv.) was slowly added via the dropping funnel and 
stirring continued for 10 minutes before the mixture was placed for 30 minutes on an ice bath. 
After cooling to 78 °C, 2-bromo-3,3,3-trifluoro-1-propene (5.19 mL, 50 mmol, 1.0 equiv.) was 
added in one portion followed after 10 minutes by paraformaldehyde (3.0 g, 100 mmol, 
2.0 equiv.). The mixture was allowed to stir for 15 minutes before the dry-ice bath was removed 
and the mixture allowed to reach room temperature over 18 h. The reaction was quenched with 
the addition of saturated ammonium chloride solution. The mixture was extracted two times 
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with Et2O, the combined extracts were washed two times with aqueous HCl (2 M) and once with 
brine, dried over magnesium sulfate and concentrated under reduced pressure (40 °C, max. 
250 mbar). The crude dark red residue was distilled at room temperature (dry-ice trap) via 
bulb-to-bulb distillation to give the product as a colorless volatile liquid which was carefully 
dried at room temperature at max. 100 mbar. 1H NMR (400 MHz, Chloroform-d) δ 4.39 (t, J = 
3.4 Hz, 2H), 2.23 (s, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ 117.8, 115.3, 112.7, 110.2, 85.3, 
73.6, 73.1, 72.6, 72.0, 50.3 ppm. IR (film, CHCl3) 3349, 2287, 1274, 1134, 1046, 983, 591 cm-1. 
HRMS (ESI): m/z calculated for C4H4OF3 [M+H+]: 125.02132, found 125.02143. 
 
8.3. Hydroxyl-Assisted Carbonylation of Alkenyltin Derivatives: Development 
and Application to a Formal Synthesis of Tubelactomicin A 
8.3.1. Representative procedure 8: Palladium Catalyzed Oxidative Methoxy 
Carbonylation of Alkenylstannanes 
 
Methyl (Z)-2-(1-hydroxy-3-phenylpropyl)hept-2-enoate - (249b) 
 
(Z)-1-Phenyl-4-(tributylstannyl)non-4-en-3-ol (1.27 g, 2.5 mmol, 1.0 equiv.) was dissolved in a 
0.1 M TFA solution in MeOH (10 mL) and stirred in an oven-dried Schlenk flask under an argon 
atmosphere. p-Benzoquinone (405 mg, 3.75 mmol, 1.5 equiv.), Ph3As (77 mg, 0.25 mmol, 
10 mol%) and Pd(OAc)2 (28 mg, 0.125 mmol, 5.0 mol%) were added in one portion and the 
mixture was flushed for 2 minutes with CO (balloon) before stirring was continued under 
positive CO pressure (balloon) at room temperature. The progress of the reaction was 
monitored by TLC (hexanes/ethyl acetate, 15:1). After 12 h the mixture was diluted with MTBE, 
and the crude mixture filtered through a plug of Celite®. The volatile materials were removed 
and the crude material was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 19:1) 
to give the product as a colorless oil (660 mg, 2.15 mmol, 86% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.31 – 7.25 (m, 2H), 7.22 – 7.15 (m, 3H), 6.13 (td, J = 7.5, 0.9 Hz, 1H), 4.23 (d, J 
= 8.7 Hz, 1H), 3.77 (s, 3H), 2.83 – 2.60 (m, 3H), 2.42 (q, J = 7.3 Hz, 2H), 2.04 – 1.86 (m, 2H), 1.47 – 
1.24 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 168.2, 143.5, 141.9, 
133.7, 128.6, 128.5, 126.0, 74.0, 51.5, 38.2, 32.4, 31.5, 29.3, 22.5, 14.0 ppm. IR (film, CHCl3) 
3435, 3027, 2954, 2927, 2859, 1706, 1496, 1454, 1435, 1378, 1205, 1143, 1032, 748, 700 cm-1. 
HRMS (ESI): m/z calculated for C17H24O3Na [M+Na+]: 299.16176, found 299.16188.  
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Methyl (Z)-2-(4-cyanobenzylidene)-3-hydroxy-3-methylbutanoate - (252) 
73% yield (89 mg, 0.363 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.64 
– 7.54 (m, 2H), 7.36 – 7.29 (m, 2H), 6.86 (s, 1H), 3.64 (s, 3H), 2.49 (s, 1H), 
1.52 (s, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 169.7, 145.0, 140.6, 132.2, 128.6, 127.1, 118.7, 
111.5, 72.3, 52.3, 29.4 ppm. IR (film, CHCl3) 3430, 2977, 2228, 1721, 1638, 1605, 1512, 1435, 
1353, 1313, 1286, 1206, 1175, 1041, 966, 944, 893, 824, 759, 677 cm-1. HRMS (ESI): m/z 
calculated for C14H15NO3Na [M+Na+]: 268.09441, found 268.09435. 
 
Methyl (Z)-2-(hydroxymethyl)dec-2-enoate - (253) 
68% yield (145 mg, 0.68 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
6.23 (tt, J = 7.3, 1.0 Hz, 1H), 4.21 (q, J = 1.0 Hz, 2H), 3.76 (s, 3H), 2.58 – 
2.46 (m, 2H), 2.43 (s, 1H), 1.49 – 1.35 (m, 2H), 1.35 – 1.16 (m, 9H), 1.00 – 0.70 (m, 3H) ppm.  
13C NMR (101 MHz, CDCl3) δ 167.7, 147.0, 130.5, 65.3, 51.5, 31.9, 29.6, 29.2, 22.7, 14.2 ppm.  
IR (film, CHCl3) 3432, 2954, 2924, 2855, 1706, 1650, 1435, 1380, 1339, 1204, 1145, 1103, 1046, 
1011 cm-1. HRMS (ESI): m/z calculated for C12H22O3Na [M+Na+]: 237.14611, found 237.14618.  
 
Methyl (Z)-2-(cyclohex-1-en-1-ylmethylene)-3-hydroxy-4-methyl-pentanoate - (254) 
55% yield (65 mg, 0.273 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.17 (p, J 
= 1.0 Hz, 1H), 5.86 (ddt, J = 4.0, 2.7, 1.2 Hz, 1H), 3.80 (ddd, J = 8.0, 6.2, 0.9 Hz, 1H), 
3.76 (s, 3H), 2.22 (d, J = 6.2 Hz, 1H), 2.18 – 2.09 (m, 2H), 2.09 – 2.01 (m, 2H), 1.83 
– 1.70 (m, 1H), 1.66 – 1.57 (m, 4H), 1.56 (s, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 170.3, 137.4, 134.5, 133.7, 130.9, 81.7, 51.8, 33.1, 26.4, 26.2, 
22.8, 22.0, 19.6, 18.6 ppm. IR (film, CHCl3) 3482, 2931, 2868, 1774, 1716, 1635, 1435, 1366, 
1214, 1180, 1135, 1102, 1017, 981, 927, 872 cm-1. HRMS (ESI): m/z calculated for C14H22O3Na 
[M+Na+]: 261.14611, found 261.14632. 
 
Methyl (Z)-5-bromo-3-hydroxy-2-(3-phenylpropylidene)hex-5-enoate - (255) 
87% yield (147 mg, 0.43 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.29 (ddd, J = 9.1, 6.4, 0.9 Hz, 2H), 7.20 (td, J = 6.5, 1.7 Hz, 3H), 6.35 – 6.27 
(m, 1H), 5.63 (dt, J = 1.9, 1.0 Hz, 1H), 5.49 (d, J = 1.6 Hz, 1H), 4.59 (tdd, J = 
7.1, 6.0, 0.9 Hz, 1H), 3.78 (s, 3H), 2.83 – 2.68 (m, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.5, 
143.5, 141.2, 132.5, 130.25, 128.5, 126.2, 119.8, 72.2, 51.7, 48.7, 35.4, 31.3 ppm. IR (film, CHCl3) 
3463,3026, 2949, 1703, 1631, 1603, 1496, 1435, 1453, 1381, 1332, 1200, 1111, 1050, 1005, 
890, 793, 748, 698 cm-1. HRMS (ESI): m/z calculated for C16H19BrO3Na [M+Na+]: 361.04099, 
found 361.04241.  
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Ethyl (2E,5Z)-5-acetoxy-4-hydroxy-3-methyldeca-2,5-dienoate - (256) 
80% yield (113 mg, 0.397 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.20 
(td, J = 7.6, 0.7 Hz, 1H), 6.07 (p, J = 1.4 Hz, 1H), 4.81 – 4.73 (m, 1H), 4.16 (qd, J 
= 7.1, 1.2 Hz, 2H), 3.76 (s, 3H), 3.00 (d, J = 7.2 Hz, 1H), 2.47 (q, J = 7.4 Hz, 2H), 
2.05 (dd, J = 1.4, 0.6 Hz, 3H), 1.49 – 1.30 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H 
ppm. 13C NMR (101 MHz, CDCl3) δ 167.7, 166.9, 157.3, 146.7, 130.9, 116.1, 77.8, 60.0, 51.8, 31.3, 
29.5, 22.6, 16.0, 14.4, 14.0 ppm. IR (film, CHCl3) 3488, 2957, 2930, 2873, 1775, 1713, 1654, 
1435, 1368, 1344, 1206, 1144, 1095, 1039 cm-1. HRMS (ESI): m/z calculated for C15H24O5Na 
[M+Na+]: 307.15159, found 307.15176.  
 
Methyl (Z)-2-(2-hydroxypropan-2-yl)hept-2-enoate - (257) 
63 yield  (63 mg, 0.32 mmol). 1H NMR (400 MHz, Chloroform-d) δ 5.99 (t, J 
= 7.5 Hz, 1H), 3.80 (s, 3H), 3.01 (s, 1H), 2.20 (q, J = 7.4 Hz, 2H), 1.41 (s, 6H), 
1.40 – 1.22 (m, 4H), 0.90 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
170.0, 139.4, 135.3, 71.8, 51.7, 31.5, 29.6, 29.4, 22.5, 14.0 ppm. IR (film, CHCl3) 3436, 2956, 
2931, 2860, 1719, 1458, 1434, 1356, 1255, 1204, 1127, 1038, 966 cm-1. HRMS (ESI): m/z 
calculated for C11H20O3Na [M+Na+]: 223.13046, found 223.13068.  
 
(anti,Z)-5-Isopropyl-4-methyl-3-nonylidenedihydrofuran-2(3H)-one - (258) 
60% yield (79 mg, 0.30 mmol). 1H NMR (300 MHz, Chloroform-
d) δ 6.08 (td, J = 7.6, 2.2 Hz, 1H), 3.75 (t, J = 5.7 Hz, 1H), 2.72 (tdd, J 
= 7.6, 5.2, 1.6 Hz, 3H), 1.84 (pd, J = 6.8, 5.7 Hz, 1H), 1.54 – 1.37 (m, 
2H), 1.37 – 1.23 (m, 12H), 1.19 (d, J = 6.7 Hz, 3H), 0.98 (d, J = 6.8 Hz, 6H), 0.94 – 0.82 (m, 3H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 170.1, 143.7, 131.0, 89.1, 37.9, 32.5, 32.0, 29.6, 29.4, 27.6, 
22.8, 20.1, 18.3, 17.4, 14.2 ppm. IR (film, CHCl3) 2960, 2924, 2855, 1751, 1667, 1466, 1370, 
1170, 1126, 1094, 1005 953 cm-1. HRMS (ESI): m/z calculated for C17H30O2 [M+]: 266.22403, 
found 266.22367. 
 
Methyl (Z)-2-(3-((tert-butyldimethylsilyl)oxy)-1-hydroxypropyl)hept-2-enoate - (259) 
77% yield (128 mg, 0.387 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.28 
(td, J = 7.5, 1.3 Hz, 1H), 4.63 – 4.53 (m, 1H), 3.88 – 3.75 (m, 3H), 3.74 (s, 3H), 
2.45 (qdd, J = 7.4, 2.1, 1.0 Hz, 2H), 1.93 – 1.83 (m, 1H), 1.81 – 1.69 (m, 1H), 
1.49 – 1.27 (m, 4H), 0.94 – 0.84 (m, 13H), 0.10 – 0.01 (m, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 
168.0, 142.4, 133.5, 72.3, 62.1, 51.4, 38.2, 31.6, 29.3, 26.0, 22.6, 18.3, 14.1, -5.4 ppm. IR (film, 
CHCl3) 3487, 2929, 2954, 2858, 1708, 1435, 1464, 1379, 1254, 1202, 1151, 1096, 1006, 914, 
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833, 776, 732 cm-1. HRMS (ESI): m/z calculated for C17H35O4Si [M+H+]: 331.22991, found 
331.22998.  
 
Methyl (Z)-2-((E)-1-hydroxypent-2-en-1-yl)hept-2-enoate - (260) 
72% yield (81 mg, 0.358 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.17 (td, J 
= 7.5, 1.0 Hz, 1H), 5.73 (dtd, J = 15.5, 6.3, 1.2 Hz, 1H), 5.54 (ddt, J = 15.4, 6.3, 1.5 
Hz, 1H), 4.76 (t, J = 6.5 Hz, 1H), 3.77 (s, 3H), 2.72 (d, J = 6.8 Hz, 1H), 2.43 (q, J = 7.3 
Hz, 2H), 2.10 – 1.99 (m, 2H), 1.50 – 1.25 (m, 4H), 0.98 (t, J = 7.5 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 168.1, 143.6, 134.7, 133.3, 129.5, 74.6, 51.5, 31.4, 29.3, 25.4, 
22.5, 14.0, 13.5 ppm. IR (film, CHCl3) 3434, 2959, 2929, 2873, 1707, 1435, 1377, 1204, 1150, 
1081, 1021, 966, 911, 799, 731 cm-1. HRMS (ESI): m/z calculated for C13H22O3Na [M+Na+]: 
249.14611, found 249.14620.  
 
Methyl (R,Z)-2-((1R,2R)-2-(5,5-dimethyl-1,3-dioxan-2-yl)-1-hydroxy-propyl)-7-((triiso-
propylsilyl)oxy)oct-2-enoate - (261) 
82% yield (345 mg, 0.689 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 6.28 (td, J = 7.5, 1.5 Hz, 1H), 4.84 (dq, J = 2.9, 1.5 
Hz, 1H), 4.53 (d, J = 2.8 Hz, 1H), 3.93 (q, J = 5.6 Hz, 1H), 3.73 (s, 3H), 
3.68 – 3.59 (m, 2H), 3.47 – 3.38 (m, 3H), 2.57 – 2.33 (m, 2H), 2.04 – 1.91 (m, 1H), 1.58 – 1.30 (m, 
4H), 1.19 (s, 3H), 1.14 (dd, J = 8.4, 6.1 Hz, 3H), 1.05 (s, 18H), 0.99 (dt, J = 9.7, 7.0 Hz, 3H), 0.89 (d, 
J = 7.2 Hz, 3H), 0.72 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.8, 142.6, 131.5, 104.5, 77.4, 
70.9, 68.5, 51.4, 40.6, 39.8, 30.5, 29.8, 25.4, 23.7, 23.0, 21.9, 18.3, 18.3, 12.6, 6.9 ppm. IR (film, 
CHCl3) 3514, 2943, 2866, 1719, 1462, 1365, 1202, 1136, 1097, 1061, 1038, 1017, 993, 923, 882, 
851, 724, 676, 654 cm-1. HRMS (ESI): m/z calculated for C27H52O6SiNa [M+Na+]: 523.34254, 
found 523.34334.  
 
8.3.2. Representative procedure 9: Ruthenium Catalyzed trans-Hydrostannation of 
Propargyl Alcohols (25 mmol scale experiment)[24] 
1-Phenylnon-4-yn-3-ol (5.4 g, 25 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (100 mL) and the 
solution stirred at room temperature in an oven-dried Schlenk flask under an argon atmosphere. 
[Cp*RuCl2]n (77 mg, 0.25 mmol, 1.0 mol%) was added followed by slow addition of Bu3SnH 
(7.1 ml, 26.3 mmol, 1.05 equiv.) over 1 h via syringe pump. Stirring was continued for another 
5 minutes before the volatile materials were removed under reduced pressure. The crude 
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material was purified by flash chromatography (SiO2, hexanes/ethyl acetate) to give the product 
as a brownish thick oil. 
 
(Z)-1-Phenyl-4-(tributylstannyl)non-4-en-3-ol - (248) 
93% yield (11.8 g, 23.3 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 
7.24 (m, 2H), 7.23 – 7.12 (m, 3H), 6.38 – 5.96 (m, 1H), 4.35 – 4.01 (m, 1H), 2.64 
(qdd, J = 13.8, 9.8, 6.1 Hz, 2H), 2.13 – 1.95 (m, 2H), 1.83 (dddd, J = 13.3, 9.7, 7.2, 6.0 Hz, 1H), 1.71 
(ddt, J = 13.5, 10.0, 6.3 Hz, 1H), 1.60 – 1.40 (m, 8H), 1.40 – 1.21 (m, 10H), 1.04 – 0.79 (m, 20H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 147.6, 142.3, 141.4, 128.6, 128.5, 125.9, 79.6, 39.4, 34.2, 32.5, 
29.4, 27.6, 22.7, 14.2, 13.8, 11.2 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.09 ppm. IR (film, 
CHCl3) 2955, 2923, 2871, 2854, 1616, 1496, 1456, 1419, 1376, 1340, 1290, 1201, 1072, 1048, 
1002, 961, 926, 863, 746, 697, 664 cm-1. HRMS (ESI): m/z calculated for C27H48OSnNa [M+Na+]: 
531.26186, found 531.26185. 
 
(Z)-Tributyl(3-(methoxymethoxy)-1-phenylnon-4-en-4-yl)stannane - (SI-19) 
 
248 (2.53 g, 5.0 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (20 mL) and the solution stirred 
on an ice bath in an oven-dried Schlenk flask under an argon atmosphere. TBAI (185 mg, 
0.5 mmol, 10 mol%) and Hünig's base (1.74 mL, 10 mmol, 2.0 equiv.) were added followed by 
dropwise addition of MOMCl (570 µL, 7.5 mmol, 1.5 equiv.). The mixture was stirred for 18 h 
while being allowed to warm to room temperature. The reaction was then quenched with 
saturated ammonium chloride solution. The mixture was extracted two times with MTBE, the 
combined extracts were washed with brine, dried over magnesium sulfate and concentrated 
under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 30:1) yielded the 
product as a colorless oil (2.62 g, 4.75 mmol, 95% yield). 1H NMR (300 MHz, Chloroform-d) δ 
7.32 – 7.24 (m, 2H), 7.22 – 7.13 (m, 3H), 6.46 – 5.87 (m, 1H), 4.66 (d, J = 6.5 Hz, 1H), 4.47 (d, J = 
6.5 Hz, 1H), 4.25 – 3.92 (m, 1H), 3.37 (s, 3H), 2.80 – 2.51 (m, 2H), 2.07 (dddd, J = 8.8, 7.0, 4.9, 1.8 
Hz, 2H), 1.91 (dddd, J = 13.2, 10.5, 7.2, 5.9 Hz, 1H), 1.68 (ddt, J = 13.5, 10.6, 6.1 Hz, 1H), 1.60 – 
1.41 (m, 6H), 1.41 – 1.14 (m, 9H), 1.01 – 0.79 (m, 18H) ppm. 13C NMR (75 MHz, CDCl3) δ 144.9, 
144.1, 142.5, 128.5, 128.5, 93.4, 84.0, 55.6, 38.4, 34.3, 32.6, 29.4, 27.6, 22.8, 14.2, 13.8, 11.3 ppm. 
IR (film, CHCl3) 2954, 2923, 2871, 2855, 1614, 1496, 1455, 1376, 1177, 1147, 1094, 1030, 960, 
920, 863, 746, 697 cm-1. HRMS (ESI): m/z calculated for C29H52O2SnNa [M+Na+]: 575.28808, 
found 575.28862. 
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(Z)-tert-Butyldimethyl((1-phenyl-4-(tributylstannyl)non-4-en-3-yl)oxy)silane - (SI-20) 
 
248 (2.53 g, 5.0 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (20 mL) and the solution stirred 
on an ice bath in an oven-dried Schlenk flask under an argon atmosphere. DMAP (61 mg, 
0.5 mmol, 10 mol%) and 1H-imidazole (681 mg, 10 mmol, 2.0 equiv.) were added followed by 
addition of tert-butyldimethylsilyl chloride (1.13 g, 7.5 mmol, 1.5 equiv.). The mixture was 
stirred for 18 h while being allowed to warm to room temperature. The reaction was then 
quenched with saturated ammonium chloride solution. The mixture was extracted two times 
with MTBE, the combined extracts were washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 30:1) 
yielded the product as a colorless oil (2.89 g, 4.64 mmol, 93% yield). 1H NMR (300 MHz, 
Chloroform-d) δ 7.32 – 7.22 (m, 2H), 7.22 – 7.11 (m, 3H), 6.08 (td, J = 7.2, 1.0 Hz, 1H), 4.11 (td, J 
= 6.6, 0.9 Hz, 1H), 2.63 – 2.43 (m, 3H), 2.13 – 1.90 (m, 3H), 1.76 (ddt, J = 13.5, 10.8, 6.2 Hz, 1H), 
1.65 (dddd, J = 13.4, 10.8, 6.7, 5.6 Hz, 1H), 1.60 – 1.40 (m, 6H), 1.40 – 1.23 (m, 12H), 1.03 – 0.71 
(m, 32H), 0.00 (d, J = 17.2 Hz, 6H) ppm. 13C NMR (75 MHz, CDCl3) δ 148.1, 142.8, 140.41, 128.5, 
128.4, 125.7, 81.1, 41.0, 34.2, 32.6, 32.5, 29.5, 27.7, 26.2, 22.8, 18.4, 14.3, 13.8, 11.3, -3.9, -4.6 
ppm. 119Sn NMR (149 MHz, CDCl3) δ -57.69 ppm. IR (film, CHCl3) 3027, 2926, 2855, 1616, 
1496, 1462, 1417, 1377, 1360, 1291, 1251, 1175, 1152, 1066, 1004, 963, 938, 875, 834, 773, 
746, 697, 666 cm-1. HRMS (ESI): m/z calculated for C33H62OSiSnNa [M+Na+]: 645.34834, found 
645.34898. 
 
(Z)-2-(Tributylstannyl)dec-2-en-1-ol - (SI-21) 
97% yield (3.1 g, 6.96 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
6.25 (tt, J = 7.2, 1.4 Hz, 1H), 4.28 – 4.12 (m, 2H), 2.04 (q, J = 7.4 Hz, 2H), 
1.61 – 1.44 (m, 6H), 1.43 – 1.25 (m, 16H), 1.22 (t, J = 6.0 Hz, 1H), 1.02 – 0.94 (m, 6H), 0.94 – 0.87 
(m, 12H) ppm. 13C NMR (101 MHz, CDCl3) δ 143.0, 142.2, 70.7, 34.8, 32.0, 30.2, 29.6, 29.4, 29.4, 
27.6, 22.8, 14.3, 13.9, 10.3 ppm. 119Sn NMR (149 MHz, CDCl3) δ -52.7 ppm. . IR (film, CHCl3) 
3305, 2955, 2922, 2871, 2852, 1462, 1418, 1376, 1340, 1290, 1181, 1148, 1072, 1000, 960, 862, 
806, 769 cm-1. HRMS (ESI): m/z calculated for C22H45OSn [M-H+]: 445.24972, found 445.25028. 
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(Z)-2-Bromo-8-phenyl-5-(tributylstannyl)octa-1,5-dien-4-ol - (SI-22) 
45% yield (1.55 g, 2.72 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.34 
– 7.25 (m, 2H), 7.24 – 7.13 (m, 3H), 6.33 (td, J = 7.2, 1.1 Hz, 1H), 5.66 (q, J = 
1.0 Hz, 1H), 5.53 (d, J = 1.6 Hz, 1H), 4.61 – 4.38 (m, 1H), 2.75 – 2.62 (m, 2H), 
2.60 – 2.47 (m, 2H), 2.43 – 2.29 (m, 2H), 1.69 (d, J = 2.7 Hz, 1H), 1.60 – 1.38 (m, 6H), 1.38 – 1.23 
(m, 6H), 1.10 – 0.93 (m, 5H), 0.89 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 146.8, 
141.8, 140.5, 130.8, 128.5, 128.5, 126.1, 119.6, 76.4, 50.0, 36.5, 36.3, 29.4, 27.6, 13.9, 11.3 ppm. 
119Sn NMR (149 MHz, CDCl3) δ -53.85 ppm. IR (film, CHCl3) 2954, 2922, 2870, 2853, 1629, 
1496, 1454, 1376, 1290, 1199, 1123, 1072, 1029, 961, 884, 746, 697 cm-1. HRMS (ESI): m/z 
calculated for C26H43BrOSnNa [M+Na+]: 593.14109, found 593.14118. 
 
Ethyl (2E,5Z)-4-hydroxy-3-methyl-5-(tributylstannyl)deca-2,5-dienoate - (SI-23) 
72% yield (2.96 g, 5.74 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.24 
(td, J = 7.2, 1.0 Hz, 1H), 6.04 (p, J = 1.4 Hz, 1H), 4.71 – 4.45 (m, 1H), 4.16 (q, J = 
7.1 Hz, 2H), 2.11 – 2.03 (m, 2H), 2.02 (d, J = 1.2 Hz, 3H), 1.66 (d, J = 3.4 Hz, 
1H), 1.44 (dddd, J = 14.1, 8.4, 7.1, 4.0 Hz, 5H), 1.40 – 1.19 (m, 13H), 0.97 – 0.83 (m, 19H) ppm.  
13C NMR (101 MHz, CDCl3) δ 167.1, 158.9, 145.1, 144.0, 114.9, 83.7, 59.7, 34.1, 32.3, 29.3, 27.5, 
22.7, 16.3, 14.5, 14.2, 13.8, 11.3 ppm. 119Sn NMR (149 MHz, CDCl3) δ -49.65 ppm. IR (film, 
CHCl3) 3482, 2955, 2923, 2871, 2854, 1718, 1698, 1650, 1463, 1377, 1340, 1288, 1210, 1142, 
1093, 1043 cm-1. HRMS (ESI): m/z calculated for C25H48O3SnNa [M+Na+]: 539.25169, found 
539.25226. 
 
(Z)-2-Methyl-3-(tributylstannyl)oct-3-en-2-ol - (SI-24) 
90% yield (3.11 g, 7.21 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.36 – 
5.86 (m, 1H), 2.11 – 1.94 (m, 2H), 1.57 – 1.40 (m, 6H), 1.38 – 1.30 (m, 12H), 
1.29 (s, 6H), 0.97 – 0.83 (m, 16H) ppm. 13C NMR (101 MHz, CDCl3) δ 153.0, 
136.6, 75.4, 33.8, 32.6, 30.9, 29.4, 27.6, 22.8, 14.3, 13.9, 12.3 ppm. 119Sn NMR (149 MHz, CDCl3) 
δ -55.51 ppm. IR (film, CHCl3) 3456, 2955, 2921, 2871, 2854, 1616, 1462, 1376, 1360, 1133, 
1071, 1002, 960, 911, 860, 761, 665 cm-1. HRMS (ESI): m/z calculated for C21H44OSnNa [M+Na+]: 
455.23056, found 455.23087. 
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(3E,6Z)-6-(Tributylstannyl)undeca-3,6-dien-5-ol - (SI-25) 
41% yield (1.3 g, 2.84 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.20 (td, J = 
7.2, 1.1 Hz, 1H), 5.64 (dtd, J = 15.5, 6.2, 1.3 Hz, 1H), 5.43 (ddt, J = 15.4, 5.9, 1.6 Hz, 
1H), 4.63 (ddt, J = 5.9, 3.5, 1.1 Hz, 1H), 2.12 – 1.93 (m, 3H), 1.54 – 1.40 (m, 6H), 
1.39 – 1.22 (m, 10H), 0.99 (t, J = 7.4 Hz, 3H), 0.97 – 0.84 (m, 20H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 146.3, 141.1, 133.3, 131.9, 80.2, 34.2, 32.4, 29.4, 27.6, 25.4, 22.8, 14.2, 13.9, 13.5, 11.2 
ppm. 119Sn NMR (149 MHz, CDCl3) δ -53.6 ppm. IR (film, CHCl3) 2956, 2922, 2853, 2871, 1458, 
1376, 1071, 1001, 966, 863, 666, 594 cm-1. HRMS (ESI): m/z calculated for C23H46OSnNa 
[M+Na+]: 481.24621, found 481.24621. 
 
(Z)-1-((tert-Butyldimethylsilyl)oxy)-4-(tributylstannyl)non-4-en-3-ol - (SI-26) 
81% yield (1.86 g, 3.31 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.20 
(td, J = 7.2, 1.2 Hz, 1H), 4.48 – 4.18 (m, 1H), 3.94 – 3.72 (m, 3H), 3.16 (d, J = 2.2 
Hz, 1H), 2.02 (td, J = 8.9, 8.1, 5.9 Hz, 2H), 1.79 – 1.64 (m, 2H), 1.58 – 1.40 (m, 
7H), 1.40 – 1.20 (m, 11H), 1.01 – 0.76 (m, 21H), 0.07 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 
147.2, 140.1, 79.3, 62.5, 39.7, 34.1, 32.5, 29.4, 27.6, 26.0, 22.7, 18.3, 14.2, 13.8, 11.2, -5.4 ppm. 
119Sn NMR (149 MHz, CDCl3) δ -55.1 ppm. IR (film, CHCl3) 2954, 2926, 2856, 1463, 1377, 
1254, 1093, 1004, 961, 939, 834, 775, 729, 664 cm-1. HRMS (ESI): m/z calculated for 
C27H58O2SiSnNa [M+Na+]: 585.31196, found 585.31235. 
 
(Z)-4-(3-Hydroxy-3-methyl-2-(tributylstannyl)but-1-en-1-yl)benzonitrile - (SI-27) 
78% yield (2.63 g, 5.52 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.60 – 
7.53 (m, 2H), 7.29 (s, 1H), 7.27 – 7.23 (m, 2H), 1.61 (s, 1H), 1.41 (s, 6H), 1.39 
– 1.26 (m, 6H), 1.26 – 1.15 (m, 6H), 0.83 (t, J = 7.2 Hz, 9H), 0.79 – 0.55 (m, 6H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 163.5, 146.0, 135.4, 131.9, 129.0, 119.1, 110.4, 76.2, 31.1, 29.2, 27.5, 13.8, 
12.9 ppm. 119Sn NMR (149 MHz, CDCl3) δ -53.0 ppm. IR (film, CHCl3) 3507, 2955, 2921, 2871, 
2228, 1602, 1500, 1462, 1362, 1201, 1142, 1073, 1020, 959, 931, 876, 849, 823, 797, 724, 667, 
594 cm-1. HRMS (ESI): m/z calculated for C24H39NOSnNa [M+Na+]: 500.19451, found 500.19430. 
 
(Z)-1-(Cyclohex-1-en-1-yl)-4-methyl-2-(tributylstannyl)pent-1-en-3-ol - (SI-28) 
72% yield (3.36 g, 7.16 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.53 (h, J = 
1.1 Hz, 1H), 5.58 (dh, J = 3.5, 1.5 Hz, 1H), 4.03 – 3.64 (m, 1H), 2.18 – 1.86 (m, 4H), 
1.68 – 1.53 (m, 6H), 1.53 – 1.36 (m, 7H), 1.36 – 1.25 (m, 6H), 0.99 – 0.78 (m, 20H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 147.4, 143.3, 139.3, 123.8, 85.3, 33.6, 29.4, 28.9, 27.7, 25.6, 
22.7, 22.2, 20.2, 17.7, 13.9, 12.0 ppm. 119Sn NMR (149 MHz, CDCl3) δ -51.6 ppm. IR (film, 
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CHCl3) 3449, 2955, 2924, 2871, 1597, 1459, 1364, 1266, 1236, 1201, 1137, 1076, 1021, 960, 
924, 848, 802, 724, 665, cm-1. HRMS (ESI): m/z calculated for C24H45OSn [M-H+]: 469.24972, 
found 469.24941.  
 
(anti,Z)-2,4-Dimethyl-5-(tributylstannyl)tetradec-5-en-3-ol - (SI-29) 
 
SI-35 (2.73 g, 6.0 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (5 mL) and stirred in an oven-
dried Schlenk flask under an argon atmosphere on a dry-ice bath. SnCl4 (6.0 mL, 6 mmol, 1 M in 
CH2Cl2, 1.0 equiv.) was slowly added and stirring was continued for 40 minutes before iso-
butyraldehyde (1.64 mL, 18 mmol, 3.0 equiv.) in dry CH2Cl2 (5 mL) was slowly added. After 
being stirred at the same temperature for 1 h, the reaction was quenched with the addition of 
saturated ammonium chloride solution. The mixture was extracted two times with CH2Cl2, the 
combined extracts were washed with water, dried over magnesium sulfate and concentrated 
under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 30:1) yielded the 
product as a pale yellow oil (1.44 g, 6.0 mmol, quant. yield). TLC (hexanes/ethyl acetate, 10:1), 
Rf = 0.56 (anti), 0.44 (syn). The crude material could not be readily separated from tin residues 
so it was used as such. 
(anti)-2,4-Dimethyltetradec-5-yn-3-ol (1.44 g, 6.0 mmol, 1.0 equiv.) and [Cp*RuCl]4 (82 mg, 
0.3 mmol, 5 mol%) were dissolved in dry CH2Cl2 (25 mL) and stirred in an oven-dried Schlenk 
flask at room temperature under an argon atmosphere. Bu3SnH (1.78 mL, 6.6 mmol, 1.1 equiv.) 
was added over 1 h by means of a syringe pump. Upon completion of addition the volatile 
materials were removed and the crude mixture loaded onto a column. Flash chromatography 
(SiO2, hexanes/ethyl acetate, 30:1) yielded the product as a slightly impured pale brown oil 
(1.56 g, 2.95 mmol, 49% yield over 2 steps, α/β = 10:1). 1H NMR (400 MHz, Chloroform-d)  
δ 6.37 – 5.94 (m, 1H), 3.16 (dt, J = 9.5, 2.1 Hz, 1H), 2.38 – 2.26 (m, 1H), 2.02 (p, J = 6.4, 5.7 Hz, 
2H), 1.87 – 1.75 (m, 1H), 1.52 – 1.41 (m, 6H), 1.40 – 1.19 (m, 24H), 1.03 (d, J = 6.9 Hz, 3H), 0.99 – 
0.79 (m, 28H) ppm. 13C NMR (101 MHz, CDCl3) δ 147.7, 143.8, 77.9, 49.6, 34.9, 32.0, 30.5, 29.7, 
29.7, 29.4, 29.4, 28.0, 27.6, 27.0, 22.8, 21.1, 18.0(2C), 17.7, 14.3(2C), 13.8, 11.6 ppm. 119Sn NMR 
(149 MHz, CDCl3) δ -54.9 ppm. IR (film, CHCl3) 2956, 2923, 2872, 2853, 1462, 1377, 1174, 
1073, 991, 875, 758, 666, 594, 504 cm-1. HRMS (ESI): m/z calculated for C28H57OSn [M-]: 
529.34362, found 529.34430.  
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The following compounds were prepared according to representative procedure 6. 
 
Ethyl (E)-4-hydroxy-3-methyldec-2-en-5-ynoate - (SI-30) 
86% yield  (3.87 g, 17.3 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.06 
(p, J = 1.3 Hz, 1H), 4.77 (q, J = 1.8 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 2.26 – 2.15 
(m, 6H), 1.56 – 1.42 (m, 2H), 1.42 – 1.30 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 0.90 
(t, J = 7.2 Hz, 3H ppm. 13C NMR (101 MHz, CDCl3) δ 166.9, 155.9, 116.0, 87.8, 78.1, 67.2, 60.1, 
30.6, 22.1, 18.5, 15.2, 14.4, 13.7 ppm. IR (film, CHCl3) 3434, 2959, 2934, 2873, 1717, 1699, 
1657, 1432, 1368, 1344, 1295, 1210, 1146, 1096, 1040, 876 cm-1. HRMS (ESI): m/z calculated 
for C13H18O3Na [M+Na+]: 245.11481, found 245.11484. 
 
2-Methyloct-3-yn-2-ol - (SI-31) 
99% yield (2.80 g, 19.7 mmol). 1H NMR (400 MHz, Chloroform-d) δ 2.18 (t, J = 
7.0 Hz, 2H), 1.88 – 1.81 (m, 1H), 1.49 (s, 7H), 1.48 – 1.35 (m, 3H), 0.90 (t, J = 7.2 Hz, 
3H) ppm. 13C NMR (101 MHz, CDCl3) δ 85.2, 82.7, 65.5, 31.9, 30.9, 22.1, 18.4, 13.8 
ppm. Analytical data in accordance with literature.[25] 
 
(E)-Undec-3-en-6-yn-5-ol - (SI-32) 
67% yield (2.23 g, 13.4 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
5.90 (dtd, J = 15.3, 6.3, 1.2 Hz, 1H), 5.58 (ddt, J = 15.3, 6.2, 1.6 Hz, 1H), 
4.88 – 4.69 (m, 1H), 2.24 (td, J = 7.1, 2.0 Hz, 2H), 2.13 – 2.04 (m, 2H), 1.80 – 1.75 (m, 1H), 1.54 – 
1.46 (m, 2H), 1.46 – 1.36 (m, 2H), 1.01 (t, J = 7.5 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 135.3, 128.7, 87.0, 79.8, 63.4, 30.8, 25.1, 22.1, 18.6, 13.7, 13.3 ppm. IR (film, 
CHCl3) 3337, 2961, 2933, 2873, 1460, 1432, 1379, 1328, 1147, 1083, 998, 966 cm-1. HRMS 
(ESI): m/z calculated for C11H18ONa [M+Na+]: 189.12498, found 189.12509. 
 
2-Bromo-8-phenyloct-1-en-5-yn-4-ol[26] - (SI-33) 
 
Sn powder (2.04 g, 17.2 mmol, 1.5 equiv.) was suspended in H2O/Et2O (25 mL/25 mL) and the 
suspension stirred vigorously at room temperature. 2,3-Dibromopropene (3.95 mL, 34 mmol, 
85% purity, 3.0 equiv.) was added followed by a few drops of concentrated aqueous HBr and 5-
phenylpent-2-ynal (1.81 g, 11.4 mmol, 1.0 equiv.) and stirring was continued at room 
temperature with the conversion monitored by TLC. Upon disappearance of starting material, 
the mixture was diluted with water and extracted two times with MTBE. The combined extracts 
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were dried over magnesium sulfate and the volatile materials were removed under reduced 
pressure to give an orange oil. The crude material was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, 9:1 to 4:1) to give the product as a yellow oil (75% yield, 2.4 g, 8.6 mmol). 
1H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.31 (m, 2H), 7.26 (td, J = 6.5, 1.6 Hz, 3H), 5.72 (dt, J 
= 1.9, 1.1 Hz, 1H), 5.56 (d, J = 1.7 Hz, 1H), 4.69 (ddt, J = 7.6, 5.7, 1.9 Hz, 2H), 2.86 (t, J = 7.5 Hz, 
3H), 2.84 – 2.71 (m, 2H), 2.55 (td, J = 7.5, 2.0 Hz, 2H), 2.41 (s, 1H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 140.5, 128.6, 128.5, 128.4, 126.4, 120.2, 85.7, 80.5, 60.5, 49.7, 34.9, 20.9 ppm. IR (film, 
CHCl3) 3349, 3027, 2924, 1632, 1603, 1496, 1427, 1453, 1340, 1200, 1113, 1141, 1032, 891, 
746, 697 cm-1. HRMS (ESI): m/z calculated for C14H15OBrNa [M+Na+]: 301.01986, found 
301.01972. 
 
4-(3-Hydroxy-3-methylbut-1-yn-1-yl)benzonitrile[27] - (SI-34) 
 
p-Bromobenzonitrile (2.73 g, 15 mmol, 1.0 equiv.) and 2-methyl-3-butyn-2-ol (1.74 mL, 
18 mmol, 1.2 equiv.) were mixed in dry THF (5 mL) and the solution was stirred in an oven-
dried Young Schlenk under an argon atmosphere. Et3N (25 mL) was added followed by 
bis(triphenylphosphine)palladium(II) dichloride (105 mg, 0.15 mmol, 1.0 mol%) and copper 
iodide (86 mg, 0.45 mmol, 3.0 mol%). The flask was sealed and the mixture heated to 60 °C for 
18 h before being left to cool to room temperature. The reaction was quenched with the addition 
of ammonium chloride solution. The mixture was extracted two times with MTBE, the combined 
extracts were washed with aqueous HCl (2 M) and brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 4:1) 
yielded the product as an orange solid (1.31 g, 7.07 mmol, 47% yield). TLC (hexanes/ethyl 
acetate, 4:1), Rf = 0.26. 1H NMR (400 MHz, Chloroform-d) δ 7.63 – 7.56 (m, 2H), 7.53 – 7.45 (m, 
2H), 2.01 (s, 1H), 1.63 (s, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 131.4, 131.2, 127.0, 117.7, 
110.9, 97.4, 79.9, 64.9, 30.5 ppm. IR (film, CHCl3) 3404, 2979, 2240, 2225, 1600, 1497, 1456, 
1401, 1361, 1272, 1161, 962, 905, 836, 560 cm-1. HRMS (ESI): m/z calculated for C12H11NONa 
[M+Na+]: 208.07328, found 208.07350.  
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Tributyl(dodeca-2,3-dien-4-yl)stannane[28] - (SI-35) 
 
Dodec-3-yn-2-ol (2.73 g, 15 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (20 mL) and the 
solution stirred in an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. 
Et3N (3.14 mL, 22.5 mmol, 1.5 equiv.) and MsCl (1.51 mL, 19.5 mmol, 1.3 equiv.) were slowly 
added and the mixture was stirred for 15 minutes before it was cooled with an ice bath. After 
another 30 minutes, the mixture was poured onto aqueous HCl (1 M), extracted two times with 
CH2Cl2, the combined extracts were washed with water, dried over magnesium sulfate and 
concentrated under reduced pressure. The crude mesylate was used as such. 
A Schlenk flask was charged with dry THF (100 mL) and di-iso-propylamine (2.31 mL, 
16.5 mmol, 1.1 equiv.) and the solution stirred on an ice bath under an argon atmosphere. n-
Butyllithium (9.4 mL, 15 mmol, 1.0 equiv.) was slowly added followed after 30 minutes by 
Bu3SnH (4.04 mL, 15 mmol, 1.0 equiv.). After another 20 minutes, the mixture was cooled with a 
dry-ice bath and CuBr·Me2S (3.08 g, 15 mmol, 1.0 equiv.) was added. Another 30 minutes later 
the crude mesylate was added in THF (10 mL) and stirring was continued for 30 minutes before 
the mixture was poured onto vigorously stirred NH4Cl/NH4OH (9:1). After 10 minutes, the 
mixture was allowed to settle for 12 h. The layers were then separated, the aqueous layer 
extracted once with MTBE, the combined extracts were washed with brine, dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/Et3N, 100:1) yielded the product as a colorless liquid contaminated with some (Bu3Sn)2 
(6.02 g, 13.2 mmol, 88% yield). 1H NMR (400 MHz, Chloroform-d) δ 4.67 – 4.43 (m, 1H), 2.05 
(td, J = 7.8, 7.4, 2.8 Hz, 2H), 1.59 (d, J = 6.8 Hz, 3H), 1.54 – 1.45 (m, 7H), 1.44 – 1.15 (m, 24H), 1.02 
– 0.80 (m, 29H) ppm. 13C NMR (101 MHz, CDCl3) δ 203.2, 93.0, 76.2, 33.3, 32.1, 30.8, 30.1, 29.6, 
29.5, 29.4, 29.2, 27.5, 22.9, 14.3, 13.9, 10.3 ppm. 119Sn NMR (149 MHz, CDCl3) δ -31.9 ppm.  
 
8.3.3. Formal Synthesis of Tubelactomicin A 
 
(R)-Hept-4-yn-2-ol - (SI-36) 
 
1-Butyne was condensed into a 500 mL two-necked flask equipped with a dropping funnel and a 
gas bubbler under dry-ice cooling until about 10 grams of liquid were obtained (175 mmol, 
2.5 equiv.). Dry THF (50 mL) was added followed by slow addition of n-butyllithium (66 mL, 
105 mmol, 1.5 equiv.). After the solution was stirred at the same temperature for a few minutes, 
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the flask was placed on an ice bath for 1 h. Dry DMPU (50 mL) was added followed by cooling of 
the mixture to 30 °C. (R)-Propylene oxide (4.90 mL, 70 mmol, 1.0 equiv.) in dry DMPU (50 mL) 
was added and the mixture was allowed to warm to room temperature over the course of 18 h. 
The reaction was then quenched with slow addition of saturated ammonium chloride solution. 
The mixture was extracted two times with diethyl ether, the combined extracts were washed 
with brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, pentane/diethyl ether, 4:1) yielded the product after careful evaporation 
of the volatile materials as a pale yellow liquid (6.7 g, 59.7 mmol, 85% yield).  [𝒂]𝑫
𝟐𝟎: 22.2° 
(c=1.02 in MeOH); -18.7° (c=1.13 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 3.98 – 3.81 (m, 
1H), 2.36 (ddt, J = 16.3, 4.8, 2.4 Hz, 1H), 2.25 (ddt, J = 16.3, 6.8, 2.4 Hz, 1H), 2.18 (qt, J = 7.5, 2.4 
Hz, 2H), 2.03 (s, 1H), 1.23 (d, J = 6.2 Hz, 3H), 1.12 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 84.8, 77.5, 66.6, 29.5, 22.3, 14.4, 12.5 ppm. HRMS (ESI): m/z calculated for C7H12ONa 
[M+Na+]: 135.07803, found 135.07811.  
 
(R)-Hept-6-yn-2-ol[29] - (298) 
 
Freshly distilled 1,3-diaminopropane (100 mL) was placed in a flame-dried two-necked flask 
under an argon atmosphere at room temperature. Lithium granula (1.25 g, 180 mmol, 6.0 equiv.) 
were added in one portion and stirring was continued until a dark blue mixture was obtained. 
The mixture was then heated to 70 °C until the color faded and a pale blueish/grey mixture was 
obtained which was allowed to cool down to room temperature. At this point and dry [2 h under 
high vacuum, 120 °C] KOtBu (13.1 g, 117 mmol, 3.9 equiv.) was added in one portion. Stirring 
was continued for 30 minutes while the mixture turned into a yellowish green. (R)-Hept-4-yn-2-
ol (SI-36) (3.36 g, 30 mmol, 1.0 equiv.) was added dropwise which resulted in a change of color 
to red and the reaction was quenched after another 30 minutes by pouring the mixture onto 
ice/water (250 mL). The mixture was extracted three times with diethyl ether, the combined 
extracts were washed with aqueous HCl (2 M), saturated sodium bicarbonate solution and brine, 
dried over magnesium sulfate and concentrated under reduced pressure to give a pale yellow 
oil. Flash chromatography (SiO2, pentane/diethyl ether, 3:1 to 2:1) yielded the product after 
careful concentration as a colorless liquid which was used directly in the next step. [𝒂]𝑫
𝟐𝟎: 14.5° 
(c=0.99 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 3.77 (qd, J = 5.9, 1.4 Hz, 1H), 2.17 (tdd, J 
= 6.7, 2.7, 1.3 Hz, 2H), 2.08 (s, 1H), 1.92 (td, J = 2.7, 1.2 Hz, 1H), 1.69 – 1.54 (m, 1H), 1.54 – 1.44 
(m, 3H), 1.15 (dd, J = 6.2, 1.4 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 84.5, 68.6, 67.5, 38.2, 
24.7, 23.6, 18.4 ppm. IR (film, CHCl3) 3297, 2930, 1457, 1433, 1374, 1327, 1183, 1128, 1085, 
Chapter 8 – Experimental Procedures 
176 
977, 944, 923, 862, 819, 624 cm-1. HRMS (ESI): m/z calculated for C7H12ONa [M+Na+]: 
135.07803, found 135.07809. 
 
(R)-(Hept-6-yn-2-yloxy)triisopropylsilane - (294) 
 
(R)-Hept-6-yn-2-ol (3.36, 30 mmol, 1.0 equiv.) and imidazole (4.08 g, 60 mmol, 2.0 equiv.) were 
dissolved in dry DMF (60 mL) and the solution was stirred at room temperature in a single-
necked flask. Tri-iso-propylsilyl chloride (9.63 mL, 45 mmol, 1.5 equiv.) was slowly added and 
stirring continued for 18 h until TLC showed complete consumption of starting material. The 
reaction was quenched with the addition of saturated ammonium chloride solution, the mixture 
was extracted three times with MTBE, the combined extracts were washed with brine, dried 
over magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
pentane) yielded the product as a colorless oil (6.4 g, 23.8 mmol, 79% yield over 2 steps). 
 [𝒂]𝑫
𝟐𝟎: 3.4° (c=1.08 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 4.04 – 3.91 (m, 1H), 2.26 – 
2.11 (m, 2H), 1.94 (t, J = 2.6 Hz, 1H), 1.66 – 1.49 (m, 4H), 1.17 (d, J = 6.1 Hz, 3H), 1.06 (s, 18H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 84.7, 68.4, 68.2, 39.0, 24.4, 23.6, 18.8, 18.3, 12.6 ppm.  
IR (film, CHCl3) 3314, 2942, 2866, 1462, 1375, 1245, 1136, 1097, 1028, 996, 918, 881, 750, 675, 
627 cm-1. HRMS (ESI): m/z calculated C16H32OSiNa [M+Na+]: 291.21146, found 291.21157. 
 
tert-Butyl (9R)-2-methyl-3-oxo-9-((triisopropylsilyl)oxy)dec-4-ynoate - (309) 
 
294 (2.27 g, 8.45 mmol, 1.0 equiv.) was dissolved in dry THF (40 mL) and the solution stirred in 
an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. n-Butyllithium 
(7.93 mL, 1.6 M in hexanes, 12.7 mmol, 1.5 equiv.) was slowly added and stirring continued for 
30 minutes before neat methyl chloroformate (1.31 mL, 16.9 mmol, 2.0 equiv.) was added. The 
mixture was allowed to warm to room temperature and stirred for 30 minutes before the 
reaction was quenched with saturated ammonium chloride solution. The mixture was extracted 
two times with MTBE, the combined extracts were washed with brine, dried over magnesium 
sulfate and concentrated under reduced pressure. The crude material was used without 
purification. 
 
Di-iso-propyl amine (3.55 mL, 25.4 mmol, 3.0 equiv.) was dissolved in dry THF (40 mL) and the 
solution stirred on an ice bath in an oven-dried Schlenk flask. n-Butyllithium (15.9 mL, 
25.4 mmol, 3.0 equiv.) was added dropwise and stirring was continued for 10 minutes before 
the mixture was cooled with a dry-ice bath. tert-Butyl propionate (3.82 mL, 25.4 mmol, 
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3.0 equiv.) was added and stirring continued for 30 minutes before the above prepared 
alkynoate in a minimum amount of THF was added dropwise. After being stirred at the same 
temperature for 2 h, the reaction was quenched with the addition of saturated ammonium 
chloride solution before being allowed to warm to room temperature. The mixture was 
extracted two times with MTBE, the combined extracts were washed with brine, dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 40:1) yielded the product as an inseperable mixture of tautomers (3.40 g, 
8.0 mmol, 95% yield). [𝒂]𝑫
𝟐𝟎: 1.6° (c=1.10 in CHCl3).TLC (hexanes/ethyl acetate, 20:1), Rf = 0.22 
and Rf = 0.45. 1H NMR (400 MHz, Chloroform-d) δ 12.28 (s, 0.65H), 4.03 – 3.90 (m, 1H), 3.48 – 
3.38 (m, 0.35H), 2.41 (dt, J = 16.5, 6.8 Hz, 2H), 1.82 (s, 2H), 1.71 – 1.52 (m, 3H), 1.50 (s, 6H), 1.46 
(s, 4H), 1.36 (d, J = 7.2 Hz, 1H), 1.16 (d, J = 6.1 Hz, 3H), 1.05 (s, 21H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 183.7, 173.1, 169.0, 152.0, 104.5, 99.8, 96.4, 82.0, 81.8, 75.4, 68.2, 68.0, 56.0, 39.2, 28.4, 
28.0, 24.1, 23.7, 19.9, 19.5, 18.3, 18.3, 13.6, 12.9, 12.6 ppm. IR (film, CHCl3) 2942, 2866, 2215, 
1737, 1680, 1645, 1601, 1459, 1369, 1353, 1252, 1151, 1120, 1026, 995, 882, 846, 817, 757, 675 
cm-1. HRMS (ESI): m/z calculated C24H44O4SiNa [M+Na+]: 447.29011, found 447.29049. 
 
tert-Butyl (2R,3R,9R)-3-hydroxy-2-methyl-9-((triisopropylsilyl)oxy)dec-4-ynoate[30] -  
(SI-37) 
 
[(R,R)-Teth-TsDpen RuCl] (24.8 mg, 0.04 mmol, 0.5 mol%) and formic acid/triethylamine 
complex (5:2, 7.1 g) were placed in an oven-dried Schlenk flask under an argon atmosphere. 309 
(3.4 g, 8.0 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (40 mL) and added to the catalyst 
solution. The mixture was stirred at room temperature with the conversion monitored by TLC 
(hexanes/ethyl acetate, 20:1). After 48 h the volatile materials were removed under reduced 
pressure and the crude yellow residue loaded onto a column. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 19:1) gave pure product (2.81 g, 6.59 mmol, 82% yield). [𝒂]𝑫
𝟐𝟎: 2.5° 
(c=1.22 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 4.52 (ddt, J = 7.2, 4.0, 2.0 Hz, 1H), 4.06 – 
3.81 (m, 1H), 3.10 (dd, J = 7.4, 2.3 Hz, 1H), 2.62 (qd, J = 7.2, 4.0 Hz, 1H), 2.21 (tt, J = 4.9, 2.0 Hz, 
2H), 1.54 (dddt, J = 8.3, 6.9, 4.4, 2.3 Hz, 4H), 1.47 (d, J = 1.8 Hz, 9H), 1.23 (dd, J = 7.2, 1.8 Hz, 3H), 
1.15 (dd, J = 6.1, 1.8 Hz, 3H), 1.05 (d, J = 1.9 Hz, 21H) ppm. 13C NMR (101 MHz, CDCl3) δ 173.8, 
86.2, 81.6, 78.8, 68.2, 64.3, 46.3, 39.2, 28.2, 24.5, 23.6, 19.1, 18.3, 18.3, 12.6, 12.2 ppm. IR (film, 
CHCl3) 3475, 2942, 2866, 1729, 1460, 1368, 1350, 1254, 1216, 1152, 1095, 1026, 918, 882, 849, 
755, 709, 675 cm-1. HRMS (ESI): m/z calculated C24H46O4SiNa [M+Na+]: 449.30576, found 
449.30589 
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(2S,3R,9R)-2-Methyl-9-((triisopropylsilyl)oxy)dec-4-yne-1,3-diol - (310) 
 
SI-37 (2.56 g, 6.0 mmol, 1.0 equiv.) was dissolved in dry THF (25 mL) and MeOH (2.5 mL) and 
the solution stirred on an ice bath in an oven-dried Schlenk flask under an argon atmosphere. 
LiBH4 (4.5 mL, 4 M in THF, 18 mmol, 3.0 equiv.) was slowly added and the mixture subsequently 
heated to 70 °C on an oil bath (CAUTION: vigorus foaming the moment the reaction starts!) with 
the conversion monitored by TLC (hexanes/ethyl acetate, 4:1). After 15 minutes complete 
consumption of starting material was observed so the mixture was allowed to cool to room 
temperature. The mixture was then poured onto ice water and acidified carefully with aqueous 
HCl (2 M). The mixture was extracted three times with ethyl acetate, the combined extracts were 
washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 2:1) yielded the product as a colorless oil 
(1.97 g, 5.52 mmol, 92% yield). [𝒂]𝑫
𝟐𝟎: 7.8° (c=1.06 in CHCl3). 1H NMR (400 MHz, Chloroform-
d) δ 4.50 (ddt, J = 5.9, 4.0, 2.0 Hz, 1H), 4.01 – 3.91 (m, 1H), 3.87 (ddd, J = 10.4, 8.3, 3.6 Hz, 1H), 
3.68 (dt, J = 10.7, 4.2 Hz, 1H), 2.79 (d, J = 5.9 Hz, 1H), 2.25 (tt, J = 6.6, 1.9 Hz, 3H), 2.08 (dqt, J = 
8.3, 7.0, 3.9 Hz, 1H), 1.65 – 1.45 (m, 4H), 1.16 (d, J = 6.1 Hz, 3H), 1.05 (s, 21H), 0.93 (d, J = 7.0 Hz, 
3H) ppm. 13C NMR (101 MHz, CDCl3) δ 87.2, 79.2, 68.3, 67.2, 66.2, 40.5, 39.2, 24.7, 23.7, 19.1, 
18.3, 18.3, 12.6 ppm. IR (film, CHCl3) 3348, 2942, 2866, 1462, 1376, 1256, 1135, 1094, 1013, 
917, 882, 756, 674 cm-1. HRMS (ESI): m/z calculated C20H40O3SiNa [M+Na+]: 379.26389, found 
379.26384. 
 
(2S,3R,9R,Z)-2-Methyl-4-(tributylstannyl)-9-((triisopropylsilyl)oxy)dec-4-ene-1,3-diol  
- (SI-38) 
 
310 (1.95 g, 5.47 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (25 mL) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere at room temperature. [Cp*RuCl2]n 
(84 mg, 0.27 mmol, 5.0 mol%) was added followed by dropwise addition of Bu3SnH (1.62 mL, 
6.01 mmol, 1.1 equiv.) over 1 h by means of a syringe pump. Upon completion, the volatile 
materials were removed under reduced pressure and the residue purified by flash 
chromatography (SiO2, hexanes/ethyl acetate, 9:1) to give the product as a colorless oil (3.11 g, 
4.80 mmol, 88% yield). [𝒂]𝑫
𝟐𝟎: 12.0° (c=1.16 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 
6.43 – 6.00 (m, 1H), 4.37 – 4.18 (m, 1H), 3.99 – 3.86 (m, 1H), 3.63 (dd, J = 5.7, 4.8 Hz, 2H), 2.17 (s, 
3H), 2.05 (qt, J = 10.3, 5.1 Hz, 2H), 1.96 (t, J = 5.7 Hz, 1H), 1.80 (d, J = 3.1 Hz, 1H), 1.73 – 1.63 (m, 
1H), 1.58 – 1.37 (m, 8H), 1.36 – 1.26 (m, 6H), 1.15 (d, J = 6.1 Hz, 3H), 1.05 (s, 21H), 0.97 – 0.91 
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(m, 8H), 0.88 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 207.2, 146.7, 140.1, 80.7, 
68.6, 67.1, 39.9, 34.9, 29.4, 27.6, 26.1, 23.6, 18.3, 18.3, 13.8, 12.6, 11.0, 10.7 ppm. 119Sn NMR 
(149 MHz, CDCl3) δ -55.5 ppm. IR (film, CHCl3) 3385, 2925, 2866, 1462, 1376, 1247, 1187, 
1133, 1098, 1029, 1013, 970, 918, 881, 758, 674 cm-1. HRMS (ESI): m/z calculated 
C32H68O3SiSnNa [M+Na+]: 671.38512, found 671.38501. 
 
 
(6S,7R,13R,Z)-15,15-Diisopropyl-2,2,3,3,6,13,16-heptamethyl-8-(tributylstannyl)-4,14-
dioxa-3,15-disilaheptadec-8-en-7-ol - (308) 
 
SI-38 (3.11 g, 4.8 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (25 ml) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. tert-Butyldimethylsilyl 
chloride (796 mg, 5.28 mmol, 1.1 equiv.) was added followed by the addition of Et3N (736 µL, 
5.28 mmol, 1.1 equiv.) over 20 minutes. Upon disappearance of starting material as determined 
by TLC, the reaction was quenched with the addition of saturated ammonium chloride solution. 
The mixture was extracted two times with CH2Cl2, the combined extracts were dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 40:1) yielded the product as a colorless oil (3.34 g, 4.38 mmol, 
91% yield). [𝒂]𝑫
𝟐𝟎: 5.7° (c=1.10 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.24 (td, J = 7.2, 
1.5 Hz, 1H), 4.36 (ddd, J = 4.0, 2.5, 1.4 Hz, 1H), 4.00 – 3.86 (m, 1H), 3.70 – 3.58 (m, 3H), 2.52 (d, J 
= 2.4 Hz, 1H), 2.15 – 1.94 (m, 2H), 1.68 – 1.57 (m, 1H), 1.56 – 1.37 (m, 9H), 1.37 – 1.24 (m, 6H), 
1.15 (d, J = 6.1 Hz, 3H), 1.05 (s, 21H), 1.00 – 0.79 (m, 26H), 0.06 (s, 7H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 145.4, 139.5, 79.1, 68.6, 67.6, 40.0, 39.6, 35.0, 29.4, 27.6, 26.2, 26.0, 23.6, 18.3, 13.9, 
12.6, 11.0, 10.1, -5.4, -5.4 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.9 ppm. IR (film, CHCl3) 
2955, 2927, 2865, 1463, 1376, 1252, 1202, 1133, 1095, 1005, 918, 882, 835, 775, 724, 673 cm-1. 
HRMS (ESI): m/z calculated C38H82O3Si2SnNa [M+Na+]: 785.47160, found 785.47165. 
 
Methyl (R,Z)-2-((1R,2S)-3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-2-methyl-propyl)-7-
((triisopropylsilyl)oxy)oct-2-enoate - (311) 
 
308 (761 mg, 1.0 mmol, 1.0 equiv.) was dissolved in TFA solution in MeOH (0.1 M, 10 mL) and 
stirred in an oven-dried Schlenk flask under an argon atmosphere. 1,4-Benzoquinone (162 mg, 
1.5 mmol, 1.5 equiv.), AsPh3 (31 mg, 0.1 mmol, 10 mol%) and Pd(OAc)2 (12 mg, 0.05 mmol, 
5.0 mol%) were added and the mixture was flushed for 2 minutes with CO (balloon) before 
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stirring was continued under positive CO pressure at 50 °C. Upon disappearance of starting 
material as judged by TLC, the mixture was filtered over Celite® with additional MTBE and the 
filtrate was concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl 
acetate, 25:1) yielded the product as a pale yellow oil (373 mg, 0.70 mmol, 70% yield). [𝒂]𝑫
𝟐𝟎: 
6.0° (c=1.15 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.24 (td, J = 7.5, 1.4 Hz, 1H), 4.65 
(tt, J = 3.6, 1.4 Hz, 1H), 3.93 (hept, J = 5.2, 4.7 Hz, 1H), 3.79 (dd, J = 9.8, 3.6 Hz, 1H), 3.72 (s, 3H), 
3.65 (dd, J = 9.8, 4.2 Hz, 1H), 3.54 (d, J = 3.7 Hz, 1H), 2.45 (qq, J = 14.1, 6.6 Hz, 2H), 1.85 (tp, J = 
7.1, 3.2 Hz, 1H), 1.59 – 1.43 (m, 4H), 1.15 (d, J = 6.0 Hz, 3H), 1.05 (s, 21H), 0.90 (s, 9H), 0.86 (d, J = 
7.1 Hz, 3H), 0.06 (d, J = 1.0 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 168.0, 142.5, 132.2, 74.7, 
68.5, 68.1, 51.3, 39.8, 38.3, 29.8, 26.0, 25.3, 23.6, 18.3, 18.3, 12.6, 10.1, -5.45, -5.51 ppm. IR (film, 
CHCl3) 3497, 2930, 2865, 1721, 1463, 1435, 1374, 1252, 1195, 1134, 1096, 1063, 1005, 918, 
882, 835, 775, 723 cm-1. HRMS (ESI): m/z calculated C28H59O5Si2 [M+H+]: 531.38956, found 
531.38965.  
 
Methyl (R,Z)-2-((1R,2S)-3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-2-methyl-propyl)-7-
((triisopropylsilyl)oxy)oct-2-enoate diol - (SI-39) 
 
311 (655 mg, 1.23 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (7 mL) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. Hünig’s base (860 µL, 
4.93 mmol, 4.0 equiv.) and MOMCl (281 µL, 3.70 mmol, 3.0 equiv.) were added in that order and 
stirring was continued at room temperature with the conversion monitored by TLC 
(hexanes/ethyl acetate, 10:1). After 24 h full conversion of starting material was observed. The 
mixture was diluted with CH2Cl2 and the reaction was quenched with the addition of saturated 
ammonium chloride solution. The organic layer was separated, the aqueous layer extracted two 
times with CH2Cl2, the combined extracts were washed with brine, dried over magnesium sulfate 
and concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 
19:1) yielded the product as a colorless oil (605 mg, 1.05 mmol, 85% yield). [𝒂]𝑫
𝟐𝟎: 60.6° 
(c=1.44 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.05 (td, J = 7.5, 1.0 Hz, 1H), 4.61 (d, J = 
6.6 Hz, 1H), 4.52 (d, J = 6.6 Hz, 1H), 4.48 – 4.38 (m, 1H), 4.02 – 3.86 (m, 1H), 3.71 (s, 3H), 3.58 
(dd, J = 9.9, 6.1 Hz, 1H), 3.48 (dd, J = 9.9, 6.0 Hz, 1H), 3.37 (s, 3H), 2.42 (dq, J = 14.7, 7.6 Hz, 2H), 
1.98 – 1.82 (m, 1H), 1.58 – 1.39 (m, 4H), 1.14 (d, J = 6.1 Hz, 3H), 1.05 (s, 22H), 0.89 (s, 13H), 0.03 
(d, J = 2.6 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.7, 142.7, 131.1, 94.8, 77.0, 68.4, 65.4, 
56.1, 51.4, 39.7, 39.6, 29.7, 26.0, 25.3, 23.7, 18.4, 18.3, 12.6, 11.5, -5.2 ppm. IR (film, CHCl3) 
2930, 2865, 1722, 1463, 1435, 1250, 1210, 1133, 1091, 1032, 921, 882, 835, 774, 674 cm-1. 
HRMS (ESI): m/z calculated C30H62O6Si2Na [M+Na+]: 597.39772, found 597.39768. 
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Methyl (R,Z)-2-((1R,2S)-3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-2-methyl-propyl)-7-
((triisopropylsilyl)oxy)oct-2-enoate - (312) 
 
SI-39 (450 mg, 0.78 mmol, 1.0 equiv.) was dissolved in THF (10 mL) and the solution stirred on 
an ice bath in a Schlenk flask under an argon atmosphere. Aqueous HCl (2 M) was added, the ice 
bath removed and stirring was continued until disappearance of starting material was judged by 
TLC. The mixture was diluted with water and extracted two times with CH2Cl2. The combined 
extracts were dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 4:1) yielded the product as a colorless oil. [𝒂]𝑫
𝟐𝟎: 
77.8° (c=1.18 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.12 (td, J = 7.5, 1.1 Hz, 1H), 4.57 
(d, J = 6.6 Hz, 1H), 4.55 – 4.48 (m, 2H), 3.97 – 3.87 (m, 1H), 3.73 (s, 3H), 3.64 – 3.51 (m, 2H), 3.39 
(s, 3H), 2.54 – 2.37 (m, 2H), 2.35 (t, J = 6.0 Hz, 1H), 1.99 – 1.87 (m, 1H), 1.58 – 1.37 (m, 4H), 1.14 
(d, J = 6.1 Hz, 3H), 1.04 (s, 21H), 0.87 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
168.0, 143.2, 130.6, 95.1, 77.1, 68.4, 65.5, 56.2, 51.6, 39.7, 29.7, 25.3, 23.6, 18.3, 12.6, 11.4 ppm. 
IR (film, CHCl3) 3468, 2942, 2891, 2866, 1720, 1462, 1436, 1377, 1210, 1136, 1096, 1029, 919, 
882, 850, 675 cm-1. HRMS (ESI): m/z calculated C24H48O6SiNa [M+Na+]: 483.31124, found 
483.31142. 
 
Methyl (R,Z)-2-((1R,2S,E)-1-(methoxymethoxy)-2-methyl-4-(tributyl-stannyl)but-3-en-1-
yl)-7-((triisopropylsilyl)oxy)oct-2-enoate - (SI-40) 
 
NaHCO3 (341 mg, 4.06 mmol, 8.0 equiv.) and Dess-Martin periodinane (345 mg, 0.81 mmol, 
1.6 equiv.) were weighed into an oven-dried Schlenk flask under an argon atmosphere and 
stirred in CH2Cl2 (4 mL) on an ice bath. 312 (234 mg, 0.51 mmol, 1.0 equiv.) was dissolved in 
CH2Cl2 (2 mL) and added to the reagent suspension. Conversion was monitored by TLC 
(hexanes/ethyl acetate, 4:1), Rf = 0.53. After about 6 h the reaction was quenched with the 
addition of saturated sodium bicarbonate solution. The mixture was diluted with saturated 
sodium thiosulfate solution, extracted two times with CH2Cl2, the combined organic layers were 
washed with saturated sodium bicarbonate solution, dried over magnesium sulfate and 
concentrated under reduced pressure. The crude aldehyde was used as such. 
 
CrCl2·THF (990 mg, 5.08 mmol, 10 equiv.) was weighed under argon into an oven-dried Schlenk 
flask. THF (10 mL) was added and the mixture stirred at room temperature under an argon 
atmosphere. DMF (393 µL, 5.08 mmol, 10 equiv.) was added dropwise and stirring continued for 
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15 minutes. A second oven-dried Schlenk flask was charged with the above prepared aldehyde 
in THF, the solvent was removed under HV and tributyl(dibromomethyl)stannane (517 mg, 
1.12 mmol, 2.2 equiv.) was added. The mixture was dissolved in THF (2 mL) and added under 
argon to the chromium suspension. The flask was subsequently covered with aluminum foil. A 
third Schlenk flask was charged with LiI (272 g, 2.03 mmol, 4.0 equiv.) which was molten at 
~10 mbar with a Bunsenburner. Upon cooling to room temperature, a stirring bar was added 
and the salt was solubilized in THF (2 mL) before it was added to the reagent mixture. The 
reaction was carried out for 18 h before it was quenched with the addition of water. The mixture 
was extracted two times with MTBE, the combined extracts were washed with brine, dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 40:1) yielded the product as a colorless oil as an inseparable mixture of 
85:15 E/Z isomers (225 mg, 0.302 mmol, 60% yield). [𝒂]𝑫
𝟐𝟎: 21.5° (c=0.87 in CHCl3). 1H NMR 
(400 MHz, Chloroform-d) δ 6.05 (td, J = 7.5, 0.9 Hz, 1H), 5.93 (d, J = 19.0 Hz, 1H), 5.90 – 5.83 
(m, 1H), 4.60 (d, J = 6.7 Hz, 1H), 4.49 (d, J = 6.7 Hz, 1H), 4.24 (d, J = 6.6 Hz, 1H), 3.92 (tt, J = 7.2, 
3.6 Hz, 1H), 3.71 (s, 3H), 3.36 (s, 3H), 2.56 – 2.47 (m, 1H), 2.47 – 2.28 (m, 2H), 1.57 – 1.36 (m, 
10H), 1.36 – 1.22 (m, 6H), 1.14 (d, J = 6.0 Hz, 3H), 1.04 (s, 24H), 0.88 (t, J = 7.3 Hz, 9H), 0.86 – 
0.81 (m, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 167.6, 151.0, 143.7, 131.2, 127.9, 94.5, 79.9, 
68.4, 56.0, 51.4, 45.7, 39.8, 29.8, 29.2, 27.4, 25.3, 23.6, 18.3, 18.3, 15.1, 13.9, 12.6, 9.5 ppm. 119Sn 
NMR (149 MHz, CDCl3) δ -49.1 ppm. IR (film, CHCl3) 2926, 2867, 1723, 1462, 1376, 1291, 
1246, 1194, 1152, 1097, 1030, 991, 920, 882, 675 cm-1. HRMS (ESI): m/z calculated 
C37H74O5SiSnNa [M+Na+]: 769.42190, found 769.42204. 
 
Methyl (R,Z)-7-hydroxy-2-((1R,2S,E)-1-(methoxymethoxy)-2-methyl-4-(tributyl-stannyl)-
but-3-en-1-yl)oct-2-enoate - (272) 
 
SI-40 (160 mg, 0.21 mmol, 1.0 equiv.) was dissolved in dry THF (2 mL) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. TBAF (343 µL, 1 M in 
THF, 0.34 mmol, 1.6 equiv.) was added and stirring was continued for 18 h while the mixture 
was allowed to warm to room. The mixture was diluted with MTBE and the reaction quenched 
with the addition of saturated ammonium chloride solution. The mixture was extracted two 
times with MTBE, the combined extracts were washed with brine, dried over magnesium sulfate 
and concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 
4:1) yielded the product as a colorless oil (76 mg, 0.215 mmol, 60% yield). [𝒂]𝑫
𝟐𝟎: 27.6° (c=1.20 
in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.07 (td, J = 7.7, 0.9 Hz, 1H), 5.92 (d, J = 19.0 Hz, 
1H), 5.85 (dd, J = 19.0, 5.9 Hz, 1H), 4.60 (d, J = 6.7 Hz, 1H), 4.49 (d, J = 6.7 Hz, 1H), 4.24 (d, J = 6.6 
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Hz, 1H), 3.87 – 3.74 (m, 1H), 3.72 (s, 3H), 3.35 (s, 3H), 2.51 (dddd, J = 13.4, 8.3, 5.8, 3.9 Hz, 2H), 
2.41 – 2.30 (m, 1H), 1.57 (d, J = 2.7 Hz, 1H), 1.54 – 1.40 (m, 10H), 1.33 – 1.22 (m, 6H), 1.18 (d, J = 
6.2 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.3 Hz, 9H), 0.85 – 0.80 (m, 6H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 167.6, 150.9, 143.5, 131.4, 128.0, 94.5, 79.9, 67.7, 56.0, 51.5, 45.7, 38.9, 29.3, 
29.2, 27.4, 25.6, 23.6, 15.1, 13.8, 9.5 ppm. 119Sn NMR (149 MHz, CDCl3) δ -49.1 ppm. IR (film, 
CHCl3) 2955, 2925, 2871, 1720, 1458, 1436, 1375, 1291, 1211, 1153, 1096, 1029, 991, 961, 921, 
863 cm-1. HRMS (ESI): m/z calculated C28H54O5SnNa [M+Na+]: 613.28847, found 613.28840.  
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8.3.4. Comparison with published data 
 
1
H-NMR 
Position Tadano et al
[31]
. [ppm] coupling constants current approach [ppm] coupling constants [ppm]
1 5.94  (d, J = 19.1 Hz, 1H) 5.92  (d, J = 19.0 Hz, 1H) 0.04 
2 5.86 (dd, J = 19.1, 5.5 Hz, 1H) 5.85  (dd, J = 19.0, 5.9 Hz, 1H) 0.01 
3 2.37  (m, 1H) 2.41 – 2.30  (m, 1H) 0.01 
4 4.25  (d, J = 6.6 Hz, 1H) 4.24  (d, J = 6.6 Hz, 1H) 0.01 
5 - - - -  - 
6 6.08 (t, J = 7.6 Hz, 1H) 6.07  (td, J = 7.7, 0.9 Hz, 1H) 0.01 
7 2.42-2.61 (m, 2H) 2.51 (dddd, J = 13.4, 8.3, 5.8, 3.9 Hz, 2H) 0.01 
8 1.40-1.59 (m, 2H) 1.40-1.54  (m, 2H) 0.02 
9 1.40-1.59  (m, 2H) 1.40-1.54  (m, 2H) 0.02 
10 3.82  (m, 1H) 3.74-3.87  (m, 1H) 0.01 
11 1.19  (d, J = 6.2 Hz, 3H) 1.18 (d, J = 6.2 Hz, 3H) 0.01 
12 1.04  (d, J = 6.8 Hz, 3H) 1.03  (d, J = 6.8 Hz, 3H) 0.01 
13a 4.62  (d, J = 6.8 Hz, 1H) 4.60  (d, J = 6.7 Hz, 1H) 0.02 
13b 4.51  (d, J = 6.8 Hz, 1H) 4.49  (d, J = 6.7 Hz, 1H) 0.02 
14 3.37  (s, 3H) 3.35  (s, 3H) 0.02 
15 - - - -  - 
16 3.73  (s, 3H) 3.72  (s, 3H) 0.01 
17 1.40-1.59  (m, 6H) 1.40-1.54   (m, 6H) 0.02 
18 1.22-1.37  (m, 6H) 1.22-1.33 (m, 6H) 0.02 
19 0.79-0.94  (m, 6H) 0.80-0.85 (m, 6H) 0.03 
20 0.89  (t, J = 7.2 Hz, 9H) 0.87  (t, J = 7.3 Hz, 9H) 0.02 
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13
C-NMR 
Position Tadano et al. 
[31]
 current approach 
1 150.8 150.9 -0.1 
2 127.9 128.0 -0.1 
3 29.2 29.3 -0.1 
4 79.8 79.9 -0.1 
5 131.3 131.4 -0.1 
6 143.4 143.5 -0.1 
7 45.6 45.7 -0.1 
8 38.8 38.9 -0.1 
9 29.1 29.2 -0.1 
10 67.6 67.7 -0.1 
11 25.5 25.6 -0.1 
12 15.0 15.1 -0.1 
13a 94.4 94.5 -0.1 
13b 94.4 94.5 -0.1 
14 55.8 56.0 -0.2 
15 167.4 167.6 -0.2 
16 51.3 51.5 -0.2 
17 23.5 23.6 -0.1 
18 27.2 27.4 -0.2 
19 9.3 9.5  -0.2 
20 13.7 13.8 -0.1 
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8.4. Oxidation of Alkenylstannanes to (Hydroxy)ketones 
8.4.1. Representative procedure 10: Copper Acetate Mediated Oxidation of 
Alkenylstannanes 
(Z)-1-Phenyl-4-(tributylstannyl)non-4-en-3-ol (248) (1.27 g, 2.5 mmol, 1.0 equiv.) was dissolved 
in reagent grade DMSO (20 mL). Copper acetate monohydrate (998 mg, 5.0 mmol, 2.0 equiv.) 
and reagent grade Et3N (1.74 mL, 12.5 mmol, 5.0 equiv.) were added to the mixture and stirring 
was continued at 45 °C to 50 °C until disappearance of starting material was judged by TLC 
(hexanes/ethyl acetate, 15:1). The mixture was diluted with MTBE and washed with saturated 
ammonium chloride solution. The organic layer was separated, the aqueous layer extracted once 
with MTBE, the combined extracts were washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 15:1) 
yielded the product as a colorless oil. 
 
4-Oxo-1-phenylnonan-3-yl acetate - (396) 
76% yield (527 mg, 1.91 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.33 – 7.27 (m, 2H), 7.24 – 7.14 (m, 3H), 4.99 (dd, J = 8.7, 4.1 Hz, 1H), 
2.84 – 2.61 (m, 2H), 2.47 (ddd, J = 17.4, 7.8, 7.0 Hz, 1H), 2.36 (dt, J = 
17.4, 7.4 Hz, 1H), 2.16 (s, 3H), 2.14 – 1.93 (m, 2H), 1.56 (dddd, J = 13.6, 9.0, 6.8, 1.2 Hz, 2H), 1.37 
– 1.17 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 207.5, 170.7, 140.6, 
128.7, 128.5, 126.4, 77.9, 38.7, 32.2, 31.7, 31.4, 22.9, 22.6, 20.8, 14.0 ppm. IR (film, CHCl3) 3028, 
2931 2956, 2861, 1727, 1742, 1604, 1497, 1455, 1373, 1230, 1041, 749, 700 cm-1. HRMS (ESI): 
m/z calculated for C17H24O3Na [M+Na+]: 299.16176, found 299.16189. 
 
1-((tert-Butyldimethylsilyl)oxy)-4-oxononan-3-yl acetate - (398) 
64% yield (106 mg, 0.32 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
5.15 (dd, J = 9.1, 3.7 Hz, 1H), 3.88 – 3.51 (m, 2H), 2.62 – 2.35 (m, 2H), 
2.13 (s, 3H), 1.99 (dddd, J = 14.2, 8.1, 6.0, 3.7 Hz, 1H), 1.86 (ddt, J = 14.0, 
9.3, 4.8 Hz, 1H), 1.66 – 1.52 (m, 2H), 1.38 – 1.20 (m, 4H), 0.88 (s, 12H), 0.04 (d, J = 1.2 Hz, 6H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 207.5, 170.6, 75.4, 58.6, 38.8, 33.4, 31.5, 26.0, 23.1, 22.6, 
20.8, 18.4, 14.1, -5.3, -5.4 ppm. IR (film, CHCl3) 2955, 2929, 2858, 1730, 1745, 1471, 1373, 1234, 
1094, 1022, 939, 834, 775, 730 cm-1. HRMS (ESI): m/z calculated for C17H35O4Si [M+H+]: 
331.22991, found 331.23006. 
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2-Oxodecyl acetate - (399) 
74% yield (79 mg, 0.37 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
4.65 (s, 2H), 2.40 (t, J = 7.4 Hz, 2H), 2.17 (s, 3H), 1.59 (dt, J = 5.2, 4.6 Hz, 
2H), 1.38 – 1.17 (m, 10H), 0.95 – 0.75 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 203.3, 169.5, 
67.2, 38.1, 31.1, 28.6, 28.4, 28.4, 22.6, 21.9, 19.8, 13.4 ppm. IR (film, CHCl3) 2913, 2848, 2873, 
1723, 1750, 1459, 1475, 1407, 1430, 1375, 1335, 1279, 1293, 1259, 1211, 1130, 1105, 1075, 
1050, 1009, 982, 960, 897, 857 cm-1. HRMS (ESI): m/z calculated for C12H22O3Na [M+Na+]: 
237.14611, found 237.14611. 
 
(Z)-1-methoxydec-2-en-2-yl acetate - (400) 
82% yield (94 mg, 0.41 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
5.31 (tt, J = 7.3, 0.7 Hz, 1H), 3.93 (q, J = 0.9 Hz, 2H), 3.32 (s, 3H), 2.18 (s, 
3H), 1.97 (q, J = 7.2 Hz, 2H), 1.48 – 1.10 (m, 10H), 0.91 – 0.78 (m, 3H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 169.0, 144.2, 121.3, 72.2, 58.0, 31.9, 29.3, 29.2, 28.9, 25.5, 22.8, 20.8, 14.2 ppm. IR 
(film, CHCl3) 2925, 2855, 1756, 1457, 1369, 1203, 1090, 1017, 942, 914, 587 cm-1. HRMS (ESI): 
m/z calculated for C13H24O3Na [M+Na+]: 251.16176, found 251.16190. 
 
2-Methyl-3-oxo-6-phenylhexan-2-yl acetate - (401) 
67% yield (83 mg, 0.33 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 
7.23 (m, 2H), 7.18 (ddt, J = 7.1, 3.1, 1.3 Hz, 3H), 2.62 (dd, J = 8.3, 6.9 Hz, 2H), 
2.45 (t, J = 7.3 Hz, 2H), 2.03 (s, 3H), 1.99 – 1.83 (m, 2H), 1.45 (s, 6H) ppm. 
13C NMR (101 MHz, CDCl3) δ 208.8, 170.4, 141.8, 128.6, 128.4, 126.0, 83.7, 35.1, 34.9, 25.1, 23.8, 
21.3 ppm. IR (film, CHCl3) 2937, 1733, 1719, 1603, 1497, 1454, 1367, 1253, 1146, 1085, 1018, 
963, 911, 849, 745, 699 cm-1. HRMS (ESI): m/z calculated for C15H20O3Na [M+Na+]: 271.13046, 
found 271.13035. 
 
6-Chloro-2-oxohexyl acetate - (402) 
68% yield (65 mg, 0.34 mmol). 1H NMR (400 MHz, Chloroform-d) δ 4.64 (s, 
2H), 3.64 – 3.47 (m, 2H), 2.46 (td, J = 6.1, 5.3, 1.3 Hz, 2H), 2.16 (s, 3H), 1.91 – 
1.67 (m, 4H) ppm. 13C NMR (101 MHz, CDCl3) δ 203.4, 170.4, 68.0, 44.6, 37.9, 31.8, 20.6 ppm.  
IR (film, CHCl3) 2938, 1729, 1416, 1373, 1273, 1228, 1073, 1048, 1026, 982, 844, 725, 647 cm-1. 
HRMS (ESI): m/z calculated for C8H13O3ClNa [M+Na+]: 215.04454, found 215.04469. 
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1-Cyclohexyl-2-oxoheptyl acetate - (403) 
65% yield (82 mg, 0.32 mmol). 1H NMR (300 MHz, Chloroform-d) δ 4.86 
(dd, J = 5.0, 1.7 Hz, 1H), 2.55 – 2.26 (m, 2H), 2.14 (d, J = 1.0 Hz, 3H), 1.87 (tq, 
J = 6.9, 4.3, 3.6 Hz, 1H), 1.80 – 1.70 (m, 2H), 1.70 – 1.47 (m, 4H), 1.41 – 1.06 (m, 10H), 1.00 – 0.82 
(m, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 207.7, 170.9, 82.6, 39.8, 39.4, 31.5, 29.6, 27.5, 26.3, 
26.1, 26.1, 22.9, 22.6, 20.8, 14.0 ppm. IR (film, CHCl3) 2928, 2855, 1742, 1726, 1451, 1371, 
1232, 1082, 1023, 990, 958, 920 cm-1. HRMS (ESI): m/z calculated for C15H26O3Na [M+Na+]: 
277.17741, found 277.17749.  
 
9-Hydroxy-4-oxo-1-phenylnonan-3-yl acetate - (404) 
50% yield (73 mg, 0.25 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
7.34 – 7.26 (m, 2H), 7.24 – 7.13 (m, 3H), 4.99 (dd, J = 8.4, 4.4 Hz, 1H), 
3.63 (t, J = 6.5 Hz, 2H), 2.70 (dq, J = 9.0, 6.5 Hz, 2H), 2.58 – 2.27 (m, 
2H), 2.15 (s, 3H), 2.12 – 1.93 (m, 2H), 1.68 – 1.48 (m, 4H), 1.48 – 1.24 (m, 3H) ppm. 13C NMR  
(75 MHz, CDCl3) δ 207.2, 170.7, 140.6, 128.7, 128.5, 126.5, 78.0, 62.7, 38.6, 32.5, 32.2, 31.7, 25.4, 
23.0, 20.8 ppm. IR (film, CHCl3) 3433, 3027, 2933, 2863, 1720, 1603, 1497, 1455, 1373, 1229, 
1041, 956, 884, 749, 700 cm-1. HRMS (ESI): m/z calculated for C17H24O4Na [M+Na+]: 315.15668, 
found 315.15662. 
 
8-Cyano-4-oxo-1-phenyloctan-3-yl acetate - (405) 
54% yield (78 mg, 0.27 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.34 – 7.27 (m, 2H), 7.25 – 7.19 (m, 1H), 7.19 – 7.12 (m, 2H), 4.99 – 4.91 
(m, 1H), 2.82 – 2.65 (m, 2H), 2.54 (dt, J = 18.0, 6.8 Hz, 1H), 2.42 (dt, J = 
17.9, 6.6 Hz, 1H), 2.33 (t, J = 6.9 Hz, 2H), 2.16 (s, 3H), 2.11 – 1.99 (m, 2H), 1.84 – 1.56 (m, 4H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 206.4, 170.8, 140.4, 128.7, 128.5, 126.5, 119.5, 77.8, 37.5, 
32.1, 31.6, 24.8, 22.2, 20.8, 17.2 ppm. IR (film, CHCl3) 3028, 2932, 1724, 1603, 1497, 1454, 
1373, 1229, 1080, 1028, 950, 911, 750, 700 cm-1. HRMS (ESI): m/z calculated for C17H21NO3Na 
[M+Na+]: 310.14136, found 310.14119. 
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9-(1,3-Dioxoisoindolin-2-yl)-4-oxo-1-phenylnonan-3-yl acetate - (406) 
63% yield (132 mg, 0.31 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 7.86 – 7.79 (m, 2H), 7.70 (m, 2H), 7.31 – 7.24 
(m, 2H), 7.23 – 7.13 (m, 3H), 4.96 (dd, J = 8.7, 4.2 Hz, 1H), 3.66 (t, 
J = 7.2 Hz, 2H), 2.81 – 2.58 (m, 2H), 2.47 (dt, J = 17.6, 7.3 Hz, 1H), 2.36 (dt, J = 17.7, 7.3 Hz, 1H), 
2.14 (s, 3H), 2.12 – 1.94 (m, 2H), 1.71 – 1.51 (m, 4H), 1.38 – 1.24 (m, 2H) ppm. 13C NMR (101 
MHz, CDCl3) δ 207.1, 170.7, 168.5, 140.5, 134.0, 132.2, 128.7, 128.5, 126.4, 123.3, 77.9, 38.4, 
37.9, 32.1, 31.6, 28.5, 26.4, 22.7, 20.8 ppm. IR (film, CHCl3) 2937, 2864, 1771, 1740, 1706, 1604, 
1497, 1466, 1455, 1436, 1395, 1369, 1229, 1188, 1081, 1041, 947, 874, 851, 794, 750 cm-1. 
HRMS (ESI): m/z calculated for C25H27NO5Na [M+Na+]: 444.17814, found 444.17851.  
 
(R)-2-Methyl-4-oxo-7-phenylheptan-3-yl acetate - (407) 
61% yield (80 mg, 0.31 mmol). [𝒂]𝑫
𝟐𝟎: 4.7° (c=2.25 in CHCl3). 1H NMR 
(300 MHz, Chloroform-d) δ 7.33 – 7.24 (m, 2H), 7.23 – 7.13 (m, 3H), 4.86 
(d, J = 4.3 Hz, 1H), 2.63 (t, J = 7.6 Hz, 2H), 2.58 – 2.31 (m, 2H), 2.26 – 2.14 (m, 
1H), 2.13 (s, 3H), 2.02 – 1.85 (m, 2H), 0.98 (d, J = 6.9 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ 207.2, 170.9, 141.7, 128.6, 128.5, 126.1, 82.8, 38.7, 35.1, 29.6, 24.8, 
20.7, 19.4, 17.0 ppm. IR (film, CHCl3) 2966, 1742, 1724, 1603, 1496, 1454, 1371, 1231, 1028, 
949, 908, 746, 699 cm-1. HRMS (ESI): m/z calculated for C16H22O3Na [M+Na+]: 285.14611, found 
285.14630. 
The enantiomeric excess was determined by HPLC analysis to be 94%.  
150 mm Chiralpak IC-3, 4.6 mm i.D., n-Heptane/2-Propanol = 98:2,  1.0 mL/min, 4.9 MPa, 298 K, 
UV 220 nm. 
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(anti)-3-Methyl-4-oxononan-2-yl acetate - (408) 
57% yield based on pure  (111 mg, 0.52 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 5.07 (dq, J = 7.9, 6.3 Hz, 1H), 2.77 (dq, J = 7.9, 7.1 Hz, 1H), 
2.49 – 2.35 (m, 2H), 1.97 (s, 3H), 1.62 – 1.48 (m, 2H), 1.34 – 1.21 (m, 4H), 1.18 (d, J = 6.3 Hz, 3H), 
1.04 (d, J = 7.1 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 212.1, 170.2, 
71.8, 50.9, 42.1, 31.5, 23.3, 22.6, 21.3, 17.1, 14.0, 12.3 ppm. IR (film, CHCl3) 2957, 2933, 2873, 
1736, 1714, 1457, 1408, 1372, 1235, 1090, 1036, 1017, 965, 946, 850 cm-1. HRMS (ESI): m/z 
calculated for C12H22O3Na [M+Na+]: 237.14611, found 237.14630.  
 
(syn)-3-Methyl-4-oxononan-2-yl acetate - (409) 
59% yield based on pure  (114 mg, 0.53 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 5.13 (p, J = 6.3 Hz, 1H), 2.70 (qd, J = 7.0, 6.1 Hz, 1H), 2.43 
(td, J = 7.3, 4.5 Hz, 2H), 2.01 (s, 3H), 1.58 – 1.48 (m, 2H), 1.37 – 1.19 (m, 4H), 
1.17 (d, J = 6.4 Hz, 3H), 1.07 (d, J = 7.0 Hz, 3H), 0.86 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 211.9, 170.4, 71.2, 50.7, 42.6, 31.5, 23.3, 22.6, 21.3, 17.9, 14.0, 12.3 ppm. IR (film, 
CHCl3) 2957, 2933, 2873, 1736, 1714, 1457, 1408, 1372, 1235, 1090, 1036, 1017, 965, 946, 850 
cm-1. HRMS (ESI): m/z calculated for C12H22O3Na [M+Na+]: 237.14611, found 237.14630.  
 
1-((2S,3S,Z)-3-Hydroxy-4-(3-phenylpropylidene)oxetan-2-yl)octan-1-one - (410) 
58% yield (87 mg, 0.29 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 
7.25 (m, 2H), 7.20 (dt, J = 8.2, 2.0 Hz, 3H), 4.99 (ddq, J = 8.7, 5.9, 1.3 Hz, 1H), 
4.70 (td, J = 7.0, 5.9 Hz, 1H), 4.43 (td, J = 7.5, 1.5 Hz, 1H), 2.78 – 2.58 (m, 2H), 
2.32 (qd, J = 7.5, 1.1 Hz, 2H), 2.01 (d, J = 9.2 Hz, 1H), 1.68 (q, J = 6.9 Hz, 2H), 
1.49 – 1.18 (m, 12H), 0.95 – 0.83 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 161.1, 142.0, 128.7, 
128.3, 125.9, 96.9, 86.5, 69.6, 36.0, 32.0, 29.7, 29.6, 29.4, 29.2, 24.7, 24.6, 22.8, 14.3 ppm.  
IR (film, CHCl3) 3407, 3027, 2924, 2855, 1716, 1604, 1496, 1454, 1365, 1304, 1234, 1201, 1144, 
1069, 984, 940, 893, 848, 746, 724 cm-1. HRMS (ESI): m/z calculated for C20H30O2Na [M+Na+]: 
325.21380, found 325.21402.  
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8.4.2. Representative procedure 11: Copper Trifluoroacetate Mediated Oxidation of 
Alkenylstannanes 
SI-54 (223 mg, 0.5 mmol, 1.0 equiv.) was dissolved in reagent grade DMSO (4 mL). Copper(II) 
trifluoroacetate hydrate (290 mg, 1.0 mmol, 2.0 equiv.) and reagent grade Et3N (349 µL, 
2.5 mmol, 5.0 equiv.) were added to the mixture and stirring was continued at 45 °C to 50 °C 
until disappearance of starting material was judged by TLC (hexanes/ethyl acetate, 15:1). The 
mixture was diluted with MTBE and washed with saturated ammonium chloride solution. The 
organic layer was separated, the aqueous layer extracted once with MTBE, the combined 
extracts were washed with brine, dried over magnesium sulfate and concentrated under 
reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 9:1) yielded the product 
as a colorless oil. 
 
4-((Tetrahydro-2H-pyran-2-yl)oxy)butan-2-one - (411) 
70% yield (60 mg, 0.35 mmol). 1H NMR (400 MHz, Chloroform-d) δ 4.55 (dd, 
J = 4.5, 2.9 Hz, 1H), 4.01 – 3.91 (m, 1H), 3.87 – 3.75 (m, 1H), 3.70 – 3.60 (m, 1H), 
3.53 – 3.41 (m, 1H), 2.67 (td, J = 6.2, 1.5 Hz, 2H), 2.15 (s, 3H), 1.81 – 1.69 (m, 
1H), 1.69 – 1.57 (m, 1H), 1.57 – 1.41 (m, 4H) ppm. 13C NMR (101 MHz, CDCl3) δ 207.3, 99.2, 
62.7, 62.4, 43.8, 30.7, 30.6, 25.5, 19.6 ppm. IR (film, CHCl3) 2942, 1714, 1355, 1324, 1260, 1201, 
1161, 1135, 1120, 1065, 1032, 1019, 979, 904, 869, 813, 755 cm-1. HRMS (ESI): m/z calculated 
for C9H16O3Na [M+Na+]: 195.09916, found 195.09925.  
 
7-Oxotetradecane-1,14-diyl dihexanoate - (412) 
50% yield (55 mg, 0.13 mmol). 1H NMR (400 MHz, Chloroform-
d) δ 4.04 (t, J = 6.7 Hz, 4H), 2.38 (td, J = 7.4, 2.3 Hz, 4H), 2.28 (t, J = 
7.6 Hz, 4H), 1.71 – 1.48 (m, 12H), 1.42 – 1.17 (m, 18H), 0.96 – 0.75 (m, 6H) ppm. 13C NMR (101 
MHz, CDCl3) δ 211.4, 174.13, 174.12, 64.4, 64.3, 42.9, 42.8, 34.5, 31.5, 29.3, 29.2, 29.0, 28.7, 28.6, 
25.9, 24.8, 23.8, 23.8, 22.5, 14.1 ppm. IR (film, CHCl3) 2931, 2858, 1734, 1464, 1416, 1359, 
1246, 1171, 1099 cm-1. HRMS (ESI): m/z calculated for C26H48O5Na [M+Na+]: 463.33939, found 
463.33932.  
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3-(Methoxymethoxy)-1-phenylnonan-4-one - (413) 
68% yield (95 mg, 0.34 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
7.34 – 7.24 (m, 2H), 7.24 – 7.14 (m, 3H), 4.66 (d, J = 0.7 Hz, 2H), 4.06 – 
3.93 (m, 1H), 3.40 (s, 3H), 2.87 – 2.61 (m, 2H), 2.49 (dd, J = 7.8, 7.0 Hz, 
2H), 2.04 – 1.91 (m, 2H), 1.69 – 1.49 (m, 2H), 1.43 – 1.18 (m, 4H), 0.93 – 0.83 (m, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ 211.6, 141.3, 128.6, 128.6, 126.3, 96.8, 82.2, 56.3, 38.6, 34.0, 31.7, 
31.6, 23.1, 22.6, 14.0 ppm. IR (film, CHCl3) 2929, 1715, 1497, 1455, 1148, 1104, 1027, 920, 747, 
699, 494 cm-1. HRMS (ESI): m/z calculated for C17H26O3Na [M+Na+]: 301.17741, found 
301.17752.  
 
2-Oxohexyl isobutyrate - (415) 
 
414 (389 mg, 1.0 mmol, 1.0 equiv.) was dissolved in reagent grade DMSO (8 mL). Copper(II) 
isobutyrate (475 mg, 2.0 mmol, 2.0 equiv.) and reagent grade Et3N (697 µL, 5.0 mmol, 5.0 equiv.) 
were added to the mixture and stirring was continued at 45 °C to 50 °C until disappearance of 
starting material was judged by TLC (hexanes/ethyl acetate, 15:1). The mixture was diluted with 
MTBE and washed with saturated ammonium chloride solution. The organic layer was 
separated, the aqueous layer extracted once with MTBE, the combined extracts were washed 
with brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 25:1) yielded the product as a colorless oil 
(76 mg, 0.41 mmol, 41% yield). 1H NMR (300 MHz, Chloroform-d) δ 4.63 (s, 2H), 2.67 (p, J = 
7.0 Hz, 1H), 2.41 (t, J = 7.4 Hz, 2H), 1.67 – 1.52 (m, 2H), 1.41 – 1.26 (m, 2H), 1.22 (d, J = 7.0 Hz, 
6H), 0.90 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 204.3, 176.5, 67.9, 38.7, 33.9, 25.5, 
22.4, 19.1, 13.9 ppm. IR (film, CHCl3) 2935, 2875, 1729, 1469, 1416, 1386, 1253, 1188, 1159, 
1126, 1099, 1075, 1022, 979 cm-1. HRMS (ESI): m/z calculated for C10H18O3Na [M+Na+]: 
209.11481, found 209.11489. 
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2-Oxohexyl benzoate - (416) 
 
414 (389 mg, 1.0 mmol, 1.0 equiv.) was dissolved in reagent grade DMSO (8 mL). Copper(II) 
trifluoroacetate hydrate (475 mg, 2.0 mmol, 2.0 equiv.), sodium benzoate (576 mg, 4.0 mmol, 
4.0 equiv.) and reagent grade Et3N (697 µL, 5.0 mmol, 5.0 equiv.) were added to the mixture and 
stirring was continued at 45 °C to 50 °C until disappearance of starting material was judged by 
TLC (hexanes/ethyl acetate, 15:1). The mixture was diluted with MTBE and washed with 
saturated ammonium chloride solution. The organic layer was separated, the aqueous layer 
extracted once with MTBE, the combined extracts were washed with brine, dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 25:1) yielded the product as a colorless oil (136 mg, 0.62 mmol, 62% 
yield). 1H NMR (300 MHz, Chloroform-d) δ 8.17 – 8.00 (m, 2H), 7.65 – 7.54 (m, 1H), 7.52 – 7.38 
(m, 2H), 4.88 (s, 2H), 2.50 (t, J = 7.4 Hz, 2H), 1.72 – 1.56 (m, 2H), 1.43 – 1.28 (m, 2H), 0.92 (t, J = 
7.3 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 204.3, 166.0, 133.5, 130.0, 129.4, 128.6, 68.5, 38.8, 
25.5, 22.4, 13.9 ppm. IR (film, CHCl3) 2959, 2933, 2873, 1718, 1601, 1452, 1414, 1377, 1315, 
1272, 1177, 1115, 1060, 1027, 804, 709 cm-1. HRMS (ESI): m/z calculated for C13H16O3Na 
[M+Na+]: 243.09916, found 243.09929. 
 
Substrate synthesis 
The following compounds were prepared according to representative procedure 9. 
 
(Z)-Tributyl(1-methoxydec-2-en-2-yl)stannane - (SI-41) 
 
An oven-dried schlenk flask was charged with NaH (180 mg, 7.5 mmol, 1.5 equiv.) under argon. 
THF (20 mL) was slowly added, the mixture was cooled with an ice bath. SI-21 (2.23 g, 
5.0 mmol, 1.0 equiv.) in a minimum amount of THF was added dropwise. Stirring was continued 
for 30 minutes at 0 °C before MeI (622 µL, 10.0 mmol, 2.0 equiv.) was slowly added and the 
mixture allowed to warm to room temperature. After being stirred for 12 h, the reaction was 
quenched with water at 0 °C and acidified with saturated ammonium chloride solution. The 
mixture was extracted twice with MTBE, the combined organic layers were dried over 
magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 30:1) yielded the product as a colorless oil (2.14 g, 4.65 mmol, 
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93% yield). 1H NMR (400 MHz, Chloroform-d) δ 6.23 (tt, J = 7.1, 1.2 Hz, 1H), 4.00 – 3.88 (m, 
2H), 3.25 (d, J = 0.9 Hz, 3H), 2.02 (q, J = 7.1 Hz, 2H), 1.55 – 1.41 (m, 6H), 1.41 – 1.19 (m, 16H), 
1.01 – 0.73 (m, 18H) ppm. 13C NMR (101 MHz, CDCl3) δ 143.5, 140.6, 80.6, 57.4, 34.8, 32.0, 30.2, 
29.6, 29.4, 29.4, 27.6, 22.8, 14.3, 13.9, 10.4 ppm. 119Sn NMR (149 MHz, CDCl3) δ -52.5 ppm.  
IR (film, CHCl3) 2955, 2853, 2871, 2815, 1624, 1463, 1419 , 1366, 1376, 1349, 1267, 1291, 
1192, 1148, 1110, 1094, 1072, 1002, 1019, 960, 915, 860 cm-1. HRMS (ESI): m/z calculated for 
C23H48OSnNa [M+Na+]: 483.26186, found 483.26238. 
 
(Z)-2-Methyl-6-phenyl-3-(tributylstannyl)hex-3-en-2-ol - (SI-42) 
quant. yield (5.16 g, 10.8 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.36 
– 7.27 (m, 2H), 7.24 – 7.12 (m, 3H), 6.16 (t, J = 7.2 Hz, 1H), 2.78 – 2.60 (m, 2H), 
2.41 – 2.28 (m, 2H), 1.57 – 1.41 (m, 6H), 1.39 – 1.31 (m, 6H), 1.31 (s, 7H), 0.99 
– 0.92 (m, 6H), 0.89 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 154.2, 142.0, 135.6, 
128.6, 128.5, 126.0, 75.5, 36.7, 35.9, 30.9, 29.4, 27.6, 13.9, 12.3 ppm. 119Sn NMR (149 MHz, 
CDCl3) δ -55.6 ppm. IR (film, CHCl3) 2955, 2853, 2871, 2815, 1624, 1463, 1419 , 1366, 1376, 
1349, 1267, 1291, 1192, 1148, 1110, 1094, 1072, 1002, 1019, 960, 915, 860 cm-1. HRMS (ESI): 
m/z calculated for C25H44OSnNa [M+Na+]: 503.23056, found 503.23061. 
 
(Z)-6-Chloro-2-(tributylstannyl)hex-2-en-1-ol - (SI-43) 
75% yield (1.58 g, 3.73 mmol). 1H NMR (400 MHz, Chloroform-d) δ 6.21 (tt, J 
= 7.1, 1.5 Hz, 1H), 4.28 – 4.12 (m, 2H), 3.54 (q, J = 6.7 Hz, 2H), 2.19 (dddd, J = 7.8, 
6.9, 6.0, 1.2 Hz, 2H), 2.00 – 1.74 (m, 2H), 1.70 – 1.38 (m, 6H), 1.38 – 1.27 (m, 6H), 1.24 (d, J = 5.9 
Hz, 1H), 1.07 – 0.93 (m, 6H), 0.89 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 145.1, 
139.4, 70.5, 44.7, 32.9, 31.8, 29.4, 27.6, 13.9, 10.4 ppm. 119Sn NMR (149 MHz, CDCl3) δ -52.3 
ppm. IR (film, CHCl3) 3312, 2955, 2923, 2871, 2851, 1622, 1458, 1376 1340, 1290, 1182, 1072, 
999, 961, 866, 767, 727, 657 cm-1. HRMS (ESI): m/z calculated for C18H36OClSn [M-H+]: 
423.14815, found 423.14812. 
 
(Z)-1-Cyclohexyl-2-(tributylstannyl)hept-2-en-1-ol - (SI-44) 
66% yield (3.2 g, 6.59 mmol). 1H NMR (400 MHz, Chloroform-d) 6.29 – 
5.84 (m, 1H), 3.87 – 3.61 (m, 1H), 2.10 – 1.89 (m, 2H), 1.83 – 1.58 (m, 3H), 
1.58 – 1.39 (m, 6H), 1.38 – 1.25 (m, 12H), 1.18 (dtt, J = 20.5, 9.1, 3.3 Hz, 2H), 
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1.02 – 0.68 (m, 22H) ppm. 13C NMR (101 MHz, CDCl3) δ 147.0, 142.1, 85.4, 43.1, 34.2, 32.5, 30.3, 
29.4, 28.8, 27.6, 26.7, 26.3, 26.3, 22.8, 14.2, 13.9, 11.3 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.5 
ppm. IR (film, CHCl3) 3482, 2955, 2921, 2851, 1615, 1451, 1376, 1257, 1202, 1148, 1069, 1001, 
961, 890, 862 cm-1. HRMS (ESI): m/z calculated for C25H49OSn [M-H+]: 485.28102, found 
485.28097. 
 
(Z)-9-Phenyl-6-(tributylstannyl)non-5-ene-1,7-diol - (SI-45) 
68% yield (2.68 g, 5.12 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
7.39 – 7.29 (m, 2H), 7.29 – 7.19 (m, 3H), 6.24 (td, J = 7.1, 1.1 Hz, 1H), 
4.37 – 4.04 (m, 1H), 3.70 (td, J = 6.4, 5.0 Hz, 2H), 2.86 – 2.53 (m, 2H), 
2.15 (q, J = 7.3 Hz, 2H), 1.99 – 1.74 (m, 2H), 1.72 – 1.60 (m, 4H), 1.60 – 1.48 (m, 4H), 1.48 – 1.28 
(m, 6H), 1.13 – 0.85 (m, 18H) ppm. 13C NMR (75 MHz, CDCl3) δ 148.4, 142.2, 140.5, 128.5, 128.4, 
125.8, 79.3, 62.8, 39.4, 34.0, 32.6, 32.4, 29.4, 27.5, 26.4, 13.8, 11.2 ppm. 119Sn NMR (112 MHz, 
CDCl3) δ -55.3 ppm. IR (film, CHCl3) 3391, 2954, 2924, 2854, 1742, 1727, 1496, 1455, 1374, 
1241, 1046, 864, 747, 698 cm-1. HRMS (ESI): m/z calculated for C27H48O2SnNa [M+Na+]: 
547.25678, found 547.25751. 
 
(Z)-7-Hydroxy-9-phenyl-6-(tributylstannyl)non-5-enenitrile - (SI-46) 
89% yield (2.3 g, 4.44 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.34 – 7.26 (m, 2H), 7.20 (m, 3H), 6.13 (td, J = 7.1, 1.1 Hz, 1H), 4.27 – 
4.03 (m, 1H), 2.76 – 2.56 (m, 2H), 2.35 (t, J = 7.2 Hz, 2H), 2.20 (q, J = 7.2 
Hz, 2H), 1.89 – 1.64 (m, 4H), 1.55 (d, J = 3.3 Hz, 1H), 1.53 – 1.38 (m, 6H), 1.38 – 1.26 (m, 6H), 1.04 
– 0.92 (m, 6H), 0.90 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 150.9, 142.0, 137.5, 
128.5, 128.5, 125.9, 119.6, 79.0, 39.4, 33.1, 32.4, 29.4, 27.5, 25.9, 16.9, 13.8, 11.2 ppm. 119Sn NMR 
(149 MHz, CDCl3) δ -54.7 ppm. IR (film, CHCl3) 3500, 3027, 2954, 2924, 2870, 2853, 1738, 
1604, 1495, 1455, 1422, 1375, 1339, 1243, 1180, 1151, 1046, 961, 915, 877, 748 cm-1. HRMS 
(ESI): m/z calculated for C27H45NOSnNa [M+Na+]: 542.24146, found 542.24170.  
 
 
 
 
Chapter 8 – Experimental Procedures 
196 
(Z)-2-(7-Hydroxy-9-phenyl-6-(tributylstannyl)non-5-en-1-yl)isoindoline-1,3-dione - (SI-
47) 
76% yield (1.02 g, 1.56 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 7.87 – 7.77 (m, 2H), 7.74 – 7.64 (m, 2H), 7.26 
(ddd, J = 7.8, 7.1, 0.9 Hz, 2H), 7.22 – 7.13 (m, 3H), 6.15 (td, J = 7.2, 
1.1 Hz, 1H), 4.28 – 4.00 (m, 1H), 3.69 (t, J = 7.2 Hz, 2H), 2.64 (qdd, J = 13.8, 9.8, 6.1 Hz, 2H), 2.10 
(q, J = 7.3 Hz, 2H), 1.87 – 1.77 (m, 1H), 1.71 (dq, J = 9.8, 6.9 Hz, 4H), 1.58 – 1.37 (m, 8H), 1.37 – 
1.18 (m, 6H), 1.08 – 0.90 (m, 6H), 0.86 (t, J = 7.3 Hz, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 
168.4, 148.6, 142.2, 140.0, 133.9, 132.1, 128.5, 128.3, 125.7, 123.2, 79.2, 39.3, 37.9, 33.8, 32.3, 
29.3, 28.4, 27.4, 27.3, 13.7, 11.1 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.2 ppm. IR (film, 
CHCl3) 2925, 2854, 1773, 1739, 1712, 1455, 1438, 1395, 1371, 1238, 1044, 961, 918, 873, 849, 
792, 747 cm-1. HRMS (ESI): m/z calculated for C35H51NO3SnNa [M+Na+]: 676.27824, found 
676.27876. 
 
(R,Z)-2-Methyl-7-phenyl-4-(tributylstannyl)hept-4-en-3-ol - (SI-48) 
91% yield (2.05 g, 4.15 mmol). [𝒂]𝑫
𝟐𝟎: 9.7° (c=2.23 in CHCl3). 1H NMR 
(400 MHz, Chloroform-d) δ 7.33 – 7.24 (m, 2H), 7.24 – 7.11 (m, 3H), 6.16 
(td, J = 7.2, 1.1 Hz, 1H), 3.71 (ddd, J = 8.1, 3.2, 1.1 Hz, 1H), 2.69 (dd, J = 9.1, 
6.6 Hz, 2H), 2.45 – 2.30 (m, 2H), 1.60 – 1.41 (m, 7H), 1.40 (d, J = 3.2 Hz, 1H), 1.37 – 1.25 (m, 6H), 
0.99 – 0.91 (m, 9H), 0.89 (t, J = 7.2 Hz, 9H), 0.79 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 148.4, 141.9, 140.6, 128.6, 128.5, 126.0, 86.3, 36.6, 36.3, 33.5, 29.4, 27.6, 20.1, 18.3, 
13.8, 11.3 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.2 ppm. IR (film, CHCl3) 3480, 3027, 2954, 
2922, 2870, 2853, 1614, 1496, 1455, 1376, 1273, 1178, 1071, 1004, 959, 874, 745, 697 cm-1. 
HRMS (ESI): m/z calculated for C26H46OSnNa [M+Na+]: 517.24621, found 517.24652. 
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The enantiomeric excess was determined by HPLC analysis to be 98%.  
150 mm Chiralpak IA-3, 4.6 mm i.D., Säule 3, n-Heptane/2-Propanol = 99.9:0.1 (v/v), 1.0 ml/min, 
6.3 MPa, 298 K, UV 220 nm. 
 
(Z)-7-(Tributylstannyl)tetradec-7-ene-1,14-diyl dihexanoate - (SI-49) 
 
SI-63 (1.69 g, 4.0 mmol, 1.0 equiv.) and [Cp*Ru(MeCN)3]PF6 (100 mg, 0.2 mmol, 5.0 mol%) were 
dissolved in dry CH2Cl2 (10 mL) and the solution was stirred at room temperature under an 
argon atmosphere (high concentration necessary for good conversion). The stannane was added 
over 2 h by means of a syringe pump. Upon completion of addition, the volatile materials were 
removed and the crude mixture purified by flash chromatography (hexanes/ethyl acetate, 19:1) 
to yield the product as a pale brown oil (2.3 g, 3.2 mmol, 81% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 4.02 (td, J = 6.7, 1.3 Hz, 4H), 2.25 (t, J = 7.5 Hz, 4H), 2.15 – 2.04 (m, 2H), 1.93 (q, 
J = 6.6 Hz, 2H), 1.70 – 1.49 (m, 6H), 1.51 – 1.36 (m, 6H), 1.28 (dddd, J = 14.4, 11.9, 8.5, 5.4 Hz, 
22H), 1.04 – 0.65 (m, 28H) ppm. 13C NMR (101 MHz, CDCl3) δ 173.9, 143.4, 140.6, 64.4, 40.7, 
35.0, 34.4, 31.4, 30.6, 30.3, 29.4, 29.2, 28.9, 28.8, 28.7, 27.5, 26.0, 25.9, 24.8, 22.4, 14.0, 13.8, 10.3 
ppm. 119Sn NMR (149 MHz, CDCl3) δ -53.2 ppm. IR (film, CHCl3) 2955, 2925, 2855, 1737, 1462, 
1377, 1360, 1244, 1205, 1169, 1098, 1000, 862 cm-1. HRMS (ESI): m/z calculated for 
C38H74O4SnNa [M+Na+]: 737.45006, found 737.45014. 
 
 
Chapter 8 – Experimental Procedures 
198 
(anti,Z)-3-Methyl-4-(tributylstannyl)non-4-en-2-ol - (SI-50) 
91% yield (9.43 g, 21.2 mmol; α/β = 12:1). 1H NMR (300 MHz, 
Chloroform-d) δ 6.17 (td, J = 7.1, 0.8 Hz, 1H), 3.48 (dqt, J = 8.0, 4.6, 1.9 Hz, 
1H), 2.26 – 2.12 (m, 1H), 2.12 – 1.97 (m, 2H), 1.86 (dd, J = 1.7, 0.8 Hz, 1H), 
1.55 – 1.42 (m, 6H), 1.42 – 1.21 (m, 8H), 1.16 (d, J = 6.0 Hz, 3H), 1.09 – 0.51 (m, 23H) ppm.  
13C NMR (75 MHz, CDCl3) δ 147.0, 143.7, 70.6, 53.9, 34.6, 32.6, 29.4, 27.6, 22.7, 20.1, 18.0, 14.2, 
13.8, 11.5 ppm. 119Sn NMR (112 MHz, CDCl3) δ -54.4 ppm. IR (film, CHCl3) 2923, 2871, 2854, 
1457, 1419, 1376, 1340, 1264, 1120, 1071, 1046, 1002, 961, 926, 666 cm-1. HRMS (ESI): m/z 
calculated for C22H46OSnNa [M+Na+]: 469.24621, found 469.24663. 
 
(syn,Z)-3-Methyl-4-(tributylstannyl)non-4-en-2-ol - (SI-51) 
62% yield (5.76 g, 12.9 mmol; α/β = 10:1). 1H NMR (400 MHz, 
Chloroform-d) δ 6.30 – 5.86 (m, 1H), 3.60 (dddd, J = 9.6, 8.6, 6.3, 3.2 Hz, 
1H), 2.40 – 2.19 (m, 1H), 2.01 (pd, J = 6.8, 2.0 Hz, 2H), 1.58 – 1.41 (m, 6H), 
1.41 – 1.24 (m, 11H), 1.15 (d, J = 6.3 Hz, 3H), 1.05 – 0.99 (m, 3H), 0.95 – 0.78 (m, 18H) ppm.  
13C NMR (101 MHz, CDCl3) δ 147.0, 141.1, 69.7, 49.7, 35.1, 32.7, 29.4, 27.6, 22.8, 21.2, 14.4, 14.3, 
13.8, 11.0 ppm. 119Sn NMR (149 MHz, CDCl3) δ -52.00 ppm. IR (film, CHCl3) 3341, 2956, 2923, 
2871, 2854, 1458, 1418, 1376, 1340, 1291, 1249, 1151, 1076, 1047, 1019, 960, 923, 899, 862, 
768 cm-1. HRMS (ESI): m/z calculated for C22H45OSn [M-H+]: 445.24972, found 445.24996. 
 
(5S,6R,Z)-1-Phenyl-4-(tributylstannyl)tetradec-3-ene-5,6-diol - (SI-52) 
54% yield (1.26 g, 2.12 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.33 – 
7.26 (m, 2H), 7.24 – 7.14 (m, 3H), 6.47 – 6.05 (m, 1H), 4.04 – 3.80 (m, 1H), 
3.44 – 3.27 (m, 1H), 2.71 (dd, J = 8.8, 6.6 Hz, 2H), 2.45 – 2.34 (m, 2H), 2.29 
(dd, J = 16.8, 3.4 Hz, 2H), 1.57 – 1.40 (m, 6H), 1.40 – 1.16 (m, 20H), 0.99 – 0.92 (m, 6H), 0.92 – 
0.85 (m, 12H) ppm. 13C NMR (101 MHz, CDCl3) δ 145.5, 142.9, 141.6, 128.5, 128.5, 126.1, 83.5, 
74.2, 36.4, 36.3, 33.0, 32.0, 29.9, 29.7, 29.5, 29.4, 27.6, 26.0, 22.8, 14.3, 13.8, 11.3 ppm. 119Sn NMR 
(149 MHz, CDCl3) δ -53.8 ppm. IR (film, CHCl3) 3397, 2922, 2954, 2853, 2870, 1615, 1496, 
1455, 1376, 1339, 1288, 1199, 1072, 1029, 961, 904, 866, 746, 723, 697 cm-1. HRMS (ESI): m/z 
calculated for C32H58O2SnNa [M+Na+]: 617.33503, found 617.33546.  
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Tributyl(4-((tetrahydro-2H-pyran-2-yl)oxy)but-1-en-2-yl)stannane - (SI-53) 
 
2-(3-Butynyloxy)tetrahydro-2H-pyran (784 µL, 5.0 mmol, 1.0 equiv.) and Bu3SnH (1.41 mL, 
5.25 mmol, 1.05 equiv.) were dissolved in dry CH2Cl2 (5 mL) and added over 1 h by means of a 
syringe pump to a stirred solution of [Cp*Ru(MeCN)3]PF6 (63 mg, 0.125 mmol, 2.5 mol%) in dry 
CH2Cl2 (20 mL) at room temperature under an argon atmosphere. Upon completion, the volatile 
materials were removed under vacuum and the residue was purified by flash chromatography 
(SiO2, hexanes/ethyl acetate, 50:1) to give the product as a pale yellow oil (1.88 g, 4.21 mmol, 
84% yield). TLC (hexanes/ethyl acetate, 20:1), Rf = 0.45. 1H NMR (400 MHz, Chloroform-d) δ 
5.94 – 5.49 (m, 1H), 5.31 – 5.09 (m, 1H), 4.58 (dd, J = 4.3, 2.7 Hz, 1H), 3.92 – 3.81 (m, 1H), 3.78 
(ddd, J = 9.7, 7.8, 6.7 Hz, 1H), 3.55 – 3.47 (m, 1H), 3.41 (ddd, J = 9.7, 7.9, 7.0 Hz, 1H), 2.54 (ddq, J = 
8.0, 6.7, 1.3 Hz, 2H), 1.90 – 1.79 (m, 1H), 1.77 – 1.68 (m, 1H), 1.67 – 1.39 (m, 10H), 1.39 – 1.24 (m, 
6H), 1.04 – 0.79 (m, 15H) ppm. 13C NMR (101 MHz, CDCl3) δ 151.5, 127.1, 99.0, 67.5, 62.5, 41.2, 
30.9, 29.3, 27.6, 25.7, 19.8, 13.8, 9.7 ppm. 119Sn NMR (149 MHz, CDCl3) δ -43.8 ppm. IR (film, 
CHCl3) 2923, 2871, 2852, 1463, 1377, 1351, 1323, 1260, 1201, 1183, 1135, 1120, 1071, 1031, 
981, 960, 915 cm-1. HRMS (ESI): m/z calculated for C21H42O2SnNa [M+Na+]: 469.20983, found 
469.21016. 
 
(Z)-2-(Tributylstannyl)hex-2-en-1-ol - (414) 
92% yield (7.19 g, 18.5 mmol). 1H NMR (300 MHz, Chloroform-d) δ 6.52 – 
5.93 (m, 1H), 4.28 – 4.09 (m, 2H), 2.10 – 1.87 (m, 2H), 1.63 – 1.41 (m, 6H), 1.41 
– 1.23 (m, 7H), 1.16 (t, J = 6.0 Hz, 1H), 0.99 – 0.92 (m, 7H), 0.89 (t, J = 7.3 Hz, 12H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 143.4, 142.0, 70.7, 36.8, 29.4, 27.6, 23.3, 14.0, 13.8, 10.4 ppm. 119Sn NMR 
(112 MHz, CDCl3) δ -52.8 ppm. IR (film, CHCl3) 3301, 2955, 2924, 2871, 2853, 1622, 1462, 
1418, 1376, 1340, 1291, 1182, 1148, 1073, 1045, 1021, 989, 960, 897, 875, 741, 664 cm-1. HRMS 
(ESI): m/z calculated for C18H38OSnNa [M+Na+]: 413.18361, found 413.18390. 
 
The following compounds were prepared according to representative procedure 6. 
2-Methyl-6-phenylhex-3-yn-2-ol - (SI-54) 
97% yield (2.75 g, 14.6 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.35 – 
7.27 (m, 2H), 7.26 – 7.16 (m, 3H), 2.82 (t, J = 7.5 Hz, 2H), 2.48 (t, J = 7.6 Hz, 2H), 
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2.07 (s, 1H), 1.49 (s, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 140.7, 128.6, 128.4, 126.4, 86.1, 
81.8, 65.3, 35.2, 31.7, 21.0 ppm. IR (film, CHCl3) 3379, 3028, 2979, 2930, 2863, 1739, 1604, 
1496, 1454, 1362, 1341, 1239, 1163, 1047, 1078, 1030, 949, 833, 861, 748, 698 cm-1. HRMS 
(ESI): m/z calculated for C13H16ONa [M+Na+]: 211.10933, found 211.10927. 
 
6-Chlorohex-2-yn-1-ol - (SI-55) 
 
5-Chloro-1-pentyne (2.14 mL, 20 mmol, 1.0 equiv.) was dissolved in THF (20 mL) and the 
solution stirred in an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. n-
Butyllithium (12.5 mL, 1.6 M in hexanes, 20 mmol, 1.0 equiv.) was dropwise added and the 
mixture placed on an ice bath for 15 minutes. Then paraformaldehyde (1.62 g, 54 mmol, 
2.7 equiv.) was added in one portion and the mixture was warmed to 45 °C for 2 h with an oil 
bath. After being cooled again to room temperature, saturated ammonium chloride solution was 
added. The mixture was extracted twice with MTBE, the combined organic layers were washed 
with brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, hexanes/MTBE, 3:1) yielded the product as a colorless oil (2.15 g, 
15.4 mmol, 95% purity, 77% yield). 1H NMR (400 MHz, Chloroform-d) δ 4.25 (t, J = 2.2 Hz, 2H), 
3.65 (t, J = 6.3 Hz, 2H), 2.42 (tt, J = 6.8, 2.2 Hz, 2H), 1.96 (p, J = 6.6 Hz, 2H), 1.83 – 1.74 (m, 1H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 84.5, 79.5, 51.4, 43.8, 31.3, 16.3 ppm. IR (film, CHCl3) 3340, 
2918, 1433, 1354, 1290, 1230, 1131, 1010, 859, 726, 652 cm-1. HRMS (ESI): m/z calculated for 
C6H9OClNa [M+Na+]: 155.02341, found 155.02346.  
 
1-Cyclohexylhept-2-yn-1-ol - (SI-56) 
98% yield (5.28 g, 24.5 mmol). 1H NMR (400 MHz, Chloroform-d) δ 4.13 
(dt, J = 6.0, 2.1 Hz, 1H), 2.21 (td, J = 7.0, 2.0 Hz, 2H), 1.79 (ddtd, J = 29.2, 
12.6, 3.2, 1.7 Hz, 3H), 1.67 (dddd, J = 12.8, 5.1, 3.1, 1.7 Hz, 1H), 1.58 – 1.44 
(m, 3H), 1.44 – 1.33 (m, 2H), 1.32 – 0.94 (m, 7H), 0.91 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 86.4, 80.2, 67.6, 44.5, 30.9, 28.7, 28.2, 26.6, 26.1, 26.0, 22.1, 18.5, 13.7 ppm. 
Spectral data in accordance with literature[32]. 
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9-Phenylnon-5-yne-1,7-diol - (SI-57) 
 
1-Hexynol (1.21 mL, 11 mmol, 1.1 equiv.) was dissolved in dry THF (20 mL) and the solution 
stirred under an argon atmosphere on a dry-ice bath. n-Butyllithium (13.8 mL, 1.6 M in hexanes, 
22 mmol, 2.2 equiv.) was added dropwise and stirring continued for 1 h at 0 °C before the 
mixture was again cooled with a dry-ice bath. Neat phenylpropionaldehyde (1.31 mL, 10 mmol, 
1.0 equiv.) was added in one portion, the dry-ice bath was removed and the mixture was allowed 
to warm to room temperature. After being stirred for 4 h, saturated ammonium chloride 
solution was added followed by aqueous HCl (2 M) to obtain a clear solution. The mixture was 
extracted two times with ethyl acetate, the combined extracts were washed with brine, dried 
over magnesium sulfate and concentrated under reduced pressure. Flash chromatography (SiO2, 
hexanes/ethyl acetate, 3:2 to 1:1) yielded the product as a colorless oil (1.76 g, 7.58 mmol, 
76% yield). 1H NMR (300 MHz, Chloroform-d) δ 7.33 – 7.24 (m, 2H), 7.21 (m, 3H), 4.36 (tt, J = 
6.5, 2.0 Hz, 1H), 3.68 (t, J = 6.2 Hz, 2H), 2.79 (t, J = 7.9 Hz, 2H), 2.28 (td, J = 6.7, 1.9 Hz, 2H), 1.99 
(tdd, J = 7.7, 6.5, 3.5 Hz, 2H), 1.93 – 1.76 (m, 2H), 1.76 – 1.51 (m, 4H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 141.6, 128.6, 128.5, 126.1, 85.6, 81.7, 62.5, 62.1, 39.8, 31.9, 31.6, 25.1, 18.6 ppm.  
IR (film, CHCl3) 3331, 2937, 2863, 1722, 1496, 1454, 1374, 1331, 1244, 1156, 1051, 1030, 915, 
749, 699 cm-1. HRMS (ESI): m/z calculated for C15H20O2Na [M+Na+]: 255.13555, found 
255.13538.  
 
7-Hydroxy-9-phenylnon-5-ynenitrile - (SI-58) 
96% yield (2.19 g, 9.64 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.33 – 7.26 (m, 2H), 7.25 – 7.15 (m, 3H), 4.36 (tdd, J = 6.5, 4.7, 3.3 Hz, 
1H), 2.78 (t, J = 7.8 Hz, 2H), 2.49 (t, J = 7.1 Hz, 2H), 2.43 (td, J = 6.8, 2.0 
Hz, 2H), 2.12 – 1.93 (m, 2H), 1.93 – 1.78 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 141.3, 128.6, 
126.2, 119.3, 83.2, 82.9, 77.4, 62.0, 39.6, 31.6, 24.5, 18.0, 16.4 ppm. IR (film, CHCl3) 3415, 3025, 
2944, 2863, 2249, 1603, 1496, 1454, 1432, 1334, 1218, 1155, 1132, 1056, 1030, 915, 749 cm-1. 
HRMS (ESI): m/z calculated for C15H17NONa [M+Na+]: 250.120233, found 250.120270.  
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2-(7-Hydroxy-9-phenylnon-5-yn-1-yl)isoindoline-1,3-dione - (SI-59) 
 
HMDS (3.13 mL, 15 mmol, 1.5 equiv.) was dissolved in dry THF (20 mL) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. n-Butyllithium 
(8.13 mL, 1.6 M in hexanes, 13 mmol, 1.3 equiv.) was added dropwise and stirring continued for 
30 minutes before the mixture was cooled to 78 °C. n-(5-Hexinyl)phthalimide (2.5 g, 11 mmol, 
1.1 equiv.) was added and stirring continued for 1 h before neat phenylpropionaldehyde 
(1.31 mL, 10 mmol, 1.0 equiv.) was added in one portion. The dry-ice bath was removed and the 
mixture was allowed to warm to room temperature. After being stirred for another 30 minutes, 
saturated ammonium chloride solution was added followed by aqueous HCl (2 M) to obtain a 
clear solution. The mixture was extracted two times with ethyl acetate, the combined extracts 
were washed with brine, dried over magnesium sulfate and concentrated under reduced 
pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 2:1) delivered pure product 
(746 mg, 2.1 mmol, 21% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.73 (m, 2H), 7.64 – 7.55 
(m, 2H), 7.23 – 7.14 (m, 2H), 7.14 – 7.04 (m, 3H), 4.26 (dt, J = 4.6, 2.1 Hz, 1H), 3.62 (t, J = 7.2 Hz, 
2H), 2.68 (t, J = 7.9 Hz, 2H), 2.40 (d, J = 4.8 Hz, 1H), 2.19 (td, J = 7.0, 2.0 Hz, 2H), 1.99 – 1.80 (m, 
2H), 1.73 (tt, J = 7.9, 6.4 Hz, 2H), 1.47 (dq, J = 9.7, 7.0 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 
168.5, 141.6, 134.0, 132.1, 128.5, 128.4, 125.9, 123.3, 84.8, 82.0, 61.9, 39.6, 37.5, 31.5, 27.5, 25.6, 
18.2 ppm. IR (film, CHCl3) 3463, 2940, 2864, 1771, 1736, 1704, 1604, 1496, 1467, 1437, 1396, 
1372, 1335, 1239, 1188, 1115, 1039, 915, 847, 792 cm-1. HRMS (ESI): m/z calculated for 
C23H23NO3Na [M+Na+]: 384.15701, found 384.15727.  
 
(R)-2-Methyl-7-phenylhept-4-yn-3-ol[33] - (SI-60) 
 
Zn(OTf)2 (2.0 g, 5.5 mmol, 1.1 equiv.) was placed in an oven-dried Schlenk flask under an argon 
atmosphere at room temperature. ()-N-Methylephedrine (1.08 g, 6.0 mmol, 1.2 equiv.) was 
added followed by dry toluene (15 mL) and the mixture was stirred for 15 minutes before Et3N 
(836 µL, 6.0 mmol, 1.2 equiv.) was added. After being stirred for 2 h, 4-phenyl-1-butyne (844 µL, 
6.0 mmol, 1.2 equiv.) was added followed after 15 minutes by iso-butyraldehyde (456 µL, 
5.0 mmol, 1.0 equiv.). Stirring was continued for 18 h before the reaction was quenched with the 
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addition of saturated ammonium chloride solution. The mixture was extracted two times with 
MTBE, the combined extracts were washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 9:1) 
yielded the product as a pale yellow oil (925 mg, 4.57 mmol, 92% yield).  
The enantiomeric excess was determined by HPLC analysis to be 97%.  
150 mm Chiralcel OD-3, 4.6 mm i.D., n-Heptane/2-Propanol = 90:10, 1.0 ml/min, 7.0 MPa, 298 K, 
UV 220 nm. 
 
 
Racemic material was synthesized according to representative procedure 6. 
2-Methyl-7-phenylhept-4-yn-3-ol - (SI-61) 
89% yield (1.08 g, 5.34 mmol). 1H NMR (300 MHz, Chloroform-d) δ 7.34 
– 7.25 (m, 2H), 7.25 – 7.17 (m, 3H), 4.13 (ddt, J = 5.6, 3.7, 2.2 Hz, 1H), 2.83 (t, 
J = 7.5 Hz, 2H), 2.59 – 2.48 (m, 2H), 1.81 (pd, J = 6.7, 5.6 Hz, 1H), 1.63 (d, J = 
5.4 Hz, 1H), 0.95 (dd, J = 6.7, 3.6 Hz, 6H) ppm. 13C NMR (75 MHz, CDCl3) δ 140.7, 128.6, 128.5, 
126.4, 85.5, 80.9, 68.3, 35.3, 34.8, 21.0, 18.2, 17.6 ppm. IR (film, CHCl3) 3382, 3028, 2959, 2929, 
2871, 1726, 1604, 1496, 1468, 1454, 1430, 1367, 1256, 1146, 1108, 1077, 1021, 959, 816, 745, 
697 cm-1. HRMS (ESI): m/z calculated for C14H18O [M+]: 202.13522, found 202.13496.  
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Non-7-yn-1-yl hexanoate - (SI-62) 
 
Non-7-yn-1-ol (1.40 g, 10 mmol, 1.0 equiv.) was dissolved in dry THF (20 mL) and stirred on an 
ice bath in an oven-dried Schlenk flask under an argon atmosphere. Pyridine (1.62 mL, 20 mmol, 
2.0 equiv.) was added followed by dropwise addition of the hexanoyl chloride (2.10 mL, 
15 mmol, 1.5 equiv.). After 10 minutes, the ice bath was removed and stirring was continued for 
another 2 h before the reaction was quenched with the addition of aqueous HCl (2 M). The 
mixture was extracted two times with MTBE, the combined extracts were washed with 
saturated sodium carbonate solution, aqueous copper sulfate solution (1 M) and brine, dried 
over magnesium sulfate and concentrated under reduced pressure. The crude material was used 
as such (2.4 g, 10 mmol, quant. yield). 1H NMR (400 MHz, Chloroform-d) δ 4.05 (t, J = 6.7 Hz, 
2H), 2.28 (t, J = 7.5 Hz, 2H), 2.12 (tq, J = 7.2, 2.6 Hz, 2H), 1.77 (t, J = 2.6 Hz, 3H), 1.69 – 1.56 (m, 
4H), 1.53 – 1.17 (m, 10H), 0.94 – 0.80 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 174.2, 79.3, 
75.6, 64.4, 34.5, 31.5, 29.0, 28.7, 25.7, 24.9, 22.5, 18.8, 14.1, 3.6 ppm.  
 
Tetradec-7-yne-1,14-diyl dihexanoate[6] - (SI-63) 
 
Pre-dried 5 Å mol sieves (~2.0 g) were placed in an oven-dried Schlenk flask under an argon 
atmosphere and dried again under high vacuum with a blowtorch. After being cooled to room 
temperature dry toluene (40 mL) was added followed by SI-62 (2.38 g, 10 mmol, 1.0 equiv.). 
After being stirred for 5 minutes, (4-methoxybenzylidyne)-tris((triphenylsilyl)oxy)molybdenum 
(208 mg, 0.2 mmol, 2.0 mol%) was added under an argon atmosphere in two portions. After 
10 minutes, TLC showed complete conversion of starting material so the mixture was filtered 
over Celite® with additional MTBE. The volatile materials were removed under reduced 
pressure and the residue purified by flash chromatography (SiO2, hexanes/ethyl actetate, 20:1) 
to give the product as a colorless thick oil (1.69 g, 4.0 mmol, 80% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 4.04 (t, J = 6.7 Hz, 4H), 2.27 (t, J = 7.6 Hz, 4H), 2.18 – 2.07 (m, 4H), 1.60 (dddd, J 
= 14.7, 7.4, 5.8, 2.6 Hz, 8H), 1.53 – 1.19 (m, 20H), 0.94 – 0.81 (m, 6H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 174.1, 80.2, 64.4, 34.5, 31.4, 29.1, 28.7, 28.6, 25.6, 24.8, 22.4, 18.8, 14.0 ppm. IR (film, 
CHCl3) 2931, 2859, 1734, 1463, 1352, 1245, 1168, 1098, 730 cm-1. HRMS (ESI): m/z calculated 
for C26H46O4Na [M+Na+]: 445.32883, found 445.32915.  
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(anti)-3-Methylnon-4-yn-2-ol - (SI-64) 
 
1-Hexyne (4.3 mL, 37.5 mmol, 1.5 equiv.) was dissolved in dry THF (50 mL) and the solution 
stirred in an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. n-
Butyllithium (23.4 mL, 1.6 M in hexanes, 37.5 mmol, 1.5 equiv.) was added dropwise and stirring 
continued for 10 minutes. Then, BF3·Et2O (4.6 mL, 37.5 mmol, 1.5 equiv.) was added followed 
after 15 minutes by neat (syn)-2,3-dimethyloxirane (2.18 mL, 25 mmol, 1.0 equiv.). The mixture 
was stirred at the same temperature for 2 h before the reaction was quenched with the addition 
of saturated ammonium chloride solution. The mixture was allowed to warm to room 
temperature and extracted twice with ethyl acetate. The combined extracts were washed with 
brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
chromatography (SiO2, hexanes/ethyl acetate, 9:1) yielded the product as a pale yellow liquid 
(3.6 g, 23.3 mmol, 93% yield). 1H NMR (400 MHz, Chloroform-d) δ 3.57 (h, J = 6.0 Hz, 1H), 2.41 
(tddd, J = 7.0, 5.6, 4.6, 2.2 Hz, 1H), 2.19 (td, J = 6.9, 2.2 Hz, 2H), 1.96 (d, J = 5.7 Hz, 1H), 1.53 – 1.44 
(m, 2H), 1.44 – 1.34 (m, 2H), 1.22 (d, J = 6.2 Hz, 3H), 1.16 (d, J = 7.0 Hz, 3H), 0.91 (t, J = 7.2 Hz, 
3H) ppm. 13C NMR (101 MHz, CDCl3) δ 83.7, 80.7, 71.1, 35.2, 31.3, 22.1, 20.9, 18.5, 17.9, 13.8 
ppm. IR (film, CHCl3) 3386, 2932 2960, 2874, 1454, 1376, 1300, 1265, 1173, 1098, 997, 1011, 
955, 913 cm-1. HRMS (ESI): m/z calculated for C10H18ONa [M+Na+]: 177.12498, found 
177.12498.  
 
(syn)-3-Methylnon-4-yn-2-ol - (SI-65) 
 
1-Hexyne (4.3 mL, 37.5 mmol, 1.5 equiv.) was dissolved in dry THF (50 mL) and the solution 
stirred in an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. n-
Butyllithium (23.4 mL, 1.6 M in hexanes, 37.5 mmol, 1.5 equiv.) was added dropwise and stirring 
continued for 10 minutes. Then, BF3·Et2O (4.6 mL, 37.5 mmol, 1.5 equiv.) was added followed 
after 15 minutes by neat (anti)-2,3-dimethyloxirane (2.18 mL, 25 mmol, 1.0 equiv.). The mixture 
was stirred at the same temperature for 2 h before the reaction was quenched with the addition 
of saturated ammonium chloride solution. The mixture was allowed to warm to room 
temperature and extracted twice with ethyl acetate. The combined extracts were washed with 
brine, dried over magnesium sulfate and concentrated under reduced pressure. Flash 
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chromatography (SiO2, hexanes/ethyl acetate, 9:1) yielded the product as a pale yellow liquid 
(3.2 g, 20.8 mmol, 83% yield). 1H NMR (400 MHz, Chloroform-d) δ 3.76 – 3.60 (m, 1H), 2.56 
(ttd, J = 7.0, 4.9, 2.2 Hz, 1H), 2.16 (td, J = 7.0, 2.3 Hz, 2H), 1.80 (d, J = 6.0 Hz, 1H), 1.53 – 1.31 (m, 
4H), 1.21 (d, J = 6.2 Hz, 3H), 1.11 (d, J = 7.1 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 83.1, 81.2, 70.6, 34.3, 31.3, 22.1, 19.5, 18.5, 16.7, 13.8 ppm. IR (film, CHCl3) 3384, 
2962, 2932, 2874, 1742, 1727, 1454, 1374, 1328, 1298, 1246, 1202, 1168, 1083, 1008, 972, 911 
cm-1. HRMS (ESI): m/z calculated for C10H18ONa [M+Na+]: 177.12498, found 177.12504.  
 
(E)-Tetradec-5-en-3-yn-1-ylbenzene - (SI-66) 
 
1-Decyne (4.51 mL, 25 mmol, 1.0 equiv.) was placed in an oven-dried Schlenk under an argon 
atmosphere and stirred at 40 °C. DIBAL-H (22.9 mL, 27.5 mmol, 1.2 M in PhMe, 1.1 equiv.) was 
added slowly before the mixture was heated to 50 °C for 5 h. After being cooled again to 40 °C, 
I2 (7.6 , 30 mmol, 1.2 equiv.) in THF (25 mL) was added slowly over 10 minutes. The mixture 
was then allowed to warm to room temperature over the course of 12 h. The mixture was 
poured carefully onto a saturated sodium thiosulfate solution/ice mixture. At room 
temperature, the mixture was extracted two times with MTBE, the combined extracts were 
concentrated to about 20 mL. The crude mixture was analyzed by GC and showed almost pure 
vinyl iodide which was used as such as a solution in PhMe. 
4-Phenyl-1-butyne (1.4 mL, 10 mmol, 1.0 equiv.) was dissolved in Et3N (10 mL) and stirred in an 
oven-dried Schlenk flask under an argon atmosphere at room temperature. Crude (E)-1-
iododec-1-ene (solution in PhMe) was added followed by CuI (114 mg, 0.6 mmol, 6.0 mol%) and 
bis-(triphenylphosphine)-palladium(II)-chloride (211 mg, 0.3 mmol, 3.0 mol%) and stirring was 
continued for 12 h with the conversion monitored by TLC (hexanes/ethyl acetate, 20:1). The 
reaction was then quenched with saturated ammonium chloride solution and acidified with 
aqueous HCl (2 M). The mixture was extracted two times with MTBE, the combined extracts 
were washed with brine, dried over magnesium sulfate and concentrated under reduced 
pressure. Flash chromatography (SiO2, hexanes) yielded the product as a pale yellow oil (1.45 g, 
5.4 mmol, 54% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.36 – 7.27 (m, 2H), 7.26 – 7.19 (m, 
3H), 6.06 (dt, J = 15.8, 7.1 Hz, 1H), 5.45 (dt, J = 15.8, 1.8 Hz, 1H), 2.97 – 2.77 (m, 2H), 2.58 (td, J = 
7.7, 2.1 Hz, 2H), 2.08 (qd, J = 7.1, 1.6 Hz, 2H), 1.46 – 1.12 (m, 12H), 0.96 – 0.84 (m, 3H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 144.0, 140.9, 128.6, 128.5, 126.4, 109.7, 87.9, 80.0, 35.5, 33.1, 32.0, 
29.6, 29.4, 29.3, 29.0, 22.8, 21.8, 14.3 ppm. IR (film, CHCl3) 3027, 2923, 2853, 1496, 1454, 1340, 
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1077, 1030, 955, 744, 697, 633, 578, 509 cm-1. HRMS (ESI): m/z calculated for C20H28 [M+]: 
268.21910, found 268.21921.  
 
(5R,6R)-1-Phenyltetradec-3-yne-5,6-diol - (SI-67) 
 
7.5 g AD-mix β was dissolved in t-BuOH (25 mL) and the solution stirred in a cooling Schlenk at 
4°C. A solution of MeSO2NH2 (514 mg, 5.4 mmol, 1.0 equiv.) in water (25 mL) was added 
followed by (E)-tetradec-5-en-3-yn-1-ylbenzene (1.45 g, 5.4 mmol, 1.0 equiv.). The mixture was 
stirred at the same temperature for 12 h. TLC indicated complete consumption of starting 
material. The reaction was quenched with the addition of saturated sodium sulfite solution at 
4 °C. The mixture was then extracted three times with ethyl acetate, the combined extracts were 
washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 4:1 to 2:1) yielded the product as a colorless 
oil which solidified upon standing (1.18 g, 3.9 mmol, 72% yield). [𝒂]𝑫
𝟐𝟎: 13.3° (c=1.60 in CHCl3). 
1H NMR (400 MHz, Chloroform-d) δ 7.34 – 7.27 (m, 2H), 7.25 – 7.17 (m, 3H), 4.10 (dt, J = 6.3, 
2.0 Hz, 1H), 3.51 (ddd, J = 8.0, 6.3, 3.4 Hz, 1H), 2.83 (t, J = 7.4 Hz, 2H), 2.53 (td, J = 7.4, 1.9 Hz, 4H), 
1.65 – 1.16 (m, 14H), 0.97 – 0.84 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 140.5, 128.5, 128.5, 
126.5, 86.4, 79.6, 75.2, 66.4, 34.9, 32.4, 32.0, 29.7, 29.7, 29.4, 25.7, 22.8, 20.9, 14.3 ppm. IR (film, 
CHCl3) 3361, 2922, 2854, 1496, 1454, 1260, 1129, 1031, 745, 697, 579, 507 cm-1. HRMS (ESI): 
m/z calculated for C20H30O2Na [M+Na+]: 325.21380, found 325.21366. 
 
8.5. Fluorination of Alkenylstannanes and Synthesis of Peptide Bioisosters 
Synthesis of silver(I) diphenylphosphinate[34] 
NaOH (1.1 g, 27.5 mmol, 1.1 equiv.) was dissolved in water (10 mL) and the solution stirred 
vigorously in a 100 mL flask. Diphenylphosphinic acid (5.73 g, 26.3 mmol, 1.05 equiv.) was 
added and the solution stirred until complete dissolution was realized (a few drops of additional 
aqueous NaOH were usually necessary to accomplish that task). Then, a solution of AgNO3 
(4.25 g, 25 mmol, 1.0 equiv.) in a minimum amount water was added rapidly and a grey 
precipitate immediately formed. The solids were filtered off with suction, the residue washed 
two times with water and acetone, then with MTBE followed by drying under high vacuum to 
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give the product as a grey powder (83% yield, 6.72 g, 20.7 mmol). The material obtained was 
used as such. 
8.5.1. Representative procedure 12: Silver Mediated Fluorination of Alkenylstannanes  
AgOP(O)Ph2 (390 mg, 1.2 mmol, 1.2 equiv.) and F-TEDA-PF6 (941 mg, 2.0 mmol, 2.0 equiv.) were 
stirred under argon in an oven-dried Schlenk at room temperature for 10 minutes until a 
homogenous greyish powder is obtained. Then, dry acetone (15 mL) was added. 248 (507 mg, 
1.0 mmol, 1.0 equiv.) was dissolved in dry acetone (5 mL) and the solution added over 
60 minutes by means of a syringe pump to the above prepared suspension. Upon complete 
addition, the mixture was diluted with MTBE and the reaction quenched with saturated 
ammonium chloride solution. The mixture was extracted two times with MTBE, the combined 
extracts were washed with brine, dried over magnesium sulfate and concentrated under 
reduced pressure. Flash chromatography of the residue (SiO2, hexanes/ethyl acetate) provided 
clean material. 
 
(Z)-1-Phenyl-4-(tributylstannyl)non-4-en-3-ol - (493) 
78% yield (184 mg, 0.78 mmol). 1H NMR (300 MHz, Chloroform-d) δ 7.34 – 
7.26 (m, 2H), 7.21 (m, 3H), 4.82 (dt, J = 37.8, 7.5 Hz, 1H), 4.08 (dt, J = 16.6, 6.7 
Hz, 1H), 2.86 – 2.63 (m, 2H), 2.24 – 2.06 (m, 2H), 2.06 – 1.91 (m, 2H), 1.80 (s, 
1H), 1.44 – 1.26 (m, 4H), 1.01 – 0.79 (m, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 159.3 (d, J = 
255.9 Hz), 141.6, 128.6, 128.5, 126.1, 107.1 (d, J = 14.1 Hz), 70.4 (d, J = 30.5 Hz), 35.6, 31.8, 31.6 
(d, J = 1.8 Hz), 23.1 (d, J = 4.5 Hz), 22.4, 14.0 ppm. 19F NMR (282 MHz, CDCl3) δ -126.7 ppm.  
IR (film, CHCl3) 3342, 3027, 2955, 2927, 2859, 1706, 1604, 1496, 1455, 1298, 1179, 1031, 936, 
830, 746, 698 cm-1. HRMS (ESI): m/z calculated for C15H21OFNa [M+Na+]: 259.14686, found 
259.14691.  
 
(Z)-2-Fluorodec-2-en-1-ol - (494) 
74% yield (64 mg, 0.37 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
4.82 (dt, J = 37.0, 7.6 Hz, 1H), 4.09 (dd, J = 16.0, 6.2 Hz, 2H), 2.09 (qd, J = 
7.4, 1.8 Hz, 2H), 1.98 (t, J = 6.3 Hz, 1H), 1.53 – 1.18 (m, 10H), 0.94 – 0.79 (m, 3H) ppm. 13C NMR 
(75 MHz, Chloroform-d) δ 157.5 (d, J = 253.2 Hz), 131.3 (d, J = 377.8 Hz), 108.4 (d, J = 14.1 Hz), 
61.5 (d, J = 32.6 Hz), 31.9, 29.3 (d, J = 1.7 Hz), 29.2 (d, J = 4.9 Hz), 23.5 (d, J = 4.2 Hz), 22.8, 14.2 
ppm. 19F NMR (282 MHz, CDCl3) δ -121.4 ppm. IR (film, CHCl3) 3328, 2924, 2856, 1709, 1458, 
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1378, 1214,1114, 1067, 1012, 919, 856, 723, 683 cm-1. HRMS (EI): m/z calculated for C10H19OF 
[M]: 174.14199, found 174.14206. 
 
(Z)-3-Fluoro-2-methyl-6-phenylhex-3-en-2-ol - (495) 
68% yield (71 mg, 34 mmol). 1H NMR (300 MHz, Chloroform-d) δ 7.35 – 
7.26 (m, 2H), 7.25 – 7.15 (m, 3H), 4.91 (dt, J = 37.9, 7.5 Hz, 1H), 2.70 (dd, J = 
8.7, 6.7 Hz, 2H), 2.47 – 2.35 (m, 2H), 1.86 (s, 1H), 1.38 (d, J = 1.2 Hz, 6H).  
13C NMR (75 MHz, Chloroform-d) δ 163.4 (d, J = 257.7 Hz), 141.7, 128.6, 128.4, 126.0, 102.1 (d, 
J = 14.9 Hz), 70.4 (d, J = 29.3 Hz), 35.7 (d, J = 1.7 Hz), 27.4, 25.2 (d, J = 5.2 Hz) ppm. 19F NMR (282 
MHz, CDCl3) δ -122.6 ppm. IR (film, CHCl3) 3380, 2930, 2858, 1702, 1496, 1454, 1364, 1280, 
1171, 1094, 1053, 1030, 1002, 955, 877, 841, 782, 747 cm-1. HRMS (ESI): m/z calculated for 
C13H17OFNa [M+Na+]: 231.11556, found 231.11565.  
 
(Z)-1-Cyclohexyl-2-fluorohept-2-en-1-ol - (496) 
56% yield (60 mg, 0.28 mmol). 1H NMR (300 MHz, Chloroform-d) δ 4.74 
(dt, J = 37.9, 7.5 Hz, 1H), 3.72 (ddd, J = 20.1, 7.3, 6.1 Hz, 1H), 2.09 (dtd, J = 
9.6, 7.8, 6.8, 2.7 Hz, 2H), 1.93 (ddq, J = 11.7, 3.5, 1.9 Hz, 1H), 1.77 (d, J = 6.1 
Hz, 1H), 1.76 – 1.47 (m, 5H), 1.33 (dq, J = 7.2, 3.6 Hz, 4H), 1.29 – 1.08 (m, 3H), 1.08 – 0.92 (m, 
2H), 0.91 (s, 3H) ppm. 13C NMR (75 MHz, Chloroform-d) δ 158.4 (d, J = 256.5 Hz), 107.9 (d, J = 
14.1 Hz), 76.1 (d, J = 29.0 Hz), 40.9, 31.6 (d, J = 1.6 Hz), 29.1 (d, J = 53.6 Hz), 26.5, 26.1 (d, J = 8.8 
Hz), 23.1 (d, J = 4.6 Hz), 22.4, 14.0 ppm. 19F NMR (282 MHz, CDCl3) δ -126.7 ppm. IR (film, 
CHCl3) 3373, 2923, 2853, 1706, 1450, 1379, 1308, 1280, 1174, 1110, 1083, 1011, 952, 935, 893, 
873, 836, 800 cm-1. HRMS (ESI): m/z calculated for C13H23OFNa [M+Na+]: 237.16251, found 
237.16266.  
 
(Z)-6-Fluoro-9-phenylnon-5-ene-1,7-diol - (497) 
62% yield (78 mg, 0.31 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
7.33 – 7.25 (m, 2H), 7.20 (m, 3H), 4.81 (dt, J = 37.6, 7.6 Hz, 1H), 4.06 (dt, 
J = 16.4, 6.7 Hz, 1H), 3.64 (t, J = 6.4 Hz, 2H), 2.71 (dh, J = 13.9, 7.1 Hz, 
2H), 2.14 (qd, J = 7.4, 1.7 Hz, 2H), 2.07 – 1.85 (m, 2H), 1.68 – 1.52 (m, 2H), 1.52 – 1.32 (m, 2H) 
ppm. 13C NMR (75 MHz, Chloroform-d) δ 159.6 (d, J = 256.6 Hz), 141.5, 128.6, 128.5, 126.1, 
106.5 (d, J = 14.1 Hz), 70.2 (d, J = 30.4 Hz), 62.7, 35.6, 32.2, 31.7, 25.5 (d, J = 1.8 Hz), 23.1 (d, J = 
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4.6 Hz) ppm. 19F NMR (282 MHz, CDCl3) δ -125.9 ppm. IR (film, CHCl3) 3338, 2932, 2861, 
1707, 1496, 1454, 1262, 1032, 933, 836, 748, 698, 494 cm-1. HRMS (ESI): m/z calculated for 
C15H21O2FNa [M+Na+]: 275.14178, found 275.14184.  
 
(Z)-6-Fluoro-7-hydroxy-9-phenylnon-5-enenitrile - (498) 
60% yield (74 mg, 0.30 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.36 – 7.27 (m, 2H), 7.21 (m, 3H), 4.82 (dt, J = 36.9, 7.6 Hz, 1H), 4.09 
(dt, J = 14.3, 6.6 Hz, 1H), 2.83 – 2.63 (m, 2H), 2.34 (t, J = 7.2 Hz, 2H), 
2.30 – 2.22 (m, 2H), 2.21 – 2.15 (m, 1H), 2.08 – 1.90 (m, 2H), 1.75 (p, J = 7.2 Hz, 2H) ppm.  
13C NMR (101 MHz, Chloroform-d) δ 161.1 (d, J = 259.1 Hz), 141.3, 128.6, 128.5, 126.1, 119.7, 
103.9 (d, J = 13.6 Hz), 69.80 (d, J = 30.4 Hz), 35.5, 31.6, 25.0 (d, J = 2.1 Hz), 22.5 (d, J = 5.0 Hz), 
16.7 ppm. 19F NMR (282 MHz, CDCl3) δ -122.9 ppm. IR (film, CHCl3) 3429, 3027, 2936, 2865, 
2249, 1707, 1603, 1496, 1454, 1424, 1295, 1140, 1063, 1030, 1013, 925, 851, 749, 699 cm-1. 
HRMS (ESI): m/z calculated for C15H18NOFNa [M+Na+]: 270.12646, found 270.12649.  
 
(Z)-2-(6-Fluoro-7-hydroxy-9-phenylnon-5-en-1-yl)isoindoline-1,3-dione - (499) 
50% yield (96 mg, 0.25 mmol). 1H NMR (300 MHz, 
Chloroform-d) δ 7.86 – 7.77 (m, 2H), 7.73 – 7.65 (m, 2H), 7.32 – 
7.22 (m, 2H), 7.22 – 7.12 (m, 3H), 4.79 (dt, J = 37.4, 7.6 Hz, 1H), 
4.18 – 3.96 (m, 1H), 3.67 (t, J = 7.3 Hz, 2H), 2.70 (hept, J = 7.1 Hz, 2H), 2.29 (d, J = 5.2 Hz, 1H), 
2.15 (qd, J = 7.4, 1.7 Hz, 2H), 2.05 – 1.83 (m, 2H), 1.82 – 1.63 (m, 2H), 1.54 – 1.33 (m, 2H) ppm. 
13C NMR (75 MHz, Chloroform-d) δ 168.5, 159.9 (d, J = 257.2 Hz), 141.5, 134.0, 132.2, 128.5, 
128.5, 126.0, 123.3, 106.0 (d, J = 14.0 Hz), 70.1 (d, J = 30.5 Hz), 37.8, 35.5, 31.7, 28.0, 26.4, 22.8 
(d, J = 4.7 Hz) ppm. 19F NMR (282 MHz, CDCl3) δ -125.5 pm. IR (film, CHCl3) 3463, 2940, 2861, 
1770, 1702, 1604, 1496, 1437, 1396, 1371, 1239, 1187, 1116, 1037, 925, 862, 793, 751, 718, 699 
cm-1. HRMS (EI): m/z calculated for C23H24NO3FNa [M+Na+]: 404.16324, found 404.16349.  
 
N-(3-Fluoro-1-phenylbut-3-en-1-yl)-4-methylbenzenesulfonamide - (500) 
65% yield (103 mg, 0.32 mmol). 1H NMR (500 MHz, Chloroform-d) δ 7.59 – 7.52 
(m, 2H), 7.22 – 7.11 (m, 5H), 7.08 (m, 2H), 5.33 (s, 1H), 4.54 (t, J = 7.2 Hz, 1H), 4.49 
(dd, J = 17.2, 3.1 Hz, 1H), 4.17 (dd, J = 49.6, 3.0 Hz, 1H), 2.71 – 2.50 (m, 2H), 2.36 (s, 
3H) ppm. 13C NMR (126 MHz, Chloroform-d) δ 161.9 (d, J = 257.1 Hz), 143.3, 139.7, 137.3, 
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129.5, 128.6, 127.8, 127.3, 126.6, 93.7, 55.3, 40.5 (d, J = 26.9 Hz), 21.6 ppm. 19F NMR (282 MHz, 
CDCl3) δ -95.7 ppm. IR (film, CHCl3) 3245, 1675, 1600, 1497, 1458, 1319, 1290, 1242, 1157, 
1095, 1060, 940, 874, 843, 811, 758, 700, 671, 597 cm-1. HRMS (EI): m/z calculated for 
C17H17NO2FS [M-H+]: 318.09696, found 318.09694.  
 
(Z)-4-(2-Fluoro-3-hydroxy-3-methylbut-1-en-1-yl)benzonitrile - (501) 
70% yield (72 mg, 0.35 mmol). 1H NMR (300 MHz, Chloroform-d) δ 7.66 – 
7.48 (m, 4H), 5.97 (d, J = 38.8 Hz, 1H), 1.96 (s, 1H), 1.52 (d, J = 1.3 Hz, 6H) 
ppm. 13C NMR (75 MHz, Chloroform-d) δ 166.9 (d, J = 276.1 Hz), 138.1, 
132.3, 129.2 (d, J = 8.0 Hz), 119.1, 110.5 (d, J = 3.0 Hz), 102.2 (d, J = 6.5 Hz), 71.0 (d, J = 29.0 Hz), 
27.7 ppm. 19F NMR (282 MHz, CDCl3) δ -110.1 ppm. IR (film, CHCl3) 3432, 2981, 2933, 2872, 
2226, 1685, 1605, 1504, 1413, 1072, 1019, 1003, 958, 895, 578 cm-1. HRMS (ESI): m/z 
calculated for C12H12NOFNa [M+Na+]: 228.07951, found 228.07953.  
 
(Z)-4-(2-Fluoro-3-hydroxy-3-methylbut-1-en-1-yl)benzaldehyde - (502) 
68% yield (71 mg, 0.34 mmol). 1H NMR (500 MHz, Chloroform-d) δ 9.97 
(s, 1H), 7.88 – 7.80 (m, 2H), 7.67 – 7.59 (m, 2H), 6.01 (d, J = 39.2 Hz, 1H), 
1.52 (d, J = 1.2 Hz, 6H) ppm. 13C NMR (126 MHz, Chloroform-d) δ 191.9, 
166.7 (d, J = 275.9 Hz), 139.7 (d, J = 2.5 Hz), 134.9 (d, J = 2.0 Hz), 130.1, 129.2 (d, J = 7.8 Hz), 
102.6 (d, J = 6.5 Hz), 71.0 (d, J = 29.2 Hz), 27.71 ppm. 19F NMR (282 MHz, CDCl3) δ -110.2 ppm. 
IR (film, CHCl3) 3430, 2979, 1677, 1600, 1566, 1463, 1421, 1363, 1311, 1299, 1254, 1213, 1190, 
1169 1071, 1004, 959, 895, 866, 809, 779, 720 cm-1. HRMS (EI): m/z calculated for C12H13O2F 
[M+]: 208.08996, found 208.08988.  
 
(Z)-N-(2-Fluoro-1-phenylhept-2-en-1-yl)-4-methylbenzenesulfonamide - (503) 
87% yield (158 mg, 0.44 mmol). 1H NMR (500 MHz, Chloroform-d) δ 7.86 
– 7.60 (m, 2H), 7.45 – 7.11 (m, 7H), 5.09 (d, J = 25.0 Hz, 1H), 5.02 (d, J = 18.0 
Hz, 1H), 4.69 (dt, J = 36.9, 7.5 Hz, 1H), 2.88 (d, J = 7.5 Hz, 1H), 2.41 (s, 3H), 
1.97 – 1.81 (m, 2H), 1.33 – 1.09 (m, 6H), 0.85 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (126 MHz, 
Chloroform-d) δ 154.8 (d, J = 255.3 Hz), 143.6, 137.4 (d, J = 56.9 Hz), 129.6, 128.8, 128.3, 127.3, 
127.1, 109.9 (d, J = 14.0 Hz), 58.4 (d, J = 29.8 Hz), 46.1, 31.2, 23.2 (d, J = 4.1 Hz), 22.3, 21.7, 13.9 
ppm. 19F NMR (282 MHz, CDCl3) δ -123.2 ppm. IR (film, CHCl3) 3293, 2951, 2858, 1598, 1496, 
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1440, 1382, 1330, 1249, 1155, 1117, 1089, 1054, 1030, 928, 875, 850, 813, 754, 699, 685 cm-1. 
HRMS (ESI): m/z calculated for C20H23NO2FS [M-H+]: 360.14391, found 360.14397.  
 
(anti,Z)-4-Fluoro-3-methylnon-4-en-2-ol - (504) 
54% yield (47 mg, 6:1 mixture of :, 0.27 mmol). Analytical of data pure 
: 1H NMR (400 MHz, Chloroform-d) δ 4.61 (dt, J = 38.7, 7.5 Hz, 1H), 3.86 
– 3.69 (m, 1H), 2.22 (dp, J = 24.7, 7.2 Hz, 1H), 2.13 – 2.00 (m, 2H), 1.76 – 
1.64 (m, 1H), 1.40 – 1.25 (m, 4H), 1.19 (dd, J = 6.2, 0.7 Hz, 3H), 1.08 (d, J = 7.1 Hz, 3H), 0.93 – 0.84 
(m, 3H) ppm. 13C NMR (101 MHz, Chloroform-d) δ 160.1 (d, J = 255.6 Hz), 107.5 (d, J = 15.6 
Hz), 68.9, 45.1 (d, J = 24.4 Hz), 31.8 (d, J = 1.8 Hz), 23.3 (d, J = 5.1 Hz), 22.4, 20.3, 14.0, 13.9 (d, J = 
2.9 Hz) ppm. 19F NMR (282 MHz, CDCl3) δ -116.9 ppm. IR (film, CHCl3) 3371, 2959, 2927, 
2860, 1702, 1458, 1379, 1277, 1171, 1096, 999, 959, 934, 909, 869, 841, 730 cm-1. HRMS (EI): 
m/z calculated for C10H19OF [M+]: 174.14199, found 174.14209.  
 
(Z)-7-Fluorotetradec-7-ene-1,14-diyl dihexanoate - (505) 
60% yield (133 mg, 0.30 mmol). 1H NMR (400 MHz, 
Chloroform-d) δ 4.44 (dt, J = 38.2, 7.4 Hz, 1H), 4.05 (td, J = 6.7, 1.2 
Hz, 4H), 2.28 (t, J = 7.6 Hz, 4H), 2.12 (dt, J = 17.4, 7.4 Hz, 2H), 2.03 
(p, J = 6.1 Hz, 2H), 1.68 – 1.53 (m, 8H), 1.53 – 1.41 (m, 2H), 1.31 (ddtd, J = 12.1, 9.9, 6.8, 3.1 Hz, 
18H), 0.96 – 0.81 (m, 6H) ppm. 13C NMR (101 MHz, Chloroform-d) δ 174.2, 174.2, 159.6 (d, J = 
252.5 Hz), 105.0 (d, J = 16.1 Hz), 64.4 (d, J = 8.9 Hz), 34.5, 32.2, 31.9, 31.5, 29.6, 28.9, 28.7, 28.7, 
28.7, 26.3, 25.9, 25.8, 24.8, 23.5, 23.5, 22.5, 14.1 ppm. 19F NMR (282 MHz, CDCl3) δ -110.0 ppm. 
IR (film, CHCl3) 2930, 2859, 1734, 1707, 1463, 1354, 1244, 1168, 1098, 1050, 992, 891, 729 cm-
1. HRMS (EI): m/z calculated for C26H47O4FNa [M+Na+]: 465.33506, found 465.33544.  
 
Ethyl (2E,5Z)-5-fluoro-4-hydroxy-3-methyldeca-2,5-dienoate - (506) 
71% yield (87 mg, 0.36 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
6.07 (p, J = 1.4 Hz, 1H), 4.91 (dt, J = 37.0, 7.6 Hz, 1H), 4.55 (d, J = 16.0 Hz, 
1H), 4.16 (q, J = 7.1 Hz, 2H), 2.37 (s, 1H), 2.18 – 2.00 (m, 5H), 1.34 (m, 
4H), 1.28 (t, J = 7.1 Hz, 3H), 0.94 – 0.82 (m, 3H) ppm. 13C NMR (75 MHz, Chloroform-d) δ 166.7, 
158.1, 154.7, 117.3, 109.5 (d, J = 13.7 Hz), 75.2 (d, J = 31.6 Hz), 60.1, 31.3 (d, J = 1.8 Hz), 23.2 (d, J 
= 4.0 Hz), 22.3, 15.4, 14.4, 13.9 ppm. 19F NMR (282 MHz, CDCl3) δ -124.3 ppm. IR (film, CHCl3) 
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3436, 2958, 2931, 2861, 1698, 1657, 1445, 1369, 1345, 1279, 1212, 1146, 1113, 1096, 1040, 
938, 880, 826 cm-1. HRMS (ESI): m/z calculated for C13H21O3FNa [M+Na+]: 267.13669, found 
267.13679.  
 
(Z)-1-((tert-Butyldimethylsilyl)oxy)-4-fluoronon-4-en-3-ol - (507) 
57% yield (82 mg, 0.28 mmol). 1H NMR (300 MHz, Chloroform-d) δ 
4.89 (dtd, J = 38.4, 7.6, 0.8 Hz, 1H), 4.44 – 4.23 (m, 1H), 3.91 (ddd, J = 
10.5, 6.5, 4.2 Hz, 1H), 3.79 (ddd, J = 10.2, 7.1, 4.1 Hz, 1H), 3.59 (d, J = 4.4 
Hz, 1H), 2.17 – 2.03 (m, 2H), 2.01 – 1.73 (m, 2H), 1.47 – 1.22 (m, 4H), 0.97 – 0.83 (m, 12H), 0.08 
(s, 6H) ppm. 13C NMR (75 MHz, Chloroform-d) δ 159.3 (d, J = 254.3 Hz), 105.9 (d, J = 13.3 Hz), 
70.4 (d, J = 33.7 Hz), 61.8, 35.5, 31.6, 26.0, 23.0 (d, J = 4.7 Hz), 22.4, 18.2, 14.0, -5.5 ppm. 19F NMR 
(282 MHz, CDCl3) δ -125.1 ppm. IR (film, CHCl3) 3408, 2955, 2929, 2858, 1709, 1470, 1389, 
1362, 1254, 1099, 1006, 939, 832, 775, 732, 664 cm-1. HRMS (ESI): m/z calculated for 
C15H31O2FSiNa [M+Na+]: 313.19696, found 313.19696.  
 
(S,Z)-N-(2-Fluoro-1-phenylhept-2-en-1-yl)-2-methylpropane-2-sulfon-amide - (531) 
76% yield (125 mg, 0.38 mmol). [𝒂]𝑫
𝟐𝟎: 3.7° (c=1.01 in MeOH).  
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.28 (m, 5H), 5.17 (dd, J = 
18.2, 9.3 Hz, 1H), 4.92 (dt, J = 36.9, 7.6 Hz, 1H), 4.50 (d, J = 9.2 Hz, 1H), 
2.14 (tdq, J = 8.5, 7.0, 2.3, 1.9 Hz, 2H), 1.39 (s, 9H), 1.38 – 1.21 (m, 4H), 0.95 – 0.86 (m, 3H) ppm. 
13C NMR (101 MHz, Chloroform-d) δ 156.6 (d, J = 255.8 Hz), 138.5, 129.0, 128.3, 127.0, 109.5 
(d, J = 14.2 Hz), 60.3, 59.2 (d, J = 29.1 Hz), 31.3, 24.3, 23.4 (d, J = 4.1 Hz), 22.4, 13.9 ppm. 19F NMR 
(282 MHz, CDCl3) δ -122.1 ppm. IR (film, CHCl3) 3287, 2957, 2931, 2858, 1705, 1495, 1451, 
1438, 1369, 1302, 1249, 1182, 1129, 1061, 1026, 923, 852, 738, 694, 605, 512 cm-1. HRMS (EI): 
m/z calculated for C17H26NO2FSNa [M+Na+]: 350.15605, found 350.15569. 
 
(S,Z)-N-(5-Fluoro-2-methyldec-5-en-4-yl)-2-methylpropane-2-sulfon-amide - (532) 
81% yield (125 mg, 0.41 mmol). [𝒂]𝑫
𝟐𝟎: 10.2° (c=1.21 in CHCl3).  
1H NMR (400 MHz, Chloroform-d) δ 4.76 (dt, J = 37.7, 7.6 Hz, 1H), 4.06 
– 3.89 (m, 2H), 2.13 – 2.00 (m, 2H), 1.73 – 1.44 (m, 3H), 1.37 (s, 9H), 1.35 
– 1.23 (m, 4H), 0.95 (d, J = 6.5 Hz, 3H), 0.93 – 0.86 (m, 6H) ppm. 13C NMR 
(101 MHz, Chloroform-d) δ 157.1 (d, J = 255.0 Hz), 108.0, 59.8, 54.7 (d, J = 27.5 Hz), 43.6, 31.4 
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(d, J = 1.6 Hz), 24.9, 24.3, 23.2 (d, J = 4.4 Hz), 22.7, 22.3 (d, J = 12.6 Hz), 13.9 ppm. 19F NMR (282 
MHz, CDCl3) δ -128.2 ppm. IR (film, CHCl3) 3274, 2957, 2872, 2931, 1706, 1458, 1367, 1301, 
1172, 1127, 1061, 1006, 964, 921, 817, 680 cm-1. HRMS (EI): m/z calculated for C15H29NO2FS 
[M-H+]: 306.19086, found 306.19105. 
 
(S,Z)-N-(5-Fluoro-2-methyldec-5-en-4-yl)-4-nitrobenzenesulfonamide - (533) 
54% yield (100 mg, 0.27 mmol). [𝒂]𝑫
𝟐𝟎: 40.7° (c=1.11 in CHCl3). 1H NMR 
(400 MHz, Chloroform-d) δ 8.36 – 8.27 (m, 2H), 8.06 – 7.94 (m, 2H), 4.77 
(d, J = 8.8 Hz, 1H), 4.52 (dt, J = 37.5, 7.5 Hz, 1H), 3.97 (ddt, J = 24.2, 8.9, 7.8 
Hz, 1H), 1.79 (dtdd, J = 14.3, 8.0, 6.6, 1.6 Hz, 1H), 1.73 – 1.60 (m, 2H), 1.49 
(td, J = 7.7, 7.2, 1.1 Hz, 2H), 1.22 – 1.00 (m, 4H), 0.92 (d, J = 4.9 Hz, 3H), 0.91 (d, J = 4.9 Hz, 3H), 
0.81 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, Chloroform-d) δ 154.8 (d, J = 255.7 Hz), 150.1, 
146.9, 128.5, 124.2, 109.0 (d, J = 14.5 Hz), 54.2 (d, J = 27.6 Hz), 42.0, 31.2, 24.6, 22.9 (d, J = 4.2 
Hz), 22.4, 22.3 (d, J = 2.6 Hz), 13.8 ppm. 19F NMR (282 MHz, CDCl3) δ -128.6 ppm. IR (film, 
CHCl3) 3301, 2932, 2959, 2871, 1609, 1527, 1352, 1332, 1308, 1158, 856, 813, 738, 682 cm-1. 
HRMS (EI): m/z calculated for C17H24N2O4FS [M-H+]: 371.14463, found 371.14485. 
 
Diphenyl (S,Z)-(5-fluoro-2-methyldec-5-en-4-yl)phosphoramidate - (530) 
84% yield (176 mg, 0.42 mmol). [𝒂]𝑫
𝟐𝟎: 6.5° (c=1.11 in CHCl3). 1H NMR 
(400 MHz, Chloroform-d) δ 7.39 – 7.28 (m, 4H), 7.28 – 7.19 (m, 4H), 
7.19 – 7.11 (m, 2H), 4.71 (dt, J = 37.7, 7.5 Hz, 1H), 3.89 (ddq, J = 23.4, 
10.2, 7.7 Hz, 1H), 3.16 (dd, J = 12.3, 10.2 Hz, 1H), 1.99 (dddt, J = 7.5, 5.9, 
3.5, 2.1 Hz, 2H), 1.65 – 1.45 (m, 2H), 1.38 (dt, J = 13.5, 7.4 Hz, 1H), 1.33 – 1.18 (m, 4H), 0.87 (d, J = 
1.5 Hz, 3H), 0.87 – 0.83 (m, 6H) ppm. 13C NMR (101 MHz, Chloroform-d) δ 157.6 (dd, J = 255.5, 
3.3 Hz), 151.0 (d, J = 1.6 Hz), 150.9 (d, J = 2.1 Hz), 129.8, 129.7, 125.08 – 125.03 (m), 125.04 – 
124.99 (m), 120.4 (d, J = 3.1 Hz), 120.3 (d, J = 3.1 Hz), 107.2 (d, J = 14.7 Hz), 52.4 (d, J = 28.6 Hz), 
43.4 (d, J = 7.1 Hz), 31.4 (d, J = 1.7 Hz), 24.7, 23.1 (d, J = 4.3 Hz), 22.4 (d, J = 25.5 Hz), 22.4, 14.0 
ppm. 19F NMR (282 MHz, CDCl3) δ -128.8 ppm. IR (film, CHCl3) 3212, 2952, 2927, 2869, 1592, 
1486, 1456, 1249, 1197, 1158, 1084, 1017, 925, 906, 779, 690 cm-1. HRMS (EI): m/z calculated 
for C23H30NO3FP [M-H+]: 418.19529, found 418.19579. 
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Benzyl (Z)-(5-fluoro-2-methyldec-5-en-4-yl)carbamate - (534) 
77% yield (124 mg, 0.39 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.43 – 7.27 (m, 5H), 5.10 (s, 2H), 4.93 – 4.84 (m, 1H), 4.77 (dt, J = 37.9, 7.7 
Hz, 1H), 4.26 (dq, J = 22.2, 8.2 Hz, 1H), 2.14 – 1.96 (m, 2H), 1.70 – 1.57 (m, 
1H), 1.52 (dt, J = 13.9, 7.1 Hz, 1H), 1.47 – 1.37 (m, 1H), 1.37 – 1.20 (m, 4H), 
0.95 – 0.91 (m, 6H), 0.89 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 MHz, Chloroform-d) δ 157.3 (d, 
J = 255.4 Hz), 155.6, 136.5, 128.7, 128.3, 128.2, 107.2 (d, J = 14.6 Hz), 67.0, 51.2 (d, J = 28.1 Hz), 
41.5, 31.5, 24.9, 23.2 (d, J = 4.4 Hz), 22.6 (d, J = 6.5 Hz), 22.3, 14.0 ppm. 19F NMR (282 MHz, 
CDCl3) δ -127.4. ppm. IR (film, CHCl3) 3322, 2956, 2930, 2871, 1696, 1527, 1250, 1112, 1027, 
1039, 735, 696 cm-1. HRMS (EI): m/z calculated for C19H28NO2FNa [M+Na+]: 344.19963, found 
344.19941. 
 
Benzyl (Z)-(4-fluoro-2-methylnon-4-en-3-yl)carbamate - (535) 
76% yield (116 mg, 0.38 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.43 – 7.28 (m, 5H), 5.11 (s, 2H), 4.96 (d, J = 9.6 Hz, 1H), 4.73 (dt, J = 38.1, 
7.5 Hz, 1H), 3.95 (ddd, J = 22.9, 9.6, 7.9 Hz, 1H), 2.15 – 1.96 (m, 2H), 1.88 
(dq, J = 13.9, 6.9 Hz, 1H), 1.43 – 1.23 (m, 4H), 0.95 (d, J = 2.7 Hz, 3H), 0.94 (d, J = 2.9 Hz, 3H), 0.92 
– 0.85 (m, 3H) ppm. 13C NMR (101 MHz, Chloroform-d) δ 156.5 (d, J = 255.5 Hz), 155.9, 136.5, 
128.7, 128.3, 128.2, 108.0 (d, J = 14.4 Hz), 67.0, 58.6 (d, J = 27.4 Hz), 31.5 (d, J = 1.7 Hz), 30.4, 
23.1 (d, J = 4.6 Hz), 22.3, 19.5, 18.8, 14.0 ppm. 19F NMR (282 MHz, CDCl3) δ -125.5 ppm.  
IR (film, CHCl3) 3326, 2959, 2930, 2873, 1697, 1510, 1455, 1264, 1228, 1096, 1022, 936, 836, 
736, 696 cm-1. HRMS (EI): m/z calculated for C18H26NO2FNa [M+Na+]: 330.18398, found 
330.18378. 
 
Substrate syntheses 
The following compounds were prepared according to representative procedure 9. 
(Z)-4-Methyl-N-(1-phenyl-2-(tributylstannyl)hept-2-en-1-yl)benzene-sulfonamide 
 - (SI-68) 
56% yield (1.41 mg, 2.23 mmol). 1H NMR (400 MHz, Chloroform-d) δ 
7.70 – 7.60 (m, 2H), 7.21 (tdd, J = 7.1, 5.6, 3.3 Hz, 5H), 7.15 – 7.07 (m, 2H), 
6.22 – 5.77 (m, 1H), 5.15 – 4.98 (m, 1H), 4.53 (d, J = 7.9 Hz, 1H), 2.40 (s, 3H), 
1.92 (qd, J = 7.0, 1.9 Hz, 2H), 1.44 – 1.08 (m, 10H), 0.90 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 7.0 Hz, 15H), 
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0.66 (ddd, J = 9.1, 5.8, 1.3 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 143.1, 142.5, 141.8, 140.8, 
138.3, 129.5, 128.5, 127.6, 127.6, 127.5, 65.0, 34.4, 32.3, 29.1, 27.5, 22.8, 21.6, 14.2, 13.7, 10.8 
ppm. 119Sn NMR (149 MHz, CDCl3) δ -51.9 ppm. IR (film, CHCl3) 3250, 2952, 2922, 2869, 2853, 
1453, 1437, 1324, 1303, 1160, 1095, 1067, 1051, 995, 937, 912, 870, 813, 765, 750, 700, 658, 
633, 595, 569 cm-1. HRMS (ESI): m/z calculated for C32H50NO2SSn [M-H+]: 632.25891, found 
632.25941. 
 
(Z)-4-(3-Hydroxy-3-methyl-2-(tributylstannyl)but-1-en-1-yl)benzaldehyde - (SI-69) 
79% yield (3.04 g, 6.35 mmol). 1H NMR (400 MHz, Chloroform-d) δ 10.00 
(s, 1H), 7.84 – 7.75 (m, 2H), 7.40 – 7.29 (m, 3H), 1.57 (d, J = 0.8 Hz, 1H), 1.43 
(s, 6H), 1.40 – 1.25 (m, 6H), 1.25 – 1.12 (m, 6H), 0.82 (t, J = 7.2 Hz, 9H), 0.78 – 
0.57 (m, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 192.0, 162.9, 147.7, 136.0, 135.0, 129.7, 129.0, 
76.2, 31.2, 29.2, 27.5, 13.8, 12.9 ppm. 119Sn NMR (149 MHz, CDCl3) δ -52.8 ppm. IR (film, 
CHCl3) 2955, 2921, 2871, 2853, 1700, 1600, 1565, 1462, 1418, 1139, 1074, 1048, 1018, 959, 
932, 877, 723, 652, 628 cm-1. HRMS (ESI): m/z calculated for C24H39O2Sn [M-H+]: 479.19769, 
found 479.19782. 
 
N-(3-Fluoro-1-phenylbut-3-en-1-yl)-4-methylbenzenesulfonamide - (SI-70) 
47% yield (1.12 g, 1.90 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.39 
(m, 2H), 7.20 – 7.11 (m, 3H), 7.11 – 7.02 (m, 4H), 5.70 (dt, J = 2.5, 1.3 Hz, 1H), 5.29 
(d, J = 2.3 Hz, 1H), 4.74 (d, J = 3.8 Hz, 1H), 4.29 (ddd, J = 9.1, 5.4, 3.8 Hz, 1H), 2.68 
– 2.48 (m, 2H), 2.35 (s, 3H), 1.54 – 1.39 (m, 6H), 1.39 – 1.25 (m, 6H), 0.98 – 0.81 (m, 15H) ppm. 
13C NMR (101 MHz, CDCl3) δ 151.2, 143.0, 140.7, 137.7, 130.1, 129.3, 128.4, 127.5, 127.4, 127.2, 
57.2, 49.7, 29.2, 27.5, 21.6, 13.8, 9.8 ppm. 119Sn NMR (149 MHz, CDCl3) δ -43.6 ppm. IR (film, 
CHCl3) 3273, 2955, 2924, 2871, 2852, 1599, 1495, 1455, 1376, 1325, 1243, 1157, 1094, 1052, 
959, 921, 863, 812, 757, 698, 665 cm-1. HRMS (ESI): m/z calculated for C29H44NO2SSn [M-H+]: 
590.21086, found 590.21190. 
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8.5.2. Representative procedure 13: Oxidation of Sulfinimides to the Corresponding 
Sulfones 
 
SI-83 (1.46 g, 5.0 mmol, 1.0 equiv.) was dissolved in dry CH2Cl2 (25 mL) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. mCPBA (1.62 g, 
80% purity, 7.5 mmol, 1.5 equiv.) was added in one portion, the cooling bath removed after 
5 minutes and stirring was continued with the conversion monitored by TLC (hexanes/ethyl 
acetate, 2:1). After 1 h saturated sodium bicarbonate solution was added and stirring continued 
for 30 minutes before the mixture was extracted twice with CH2Cl2. The combined extracts were 
washed with saturated sodium bicarbonate solution and water, dried over magnesium sulfate 
and concentrated under reduced pressure. The crude material was used as such for the ensuing 
hydrostannation. 
 
The following compounds were prepared following representative procedure 9. 
(S,Z)-2-Methyl-N-(1-phenyl-2-(tributylstannyl)hept-2-en-1-yl)propane-2-sulfonamide  
- (SI-71) 
56% yield over 2 steps (1.67 g, 2.79 mmol). [𝒂]𝑫
𝟐𝟎: 20.6° (c=1.38 in 
CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.28 (m, 4H), 7.28 – 
7.17 (m, 2H), 6.43 (td, J = 7.2, 1.4 Hz, 1H), 5.32 – 5.12 (m, 1H), 4.02 (d, J = 
9.5 Hz, 1H), 2.17 (q, J = 7.1 Hz, 2H), 1.52 – 1.41 (m, 2H), 1.39 (s, 8H), 1.37 – 1.11 (m, 13H), 1.00 – 
0.90 (m, 4H), 0.82 (t, J = 7.1 Hz, 9H), 0.73 – 0.62 (m, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 
143.0, 142.1, 141.3, 128.8, 127.8, 127.7, 65.6, 60.1, 34.5, 32.5, 29.1, 27.5, 24.4, 22.8, 14.3, 13.8, 
10.8 ppm. 119Sn NMR (149 MHz, CDCl3) δ -52.5 ppm. IR (film, CHCl3) 3279, 2924, 2955, 2854, 
2871, 1454, 1377, 1302, 1182, 1127, 1067, 1003, 939, 874, 757, 698, 654, 560 594, 513 cm-1. 
HRMS (ESI): m/z calculated for C29H53NO2SSnNa [M+Na+]: 622.27105, found 622.27143.  
 
 
 
 
Chapter 8 – Experimental Procedures 
218 
(S,Z)-2-Methyl-N-(2-methyl-5-(tributylstannyl)dec-5-en-4-yl)propane-2-sulfonamide  
- (SI-72) 
62% yield over 2 steps (1.78 g, 3.08 mmol). [𝒂]𝑫
𝟐𝟎: 8.6° (c=1.23 in 
CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.34 – 5.86 (m, 1H), 4.17 – 
3.89 (m, 1H), 3.63 (d, J = 8.9 Hz, 1H), 2.12 – 1.87 (m, 2H), 1.81 – 1.59 (m, 
2H), 1.55 – 1.39 (m, 6H), 1.35 (s, 9H), 1.35 – 1.27 (m, 14H), 0.98 – 0.92 (m, 9H), 0.89 (t, J = 7.2 Hz, 
12H) ppm. 13C NMR (101 MHz, CDCl3) δ 145.3, 141.7, 62.1, 59.5, 48.5, 34.5, 32.3, 29.4, 27.6, 
24.8, 24.5, 22.7, 22.6, 14.2, 13.8, 11.1 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.1 ppm. IR (film, 
CHCl3) 3273, 2925, 2955, 2871, 1457, 1420, 1377, 1301, 1125, 1061, 692, 663, 594, 539, 512 
cm-1. HRMS (ESI): m/z calculated for C27H57NO2SSnNa [M+Na+]: 602.30235, found 602.30270.  
 
(S,Z)-N-(2-Methyl-5-(tributylstannyl)dec-5-en-4-yl)-4-nitrobenzene-sulfonamide - (SI-73) 
67% yield (1.39 g, 2.16 mmol).  [𝒂]𝑫
𝟐𝟎: 9.6° (c=1.35 in CHCl3). 1H NMR 
(400 MHz, Chloroform-d) δ 8.30 (dq, J = 9.0, 2.1 Hz, 2H), 8.05 – 7.88 (m, 
2H), 6.15 – 5.64 (m, 1H), 4.45 (d, J = 7.6 Hz, 1H), 4.18 – 3.82 (m, 1H), 1.90 – 
1.71 (m, 2H), 1.62 (dq, J = 13.4, 6.7 Hz, 1H), 1.49 – 1.33 (m, 7H), 1.33 – 1.19 
(m, 12H), 1.19 – 1.09 (m, 2H), 0.91 – 0.87 (m, 9H), 0.86 (s, 6H), 0.83 – 0.77 (m, 6H) ppm.  
13C NMR (101 MHz, CDCl3) δ 149.9, 147.4, 143.7, 142.3, 128.7, 124.2, 62.1, 46.7, 34.3, 32.3, 29.3, 
27.5, 24.7, 22.7, 22.6, 22.3, 14.1, 13.7, 11.1 ppm. 119Sn NMR (149 MHz, CDCl3) δ -55.3 ppm.  
IR (film, CHCl3) 3285, 2956, 2925, 2871, 1608, 1531, 1464, 1417, 1347, 1310, 1164, 854, 811, 
735, 747, 758, 685, 667, 612, 580, 535, 462 cm-1. HRMS (ESI): m/z calculated for 
C29H52N2O4SSnNa [M+Na+]: 667.25613, found 667.25650. 
 
Diphenyl (S,Z)-(2-methyl-5-(tributylstannyl)dec-5-en-4-yl)phosphor-amidate - (SI-74) 
65% yield (1.62 g, 2.35 mmol). [𝒂]𝑫
𝟐𝟎: 14.2° (c=1.34 in CHCl3). 1H NMR 
(400 MHz, Chloroform-d) δ 7.37 – 7.25 (m, 5H), 7.22 (tt, J = 8.7, 1.1 Hz, 
3H), 7.18 – 7.08 (m, 2H), 6.13 (td, J = 7.2, 0.9 Hz, 1H), 4.07 – 3.81 (m, 1H), 
2.92 (dd, J = 12.5, 9.2 Hz, 1H), 1.98 (dtd, J = 12.9, 7.1, 5.8, 3.8 Hz, 2H), 1.60 
(dq, J = 13.7, 6.9 Hz, 1H), 1.53 – 1.39 (m, 6H), 1.38 – 1.21 (m, 12H), 0.95 – 0.84 (m, 24H) ppm.  
13C NMR (101 MHz, CDCl3) δ 151.2, 151.2, 151.2, 151.1, 145.9, 145.8, 141.3, 129.7, 129.6, 124.7, 
120.5, 120.4, 120.3, 120.2, 60.2, 47.9, 47.8, 34.3, 32.3, 29.3, 27.6, 24.7, 22.7, 22.7, 22.4, 14.2, 13.7, 
11.2 ppm. 119Sn NMR (149 MHz, CDCl3) δ -56.3 ppm. IR (film, CHCl3) 3200, 2924, 2955, 2870, 
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1593, 1491, 1457, 1422, 1376, 1255, 1195, 1220, 1162, 1071, 1025, 929, 899, 753, 687 cm-1. 
HRMS (ESI): m/z calculated for C35H58NO3PSnNa [M+Na+]: 714.30678, found 714.30658. 
 
Benzyl (Z)-(2-methyl-5-(tributylstannyl)dec-5-en-4-yl)carbamate - (SI-75) 
68% yield (1.86 g, 3.14 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.43 
– 7.27 (m, 5H), 6.15 (t, J = 7.2 Hz, 1H), 5.15 – 4.99 (m, 2H), 4.56 (d, J = 8.5 
Hz, 1H), 4.21 (q, J = 7.8 Hz, 1H), 1.99 (tt, J = 13.6, 7.1 Hz, 2H), 1.68 – 1.54 (m, 
1H), 1.54 – 1.38 (m, 6H), 1.38 – 1.19 (m, 10H), 1.01 – 0.77 (m, 26H) ppm. 
13C NMR (101 MHz, CDCl3) δ 155.4, 144.4, 141.4, 136.9, 128.6, 128.3, 128.2, 66.5, 58.2, 45.6, 
34.4, 32.4, 29.3, 27.6, 24.9, 22.7, 14.2, 13.8, 11.0 ppm. 119Sn NMR (149 MHz, CDCl3) δ -53.4 ppm. 
IR (film, CHCl3) 2954, 2924, 2870, 1707, 1497, 1455, 1403, 1337, 1213, 1027, 864, 734, 695 cm-
1. HRMS (ESI): m/z calculated for C31H55NO2SnNa [M+Na+]: 616.31463, found 616.31451.  
 
Benzyl (Z)-(2-methyl-4-(tributylstannyl)non-4-en-3-yl)carbamate - (SI-76) 
81% yield (2.85 g, 4.93 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.42 
– 7.27 (m, 5H), 6.26 – 5.87 (m, 1H), 5.18 – 4.98 (m, 2H), 4.66 (dd, J = 19.2, 
8.8 Hz, 1H), 4.05 – 3.74 (m, 1H), 2.12 – 1.92 (m, 1H), 1.62 – 1.38 (m, 6H), 
1.31 (h, J = 7.2 Hz, 10H), 0.99 – 0.79 (m, 26H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.8, 143.7, 
141.3, 136.9, 128.6, 128.2, 128.1, 66.6, 65.6, 34.5, 32.5, 29.3, 27.6, 22.7, 20.7, 17.9, 14.2, 13.8, 
10.9 ppm. 119Sn NMR (149 MHz, CDCl3) δ -54.1 ppm. IR (film, CHCl3) 2955, 2924, 2871, 1705, 
1497, 1456, 1402, 1338, 1213, 1072, 1024, 873, 752, 695 cm-1. HRMS (ESI): m/z calculated for 
C30H53NO2SnNa [M+Na+]: 602.29898, found 602.29917.  
 
(E)-N-Benzylidene-4-methylbenzenesulfonamide[35] - (SI-77) 
 
Tosylamide (5.14 g, 30 mmol, 1.0 equiv.) and benzaldehyde (3.05 mL, 30 mmol, 1.0 equiv.) were 
suspended in (EtO)4Si (7.03 mL, 31.5 mmol, 1.05 equiv.) and the suspension was stirred in a 
single-necked flask equipped with a Dean-Stark head under an argon atmosphere. The mixture 
was heated to 160 °C and stirred for 12 h before it was cooled to room temperature. The crude 
yellow solid was dissolved in ethyl acetate and concentrated until a small amount of precipitate 
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already formed. Then, about 400 mL of hexanes were added, the colorless solid was filtered off, 
washed once with hexanes and dried under vacuum. The material was used as such. 
 
4-Methyl-N-(1-phenylhept-2-yn-1-yl)benzenesulfonamide - (SI-78) 
 
1-Hexyne (1.49 mL, 13 mmol, 1.3 equiv.) was dissolved in dry THF (30 mL) and the solution 
stirred in an oven-dried Schlenk flask under an argon atmosphere on a dry-ice bath. n-
Butyllithium (7.5 mL, 1.6 M in hexanes, 12 mmol, 1.2 equiv.) was slowly added and stirring 
continued for 30 minutes before a solution of SI-77 (2.59 g, 10 mmol, 1.0 equiv.) in THF (5 mL) 
was added. Stirring was continued for 18 h while the mixture was allowed to warm to room 
temperature. The reaction was then quenched with the addition of saturated ammonium 
chloride solution. The mixture was extracted two times with MTBE, the combined extracts were 
washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. 
Flash chromatography (SiO2, hexanes/ethyl acetate, 9:1 to 4:1) yielded the product as a yellow 
solid (2.65 g, 7.76 mmol, 78% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.87 – 7.68 (m, 2H), 
7.52 – 7.42 (m, 2H), 7.39 – 7.17 (m, 5H), 5.30 (dt, J = 8.9, 2.2 Hz, 1H), 4.81 (d, J = 8.9 Hz, 1H), 2.43 
(s, 3H), 1.98 (tt, J = 6.9, 2.2 Hz, 2H), 1.28 (dtdd, J = 7.2, 5.6, 3.4, 1.4 Hz, 4H), 0.98 – 0.75 (m, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 143.4, 138.3, 137.7, 129.5, 128.7, 128.3, 127.6, 127.4, 87.6, 
76.7, 49.6, 30.5, 22.0, 21.7, 18.4, 13.7 ppm. IR (film, CHCl3) 3282, 2930, 1597, 1493, 1451, 1428, 
1326, 1155, 1091, 1037, 937, 905, 815, 751, 698, 666, 635, 571 cm-1. HRMS (ESI): m/z 
calculated for C20H23NO2SNa [M+Na+]: 364.13417, found 364.13414.  
 
4-(3-Hydroxy-3-methylbut-1-yn-1-yl)benzaldehyde - (SI-79) 
Following the same procedure as for 4-(3-Hydroxy-3-methylbut-1-yn-1-
yl)benzonitrile SI-34. The product as obtained as an orange oil (2.8 g, 
14.9 mmol, 99% yield). 1H NMR (400 MHz, Chloroform-d) δ 9.99 (s, 1H), 
7.86 – 7.78 (m, 2H), 7.62 – 7.45 (m, 2H), 2.18 (s, 1H), 1.63 (s, 6H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 191.6, 135.6, 132.3, 129.6, 129.2, 97.9, 81.5, 65.8, 31.5 ppm. IR (film, CHCl3) 3392, 
2981, 1698, 1601, 1563, 1363, 1303, 1272, 1206, 1163, 962, 905, 828, 789 cm-1. HRMS (ESI): 
m/z calculated for C12H13O2 [M+H+]: 189.09101, found 189.09111.  
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4-Methyl-N-(1-phenylbut-3-yn-1-yl)benzenesulfonamide[36] - (SI-80) 
 
SI-77 (2.59 g, 10 mmol, 1.0 equiv.), propargyl bromide (1.67 mL, 80% in PhMe, 15 mmol, 
1.5 equiv.), zinc powder (3.27 g, 50 mmol, 5.0 equiv.) and 1,2-diiodoethane (2.82 g, 10 mmol, 
1.0 equiv.) were combined in a Schlenk flask under argon atmosphere. The flask was equipped 
with an argon balloon and sonicated for 2.5 h at room temperature. The mixture was then 
poured onto aqueous HCl (2 M) and extracted two times with CH2Cl2. The combined extracts 
were washed with brine, dried over magnesium sulfate and concentrated under reduced 
pressure. The residue was dissolved in a minimum amount of hot EtOH and then placed for 2 h 
in the freezer. The liquids were decanted off, the solid washed with hexanes and dried under 
high vacuum to give a colorless solid (2.06 g, 6.88 mmol, 69% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.63 (d, J = 8.0 Hz, 2H), 7.17 (ddd, J = 11.6, 6.3, 3.0 Hz, 7H), 5.63 (d, J = 7.6 Hz, 
1H), 4.51 (q, J = 6.6 Hz, 1H), 2.62 (dd, J = 6.2, 2.7 Hz, 2H), 2.36 (s, 3H), 1.95 (t, J = 2.7 Hz, 1H) ppm. 
13C NMR (101 MHz, CDCl3) δ 143.3, 139.3, 137.3, 129.5, 128.4, 127.8, 127.2, 126.6, 79.3, 72.1, 
56.0, 27.4, 21.5 ppm. IR (film, CHCl3) 3258, 1462, 1319, 1156, 1087, 1066, 945, 838, 811, 763, 
703, 651, 585, 555 cm-1. HRMS (ESI): m/z calculated for C17H17NO2SNa [M+Na+]: 322.08722, 
found 322.08729. 
 
8.5.3. Representative procedure 14: Pyrrolidine Catalyzed Condensation of Aldehydes 
and Amines[37] 
(S,E)-N-Benzylidene-2-methylpropane-2-sulfinamide - (SI-81) 
 
(S)-tert-Butylsulfinamide (2.42 g, 20 mmol, 1.0 equiv.) and benzaldehyde (2.03 mL, 20 mmol, 
1.0 equiv.) were dissolved in CH2Cl2 (60 mL). Pyrrolidine (334 µL, 4.0 mmol, 0.2 equiv.) and 4 Å 
mol sieves were added and stirring was continued at room temperature for 4 days. The mixture 
was then filtered through a plug of silica with additional CH2Cl2. The volatile materials were 
removed under reduced pressure and the oil dried under high vacuum (3.61 g, 17.2 mmol, 
85% yield). [𝒂]𝑫
𝟐𝟎: 148.9° (c=1.30 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 8.59 (s, 1H), 
7.90 – 7.78 (m, 2H), 7.58 – 7.42 (m, 3H), 1.27 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 162.9, 
134.2, 132.6, 129.5, 129.1, 57.9, 22.7 ppm. IR (film, CHCl3) 2960, 2925, 2867, 1572, 1605, 1449, 
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1474, 1362, 1391, 1171, 1082, 727, 756, 689 cm-1. HRMS (ESI): m/z calculated for C11H15NOSNa 
[M+Na+]: 232.076655, found 232.076520. 
 
(S,E)-2-Methyl-N-(3-methylbutylidene)propane-2-sulfinamide - (SI-82) 
96% yield (from 2.0 equiv. of aldehyde, 3.62 g, 19.1 mmol). [𝒂]𝑫
𝟐𝟎: 485.5° 
(c=1.70 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 8.05 (t, J = 5.2 Hz, 1H), 
2.40 (ddd, J = 6.6, 5.2, 1.5 Hz, 2H), 2.06 (dt, J = 13.5, 6.7 Hz, 1H), 1.19 (s, 9H), 
0.99 (d, J = 1.4 Hz, 3H), 0.97 (d, J = 1.3 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 169.6, 56.7, 
45.1, 26.3, 22.8, 22.5 ppm. IR (film, CHCl3) 2958, 2871, 1621, 1461, 1363, 1168, 1083, 753, 676, 
585, 456, 482 cm-1. HRMS (ESI): m/z calculated for C9H19NOSNa [M+Na+]: 212.10796, found 
212.10786.  
 
8.5.4. Representative procedure 15: Diastereoselective Addition of Magnesium 
Acetylides to Sulfinimides[38] 
(S)-2-Methyl-N-((S)-1-phenylhept-2-yn-1-yl)propane-2-sulfinamide - (SI-83) 
 
1-Hexyne (4.36 mmol, 38 mmol, 2.2 equiv.) was dissolved in dry THF (5 mL) and stirred in an 
oven-dried Schlenk flask under an argon atmosphere on an ice bath. iso-Propylmagnesium 
chloride (17.3 mL, 2 M solution in THF, 34.5 mmol, 2.0 equiv.) was added, the cooling bath 
removed and stirring continued for 60 minutes. SI-81 (3.6 g, 17.2 mmol, 1.0 equiv.) was 
dissolved in dry CH2Cl2 (80 mL) and stirred in an oven-dried Schlenk flask under an argon 
atmosphere on a dry-ice bath. The above prepared Grignard reagent was added dropwise by 
means of a cannula over about 15 minutes and stirring was continued at the same temperature 
for 2 h and 12 h at room temperature. The reaction was then quenched with saturated 
ammonium chloride solution. The mixture was extracted two times with MTBE, the combined 
extracts were washed with brine, dried over magnesium sulfate and concentrated under 
reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 4:1) yielded the product 
as a yellow thick oil (3.4 g, 11.7 mmol, > 20:1 d.r., 68% yield). [𝒂]𝑫
𝟐𝟎: 32.3° (c=1.24 in CHCl3).  
1H NMR (400 MHz, Chloroform-d) δ 7.53 – 7.45 (m, 2H), 7.39 – 7.27 (m, 3H), 5.20 (dt, J = 5.7, 
2.2 Hz, 1H), 3.59 (d, J = 5.8 Hz, 1H), 2.25 (td, J = 7.1, 2.1 Hz, 2H), 1.60 – 1.46 (m, 2H), 1.46 – 1.32 
(m, 2H), 1.20 (s, 9H), 0.90 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 139.9, 128.7, 
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128.2, 127.8, 87.6, 78.9, 56.3, 51.2, 30.7, 22.7, 22.1, 18.7, 13.8 ppm. IR (film, CHCl3) 3186, 2931 
2956, 2870, 1493, 1455, 1381, 1327, 1251, 1188, 1139, 1061, 1005, 923, 792, 751, 697 cm-1. 
HRMS (ESI): m/z calculated for C17H25NOSNa [M+Na+]: 314.15491, found 314.15462. 
 
(S)-2-Methyl-N-((S)-2-methyldec-5-yn-4-yl)propane-2-sulfinamide - (SI-84) 
74% yield (3.85 g, 14.2 mmol, > 20:1 d.r.).  [𝒂]𝑫
𝟐𝟎: 49.5° (c=1.35 in 
CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 4.02 (dddd, J = 8.4, 7.2, 
4.2, 2.1 Hz, 1H), 3.18 (d, J = 6.5 Hz, 1H), 2.18 (td, J = 7.1, 2.1 Hz, 2H), 1.83 
(dp, J = 13.5, 6.7 Hz, 1H), 1.57 – 1.51 (m, 2H), 1.51 – 1.42 (m, 2H), 1.42 – 1.31 (m, 2H), 1.20 (s, 
9H), 0.93 – 0.86 (m, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 85.4, 80.1, 56.1, 46.6, 30.9, 25.1, 
22.8, 22.7, 22.2, 22.1, 18.6, 13.7 ppm. IR (film, CHCl3) 3198, 2956, 2931, 2869, 1467, 1364 1385, 
1159, 1057, 877, 795, 752, 663, 605, 478 cm-1. HRMS (ESI): m/z calculated for C15H29NOSNa 
[M+Na+]: 294.18621, found 294.18593. 
 
8.5.5. Representative procedure 16: Acid Mediated Deprotection of Sulfonamides[38] 
(S)-2-Methyldec-5-yn-4-aminium chloride - (SI-85) 
 
SI-81 (1.61 g, 5.5 mmol, 1.0 equiv.) was dissolved in dry MeOH (20 mL) and the solution stirred 
in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. HCl (4.5 mL, 4 M in 
1,4-dioxane, 18 mmol, 2.0 equiv.) was added in one portion and stirring was continued with the 
conversion monitored by TLC (hexanes/ethyl acetate, 2:1). After disappearance of starting 
material, the volatile materials were removed under reduced pressure and the crude ammonium 
salt used as such. 
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(S)-N-(2-Methyldec-5-yn-4-yl)-4-nitrobenzenesulfonamide - (SI-86) 
 
SI-85 (917 mg, 4.5 mmol, 1.0 equiv.) was dissolved in dry DMF (20 mL) and stirred at room 
temperature in an oven-dried Schlenk flask under an argon atmosphere. Et3N (1.88 mL, 
13.5 mmol, 3.0 equiv.) and 4-nitrobenzenesulfonyl chloride (1.2 g, 5.4 mmol, 1.2 equiv.) were 
added and stirring was continued for 12 h at the same temperature. The mixture was then 
poured onto saturated ammonium chloride solution. The mixture was extracted two times with 
CH2Cl2, the combined extracts were washed with water, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate) 
yielded the product as an orange solid (1.13 g, 3.2 mmol, 71% yield). [𝒂]𝑫
𝟐𝟎: 94.2° (c=1.74 in 
CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 8.35 (dq, J = 9.0, 2.1 Hz, 2H), 8.22 – 7.96 (m, 2H), 
4.65 (d, J = 9.4 Hz, 1H), 4.35 – 3.97 (m, 1H), 1.89 – 1.74 (m, 3H), 1.62 – 1.44 (m, 2H), 1.23 – 1.08 
(m, 4H), 0.92 (dd, J = 9.0, 6.6 Hz, 6H), 0.85 – 0.75 (m, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
150.2, 146.7, 128.9, 124.1, 85.8, 77.9, 46.3, 45.1, 30.6, 24.8, 22.3, 22.2, 22.0, 18.1, 13.6 ppm. IR 
(film, CHCl3) 3271, 2933 2958, 2871, 1524, 1346, 1311, 1155, 1090, 1053, 855, 739, 619, 550 
cm-1. HRMS (ESI): m/z calculated for C17H24N2O4SNa [M+Na+]: 375.13490, found 375.13471. 
 
(S)-N-(2-Methyldec-5-yn-4-yl)-4-nitrobenzenesulfonamide - (SI-87) 
 
SI-85 (917 mg, 4.5 mmol, 1.0 equiv.) was dissolved in dry DMF (20 mL) and the solution stirred 
at room temperature in an oven-dried Schlenk flask under an argon atmosphere. Et3N (1.88 mL, 
13.5 mmol, 3.0 equiv.) and diphenylchlorophosphate (1.2 mL, 5.4 mmol, 1.2 equiv.) were added 
and stirring was continued for 12 h at the same temperature. The mixture was then poured onto 
saturated ammonium chloride solution. The mixture was extracted two times with CH2Cl2, the 
combined extracts were washed with water, dried over magnesium sulfate and concentrated 
under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 9:1) yielded the 
product as an orange solid (1.45 g, 3.6 mmol, 81% yield). [𝒂]𝑫
𝟐𝟎: 33.1° (c=1.21 in CHCl3). 
1H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.23 (m, 8H), 7.16 (dddd, J = 8.0, 5.9, 4.2, 1.1 Hz, 
2H), 4.14 (dtdt, J = 10.5, 8.7, 6.9, 2.1 Hz, 1H), 3.16 (dd, J = 12.6, 10.1 Hz, 1H), 2.10 (td, J = 6.9, 2.1 
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Hz, 2H), 1.77 (ddt, J = 13.1, 8.0, 6.6 Hz, 1H), 1.56 – 1.28 (m, 6H), 0.89 (d, J = 1.7 Hz, 4H), 0.88 – 
0.84 (m, 5H) ppm. 13C NMR (101 MHz, CDCl3) δ 151.0, 151.0, 150.9, 129.7, 129.7, 125.0, 120.6, 
120.6, 120.4, 120.4, 84.1, 80.4, 80.4, 47.7, 47.7, 43.2, 30.8, 25.0, 22.8, 22.0, 18.4, 13.7 ppm. IR 
(film, CHCl3) 3204, 2932 2956, 2870, 1591, 1489, 1255, 1219, 1191, 1162 , 928, 752, 688 cm-1. 
HRMS (ESI): m/z calculated for C23H30NO3PNa [M+Na+]: 422.18555, found 422.18526. 
 
8.5.6. Representative procedure 17: Synthesis of -Amidoalkyl Sulfones[39] 
 
Benzyl carbamate (2.27 g, 15 mmol, 1.0 equiv.) and benzenesulfinic acid sodium salt (2.46 g, 
15 mmol, 1.0 equiv.) were dissolved in THF (15 mL) and H2O (6 mL) and the solution was stirred 
at room temperature in a single-necked flask. iso-Valeraldehyde (1.77 mL, 16.5 mmol, 1.1 equiv.) 
and HCO2H (3.96 mL, 105 mmol, 7.0 equiv.) were added and stirring was continued for 18 h. A 
colorless solid formed over the course of the reaction. The flask was placed for 30 minutes in the 
freezer before the precipitate was filtered off, washed with ice cold water and dried under high 
vacuum. NMR showed slightly impured material which was used as such. 
 
Benzyl (3-methyl-1-(phenylsulfonyl)butyl)carbamate - (SI-88) 
77% yield (4.18 g, 11.6 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.93 – 7.81 
(m, 2H), 7.58 (ddt, J = 8.8, 7.1, 1.3 Hz, 1H), 7.48 – 7.38 (m, 2H), 7.34 (ddt, J = 5.5, 
3.8, 2.2 Hz, 3H), 7.24 – 7.13 (m, 2H), 5.32 (d, J = 10.8 Hz, 1H), 4.95 (td, J = 11.1, 3.1 
Hz, 1H), 4.88 (d, J = 12.2 Hz, 1H), 4.81 (d, J = 12.2 Hz, 1H), 2.07 – 1.95 (m, 1H), 1.83 
– 1.69 (m, 2H), 0.99 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 154.8, 136.5, 135.7, 134.1, 129.3, 129.1, 128.6, 128.5, 128.3, 70.2, 67.4, 34.7, 24.8, 
23.4, 21.2 ppm. IR (film, CHCl3) 3279, 3064, 2958, 1718, 1692, 1537, 1448, 1388, 1315,1267 
,1240 1218, 1179, 1140, 1039, 983, 914, 856, 790, 773, 703, 677, 607, 587 cm-1. HRMS (ESI): 
m/z calculated for C19H23NO4SNa [M+Na+]: 384.12400, found 384.12365. 
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Benzyl (2-methyl-1-(phenylsulfonyl)propyl)carbamate - (SI-89) 
67% yield (2.34 g, 6.74 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.91 – 7.72 
(m, 2H), 7.58 (ddt, J = 8.7, 7.1, 1.3 Hz, 1H), 7.45 – 7.39 (m, 2H), 7.38 – 7.33 (m, 3H), 
7.23 – 7.17 (m, 2H), 5.44 (d, J = 11.2 Hz, 1H), 4.89 (d, J = 12.2 Hz, 1H), 4.83 (d, J = 
12.2 Hz, 1H), 4.77 (dd, J = 11.2, 3.5 Hz, 1H), 2.78 (pd, J = 6.9, 3.5 Hz, 1H), 1.13 (d, J 
= 6.8 Hz, 3H), 1.08 (d, J = 6.9 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.3, 137.7, 135.7, 
134.0, 129.1, 129.0, 128.7, 128.5, 128.3, 75.0, 67.6, 26.9, 20.8, 17.0 ppm. IR (film, CHCl3) 3330, 
2965, 1721, 1525, 1496, 1447, 1390, 1308, 1284, 1228,1138 1098, 1079, 1029, 614, 596, 580, 
559 cm-1. HRMS (ESI): m/z calculated for C18H21NO4SNa [M+Na+]: 370.10805, found 370.10835. 
 
8.5.7. Representative procedure 18: Alkylation of -Amidoalkyl Sulfones[39] 
1-Hexyne (1.15 mL, 10 mmol, 2.0 equiv.) was dissolved in dry THF (40 mL) and the solution 
stirred in an oven-dried Schlenk flask under an argon atmosphere on an ice bath. n-Butyllithium 
(6.56 mL, 1.6 M in hexanes, 10.5 mmol, 2.1 equiv.) was added and stirring continued for 
30 minutes before the mixture was cooled with a dry-ice bath. SI-88 (1.81 g, 5.0 mmol, 
1.0 equiv.) dissolved in dry THF (10 mL) was added slowly and stirring was continued at the 
same temperature for 1 h before the reaction was quenched with of saturated ammonium 
chloride solution. The mixture was allowed to warm to room temperature and extracted two 
times with MTBE. The combined extracts were washed with brine, dried over magnesium sulfate 
and concentrated under reduced pressure. Flash chromatography (hexanes/ethyl acetate, 19:1) 
yielded the product as a colorless thick oil. 
 
Benzyl (2-methyldec-5-yn-4-yl)carbamate - (SI-90) 
97% yield (1.46 g, 4.84 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.40 
– 7.27 (m, 5H), 5.24 – 5.00 (m, 2H), 4.82 (d, J = 8.8 Hz, 1H), 4.48 (q, J = 8.2 
Hz, 1H), 2.22 – 2.09 (m, 2H), 1.77 (dq, J = 13.4, 6.7 Hz, 1H), 1.57 – 1.31 (m, 
6H), 1.00 – 0.78 (m, 9H) ppm. 13C NMR (101 MHz, CDCl3) δ 155.5, 136.5, 
128.6, 128.3 (2C), 83.7, 79.5, 66.9, 45.9, 42.3, 30.9, 25.2, 22.9, 22.0, 18.4, 13.7 ppm. IR (film, 
CHCl3) 3327, 2956, 2932, 2871, 1697, 1500, 1455, 1368, 1325, 1278, 1241, 1170, 1112, 1038, 
912, 751, 696 cm-1. HRMS (ESI): m/z calculated for C19H26NO2 [M-H+]: 300.19718, found 
300.19690. 
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Benzyl (2-methylnon-4-yn-3-yl)carbamate - (SI-91) 
91% yield (1.76 g, 6.12 mmol). 1H NMR (400 MHz, Chloroform-d) δ 7.44 
– 7.28 (m, 5H), 5.17 – 5.04 (m, 2H), 4.94 (d, J = 9.0 Hz, 1H), 4.35 (dq, J = 7.5, 
2.7 Hz, 1H), 2.17 (td, J = 6.9, 2.2 Hz, 2H), 1.96 – 1.81 (m, 1H), 1.53 – 1.30 (m, 
4H), 0.96 (dd, J = 6.8, 4.4 Hz, 6H), 0.90 (t, J = 7.2 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 
155.6, 136.5, 128.6, 128.3, 128.3, 84.6, 77.6, 66.9, 49.6, 33.3, 30.9, 22.0, 19.0, 18.4, 17.6, 13.7 
ppm. IR (film, CHCl3) 3325, 2959, 2931, 2872, 1696, 1499, 1455, 1386, 1332, 1302, 1229, 1126, 
1026, 736, 696 cm-1. HRMS (ESI): m/z calculated for C18H25NO2Na [M+Na+]: 310.17775, found 
310.17765. 
 
8.6. Diverted Total Synthesis of 5,6-Dihydrocineromycin B 
(2R,3S)-3-Methyloct-6-yn-2-yl (4R,7S,E)-7-((tert-butyldimethylsilyl)oxy)-4-methyl-4-
((triethylsilyl)oxy)dec-2-en-8-ynoate – (SI-92) 
 
(2R,3S)-3-Methyloct-6-yn-2-ol (648) (635 mg, 4.53 mmol, 1.05 equiv.) and (4R,7S,E)-7-((tert-
butyldimethylsilyl)oxy)-4-methyl-4-((triethylsilyl)oxy)dec-2-en-8-ynoic acid (650) (1.90 g, 
4.31 mmol, 1.0 equiv.) were dissolved in dry CH2Cl2 (30 mL) and the solution was stirred under 
ice cooling in an oven-dried Schlenk flask under an argon atmosphere. N,N'-
Dicyclohexylcarbodiimide (1.16 g, 5.60 mmol, 1.3 equiv.) and DMAP (53 mg, 0.43 mmol, 
0.1 equiv.) were added successfully and the conversion was monitored by TLC. After about 
30 minutes complete conversion of the starting acid was observed so the mixture was filtered 
over Celite® with the aid of additional CH2Cl2 (200 mL) and the volatile materials were removed 
under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 40:1 to 30:1) 
yielded the product as a colorless oil (2.04 g, 4.31 mmol, 84 % yield). TLC (hexanes/ethyl 
acetate, 4:1), Rf = 0.74. [𝒂]𝑫
𝟐𝟎: 13.4° (c=1.0 in MeOH). 1H NMR (400 MHz, Chloroform-d) δ 6.83 
(d, J = 15.5 Hz, 1H), 5.91 (d, J = 15.5 Hz, 1H), 4.88 (p, J = 6.3 Hz, 1H), 4.30 (ddt, J = 5.6, 3.7, 2.1 Hz, 
1H), 2.29 – 2.15 (m, 1H), 2.10 (dtq, J = 13.6, 8.0, 2.5 Hz, 1H), 1.81 (d, J = 2.1 Hz, 3H), 1.77 (t, J = 2.5 
Hz, 3H), 1.75 – 1.61 (m, 4H), 1.59 – 1.49 (m, 1H), 1.36 (s, 3H), 1.29 (dtd, J = 9.3, 8.1, 4.6 Hz, 1H), 
1.19 (d, J = 6.4 Hz, 3H), 0.95 (t, J = 7.9 Hz, 9H), 0.90 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.65 – 0.56 (m, 
6H), 0.09 (s, 3H), 0.08 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 166.3, 154.3, 119.1, 80.5, 79.9, 
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78.6, 75.4, 74.7, 73.8, 62.9, 38.3, 36.4, 34.8, 33.2, 31.5, 27.9, 25.7, 18.1, 16.4, 16.0, 14.2, 6.9, 6.5, 
3.3, 3.3, -4.7, -5.2 ppm. IR (film, CHCl3) 2955, 2932, 2120, 1717, 1655, 1459, 1362, 1254, 1159, 
1082, 1004, 836, 776, 724 cm-1. HRMS (ESI): calculated for C32H58O4Si2Na [M + Na+]: 585.37601, 
found 585.37659. 
 
(5R,8S,13S,14R,E)-8-((tert-Butyldimethylsilyl)oxy)-5,13,14-trimethyl-5-((triethyl-silyl)-
oxy)oxacyclotetradec-3-en-9-yn-2-one – (655b) 
 
6 g of dry 5Å mole sieves were placed in an oven-dried 2-necked flask and flame-dried under 
high-vacuum for 10 minutes. After being cooled to room temperature dry toluene (750 mL) and 
SI-92 (800 mg, 1.42 mmol, 1.0 equiv.) were added and the mixture was stirred for 1 h at room 
temperature under an argon atmosphere. Then, potassium benzylidynetetrakis-
((triphenylsilyl)oxy)molybdate(VI) (188 mg, 0.14 mmol, 10 mol%) was added and stirring was 
continued at room temperature with the conversion monitored by TLC (hexanes/ethyl acetate, 
2 times 30:1). After 2 h complete conversion of starting material was observed so the mixture 
was filtered through a plug of Celite® with the aid of ethyl acetate (250 mL) and the volatile 
materials were removed under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl 
acetate, 30:1 to 20:1) yielded the product as a colorless oil (672 mg, 1.32 mmol, 92% yield). TLC 
(hexanes/ethyl acetate, 20:1), Rf = 0.61. 1H NMR (400 MHz, Chloroform-d) δ 7.05 (d, J = 15.3 
Hz, 1H), 5.97 (d, J = 15.3 Hz, 1H), 4.68 (dq, J = 9.1, 6.3 Hz, 1H), 4.34 (dq, J = 8.4, 2.1 Hz, 1H), 2.27 
(dddd, J = 17.0, 7.0, 5.2, 1.9 Hz, 1H), 2.15 (dddd, J = 17.0, 8.6, 5.2, 2.0 Hz, 1H), 1.95 – 1.76 (m, 2H), 
1.66 (dtd, J = 9.1, 6.8, 3.8 Hz, 1H), 1.62 – 1.54 (m, 2H), 1.54 – 1.35 (m, 2H), 1.32 (s, 3H), 1.27 (d, J 
= 6.3 Hz, 3H), 0.96 (t, J = 7.9 Hz, 9H), 0.90 (d, J = 6.9 Hz, 3H), 0.87 (s, 9H), 0.65 – 0.57 (m, 6H), 
0.08 (s, 3H), 0.07 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 166.6, 155.1, 119.0, 85.4, 81.5, 75.5, 
74.9, 63.4, 39.3, 37.6, 33.3, 32.9, 27.5, 25.9, 19.2, 18.3, 17.0, 16.9, 7.2, 6.9, -4.3, -4.8 ppm. IR (film, 
CHCl3) 2955, 2932, 2877, 1715, 1459, 1342, 1251, 1162, 1106, 1081, 1048, 1005, 976, 836, 777, 
724 cm-1. HRMS (ESI): calculated for C28H52O4Si2Na [M + Na+]: 531.32927, found 531.32964. 
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(5R,8S,13S,14R,E)-5,8-Dihydroxy-5,13,14-trimethyloxacyclotetradec-3-en-9-yn-2-one  
– (SI-93) 
 
655b (1.31 g, 60% purity, 1.54 mmol, 1.0 equiv.) was dissolved in dry THF (15 mL) and the 
solution stirred at room temperature in a PTFE vial. Pyridine (1.5 mL, 18.5 mmol, 12.0 equiv.) 
followed by HF·pyridine complex (795 µL, 70 % in pyridine, 6.18 mmol, 4.0 equiv.) was added 
and stirring continued with the conversion monitored by TLC (hexanes/ethyl acetate, 2:1). After 
5 h some monodeprotected material was left so another 1.0 equiv. of HF pyridine was added and 
stirring continued for 12 h. The reaction was quenched with the dropwise addition of saturated 
sodium bicarbonate solution, the mixture was extracted twice with ethyl acetate, the combined 
organic layers were washed with brine, dried over magnesium sulfate and concentrated under 
reduced pressure to yield a crude yellowish oil. Purification by flash chromatography (SiO2, 
hexanes/ethyl acetate, 2:1 to 1:1 to 1:2) afforded the product as a colorless solid (365 mg, 
1.30 mmol, 84% yield). TLC (hexanes/ethyl acetate, 2:1), Rf = 0.18. [𝒂]𝑫
𝟐𝟎: 50.2° (c=1.0 in 
MeOH). M. p.: 150-152 °C. 1H NMR (400 MHz, Chloroform-d) δ 7.17 (d, J = 15.6 Hz, 1H), 6.02 
(d, J = 15.6 Hz, 1H), 4.69 (dq, J = 12.5, 6.5 Hz, 1H), 4.50 – 4.37 (m, 1H), 2.39 – 2.25 (m, 1H), 2.25 – 
2.13 (m, 1H), 1.87 (ddd, J = 13.8, 10.8, 6.0 Hz, 3H), 1.80 – 1.57 (m, 4H), 1.48 (p, J = 6.3, 5.6 Hz, 
2H), 1.34 (s, 3H), 1.29 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) 
δ 166.2, 154.2, 119.1, 87.2, 80.6, 75.2, 73.3, 62.7, 39.1, 37.0, 32.9, 31.8, 27.3, 19.1, 17.0, 17.0 ppm. 
IR (film, CHCl3) 3402, 2972, 2934, 1698, 1455, 1379, 1339, 1268, 1102, 1036, 977 cm-1. HRMS 
(ESI): calculated for C16H24O4Na [M + Na+]: 303.15665, found 303.15668. 
 
(1S,5R,6S,11S,14R)-11-Hydroxy-5,6,14-trimethyl-4,15-dioxabicyclo[12.1.0]-penta-dec-9-
yn-3-one – (659) 
 
655b (127 mg, 0.25 mmol, 1.0 equiv.) was dissolved in dry THF (10 mL) and the solution stirred 
at room temperature. TBAF (750 µL, 0.75 mmol, 1 M in THF, 3.0 equiv.) was added and stirring 
continued with the conversion monitored by TLC (hexanes/ethyl acetate, 2:1). After 4 h the TLC 
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showed still a mixture of deprotected starting material and epoxide formation so another 
3 equiv. of TBAF was added. Stirring was continued for 12 h at room temperature. The reaction 
was quenched with the addition of water and the mixture was extracted twice with MTBE. The 
combined organic layer were washed with brine, dried over magnesium sulfate and 
concentrated under reduced pressure. Flash chromatography (SiO2, hexanes/ethyl acetate, 6:1 
to 4:1 to 2:1 to 1:1) yielded the product as a colorless oil which solidifies upon standing (68 mg, 
0.24 mmol, 97% yield). TLC (hexanes/ethyl acetate, 2:1), Rf = 0.33. [𝒂]𝑫
𝟐𝟎: 57.3° (c=1.0 in 
MeOH). Melting point: 102 °C. 1H NMR (400 MHz, Chloroform-d) δ 4.79 – 4.69 (m, 2H), 4.59 
(dd, J = 11.3, 2.0 Hz, 1H), 2.58 (dd, J = 14.1, 2.0 Hz, 1H), 2.54 (s, 1H), 2.34 (dd, J = 14.1, 11.3 Hz, 
1H), 2.23 (ddt, J = 7.8, 5.3, 2.6 Hz, 2H), 2.12 – 1.89 (m, 3H), 1.86 – 1.73 (m, 2H), 1.69 – 1.58 (m, 
1H), 1.53 (dddd, J = 14.0, 4.9, 2.4, 1.2 Hz, 1H), 1.28 (d, J = 6.3 Hz, 3H), 1.17 (s, 3H), 1.05 (d, J = 7.2 
Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 171.2, 90.4, 79.8, 75.3, 75.2, 68.5, 66.2, 37.5, 36.1, 
34.4, 29.7, 25.8, 24.3, 19.1, 16.4, 15.0 ppm. IR (film, CHCl3) 3468, 2933, 1731, 1449, 1380, 1286, 
1247, 1155, 1101, 1061, 1001, 958 cm-1. HRMS (ESI): calculated for C16H24O4Na [M + Na+]: 
303.15674, found 303.15668. 
 
(3E,5R,8S,9Z,13S,14R)-5,8-Dihydroxy-5,13,14-trimethyloxacyclotetradeca-3,9-dien-2-one 
- (658) 
 
Palladium on BaSO4 (0.76 mg, 5% on BaSO4, 0.4 µmol, 0.5 mol%) was suspended in dry pyridine 
(1 mL) and stirred at room temperature. Hydrogen (balloon) was bubbled through the solution 
for 10 minutes until the solid particles turned black. The hydrogen balloon was refilled before 
655a (20 mg, 71 µmol, 1.0 equiv.) was added as a solution in dry THF (1 mL). The conversion 
was monitored by TLC (hexanes/ethyl acetate, 1:1). The starting material and the product share 
the same Rf value though the product is UV active on TLC. After 3 h the reaction was quenched 
by passing the mixture through a plug of Celite® with the aid of ethyl acetate (100 mL). The 
volatile materials were removed under reduced pressure and the residue purified by flash 
chromatography (SiO2, hexanes/ethyl acetate, 1:1) to give the product as a colorless foam 
contaminated with 5% of alkane byproduct (15 mg, 53 µmol, 74% yield). TLC (hexanes/ethyl 
acetate, 2:1), Rf = 0.18. [𝒂]𝑫
𝟐𝟎: 31.1° (c=1.0 in CHCl3). 1H NMR (400 MHz, Chloroform-d) δ 6.89 
(d, J = 15.7 Hz, 1H), 6.03 (dd, J = 15.7, 1.4 Hz, 1H), 5.48 (tdd, J = 10.0, 5.6, 0.9 Hz, 1H), 5.37 (ddt, J 
= 10.8, 9.0, 1.1 Hz, 1H), 4.65 (dq, J = 9.9, 6.3 Hz, 1H), 4.31 (tt, J = 9.3, 1.6 Hz, 1H), 2.20 – 2.08 (m, 
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1H), 2.04 – 1.90 (m, 2H), 1.84 – 1.75 (m, 1H), 1.60 – 1.44 (m, 2H), 1.40 (s, 3H), 1.38 – 1.31 (m, 
1H), 1.29 (d, J = 6.3 Hz, 3H), 1.27 – 1.21 (m, 2H), 1.21 – 1.04 (m, 2H), 0.93 (d, J = 6.9 Hz, 3H) ppm. 
13C NMR (101 MHz, CDCl3) δ 166.0, 153.1, 133.2, 131.3, 120.8, 76.3, 74.0, 69.7, 41.1, 39.2, 35.0, 
31.7, 29.0, 27.9, 19.4, 17.3 ppm. IR (film, CHCl3) 3402, 2925, 1694, 1454, 1378, 1260, 1043, 730 
cm-1. HRMS (ESI): calculated for C16H26O4Na [M + Na+]: 305.17227, found 305.17233. 
 
Following representative procedure 8. 
Methyl (2R,3S,6Z,8S,11R,12E)-8,11-dihydroxy-2,3,11-trimethyl-14-oxooxacyclo-
tetradeca-6,12-diene-7-carboxylate – (660) 
69% yield (10.3 mg, 30 µmol). [𝒂]𝑫
𝟐𝟎: 58.3° (c=0.83 in CHCl3). 1H NMR (300 
MHz, Chloroform-d) δ 6.77 (d, J = 15.7 Hz, 1H), 6.25 (dd, J = 9.2, 5.0 Hz, 1H), 
5.98 (d, J = 15.7 Hz, 1H), 4.63 (dq, J = 9.9, 6.2 Hz, 1H), 4.21 (s, 1H), 3.77 (s, 3H), 
2.76 (dddd, J = 16.2, 9.3, 6.8, 4.5 Hz, 1H), 2.60 (s, 1H), 2.31 – 2.10 (m, 1H), 1.96 
– 1.81 (m, 2H), 1.81 – 1.65 (m, 2H), 1.65 – 1.40 (m, 2H), 1.35 (s, 4H), 1.31 (d, J = 6.3 Hz, 4H), 0.96 
(d, J = 6.9 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) δ 168.1, 165.8, 153.4, 145.6, 132.3, 120.2, 
76.3, 75.6, 73.6, 51.7, 39.3, 38.9, 33.3, 31.6, 28.8, 27.4, 19.2, 18.0 ppm. IR (film, CHCl3) 3434, 
2954, 2933, 2874, 1703, 1642, 1439, 1377, 1267, 1226, 1153, 1107, 1041, 987 cm-1. HRMS 
(ESI): m/z calculated for C18H28O6Na [M+Na+]: 363.17781, found 363.17801. 
 
Following representative procedure 10. 
(2R,3S,8S,11R,E)-11-Hydroxy-2,3,11-trimethyl-7,14-dioxooxacyclotetradec-12-en-8-yl 
acetate – (661) 
81% yield (12 mg, 35 µmol). [𝒂]𝑫
𝟐𝟎: 59.5° (c=1.20 in CHCl3). 1H NMR (400 MHz, 
Chloroform-d) δ 6.68 (d, J = 15.8 Hz, 1H), 5.98 (d, J = 15.7 Hz, 1H), 4.73 – 4.59 
(m, 2H), 2.51 (dt, J = 17.2, 7.3 Hz, 1H), 2.16 (dt, J = 17.3, 6.6 Hz, 1H), 2.11 (s, 3H), 
1.87 – 1.75 (m, 2H), 1.74 – 1.47 (m, 5H), 1.38 (s, 3H), 1.28 (d, J = 6.3 Hz, 3H), 1.22 
– 1.07 (m, 1H), 1.02 (ddt, J = 13.4, 9.0, 7.3 Hz, 1H), 0.90 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (101 
MHz, CDCl3) δ 208.1, 170.7, 165.7, 153.0, 120.7, 78.9, 76.9, 73.4, 40.4, 36.8, 36.0, 34.2, 28.9, 24.5, 
22.3, 20.9, 19.4, 17.1 ppm. IR (film, CHCl3) 3488, 2969, 2934, 2876, 1739, 1711, 1644, 1455, 
1374, 1234, 1156, 1107, 1036, 992, 918, 876, 812, 777, 731, 686 cm-1. HRMS (ESI): m/z 
calculated for C18H28O6Na [M+Na+]: 363.17781, found 363.17764. 
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Following representative procedure 12. 
(3E,5R,8S,9Z,13S,14R)-9-Fluoro-5,8-dihydroxy-5,13,14-trimethyloxacyclo-tetra-deca-3,9-
dien-2-one – (662) 
84% yield (11 mg, 37 µmol). [𝒂]𝑫
𝟐𝟎: 53.0° (c=1.10 in CHCl3). 1H NMR (500 MHz, 
Chloroform-d) δ 6.76 (d, J = 15.7 Hz, 1H), 5.99 (d, J = 15.6 Hz, 1H), 4.86 (ddd, J = 
36.2, 10.1, 4.9 Hz, 1H), 4.59 (dq, J = 10.1, 6.1 Hz, 1H), 3.93 (ddd, J = 20.7, 10.0, 3.1 
Hz, 1H), 2.19 (dddd, J = 14.6, 10.0, 7.8, 4.2 Hz, 1H), 2.03 – 1.92 (m, 2H), 1.87 (ddd, 
J = 14.9, 9.9, 5.0 Hz, 1H), 1.83 – 1.75 (m, 1H), 1.71 (dddd, J = 14.4, 9.9, 5.5, 3.2 Hz, 
2H), 1.54 (tdd, J = 12.2, 6.1, 3.0 Hz, 1H), 1.50 – 1.38 (m, 2H), 1.36 (s, 3H), 1.31 (d, J = 6.1 Hz, 3H), 
0.94 (d, J = 6.9 Hz, 3H), 0.93 – 0.86 (m, 1H) ppm. 13C NMR (126 MHz, Chloroform-d) δ 165.9, 
157.0 (d, J = 257.1 Hz), 152.4, 120.0, 109.1 (d, J = 14.2 Hz), 74.7, 73.0, 72.1 (d, J = 27.7 Hz), 38.8, 
37.1, 32.5, 28.9, 27.9, 19.3, 18.6 (d, J = 5.1 Hz), 16.7 ppm. 19F NMR (282 MHz, CDCl3) δ -124.9 
ppm. IR (film, CHCl3) 3408, 2958, 2927, 2873, 1697, 1643, 1456, 1377, 1261, 1152, 1103, 1043, 
976, 871, 727, 678, 559, 438 cm-1. HRMS (EI): m/z calculated for C16H25O4FNa [M+Na+]: 
323.16291, found 323.16327. 
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9. Appendix 
9.1. Crystallographic Data 
9.1.1. Crystallographic Data of (1S,5R,6S,11S,14R)-11-Hydroxy-5,6,14-trimethyl-4,15-
dioxabicyclo[12.1.0]-pentadec-9-yn-3-one – (659) 
 
Identification code  8977 
Empirical formula  C16 H24 O4 
Color  colorless 
Formula weight  280.35  g · mol-1  
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  ORTHORHOMBIC 
Space group  P212121,  (no. 19)  
Unit cell dimensions a = 7.2789(9) Å = 90°. 
 b = 10.7001(13) Å = 90°. 
 c = 19.387(2) Å  = 90°. 
Volume 1510.0(3) Å3 
C16
C11
C12
O4
C13
C10
C14
C1
C5
O1
C6
C7
C8
C9
O3
C3
C2
C4
O2
C15
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Z 4 
Density (calculated) 1.233  Mg · m-3 
Absorption coefficient 0.707 mm-1 
F(000) 608 e 
Crystal size 0.30 x 0.12 x 0.03 mm3 
 range for data collection 4.561 to 55.082°. 
Index ranges -7  h  7, -11 k  11, -20  l  20 
Reflections collected 17540 
Independent reflections 1896 [Rint = 0.0652] 
Reflections with I>2(I) 1741 
Completeness to  = 67.679° 70.9 %  
Absorption correction Gaussian 
Max. and min. transmission 0.98 and 0.86 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1896 / 0 / 186 
Goodness-of-fit on F2 1.042 
Final R indices [I>2(I)] R1 = 0.0339 wR
2 = 0.0805 
R indices (all data) R1 = 0.0400 wR
2 = 0.0840 
Absolute structure parameter -0.01(13) 
Extinction coefficient 0.0054(8) 
Largest diff. peak and hole 0.2 and -0.2 e·Å-3 
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9.1.2. Crystallographic Data of (Z)-4-Methyl-N-(1-phenyl-2-(tributylstannyl)hept-2-en-1-
yl)benzenesulfonamide – (503) 
 
Identification code  9954 
Empirical formula  C32 H51 N O2 S Sn 
Color  colorless 
Formula weight  632.48  g · mol-1  
Temperature  100.15 K 
Wavelength  0.71073 Å 
Crystal system  MONOCLINIC 
Space group  P21/c,  (no. 14)  
Unit cell dimensions a = 15.041(3) Å = 90°. 
 b = 22.972(3) Å = 97.301(7)°. 
 c = 9.4505(2) Å  = 90°. 
C1
C31A
C31B
C10
C32A
C32B
C9
C11
C30A
C29B
C4
C2
C30BC29A
C5
C3
C8
C12
C6
N1
O1
C7
C13
C19
Sn1
C18
S1
C14
C25
C17 C21
C20
C15
O2
C26
C16
C22
C27
C28
C23C24
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Volume 3239.0(7) Å3 
Z 4 
Density (calculated) 1.297  Mg · m-3 
Absorption coefficient 0.880 mm-1 
F(000) 1328 e 
Crystal size 0.26 x 0.14 x 0.06 mm3 
 range for data collection 2.805 to 36.045°. 
Index ranges -24  h  24, -38 k  38, -15  l  15 
Reflections collected 86733 
Independent reflections 15364 [Rint = 0.0360] 
Reflections with I>2(I) 12313 
Completeness to  = 25.242° 99.8 %  
Absorption correction Gaussian 
Max. and min. transmission 0.95 and 0.83 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15364 / 0 / 335 
Goodness-of-fit on F2 1.051 
Final R indices [I>2(I)] R1 = 0.0387 wR
2 = 0.0850 
R indices (all data) R1 = 0.0551 wR
2 = 0.0946 
Largest diff. peak and hole 1.5 and -2.5 e · Å-3 
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9.1.3. Crystallographic Data of (Z)-N-(2-Fluoro-1-phenylhept-2-en-1-yl)-4-
methylbenzenesulfonamide – (508) 
 
Identification code  9977 
Empirical formula  C20 H24 F N O2 S 
Color  colorless 
Formula weight  361.46  g · mol-1  
Temperature  100.15 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2,  (no. 5)  
Unit cell dimensions a = 25.7470(12) Å = 90°. 
 b = 5.272(2) Å = 114.977(13)°. 
 c = 15.2010(19) Å  = 90°. 
C7
C6
C5
C4
C3
C20
C18
C17
C2
C19
C9
F1
C10
C1
C16
C8
C14
C11
C15
O2
C13
N1
C12
S1
O1
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Volume 1870.4(8) Å3 
Z 4 
Density (calculated) 1.284  Mg · m-3 
Absorption coefficient 0.195 mm-1 
F(000) 768 e 
Crystal size 0.25 x 0.07 x 0.05 mm3 
 range for data collection 2.726 to 33.162°. 
Index ranges -39  h  39, -8 k  8, -23  l  23 
Reflections collected 27424 
Independent reflections 7129 [Rint = 0.0518] 
Reflections with I>2(I) 6241 
Completeness to  = 25.242° 99.7 %  
Absorption correction Gaussian 
Max. and min. transmission 0.99 and 0.97 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7129 / 1 / 232 
Goodness-of-fit on F2 1.035 
Final R indices [I>2(I)] R1 = 0.0455 wR
2 = 0.0984 
R indices (all data) R1 = 0.0572 wR
2 = 0.1053 
Absolute structure parameter 0.08(5) 
Largest diff. peak and hole 0.4 and -0.4 e · Å-3 
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9.2. Abbreviations 
 
Ac  
 
 
acetyl  
acac  acetylacetonate  
Ad adamantyl 
AgDPP silver diphenylphosphinate 
AIBN  azobisisobutyronitrile  
aq aqueous  
Ar  aryl  
BBN  9-borabicyclo(3.3.1)nonane  
BINAL 2,2′-dihydroxy-1,1‘-binaphthyl-lithium aluminum hydride 
Bn  benzyl  
Boc tert-butyloxycarbonyl 
Ph-BPE 1,2-Bis[2,5-diphenylphospholano]ethane 
BQ benzoquinone 
br  broad  
Bu  butyl  
Bz  benzoyl  
calcd  calculated  
CAN ceric ammonium nitrate 
cat. catalytic 
CBS Corey-Bakshi-Shibata reagent 
cm  centimeter  
cod  cyclooctadienyl  
conc. concentration 
Cp cyclopentadienyl 
Cp* pentamethyl cyclopentadienyl 
CSA  camphorsulfonic acid  
Cy  cyclohexyl  
d.r.  diastereomeric ratio  
DABCO  1,4-diazabicyclo[2.2.2]octane  
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene  
dba dibenzylideneacetone 
DCC  dicyclohexylcarbodiimide  
DCE  1,2-dichloroethane  
dd  doublet  
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DIBAL-H  diisobutylalumnium hydride  
DMAP  N,N-dimethyl 4-aminopyridine  
DMF  dimethylformamide  
DMP  Dess-Martin Periodinane  
DMPU  1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone  
DMS  dimethyl sulfide  
DMSO  dimethylsulfoxide  
DPP diphenylphosphinate 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
DTBMP di-tert-butylmethyl pyridine 
DTS diverted total synthesis 
ee  enantiomeric excess  
ent  enantiomeric  
epi  epimeric  
eq/equiv. equivalents 
Et  ethyl  
F-TEDA 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
g  gram  
h  hour  
hep  heptet  
HMPA hexamethylphosphoramide 
HPLC  high pressure liquid chromatography  
HRMS high-resolution mass spectrometry 
i  iso (branched)  
IBX 2-iodoxybenzoic acid 
IC50  half maximal inhibitory concentration  
ipc isopinocampheyl 
IR  infrared spectroscopy  
KHMDS  potassium hexamethyldisilazide  
l  liter  
LDA  lithium diisopropylamide  
LiHMDS  lithium hexamethyldisilazide  
M  molar (mol/L)  
m  multiplet  
mCPBA meta-chloroperbenzoic acid 
Me  methyl  
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Mes  mesityl  
mg  miligram  
min  minute  
mL  mililiter  
MOM  methoxy methyl  
mp.  melting point  
Ms  methanesulfonyl, mesyl  
MTBE  tert-butylmethylether  
μg  microgram  
μL  microliter  
NaHMDS  sodium hexamethyldisilazide  
n.d.  not determined  
NBS N-bromosuccinimide 
NIS N-iodosuccinimide 
NME N-methylephedrine 
NMR  nuclear magnetic resonance  
Ns 4-nitrobenzenesulfonyl, Nosyl  
Ph  phenyl  
pin  pinacol  
PG  protecting group  
PMB  para-methoxybenzyl  
Pr  propyl  
q  quartet  
quant  quantitative  
r.r.  regioisomeric ratio  
rac  racemic  
RCAM  ring closing alkyne metathesis  
RCM  ring closing (olefin) metathesis  
r.t.  room temperature  
s  singlet  
sat.  saturated  
Suc succinimid 
t  triplet  
TAS tris(dimethylamino)sulfonium 
TBAF  tetra-n-butylammonium fluoride  
TBDPS  tert-butyldiphenylsilyl  
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TBDPP Tetra-n-butylammonium diphenylphosphinate 
TBHP tert-butyl hydroperoxide 
TBS  dimethyl-tert-butylsilyl  
TBT tetrabutyltriazolyl 
TC  thiophene-2-carboxylate  
TES  triethylsilyl  
Tf  trifluoromethanesulfonyl  
TFA  trifluoroacetic acid  
THF  Tetrahydrofuran  
Thx thexyl 
TLC  thin layer chromatography  
TMAO trimethylamine N-oxide 
TMS  trimethylsilyl  
TMP tetramesityl porphyrine 
Tol  ortho-tolyl  
Ts  p-toluenesulfonyl  
 
 
 
 243 
(Z)-2-(4-(tert-Butyl)cyclohex-1-en-1-yl)-6-((tert-butyldiphenylsilyl)oxy)hex-2-en-1-ol – (140) 
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(Z)-2-(4-(tert-Butyl)cyclohex-1-en-1-yl)-6-((tert-butyldiphenylsilyl)oxy)hex-2-en-1-ol – (140) 
 
 245 
(Z)-2-(3-Phenylpropyl)hex-2-en-1-ol – (167) 
 
 246 
(Z)-2-(3-Phenylpropyl)hex-2-en-1-ol – (167) 
 
 247 
Methyl (Z)-5-bromo-3-hydroxy-2-(3-phenylpropylidene)hex-5-enoate – (255) 
 
 248 
Methyl (Z)-5-bromo-3-hydroxy-2-(3-phenylpropylidene)hex-5-enoate – (255)
 
 249 
Methyl (R,Z)-2-((1R,2R)-2-(5,5-dimethyl-1,3-dioxan-2-yl)-1-hydroxypropyl)-7-((triisopropylsilyl)oxy)oct-2-enoate – (300) 
 
 250 
Methyl (R,Z)-2-((1R,2R)-2-(5,5-dimethyl-1,3-dioxan-2-yl)-1-hydroxypropyl)-7-((triisopropylsilyl)oxy)oct-2-enoate – (300)
 
 251 
Methyl (R,Z)-7-hydroxy-2-((1R,2S,E)-1-(methoxymethoxy)-2-methyl-4-(tributylstannyl)but-3-en-1-yl)oct-2-enoate – (302) 
 
 252 
Methyl (R,Z)-7-hydroxy-2-((1R,2S,E)-1-(methoxymethoxy)-2-methyl-4-(tributylstannyl)but-3-en-1-yl)oct-2-enoate – (302)
 
 253 
1-((tert-butyldimethylsilyl)oxy)-4-oxononan-3-yl acetate – (398)
 
 254 
1-((tert-butyldimethylsilyl)oxy)-4-oxononan-3-yl acetate – (398) 
 
 255 
(Z)-1-methoxydec-2-en-2-yl acetate – (400)
 
 256 
(Z)-1-methoxydec-2-en-2-yl acetate – (400)
 
 257 
 
 258 
 
 259 
 
 260 
 
 261 
 
 262 
 
 263 
 
 264 
4-((Tetrahydro-2H-pyran-2-yl)oxy)butan-2-one – (411)
 
 265 
4-((Tetrahydro-2H-pyran-2-yl)oxy)butan-2-one – (411)
 
 266 
(Z)-1-((tert-Butyldimethylsilyl)oxy)-4-fluoronon-4-en-3-ol – (507)
 
 267 
(Z)-1-((tert-Butyldimethylsilyl)oxy)-4-fluoronon-4-en-3-ol – (507)
 
 268 
Diphenyl (S,Z)-(5-fluoro-2-methyldec-5-en-4-yl)phosphoramidate – (530)
 
 269 
Diphenyl (S,Z)-(5-fluoro-2-methyldec-5-en-4-yl)phosphoramidate – (530)
 
 270 
(2R,3S)-3-Methyloct-6-yn-2-yl (4R,7S,E)-7-((tert-butyldimethylsilyl)oxy)-4-methyl-4-((triethylsilyl)oxy)dec-2-en-8-ynoate – (SI-94)
 
 271 
(2R,3S)-3-Methyloct-6-yn-2-yl (4R,7S,E)-7-((tert-butyldimethylsilyl)oxy)-4-methyl-4-((triethylsilyl)oxy)dec-2-en-8-ynoate – (SI-94)
 
 272 
(5R,8S,13S,14R,E)-8-((tert-Butyldimethylsilyl)oxy)-5,13,14-trimethyl-5-((triethylsilyl)-oxy)oxacyclotetradec-3-en-9-yn-2-one – (655b)
 
 273 
(5R,8S,13S,14R,E)-8-((tert-Butyldimethylsilyl)oxy)-5,13,14-trimethyl-5-((triethylsilyl)-oxy)oxacyclotetradec-3-en-9-yn-2-one – (655b)
 
 274 
(5R,8S,13S,14R,E)-5,8-Dihydroxy-5,13,14-trimethyloxacyclotetradec-3-en-9-yn-2-one - (655a)
 
 275 
(5R,8S,13S,14R,E)-5,8-Dihydroxy-5,13,14-trimethyloxacyclotetradec-3-en-9-yn-2-one – (655a)
 
 276 
(1S,5R,6S,11S,14R)-11-Hydroxy-5,6,14-trimethyl-4,15-dioxabicyclo[12.1.0]-penta-dec-9-yn-3-one – (659)
 
 277 
(1S,5R,6S,11S,14R)-11-Hydroxy-5,6,14-trimethyl-4,15-dioxabicyclo[12.1.0]-penta-dec-9-yn-3-one – (659)
 
 278 
(3E,5R,8S,9Z,13S,14R)-5,8-Dihydroxy-5,13,14-trimethyloxacyclotetradeca-3,9-dien-2-one – (658)
 
 279 
(3E,5R,8S,9Z,13S,14R)-5,8-Dihydroxy-5,13,14-trimethyloxacyclotetradeca-3,9-dien-2-one – (658)
 
 280 
Methyl (2R,3S,6Z,8S,11R,12E)-8,11-dihydroxy-2,3,11-trimethyl-14-oxooxacyclotetradeca-6,12-diene-7-carboxylate – (660) 
 
 281 
Methyl (2R,3S,6Z,8S,11R,12E)-8,11-dihydroxy-2,3,11-trimethyl-14-oxooxacyclotetradeca-6,12-diene-7-carboxylate – (660)
 
 282 
(2R,3S,8S,11R,E)-11-hydroxy-2,3,11-trimethyl-7,14-dioxooxacyclotetradec-12-en-8-yl acetate – (661)
 
 283 
(2R,3S,8S,11R,E)-11-hydroxy-2,3,11-trimethyl-7,14-dioxooxacyclotetradec-12-en-8-yl acetate – (661)
 
 284 
(3E,5R,8S,9Z,13S,14R)-9-Fluoro-5,8-dihydroxy-5,13,14-trimethyloxacyclotetradeca-3,9-dien-2-one - (662)
 
 285 
(3E,5R,8S,9Z,13S,14R)-9-Fluoro-5,8-dihydroxy-5,13,14-trimethyloxacyclotetradeca-3,9-dien-2-one – (662)
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